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ABSTRACT 
 
In Australia, the principal mechanism for facilitating access to medications is through the 
Pharmaceutical Benefits Scheme (PBS), which subsidises more than 90% of medications 
dispensed in Australia and contributes up to 80% of the cost of each medication. Although 
it ensures the availability of medication for the population, one unintended effect of this 
subsidisation is that it can encourage overconsumption and hoarding of medications, 
thereby contributing to waste and escalating healthcare costs. 
 
Various policies to control expenditure and facilitate the efficient use of medications have 
been implemented, from the prescribing to the dispensing of the PBS medicine. An 
important policy influencing patient demand is cost sharing in the form of a patient 
copayment. Apart from reducing government expenditure, the copayment policy is 
intended to sensitise patients to the cost of the medication and to discourage 
overconsumption. However, some patients on multiple medications may respond to cost 
increases by modifying, reducing or ceasing their medication altogether. If these 
modifications affect the use of essential medications for the treatment of chronic diseases, 
then it may represent false economy in the long run for the government.  
 
Aim  
 
The aims of this research are to: 1) describe the pattern of PBS medication use in 
Queensland, Australia prior to an unusually large (21%) copayment increase; 2) establish 
whether the copayment increase resulted in a change in the overall purchasing of PBS 
medicines; and, 3) investigate changes according to characteristics of the patient and the 
therapeutic class of the medication. 
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Methods 
 
Data for this study were Federal Government records of PBS medications supplied to 
Queensland residents during 2004 and 2005. Randomly selected data on medications 
supplied to patients were provided from a claims database by Medicare Australia, an 
organisation which administers the PBS. A comparative analysis was conducted of the 
purchasing pattern in the calendar year 2004, just before a copayment rise came into 
effect, with the corresponding pattern in 2005.  
 
The analysis included descriptive statistics of prescription use in 2004 and hypothesis 
testing of changes in prescription use in 2005 across patient and medication-related 
variables. In addition, an in-depth analysis was conducted for prescriptions for the 
management of the National Health Priority Area chronic diseases, and conditions of 
mental health, cardiovascular disease, diabetes, arthritis and asthma. Antibiotics were also 
included because they are a commonly used medication group independent of age and 
gender. The inclusion of antibiotics in the analysis for the thesis also facilitated an 
examination of the impact of cost on the purchasing of medications for the treatment of 
acute illness and provided a useful benchmark for the interpretation of medication use in 
patients with chronic conditions.  
 
Results 
 
The profile of medication use in 2004 indicated that while females purchased more 
medication overall than males, the difference narrowed with age. Although there was a 
pattern of increasing use with age for most medications, for some, such as 
antidepressants, anxiolytics and cholesterol lowering drugs, the increase started earlier, 
probably reflecting a change in focus to early detection and aggressive treatment. While 
multiple medication use increased with age and peaked in older patients, there was also 
an indication of a creep in multiple medication use in to younger age groups.  
 
By contrast, the increase in patient copayment was associated with a change in the 
purchasing pattern of PBS medications in 2005. However, while the number of 
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prescriptions overall increased in 2005, reductions in some purchases were observed in 
2005. For example, patients who purchased an average of five or more prescription 
medications per month (representing major polypharmacy) in 2004 purchased significantly 
fewer medications in 2005.  
 
Differences in the purchasing of anti-infective medications were used as a measure of 
changes in medication purchased for the treatment of acute illnesses. Results indicated 
that there was no significant change in the total number of anti-infective medications 
purchased between 2004 and 2005.  
 
Analysis of purchasing patterns indicated that some patient groups reacted differently to 
the 21% copayment increase with complex relationships being identified. For example, 
prescriptions for the CVD group of medications increased significantly for males and 
females and across all age groups despite the increase in copayment. Patients who paid 
the general payment rate and used an average of two to four prescriptions per month 
(minor polypharmacy), significantly decreased their nervous system medication use 
following the copayment rise. Prescriptions for anxiolytics increased for females aged 25-
64, patients affected by minor polypharmacy, and general patients, while prescriptions for 
non-steroidal anti-inflammatory drugs (NSAIDS) decreased significantly for both genders, 
all age groups, all levels of medication use and both payment categories (i.e. both 
concessional and general patients). Prescriptions for analgesics increased in 2005, but 
this was mainly related to an increase in the prescribing of opioid analgesics. The 
purchasing of non-opioid analgesics decreased significantly after the copayment increase 
in 2005. 
 
Conclusion 
 
This research suggests that the pattern of medication use is changing with the change in 
paradigm towards early detection, aggressive management and guideline-based treatment 
of chronic diseases. Multiple medication use is also on the rise and is extending into the 
younger age groups. Given the relationship between cost and medication adherence, 
general patients who pay a much higher copayment, and concessional patients taking 
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multiple chronic disease medications could be at risk of nonadherence when unusually 
large copayment increases are implemented. Recommendations are: 1) phasing in large 
copayment increases over a longer timeframe rather than introducing increases all at 
once; 2) implementing systems to monitor the impact of large copayment increases on 
general patients, and concessional patients on multiple medications; 3) maintaining health 
provider incentives aimed at promoting quality use of medications; and 4) addressing 
polypharmacy by implementing guidelines for deprescribing, or extending the scope of 
home medicines review to include deprescribing. 
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PREFACE 
 
Although it is unusual to present a list of abbreviations, acronyms and definition of terms in 
the preface of a thesis, one is included here. The main reason for this is that I am a 
Pharmacist and my daily work requires me to work within mandated Australian health care 
legislation and processes. This specialist familiarity with the Pharmaceutical Benefits 
Scheme is probably not a major concern in the working life of other health professionals, 
and for this reason I have included a list of abbreviations and terms used in the first two 
chapters of this thesis.  More specific terms related to the research and operational 
definitions are presented at the end of Chapter 1. 
 
Definition of Key Terms Used in Chapters 1 and 2 
 
Concessional patient: A patient who holds a Medicare card, and one of the following 
cards: Pensioner Concession Card; Commonwealth Seniors Health Card; Health 
Care Card; Repatriation Health Card. Concessional patients are entitled to further 
subsidy through the Safety Net Entitlement Card.  
Copayment/Cost sharing/Patient contribution: A form of cost sharing where a patient 
pays a fixed fee per prescription out-of-pocket for a specified PBS listed medicine. 
The government covers the remainder of the cost.  
Discretionary medications: Medications that are used to manage acute conditions and 
provide relief of symptoms rather than effecting the underlying disease process. 
Deductible: What the patient pays for the prescription before the government or the plan 
begins to pay. 
Dual-eligible beneficiaries: This is an American term used in U.S literature. It refers to 
patients covered by the U.S. Medicare and Medicaid programs.  
Essential medications: Medicine prescribed to manage chronic diseases. These are 
intended to prevent deterioration in health, or to prolong life, and are not likely to be 
prescribed in the absence of a definitive diagnosis.  
General patient: A PBS beneficiary who holds a Medicare card only, and has no 
concessional cards.  
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Health Care Provider: For ease of reading the term “health care provider” includes all 
health professionals involved in patient care such as doctors, nurses and 
pharmacists while the term “prescriber” and “doctor” are used interchangeably. 
Home Medicines Review: Review of medication conducted on selected patients living in 
the community setting. This is initiated by a patient’s GP who assesses the patient’s 
need for the service. The goal of a HMR is to maximise an individual patient’s 
benefit from their medication regimen, and prevent medication-related problems 
through a team approach, which may also involve other relevant members of the 
health care team, such as nurses in community practice or carers. 
National Health Priority Areas: Diseases and conditions which have been chosen for 
focused attention because they contribute significantly social and financial costs on 
the Australian society. There are currently nine NHPAs. This research focusses on 
five of these: cardiovascular disease (high blood pressure); mental health 
(depression); arthritis and musculoskeletal conditions; asthma; and, diabetes 
mellitus. 
Medicare card:  Access to PBS-subsidised medicines is restricted to holders of the 
Medicare card.  
Major polypharmacy: In Australia a frequently used definition of major polypharmacy is 
the treatment with five or more medications (Hilmer, 2008). In this thesis major 
polypharmacy refers to a mean five or more medications purchased per month 
during a calendar year. 
Minor polypharmacy: Represents treatment with two to four medications (Werder & 
Preskorn, 2003).  In this thesis minor polypharmacy refers to a mean of two to fewer 
than 5 medications purchased per month during a calendar year. 
Moral hazard: In economic theory, a moral hazard is a situation where a person tends to 
take risks because the costs will not be felt by them. In this thesis a moral hazard 
situation refers to the tendency of people to purchase more medication than they 
need because someone else (the tax payer) is paying for it.  
Non-polypharmacy: A mean of fewer than two medications purchased per month during 
a calendar year. 
Payment category: These terms are used interchangeably in the thesis and refer to 
patient type under the PBS – concessional or general. 
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Pharmaceutical Benefits Scheme (PBS): A national scheme that subsidises the cost of 
a wide range of medications to Australian residents. The Repatriation 
Pharmaceutical Benefits Scheme (RPBS) is a similar scheme for returned service 
men and women.  
PBS medication: A prescription medicine prescribed by a medical practitioner and 
purchased from a pharmacy.  
Polypharmacy: Polypharmacy refers to the use of multiple acute and chronic disease 
medications. In this thesis the terms polypharmacy and multiple medication use are 
used interchangeably and refers to the mean purchase of 2 or more medications 
per month over a calendar year. Further division is made into minor polypharmacy 
(mean of 2-4 medications per month) and major polypharmacy (mean of 5 or more 
medications per month).    
Prescription medicine: A medicine which can only be supplied after the issue of a 
prescription by a medical practitioner. Prescribed medicines in Australia fall into one 
of three categories: 1) medicines that attract a government subsidy under the PBS 
(PBS benefit medication); 2) PBS listed medicines that do not attract a government 
subsidy, i.e. a medicine that costs below the PBS copayment level (below-
copayment medication); and, 3) prescribed medicines not listed on the PBS 
schedule (private prescription). In this thesis the words “medication” and 
“prescription” are used interchangeably. This because a PBS medication had to be 
purchased from a pharmacy on the issue of a prescription to be recorded on the 
PBS database used in the research for this thesis.   
Private medicine: A prescribed medicine which is not listed on the PBS, so the patient 
pays the full price for the medication. 
Residential Medication Management Review: Review of medications conducted on 
permanent residents of a residential aged care facility and involves collaboration 
between a doctor and a pharmacist to review the medication management needs of 
a resident.  
Safety net threshold (SNT): Once a concessional patient/family reaches a predetermined 
expenditure on medications during the calendar year they qualify to receive PBS 
medicines free of charge for the rest of the year. In 2005 the concessional patient 
safety net threshold was $239.20. The corresponding SNT for general patient/family 
xix 
 
was $874.90, which entitled them to receive PBS medicines at $4.70 (concessional 
rate) for the rest of the calendar year. 
Statutory price reduction: A statutory price reduction of 16% is applied to existing PBS-
listed products when the first new brand or item that is bioequivalent or biosimilar 
and has the same manner of administration as an existing brand or item is listed on 
the PBS.  
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List of Acronyms and Abbreviations 
 
ABS  Australian Bureau of Statistics 
AIHW  Australian Institute of Health and Welfare 
COPD  Chronic obstructive pulmonary disease 
CRN  Cost-related nonadherence 
DoHA  (Australian Government) Department of Health and Ageing 
GP  General Practitioner 
HMR  Home Medicines Review 
NHPA  National Health Priority Area 
NHFA  National Heart Foundation of Australia 
OECD  Organisation of Economic Cooperation and Development 
QUM  Quality use of medications 
RMMR Residential Medication Management Review 
SNT  Safety net threshold 
SNRI  Serotonin (and) noradrenaline reuptake inhibitor. 
SSRI  Selective serotonin receptor inhibitor 
NSAID Non-steroidal anti-inflammatory drug 
NHMRC  National Health and Medical Research Council 
PBS   Pharmaceutical Benefits Scheme 
WHO  World Health Organization 
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Medications discussed in this research, associated health condition and body 
system  
 
Health condition 
being managed 
Body system(s) Medication classes examined 
Cardiovascular 
disease 
Heart, Circulatory Essential: Cholesterol lowering medications, 
antihypertensives, Vasodilators and beta-
blockers, blood thinners 
Diabetes Endocrine Essential: Diabetes medications, Thyroid 
preparations 
Arthritis Musculoskeletal  Discretionary: Anti-inflammatory agents, Gout 
medications 
Mental health Nervous system Essential: Antidepressants, anxiolytics, anti-
psychotics; Discretionary: sedatives and 
hypnotics 
Asthma Respiratory Essential: Asthma preventer medications; 
Essential/discretionary: Asthma reliever 
medications 
Infection Non specific Essential: Antibiotics 
Pain  Non specific Essential /discretionary: Opioids, Simple (non- 
opioid) analgesics 
Reflux and ulcer Upper alimentary 
tract 
Discretionary: anti-ulcerants (ulcer and reflux 
medications) 
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CHAPTER 1.  BACKGROUND AND SIGNIFICANCE 
 
Introduction 
 
Australian health survey data show that the use of medications is a common health-
related activity among Australians (ABS, 2013). In 2011, over two-thirds of visits to the 
doctor involved recommendations about a medication (Britt et al., 2010) resulting in over 
194 million prescriptions being dispensed through community pharmacies (Department of 
Health and Ageing [DoHA], 2012a, p.2).  
 
The majority of prescription medications in Australia are supplied through the 
Pharmaceutical Benefits Scheme (www.health.gov.au/pbs). The Federal Government, 
which funds the PBS, subsidises approximately 80% of prescription medications 
dispensed in Australia (Lopert, 2009). In addition to this, the government contributes up to 
83% of the cost of the medicine, with the consumer paying the remainder through a 
copayment (DoHA, 2012c). Generally the copayment is in keeping with increases in the 
Consumer Price Index (CPI). However in 2005 the copayment increased by 21% as a 
result of a 2002 Federal budget decision to shift more costs back to consumers (Brown, 
Abello & Harding, 2006). 
 
This thesis presents an analysis of medication purchase patterns before and after 
this substantial increase in copayment came into effect. 
 
The Pharmaceutical Benefits Scheme.   
The PBS is a health insurance scheme administered for the Australian Government 
by Medicare, a section of the Department of Human Services. The PBS began as a limited 
scheme in 1948, with free medicines for pensioners and a list of 139 ‘life-saving and 
disease preventing’ medicines free of charge for others in the community (DoHA, 2014a). 
Since then, the number and type of subsidised medications has grown substantially. 
Currently the PBS aims to provide “timely, reliable and affordable access to necessary 
medicines to all Australians” (DoHA, 2014a) and is part of the Australian Government’s 
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broader National Medicines Policy (DoHA, 2000). It is financed from general tax revenue 
rather than premiums paid directly by patients.  Access to PBS benefits requires a 
Medicare card which is available to all Australian residents and eligible foreign visitors 
from countries which have a reciprocal health care agreement with Australia.  
 
The PBS is governed by a framework of policies and regulations regarding the 
process of prescribing and supply of medication to the patient. These policies aim to 
facilitate affordable and timely access to prescription medicines, while at the same time 
controlling government expenditure on the PBS. An important policy regarding the latter 
aim is the patient copayment which requires the consumer to pay a proportion of the cost 
of the medication. In practice, this entails the PBS reimbursing the dispensing pharmacy 
the difference between the cost of the medicine and the patient copayment after the 
patient has purchased the medication from the pharmacy. 
 
The PBS has two types of patients — general and concessional. Under the PBS 
cost sharing arrangement, concessional patients (income support recipients such as aged 
pensioners and the unemployed) pay a lower copayment than general patients. For 
example, in 2015, a concessional patient contributed a copayment of $6.10 towards the 
cost of each PBS prescription medicine while a general patient paid a copayment of 
$37.70 (DoHA 2014b). The copayments are subject to a safety net threshold which allows 
for a reduction in the copayment once the total cost incurred by the patient during the 
calendar year exceeds the amount set as the safety net threshold for that year. Australia is 
considered to have one of the most equitable pharmaceutical schemes in the world 
(Duckett, 2004), although the copayment is also among the highest in the world (Kemp, 
Preen, Glover, Semmens & Roughhead, 2011). 
 
The copayment was first introduced in 1960 with the objective of generating 
revenues to offset drug budget costs and discourage unnecessary purchase of PBS 
medicines (Sloan, 1995). Table 1.1 shows that for most years the copayment increased 
gradually, with the exception of substantial increases in 1990 and 2005. In 1990 the 
copayment for general patients rose to $15, and concessional patients faced a copayment 
of $2.50 for the first time (DoHA, 2012b). Since their introduction, patient copayments have 
risen incrementally in line with inflation. The increases (with the exception of the 1990 
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increase) prior and subsequent to 2005 were between 2% and 6%. In the calendar year 
2005, however, the copayment increased by 21% for both categories of PBS beneficiaries 
as of the first of January. This was the result of a federal budget measure aimed at 
curtailing government expenditure (Brown et al. 2006). Table 1.1 presents a list of the PBS 
copayment changes from 1960 to 2015. 
 
      Table 1.1. Copayment 1960, 1997, 2000-2012 and annual changes 2000 to 2015 
Date of change General ($) Change (%) Concessional ($)  Change (%)  
1/3/1960 0.50 - Free - 
1/11/1990 15.00 - 2.50 - 
1/1/1997 20.00 - 3.20 - 
1/1/2000 20.60 - 3.30 - 
1/1/2001 21.90 6.3% 3.50 6.1% 
1/1/2002 22.40 2.4% 3.60 2.5% 
1/1/2003 23.10 3.1% 3.70 2.8% 
1/1/2004 23.70 2.6% 3.80 2.7% 
1/1/2005 28.60 20.7% 4.60 21.1% 
1/1/2006 29.50 3.1% 4.70 2.2% 
1/1/2007 30.70 4.1% 4.90 4.3% 
1/1/2008 31.30 2.0% 5.00 2.0% 
1/1/2009 32.90 5.1% 5.30 6.0% 
1/1/2010 33.30 1.2% 5.40 1.9% 
1/1/2011 34.20 2.7% 5.60 3.7% 
1/1/2012 35.40 3.5% 5.80 3.6% 
1/1/2013 36.10 2.0% 5.90 1.7% 
1/1/2014 36.90 2.2% 6.00 1.7% 
1/1/2015 37.70 2.1% 6.10 1.7% 
Sources: (DoHA, 2012b; DoHA, 2013; DoHA, 2014c; DoHA, 2015) 
PBS Expenditure.  
Total government expenditure on the PBS has been increasing by an average of 
8.3% per year since 2000-01, and reached $18.4 billion in the 2011-12 financial year 
(Australian Institute of Health and Welfare [AIHW], 2012). In 2011-12, recurrent 
expenditure on prescription medicines dispensed in community and hospital pharmacies 
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was estimated to be $15.9 billion, of which 61.6% (or $9.8 billion) represented government 
expenditure on benefit-paid (subsidised) medicines (AIHW, 2012). In the same financial 
year, patient copayments collected at the pharmacies contributed 26.6% of the total cost of 
PBS prescriptions and amounted to $1,505.1 million (AIHW, 2012).  
 
The Department of Health and Ageing (2012a) also reported that in the financial 
year ending 30 June 2012, government expenditure on PBS prescriptions directed at 
concessional patients amounted to $5,866.3 million (77.8% of total government PBS 
expenditure). This was a slight increase on the $5,698.4 million (77.7% of the total) 
compared to the previous financial year. While the growth of government expenditure on 
the PBS has been decelerating since 2007 (Haas, 2010), the cost of the PBS remains one 
of the fastest growing components of total health expenditure in Australia (AIHW, 2012). 
This has led to concerns about the sustainability of the PBS and concomitant interest in 
measures to contain expenditure on PBS medicines.  
 
Effects of Cost Sharing on Medication Use 
 
While copayment and copayment increases may reduce the initial cost burden to 
government, they may also contribute to unintended effects elsewhere in the health 
system. An important effect from the consumer perspective is medication nonadherence, 
which, according to the World Health Organisation, is related to social and economic 
factors, health care system characteristics, disease and therapy-related characteristics 
and patient-related factors (World Health Organisation [WHO], 2003).  
 
Addressing the problem of medication nonadherence therefore requires addressing 
issues relating to each of the above factors. Financial barriers to medication use has 
emerged as an especially important factor, with an increasing number of studies identifying 
cost to the consumer as an important predictor of medication use (see for example, 
Goldman, Joyce & Zheng, 2007; Gelland, Grenard & McGlynn, 2009). Therefore, national 
policy change regarding copayment has the ability to potentially increase individuals’ 
adherence to medication regimes, as well as reduce stockpiling and waste by fine tuning 
the copayment of medication groups. This issue will be explored in more detail later in this 
thesis.  
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The international perspective on medication cost and use. 
Evidence that cost affects the use of medications comes from a Cochrane Review 
(Austvoll-Dahlgren et al., 2008), and major reviews of studies from the USA and Canada 
(Lexchin & Grootendorst, 2004; Gibson, Ozminkowski & Goetzel 2005a; Goldman et al., 
2007; Gelland, Grenard & McGlynn, 2009). These studies consistently show that increases 
in cost sharing influence medication use in both positive and negative ways.  
 
Austvoll-Dahlgren et al. (2008) examined evidence on the impact of cost sharing 
policies on medicine use, health outcomes and expenditure on medicines from a wide 
range of studies. This meta-analysis of 30 evaluations of 21 studies included randomised 
control trials, non-randomised control trials, interrupted time series analyses, repeated 
measures studies and controlled before-after studies. The review concluded that while 
caps and copayment policies save expenditure on drugs, they may also contribute to 
reductions in the use of life-sustaining medications or drugs used for treating chronic 
conditions. 
 
Tamblyn et al., (2001) and Goldman et al., (2007) and also reported that user 
charges contribute to savings in drug expenditure at the expense of unintended effects. 
These findings were based on a synthesis of evidence from studies conducted in the 
United States on the association between the level of cost sharing and the use of 
prescription drugs, non-pharmaceutical services, and health outcomes. Key unintended 
effects included lower rates of drug treatment, reduced adherence to therapy and 
increased discontinuation of therapy. For persons with chronic illnesses, these unintended 
effects contributed to increased use of downstream medical services such as emergency 
department attendances and hospitalisations.  
 
Similarly, Gibson et al., (2005a) used claims-based data from the United States and 
Canada in which cross-sectional or longitudinal variation in the amount of the copayment 
occurred, thus permitting an examination of the relationship between the variation in cost-
sharing and medication use. These authors found that while higher levels of prescription 
drug cost sharing decreased the consumption of prescription drugs, it was also associated 
with treatment disruptions which included reduced initiation and adherence to therapy with 
medications for chronic disease.  
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Not unexpectedly, disruptions to treatment due to cost-related nonadherence has 
been found to have long term effects on patients’ health status, especially for low income 
populations with chronic conditions. Lexchin and Grootendorst (2004) undertook a 
systematic review of the effects of cost sharing on vulnerable groups and found that 
copayments and caps on the monthly number of subsidised medications led to decreases 
in the purchasing of prescription medications. An important unintended effect identified by 
this review was a decrease in the use of essential medications, which are used to manage 
chronic diseases and prevent deterioration in health. This differential impact is evident in 
the United States where medication use for the management of chronic diseases 
decreased relative to medication use for acute medical conditions when medication cost 
rose (Goldman et al., 2004; Gleason, Gunderson & Gericke, 2005).  
 
Other studies have shown similar cost-related medication patterns, such as use 
between medicines to prevent deterioration in health or to prolong life, and those which are 
used for symptom control (Lexchin & Grootendorst, 2004; Piette, Heisler & Wagner, 
2004b). The latter group of medications, referred to in this thesis as discretionary 
medication, include medications for the symptomatic treatment of conditions such as pain, 
migraine, asthma and arthritis. It is possible that increases in the copayment for 
discretionary medications for symptom control may undermine the role of essential 
medicines in the long term management of chronic diseases and, therefore, may not be 
cost-effective in the long term.  
 
Gemmill, Thomson and Mossialos (2008) reviewed literature on user charges from 
15 high-income countries that comprise the Organisation for Economic Cooperation and 
Development (OECD) and concluded that, while prescription drug charges contribute to 
savings in the use of services such as doctor and pharmacy visits, the savings may be 
outweighed by increased use of resource-intensive downstream services such as 
emergency department visits and hospital stays. This finding supports an earlier Cochrane 
review which concluded that user charges for prescription medicines result in increases in 
the use of downstream healthcare services and, therefore, increase overall expenditure on 
health (Austvoll-Dahlgren et al., 2008). Similarly, in Canada, Tambolyn et al. (2001) 
reported that prescription copayment for elderly and welfare recipients contributed to 
significant increases in emergency department and acute care occasions of service. 
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Increases in medication charges have also been found to contribute to adverse 
effects on other parts of the health sector. Piette, Heisler, and Wagner (2004a) reported 
that medication nonadherence because of cost may undermine efforts to prevent 
complications of chronic diseases, particularly among low-income groups and the elderly. 
Buntin, Haviland, McDevitt, and Sood (2011) concluded that enrolment in high-deductible 
health plans led to reductions in the use of preventive care services. Both, Chandra, 
Gruber & McKnight (2014) and Hsu et al. (2006) demonstrated that higher cost sharing is 
detrimental to the health of the poor and the chronically ill.  
On the other hand, measures that increase accessibility to prescription medicines, 
such as increased insurance coverage or no copayment at all increase prescription use. 
This was evident in the United States when Medicare Part D was implemented to provide 
prescription drug insurance to disabled and older adults. Evidence clearly shows that Part 
D implementation in 2006 increased prescription medicine use and reduced out-of-pocket 
costs particularly in beneficiaries without previous drug coverage (Lau, Briesacher, 
Touchette, Stubbings & Ng, 2011; Millett, Everett, Matheson, Bindman & Mainous, 2010)  
However, what remains less clear is whether it improved the quality of medication use and 
optimised health outcomes (Lau et al., 2011).  
  
The Australian context. 
Australian studies on medication use have mainly concentrated on elderly 
concessional patients (i.e. those entitled to the maximum medication subsidy) on multiple 
medications, with the objective of addressing adverse and side effects associated with 
polypharmacy and improving quality of medication use (See, for example, Elliott, 2006; 
Runganga, Peel & Hubbard, 2014). These studies have generally relied on small sample 
sizes and have used methodologies which did not take contextual factors into account. 
These contextual factors include potential barriers to medication adherence such as 
elderly people living in the community (rather than in residential care), complex treatment 
regimens, frequent dosing, adverse drug effects, and specific medical conditions 
associated with ageing such as depression and dementia (Elliot, 2006).  
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Some Australian studies are limited by methodological shortcomings, including the 
use of cross-sectional and self-reported data. The outcomes measures have generally 
been time-series changes in prescription use and health outcomes rather than changes at 
the patient level. For example, a survey in 2008 administered by the National Prescribing 
Service (NPS) found that one in five respondents aged 50 years and over who used 
medicines reported that their adherence to prescribed medicines was affected by cost 
(Morgan et al., 2012). However, a major limitation of this study was that the self-report 
nature of the data was subject to recall and social desirability biases common to all self-
report measures. 
 
Studies that assess the effects of copayment on adherence to prescription 
medicines in specific populations rather than in the general population, are also limited 
because the results are not generalizable (Lexchin & Grootendorst, 2004). Gaps and 
opportunities therefore exist to expand the scope of these studies by focussing on the 
patient rather than the prescription and by including sociodemographic variables, use of 
multiple medications, and general PBS patients (who pay the highest copayment). This 
thesis will address these gaps by using PBS claims data and a longitudinal methodology to 
examine patient and medication-related factors in addition to changes in medication 
purchases following an unusually high increase in patient copayments for both categories 
of PBS beneficiaries (i.e. concessional and general patients). 
 
This latter group consists of employed, working-age adults and has not been 
investigated in depth before. McManus et al., (1996) examined changes in prescription use 
in the community after an increase of 36.4% in the general copayment rate and an 
introduction of a $2.50 copayment for pensioners in 1990, and Repatriation (war veterans) 
patients in 1992.  The authors used an interrupted time series analysis to estimate 
changes in prescription levels for essential medications such as antihypertensive and 
asthma inhalers and discretionary medicines such as nonsteroidal anti-inflammatory drugs 
(NSAIDs) and analgesics. A major finding was that cost increases were associated with 
decreases in prescription purchases for both essential and discretionary medicines, with 
the decreases being substantially larger and more sustained for discretionary medicines. 
However, this study is limited because the effect of these copayment increases was not 
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investigated for people in younger age groups or according to gender. The research 
presented in this thesis will fill this gap. 
 
In a more recent study which used PBS claims data, Hynd et al. (2008) compared 
prescriptions dispensed from the period January 2000 to December 2004 with 
corresponding prescriptions for the period January 2005 to September 2007. They found 
that concessional patients were particularly sensitive to the negative effects of the 
copayment increases. More specifically, the authors found that the copayment increase in 
2005 had a significant effect on consumers’ ability to afford essential and discretionary 
medicines for the treatment of a range of acute and chronic medical conditions. These 
findings are limited, however, in that Hynd et al. (2008) compared un-paired groups. Also, 
the data spanned a four year period, both prior to and following the January 2005 
copayment increase. This makes it difficult to pinpoint the copayment increase as the only 
factor in changes over this eight year period. I will address that limitation in this thesis and 
extend the scope of the Hynd et al. (2008) study by examining the immediate cost-related 
changes in prescription use. In this way the use of paired data and the follow-up of the 
same cohort of patients over two consecutive years will enable a longitudinal examination 
of the immediate effects of the copayment increase in 2005.  
 
This thesis also includes an examination of the impact of a larger than usual 
copayment change on the purchasing of medications by general patients who pay a much 
higher copayment than concessional patients. This group of PBS beneficiaries have not 
been the subject of many studies because the majority of them are primarily working age 
adults who do not hold a concessional card, and tend not to be on multiple medications. 
Knowledge about the pattern of medication use, level of multiple medication use, and the 
response of working aged adults to changes in the copayment is therefore limited mainly 
to patients who hold a concession card.  
 
 One Australian study which focused on general patients modelled the effects of a 
hypothetical 25% rise in the copayment on the purchasing of PBS medicine. It reported 
that general patients were particularly sensitive to copayment increases (Walker, 2000). 
This study modelled a pattern of decline in medicine use by general patients which 
mirrored increases in out-of-pocket cost over time. Although the proportion of general 
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patients is not expected to increase at the same rate as that of concessional patients, this 
finding is significant because changes in medical practice, such as early detection of 
disease and aggressive treatment of chronic diseases, are expected to expose general 
patients to PBS medications earlier in their lives (Richardson, 2005).  
 
Queensland context. 
The research presented in this thesis uses data relating to Queensland patients. 
Queensland’s population of 3,906,535 at the 2006 Census of Population and Housing 
represented approximately 20% of the Australian population (ABS, 2007). About two-thirds 
of the Queensland population live in the urban centres of South East Queensland (SEQ) 
which in 2006 had a population of 2,742,037. The average growth (10.7%) of the 
Queensland population over the period 2001 to 2006 was higher than the national average 
(Roiko et al., 2012). 
 
Because of its pleasant climate, attractive beaches, and the abolition of death 
duties on estates passing to either a spouse or a child in 1978 (Grossman, 1989), 
Queensland has long represented a retirement alternative for individuals from the southern 
states. In 2006, persons aged 65 and over, who were potentially PBS concessional 
patients, represented 12.9% of the Queensland population (ABS, 2007), and showed the 
fastest growth (18%) between 2001 and 2006 compared to those aged under 15 years and 
between 15 and 64 years inclusive (8.2% and 14.2% respectively). While Queensland has 
been attracting large numbers of interstate retirees, the majority of migration to and from 
Queensland over the last 30 years has been by working age people under 60 years of age 
(Barker, 2008). As a result, in 2006 just over half (53%) of the Queensland population 
were aged between 25-64 years inclusive and were most likely general patients in terms of 
the PBS.  
 
The 2006 Census (ABS, 2008c) also reported slightly more females than males in 
the Queensland population (50.4% v 49.6%). The gender difference at this Census was 
much wider in persons aged over 65 years, with females (53.6%) outnumbering males 
(46.1%). The widening gender difference of the Queensland population with ageing can 
partly be explained by women living longer than men. However, it may also be attributable 
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to increased female retiree migration to Queensland, the impact of which could be quite 
significant in terms of health services utilisation and medication use. A longitudinal study 
on women’s health found that, after adjusting for socio-economic and marital status, 
mobility among middle-aged Australian women was positively associated with long-term 
and chronic poor health (Larson, Bell & Young, 2004). This study concluded that as the 
population ages, the health of receiving areas may be adversely affected by relatively 
unhealthy in-migrants seeking amenities not provided in their former place of residence.  
 
Another contributor to the PBS general patient pool in Queensland is overseas 
migration. While Queensland’s overseas migrant intake has historically been well below 
that of other states, there was a turnaround from the late 1990s, with Queensland 
capturing more than 23% of Australia’s net overseas migration between 2002 and 2005 
(Barker, 2008). This proportion peaked at 25.4% in 2004 before declining to 18.9% in 
2007. Many immigrants to Queensland were temporary workers sponsored not so much 
by the mining industry as by employers in healthcare and construction (Barker, 2010). 
Others were New Zealanders who were disproportionately attracted to Queensland, 
capturing more than 40% of the national movement each year since 2003. Irrespective of 
changing trends in interstate migration, overseas migration is projected to continue to be a 
key driver of Queensland's population growth, as will natural population increase. Both of 
the latter scenarios are expected to add to the pool of PBS general beneficiaries in 
Queensland.  
 
National health priority area perspectives. 
The research presented in this thesis will add to the findings of previous research by 
taking a closer look at cost-related changes in the purchasing of PBS medicines for 
chronic diseases which belong to the NHPA. Australian National Health Priority Area 
(NHPA) chronic diseases and conditions include cardiovascular disease, musculoskeletal 
conditions (focussing on arthritis), asthma, mental health (focussing on depression), and 
diabetes (AIHW, 2013a). Collectively these NHPA chronic diseases and cancer account 
for at least 60% of the total burden of disease in Australia, and approximately $20 billion, 
or 42% of allocated health system expenditure (Begg et al., 2007). Results from the 2011-
12 National Health Survey of Australians conducted throughout Australia from March 2011 
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to March 2012 indicated that arthritis, mental health disorders (depression and anxiety), 
hypertension and asthma are the most prevalent long-term chronic conditions, affecting 
about 14.8%, 13.6%, 10.6% and 10.2% of the population respectively (ABS, 2012). The 
same survey found that diabetes affects fewer (4.6%) of Australians aged two years and 
over, but the potential for morbidity from this condition is substantial.  
 
The NHPA chronic diseases and conditions generally require treatment with 
essential chronic disease medications on a daily basis, not only to treat the symptoms but 
also to avert progression to serious complications. In 2004, medications associated with 
cardiovascular disease, musculoskeletal conditions, respiratory system, mental health and 
alimentary tract disorders (which included antidiabetics) accounted for just over three-
quarters of total PBS prescriptions dispensed that year (DoHA, 2007). 
 
Some NHPA chronic diseases, such as arthritis and asthma, additionally require 
discretionary medicines for symptom relief and acute treatment. Other NHPA conditions, 
notably some mental health disorders, require medications with the potential for adverse 
and unpleasant side-effects which affect medication adherence. Therefore, if the 
copayment increase is found to be an additional barrier to the purchasing and adherence 
to chronic disease medications, this could further decrease adherence with the resultant 
effect of increase health expenditure on acute health services. This is the reasoning that 
underlies the need for the research presented in this thesis. 
 
National medicines policy Implications. 
The National Medicines Policy, which provides the framework for policy 
development on medicines in Australia, has stated that easy access to medicines can 
work against the quality use of medications through consumers stocking up unnecessarily 
on prescription medicines when they are available free or at low cost (DoHA, 2000). The 
consumption of stockpiled medications is a health hazard if the directions change or the 
use by date is reached. Additionally if the therapy ceases or is altered, the stockpiled 
medication is wasted.  
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The research for this thesis will profile PBS prescribing patterns at the community 
level. It will provide valuable baseline information on the prescribing pattern of the 
medication classes that comprise six of the nine NHPAs in Australia. Quantification of 
medication prescribing patterns in the general population is important for a variety of 
reasons. First, it may serve as an indirect measure of the burden of NHPA chronic 
diseases in the community. Second, if prescribing patterns vary across sociodemographic 
groups or geographical regions it may serve as a proxy for the ability of the health system 
to meet community health needs. Finally, medication-related hospital admissions remain a 
significant problem in the Australian healthcare system. It has been estimated that 190,000 
medication-related hospital admissions occur every year in Australia, with an estimated 
cost to the health system of $660 million (Roughead & Semple, 2009). For chronic 
diseases such as diabetes, hypercholesterolemia, hypertension and congestive heart 
failure, hospitalization rates and associated medical costs have been found to be 
significantly lower for patients with high medication adherence (Sokol, McGuigan, 
Verbrugge & Epstein, 2005). 
 
In the 2009-10 financial year, almost all (99.5%) cases of accidental poisoning 
cases in Australia were related to medication and other biological substances (Tovell, 
McKenna, Bradley & Pointer, 2012). Of this, about 57% were due to exposure to 
medications which act on the nervous system including antianxiety agents, sedatives and 
hypnotics, antidepressants and opioid analgesics. In addition to misadventures involving 
nervous system agents, about one-quarter of the cases of accidental poisonings were 
associated with a diverse group of chronic disease medications including anticoagulants, 
hypoglycaemics and antihypertensives. This research will provide a snapshot of the 
prevalence of prescription drug abuse, particularly of benzodiazepines and opioids, which 
is becoming a growing problem in Australia (Roxburgh, Bruno, Larance & Burns, 2011).  
 
At the patient level, while the primary aim of the prescription copayment is to control 
the growth in the cost of the PBS by transferring some of the costs to the patient, it is also 
intended to send a price signal to medicine users, minimise inappropriate use and 
wastage, and enhance efficiency (Doran & Robertson, 2011). However, policies that 
provide a disincentive to the stockpiling of medications also have important health and 
safety implications that extend beyond the individual patient, such as deliberate and 
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accidental misuse by third parties, and this study will provide essential information which 
can contribute to the establishment of the optimal balancing point.  
 
Polypharmacy. 
Multiple medication use, or polypharmacy, is prevalent in patients with comorbidities 
requiring the need for many different medications. Although there are several different 
criteria regarding the level of polypharmacy, treatment with three or more medications 
concurrently is considered polypharmacy (Bjerrum, Rosholm, Hallas & Kragstrup, 1997). 
Some studies have used a lower level of multiple medication use, minor polypharmacy, 
which refers to treatment with two to four medications (Werder & Preskorn, 2003), while a 
more serious form of multiple medication use representing the concurrent treatment with 
five or more medications (Hilmer, 2008) has been used in other studies. This latter criteria 
for major polypharmacy, is the one adopted in the research presented in this thesis. 
 
To date, most studies on polypharmacy in Australia have targeted elderly 
institutionalized subjects (See for example, Hubbard et al., 2015; Elliot, 2006; Caughey, 
Vitry, Gilbert & Roughead, 2008). In this population, polypharmacy, defined as a regular 
use of five (5) prescribed medicines or more, has been reported to be associated with an 
increased risk of impaired physical and cognitive function, institutionalisation and 
hospitalisation. These associations appear to be independent of the underlying diseases 
(Hilmer & Gnjidic, 2009).  
 
Very few Australian studies on polypharmacy have used population-based samples, 
age groups other than the elderly, or levels of medication use other than the concurrent 
use of five or more medications (major polypharmacy). This thesis will address this gap by 
providing a profile of the prevalence of both minor polypharmacy and major polypharmacy 
in the community and its associations with age, gender, level of copayment and 
medication type. A second major aim of this thesis is to investigate the effect of a 21% 
across-the-board increase in copayment on both levels of multiple medication use. 
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Objectives of the Study 
 
The three specific aims of this study are to:  
1:  Describe the pattern of PBS medication use prior to a copayment change according 
to age, gender, level of copayment, level of medication use and medication 
characteristics.  
2:  Identify the effect of an unusually large copayment increase on the overall 
purchasing patterns of PBS medications. 
3:  Investigate if a 21% increase in copayment is associated with changes to 
medication purchases according to patient characteristics and the therapeutic class 
of the medication.  
 
Specific research questions are: 
1. Did the copayment increase in 2005 coincide with a change in the volume of 
prescriptions purchased compared to 2004? 
 
2. If there was a change in volume of prescriptions purchased, did it vary according to 
age, gender and the concessional status of the consumer?  
 
3. Did consumers on multiple medications respond differently to the increase in 
copayment? 
 
4. If there were differences in medication purchases between 2004 and 2005, were 
they distributed equally across therapeutic classes of medications, or did some 
classes experience bigger changes in prescriptions than others? 
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Significance of this Research 
 
The findings of this study have implications for patients, research and policy. As 
discussed above, cost is an important factor in the purchasing behaviour of patients. 
However, it is not the sole factor. The literature review presented in the next chapter 
identifies patient, prescriber and medication characteristics, and contextual issues that 
affect consumer behaviour in relation to the use of medications. Understanding these 
relationships will enable clinicians and policy-makers to better design initiatives to 
minimise cost-related nonadherence to PBS medications and to implement copayment 
increases without disrupting timely and affordable access to prescription medications. 
 
Unique features of the research presented in this thesis are: 1) a focus on the 
patient rather than on prescription use; 2) the follow-up of the same cohort of patients, 
rather than two independent groups, over two consecutive years prior to and following 
large increases in PBS copayments; and 3) a focus on both categories of PBS 
beneficiaries, i.e. concessional and general patients.  This research uses a state-wide 
prescription data set which links patient characteristics to medication purchasing to 
examine changes in patients’ purchasing of medications. It is therefore possible to identify 
patient and medication characteristics which may contribute to cost-related changes in 
medication use at the patient level. 
 
Significance of this research to patients. 
Given the wide variation in individuals’ capacity to manage increased out-of-pocket 
costs, copayments may place a potential barrier to timely and affordable access to 
prescription medications. In Australia, copayments for medicines are high by international 
standards. Australia is ranked fourth highest out of 14 OECD countries in terms of out-of-
pocket costs expenses for medicines (Kemp et al., 2011). International research suggests 
that increases in copayments may affect adherence to medication therapy in vulnerable 
populations, such as people on low incomes and multiple medication users. It is a 
particularly serious problem in persons aged 65 years and over because this group of PBS 
consumers are usually low income earners as well as affected by multiple chronic 
diseases requiring therapy with multiple medications (Caughey et al., 2008).  
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Most Australians believe cost sharing is appropriate policy despite many facing 
difficulties with prescription costs. This was found in a recent telephone survey of randomly 
selected prescription medicine users comprising almost equal numbers of concessional 
and general patients. In this survey, 75% of the respondents reported that a copayment 
increase would cause financial difficulties but only 28% indicated this would change their 
medication use (Doran, Robertson & Salkeld, 2011). The authors concluded that although 
most Australian are cost conscious and resistant to making changes to their medications in 
the face of cost increases, further increases in copayment could compromise prescription 
affordability, particularly for general beneficiaries. 
 
Under-use of medications in response to cost pressures has been found in 
analyses of medication use across seven countries, including Australia (Kemp, Roughead, 
Preen, Glover & Semmens, 2010). Australian studies confirm that nonadherence is 
common in older Australians and that cost is one of the reasons given by the elderly for 
intentional nonadherence (Elliott, 2006). It is important to ensure that cost increases do not 
deter patients from purchasing essential medicines, as nonadherence to chronic disease 
medications may lead to unintended effects such as increased doctor visits or 
hospitalizations. The research presented in this thesis provides information about the 
effects of copayment changes on several vulnerable population groups.  
 
The findings of this study have important implications for concessional patients, the 
majority of whom are aged 65 and over and major consumers of NHPA chronic disease 
medications. In Australia nearly 80% of total government subsidies through the PBS are 
spent on concessional patients (Abello, Lymer, Brown, Harding & Phillips, 2008). One of 
the implications of this is that the number of people aged 65 and over are projected to 
double as a proportion of the population, increasing from 13% in 2005 to 27% by 2050 
(Schofield & Earnest, 2006). More importantly, the proportion of persons aged 85 years 
and over, who comprised 1.6% of the population in 2007, is projected to increase to 
between 4.9% and 7.3% by 2050 (ABS, 2008a). These changes are expected to have 
important implications for PBS medication use as well as medication-related costs for 
other parts of the health system.  
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While the PBS medications are provided to concessional patients at low or no 
copayment the “working poor” general patients do not have the same benefits. The 
findings of this research will therefore be important for general patients who comprise 
about 75% of the population and pay a much higher copayment than concessional 
beneficiaries. The number of medications that fall below the general copayment cut-off 
increases with every copayment increase. For example, in 2004 when the general patient 
copayment was $23.70, 12% of all community prescribing was not subsidised as the cost 
was less than the general copayment (Colvin et al., 2009). This included many commonly 
prescribed NSAID, anti-infective, diuretic, benzodiazepine and antidepressant groups of 
medications which were only subsidised to concessional patients who paid $3.80 per 
prescription. In 2008, the number of below-copayment medications increased to 18% of 
PBS prescriptions requiring general patients to pay the full cost (AIHW, 2010a, p.393). 
This represents an increase in 6% in the number of medications on the PBS becoming 
unsubsidised to general patients from 2004 to 2008. 
 
Research on the impact of copayment increases on general patients has been 
limited by a current research focus on the elderly and concessional beneficiaries. While 
the proportion of general beneficiaries is not expected to increase at the same rate as their 
concessional counterparts, a number of changes in medical practice, such as early 
detection, aggressive management and guidelines based treatment for conditions such as 
cardiovascular diseases, are expected to expose general patients to chronic disease 
medications earlier in their lives. Furthermore, a baseline for the prevalence of 
polypharmacy in general patients has not been established. This is a problem because it is 
not possible to monitor the impact of the copayment change on general patients, 
especially those who are affected by multiple medications. The research for this thesis will 
fill this gap by establishing a baseline in 2004 at the minor polypharmacy and major 
polypharmacy levels.  
 
In addition to investigating essential medications for the management of NHPA 
chronic diseases, the research presented in this thesis will examine the impact of out-of-
pocket costs on the use of discretionary medicines for the symptomatic treatment of 
conditions which tend flare up sporadically, such as asthma. It will examine changes in the 
use of these medications in the management of musculoskeletal and respiratory system 
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disorders. Both these conditions require the use of discretionary medications for symptom 
control on a short term basis across all age groups. For adults of working age, the impact 
of copayment increases on the use of discretionary medicines for musculoskeletal 
conditions is an important issue because these conditions cause significant suffering and 
loss of productivity in Australia (AIHW, 2005). When the Australian Bureau of Statistics 
surveyed Australians about their health in 2005, arthritis and back pain were among the 
most common long-term conditions reported by young adults (ABS, 2006a). As working 
age adults form the bulk of the general patient category under the PBS, it is therefore 
important to monitor the potential effects of shifting increased medication costs to this 
group of consumers, particularly when large increases occur, as was the case with the 
copayment change in 2005. 
 
Furthermore, illicit use and trade in prescription medicines is a growing problem 
both internationally and in Australia (see, for example, Inciardi, Surratt, Kurtz & Cicero, 
2007; El-Aneed et al., 2009; Rodwell, Ringland & Bradford, 2010). The World Health 
Organization warns that misuse of prescription drugs could soon exceed that of illicit 
narcotics (Zarocostas, 2007). These activities are the result of easy and affordable access 
to PBS medications and contribute to wasted resources. This research combines 
prescription claims data with sociodemographic information to establish baseline 
information on the prescribing of opioid and benzodiazepines on the PBS, as well as to 
identify the type of patients who are major consumers of these medications.  
 
Medication groups most commonly sought through illicit trade in prescriptions 
medicines are opioids and benzodiazepines (Rigg, Kurtz & Surratt, 2012), the co-use of 
which has been reported to be ubiquitous around the world (Jones, Mogali & Comer, 
2012). Jones et al. (2012) reviewed studies from 1970 – 2012 which examined the 
pharmacological interactions and epidemiology of the combined use of opioids and 
benzodiazepines. They reported that, while the reasons for the co-abuse of these 
medications are not entirely clear, co-users reported seeking benzodiazepine prescriptions 
and using it in doses that exceed the therapeutic range for the purpose of enhancing 
opioid intoxication or “high”. As anxiety disorders are also highly comorbid, particularly with 
alcohol dependence and substance abuse (McEvoy, Grove & Slade, 2011), the co-use of 
benzodiazepines, alcohol and opioids has negative consequences for general health, 
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overdose lethality, and treatment outcome, necessitating the need for increased vigilance 
and more cautious prescribing by doctors. These medication classes will be investigated 
as part of the research for his thesis.  
 
Despite increasing concerns about the abuse potential of prescription medicines, 
particularly benzodiazepines and opioids, little is known about how prescription medicines 
are diverted into illicit use in Australia, the persons engaged in this practice, and 
prescribers who may be facilitating this behaviour. A recent study in the United States 
reported that 10% of all patients prescribed opioid analgesics were prescribed high doses 
and a majority of these patients acquired these opioids from multiple prescribers through 
the practice of doctor or prescription shopping (Jena, Goldman, Weaver & Karaca-Mandic, 
2014). This study also reported men to be more likely to engage in the practice of 
prescription shopping.  
 
This research will also establish baseline information on antidepressant use in 
2004. Antidepressant use has been increasing despite questions regarding the efficacy of 
these drugs in mild to moderate depression (Stephenson, Karanges & McGregor, 2013). 
During 2004 and 2005, antidepressant use was also affected by the Australian 
Government Therapeutic Goods Administration (TGA) notifications of adverse reactions 
associated with some of the newer classes of this group of medications. The most serious 
of these adverse events included serotonin toxicity in 2004 (Adverse Drug Reactions 
Advisory Committee [ADRAC], 2004) and increased tendency for suicidal behaviour in 
young persons in 2005 (ADRAC, 2005a). The current research will be able to assess 
whether the TGA notifications combined with increased copayment affected the 
purchasing of antidepressants, a class of medication important to NHPA for mental health.  
 
Methodological significance of this research. 
According to the World Health Organization, the relationship between medication 
adherence and cost is multifactorial. It is related to social and economic factors, a nation’s 
health care system, characteristics of particular diseases, and patient-related factors 
(WHO, 2003). Solving the problems related to each of these factors is necessary if 
patients’ adherence to therapies is to be improved. As a result, an investigation of 
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consumer response to increases in cost sharing should not be restricted to a single effect 
of the total number of medications purchased, as has been amply reported in Australian 
studies (see for example, McManus et al., 1996; Hynd et al., 2008; Ampon, Reddel, 
Correll, Poulos & Marks, 2009; Hind et al., 2009). 
 
This study will use the theoretically grounded conceptual framework of Piette, 
Heisler, Horne & Alexander (2006) to examine changes in the purchasing of PBS 
medications after an increase in copayment (Figure 1.1). This framework is based on a 
review and synthesis of evidence from a range of studies on the association between out-
of-pocket costs and medication adherence. It provides a conceptual tool to understand the 
influence of patient, medication, clinician, and health system factors on consumers’ 
responses to medication costs. Furthermore, financial pressures and the number and 
complexity of the medication regimen (represented by the thick black lines in Figure 1.1) 
are hypothesised to be the primary drivers of cost-related nonadherence (CRN). 
Moderating effects of other domains on patients’ response to cost pressures (thick 
dashed lines) include doctor, patient and prescription characteristics. Thin dashed lines 
in Figure 1.1 represent possible ways in which clinicians and health systems may buffer 
the effects of medication costs on patients’ self-care and health status. 
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Legend 
Thick black lines represent primary drivers of cost-related nonadherence to medications. 
Thick dashed lines represent moderating effects of other domains on patients’ response to 
cost pressures.  
Thin dashed lines represent ways that the clinician and health system may buffer effects of 
medication costs. 
 
Figure 1.1. Domains and Factors Affecting Responses of Chronically Ill Patients to 
Medication Cost Pressures (modified from Piette et al., 2006) 
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The focus of the Piette et al. (2006) framework on nonadherence to medication 
regimes, rather than on the impact of health benefits schemes on medication purchase, 
makes it possible to adapt and apply the framework to patients in other health care 
settings. This thesis applies that framework to the PBS in Australia as it relates to an 
increase in patient copayment, enabling an examination of a range of factors which have 
an impact on cost-related medication adherence across the health care continuum. These 
include patient-related factors of age and gender (Patient Characteristics according to 
Piette’s framework), level of copayment (Financial Pressures), and the medication-related 
factors of level of medication use (Regimen Complexity) and type of medication (Rx 
Characteristics).  While factors associated with the health system and the clinician are also 
operand in the Australian health care environment and may impact on PBS medication use 
an examination of these is outside the scope of this thesis.  
 
The framework of Piette et al. (2006) has been applied in several studies to 
facilitate understanding of consumer response to cost pressure. Sales et al. (2009) applied 
the framework to assess indicators of adherence to guideline-recommended therapy in 
people with myocardial infarctions (MI). These guidelines related to five evidence based 
therapies associated with MI: aspirin use; beta blocker use; lipid lowering medication use; 
ACE inhibitor use in patients with diabetes and hypertension; and the use of ACE inhibitors 
in patients with chronic heart failure. The authors concluded that the framework was useful 
for two reasons. First, it could facilitate more thoughtfulness about how patients with 
multiple chronic conditions could be treated, and second, it could be used to target patient 
groups or providers for education and knowledge translation activities to promote improved 
adherence to guideline recommendations.  
 
Briesacher, Gurwitz and Soumerai (2007) applied the conceptual framework of 
Piette et al. (2006) to review empirical literature on cost-related risk factors of 
nonadherence to medications. This review identified 19 studies which provided evidence 
that some patients are susceptible to nonadherence, with the strongest link being non 
adherence due to financial pressures, heavy disease burden and symptoms of depression. 
The authors concluded that efforts to reduce cost related nonadherence require a broad 
approach that addresses patient and medication-related factors in addition to the level of 
insurance coverage (copayment). The reviewers also identified older patients with chronic 
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diseases and those with mood disorders as being at-risk of cost-related medication 
nonadherence, even if covered by prescription subsidies.   
 
Significance of this research to policy. 
According to Sansom (1999), one of the roles of government is to ensure that safe 
and efficacious medicines are available for people in a timely manner and that access to 
medications is not denied because of financial barriers. The central question for health 
planners and policy makers is first, how to monitor the implementation of increased cost 
sharing, and secondly, how to make modifications to reduce unintended effects. In order to 
inform policy makers about these issues, this thesis investigates the patterns of medication 
use before and immediately after large increases in the copayments for both general and 
concessional PBS beneficiaries. The findings of this research will provide baseline 
information from which to monitor the impact of future copayment changes on medication 
use.  
 
Evidence from major reviews (see, for example, Lexchin & Grootendorst, 2004; 
Goldman et al., 2007; Austvoll-Dahlgren et al., 2008) consistently show that while caps 
and copayment policies save expenditure on medications, increases in cost sharing and 
patient charges act to decrease the use of essential medications, especially by vulnerable 
groups (Lexchin & Grootendorst, 2004). These studies also report that any potential 
savings from cost sharing policies could well be offset by increases in expenditure on other 
health services.  A degree of sensitivity is therefore required when introducing policies that 
increase financial demands on the patient to ensure that financial pressures do not deter 
patients from purchasing essential medicines. 
 
Programs that promote quality use of medication, improve adherence and reduce 
polypharmacy save money for the health system as well as the patient (Chumney & 
Robinson, 2006). The research presented in this thesis will identify groups affected by 
minor and major polypharmacy across sociodemographic and medication-related 
contextual factors. The World Health Organisation estimates that reducing unnecessary 
expenditure on medicines, using them more appropriately and improving quality control 
could save countries up to five per cent of their health expenditure (WHO, 2010a, p.xvii). 
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Initiatives which are particularly relevant to reducing waste of resources associated with 
polypharmacy in Australia are medication reviews and deprescribing. A recent evaluation 
of the Home Medication Review program concluded that it is effective in improving 
appropriateness of prescribing as well as quality use of medications (Castelino, Bajorek & 
Chen, 2010). 
 
The overuse, underuse or misuse of medications results in wastage of scarce 
resources and widespread health hazards. The WHO estimates that irrational use of 
medicines is an extremely serious global problem that is wasteful and harmful (WHO, 
2012), and that policies are necessary to combat this. In theory, copayments are intended 
to reduce drug expenditure by reducing moral hazards associated with medications 
supplied at reduced or zero cost (Sinnott, Buckley, O’Riordan, Bradley & Whelton, 2013). 
The National Medicines Policy, which provides the framework for policy development on 
medicines in Australia, acknowledges this moral hazard risk and has stated that easy 
access to medicines can work against the quality and rational use of medications through 
consumers stocking up unnecessarily on prescription medicines when they are available 
free or at low cost (DoHA, 2000). Because the community bears the cost of medication 
subsidies, access to medicines should, as far as possible, support the rational use of those 
medicines. This includes disincentives to wastage, stockpiling and inappropriate 
medication use.  
 
The overall aim of the National Medicines Policy (NMP) is to meet medication and 
related service needs, so that both optimal health outcomes and economic objectives are 
achieved (DoHA, 2000). In 2012, a national survey of medication use identified a high 
prevalence of medication use and polypharmacy in older Australians (Morgan et al., 2012) 
as possible barriers to achieving these objectives. However the NMP was originally 
developed almost two decades ago when substantially fewer medications were listed on 
the PBS and medication issues were much less complex. It is therefore necessary to 
revisit and refocus the NMP to ensure that its quality use of medication and economic 
objectives remain realistic and achievable in the current health system environment. In 
addition, to achieving quality use of medications, all components, including consumer 
behaviour, need to be incorporated into a revised national policy for appropriate drug 
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prescription, dispensing and monitoring. This research aims to provide both a snapshot of 
medication purchasing patterns and longitudinal use of medications to inform such policy. 
 
In 1992, the Australian Government adopted a policy on the quality use of 
medicines (Department of Health, Housing and Community Service [DHHCS], 1992). The 
primary aim of QUM is to foster judicious, appropriate, safe and efficacious use of 
medications through a partnership between the consumer, health professionals, the 
pharmaceutical industry and the government. The research presented in this thesis should 
inform policy development based on this collaboration. 
 
Summary of Chapter 1  
 
Evidence that cost influences medication use comes from Australia and other 
countries where the access to medicines by consumers is governed by cost sharing 
arrangements. Research in this area has also found that cost-related differences in 
purchasing patterns are associated with sociodemographic elements, and may vary across 
factors such as levels of cost sharing, level of medication use, and type of medication. 
 
The focus of Australian research to date has been on the type of prescription rather 
than the users of the prescription. The research presented in this thesis seeks to 
investigate the PBS copayment policy from the perspective of the patient rather than the 
prescriber or dispenser of the prescription. It also seeks to clarify the relationship between 
cost sharing and the purchasing of PBS medications at the patient level. This focus is an 
important variation to current PBS policy development as it will enable patient purchasing 
behaviour to drive PBS policy on the demand side rather than change in prescriptions. 
This thesis also seeks to address gaps in the knowledge of the relationship between 
patient and medication-related factors on the purchasing of PBS medicines in response to 
large changes to the copayment, in the general population. 
 
Previous studies on the impact of the copayment on consumer behaviour using 
PBS claims data have investigated modest increases of 2% to 5%. The level of increase 
being investigated in this thesis is 20.7% for general, and 21.1% for concessional patients. 
If an association exists between out-of-pocket costs and consumer purchasing of PBS 
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medicines, then this magnitude of increase is more likely to identify effects missed by 
previous studies. These effects include the impact of copayment increases on essential 
medication use by general patients and the changes in medication use by concessional 
patients using multiple medications.  
 
There are several distinctive features of this thesis: 1) the use of a national 
secondary prescriptions dataset to extract medication purchase data for 13,500 
Queensland consumers; 2) the follow-up of the same cohort of consumers; and 3) the 
focus on the (anonymous) patient rather than on the prescription. This research also 
investigates the immediate impact of one of the largest copayment increases in the history 
of the PBS on the purchasing of medications by both categories of PBS beneficiaries.  
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Definition of Terms 
 
Terms and abbreviations related to pharmacological agents 
ACE: Angiotensin Converting Enzyme, used to treat hypertension. 
ARB: Angiotensin 2 Receptor Blocker, used to treat hypertension. 
Benzodiazepines: Refers to drugs such as alprazolam (Xanax, Kalma), diazepam 
(Valium, Antenex, Ducene, Valpam), temazepam (Normison, Euhypnos, 
Temaze), oxazepam (Serepax, Alepam, Murelax). These drugs are mainly 
used to treat anxiety. 
Brand name drug: A drug manufactured by a specific drug company that is 
trademarked by that company. These drugs are generally patented for a 
certain amount of time, meaning no other drug company can create a 
“generic” version until the patent has expired. 
COPD: Chronic obstructive pulmonary disease 
COX-2: Cyclooxygenase 2. Inflammation causes the induction of the enzyme 
cyclooxygenase-2 (Cox-2) leading to the release of prostaglandins which 
produce localized pain. COX-2 inhibitors are selective NSAID which act by 
preventing the release of cyclooxygenase-2. These drugs are used mainly to 
treat pain and inflammation. 
NSAID: Nonsteroidal anti-inflammatory drug. These drugs are used to treat pain 
and inflammation. 
Proton Pump Inhibitors: Refers to a class of medications used for alimentary tract 
disorders such as ulcers and gastric reflux. 
Prescription medicine: A medicine which can only be supplied after the issue of a 
prescription by a medical practitioner. Prescribed medicines in Australia fall 
into one of three categories: medicines that attract a government subsidy 
under the PBS (PBS benefit medication); PBS listed medicines that do not 
attract a government subsidy, i.e. a medicine that costs below the PBS 
copayment level (below-copayment medication); and prescribed medicines 
not listed on the PBS schedule (private medication).  
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Essential medications: Medicine prescribed to manage chronic diseases. These 
are intended to prevent deterioration in health, or to prolong life, and are not 
likely to be prescribed in the absence of a definitive diagnosis.  
Generic drug: An identical drug to a brand-name drug that is produced once a 
patent has expired. 
Discretionary medications: Medications that are used to manage acute 
conditions. These medications provide relief of symptoms and are less likely 
to have an effect on the underlying disease process. 
Preventer medications: Oral and inhaled steroids that control the underlying 
inflammation in the lungs which is caused by asthma. 
Reliever medications: Bronchodilators which open up the airways and help people 
breathe more easily. 
Serotonin noradrenaline reuptake inhibitor: A class of antidepressant 
medications which act by blocking the reuptake into the brain of serotonin 
and noradrenaline. These are used mainly to treat depression. 
Selective serotonin receptor inhibitors: A class of antidepressant which act by 
blocking the reuptake into the brain of serotonin. These are used mainly to 
treat depression. 
 
Terms used related to the research methodology 
 
Anatomical Therapeutical Chemical (ATC): The PBS Schedule is organised according 
to the Anatomical Therapeutical Chemical (ATC), an internationally recognised 
classification for drugs maintained by the WHO collaborating centre for Drug 
Statistics Methodology in Oslo. The ATC code has five levels from the broadest to 
the most specialised action: 1) anatomical main group; 2) therapeutic main group; 
3) therapeutic subgroup; 4) chemical/therapeutic subgroup; and 5) generic drug 
name.  
Negative ranks: A statistical term which represents the number of patients who reduced 
medication purchases in 2005 compared to 2004.  
PIN:  Personal Identification Number linked to a Medicare number which is unique to 
each patient and does not change on the reissue of the card. 
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Positive ranks: A statistical term which represents the number of patients who increased 
medication purchases in 2005 compared to 2004.  
 
Organization of the Thesis 
 
This thesis is presented in five chapters. The following chapter, Chapter 2, includes 
a review of the literature in the substantive area of medication purchasing behaviour. A 
discussion of the theoretical framework is also included in this chapter. Chapter 3 presents 
the methodology of the research, followed by the results in Chapter 4. Finally, a discussion 
of the results, conclusion and recommendations is presented in Chapter 5. 
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CHAPTER 2. REVIEW OF THE LITERATURE  
  
Introduction 
 
There is ample evidence from Australia and internationally that patient, clinician, 
health system and medication factors play a role in predicting cost-related changes in the 
purchasing and use of medications. Research has also identified that sociodemographic 
and medication factors may interact with cost to influence medication use. The aim of this 
chapter is to critically examine the literature on factors associated with medication use in 
the community, and the evidence on the relationship between cost and the purchasing of 
medications.  
 
Theoretical Framework  
 
This study uses the theoretical framework of Piette et al., (2006) to structure the 
literature review and examine the relationship between cost and medication use.  The 
framework is based on a synthesis of evidence from cross sectional and longitudinal 
studies using claims data from the United States and Canada. Piette et al. conducted an 
extensive literature review and developed the hypothesis that, although the magnitude of 
out-of-pocket costs may vary across health care systems and countries, many of the 
factors which contribute to cost-related changes in medication use in the United States 
and Canada may also apply to patients groups in other countries. This includes Australia.  
 
Piette et al., (2006) found that many patients struggle with both cost related and 
non-cost related problems with regards to their medication. According to their 
conceptualisation, patients’ cost related adherence to prescribed medication is driven by 
financial pressures and the number of medications an individual is prescribed, which in 
turn is affected by multiple contextual factors including patient demographics, 
characteristics of the medication and the mental and physical health of the patient. 
Clinicians and the broader health system also play a role by mediating both the drivers and 
contextual factors of medication purchase. Their framework posits that contextual factors 
may interact with financial cost pressures through:  
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 Interaction between cost and non-cost factors that affect adherence. For example, 
patients with depression have more than twice the risk of cost-related medication 
under-use than those without depression (Piette, Heisler, Krein & Kerr, 2005), 
indicating an interplay between cost and non-cost factors. 
 Sociodemographic variation in cost-related underuse. For example, “non-white” 
Americans are more than three times as likely to report cutting back on medication 
use due to cost than Caucasians (Steinman, Sands & Covinsky, 2001). However 
older patients are less likely to forgo medications when facing cost pressures than 
their younger counterparts (Piette, Heisler & Wagner, 2004a).  
 Short term benefits versus long term outcomes. For example, patients may be more 
cost-sensitive to “reliever” medications for short term relief of asthma and pain 
symptoms compared to medications essential for the prevention of future adverse 
effects such as high blood pressure, heart failure, stroke and diabetes (Goldman et 
al., 2004). 
 Medication side-effects. Medications associated with adverse side-effects which 
may contribute to nonadherence are more likely to be underused when the cost to 
the consumer increases (Gandhi et al., 2000; Gandhi et al., 2003) A number of 
medications currently used in the treatment of nervous system disorders belong to 
this category (Perkins, 2002). 
 
In summary, cost is an important factor in influencing consumer behaviour in 
relation to the purchasing and use of medications. However, it is not the sole factor. The 
synthesis of literature by Piette et al. (2006), identified a number of important contextual 
factors which interact with cost to affect consumer medication purchase. These contextual 
factors can be broadly grouped as: 1) provider factors; 2) health system factors; 3) patient 
characteristics; and 4) factors related to the medication.  
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Provider Factors and Medication Use 
 
Provider factors include the patient-provider relationship, communication about 
medication costs, and availability of generic substitutes. The term “provider” in this case 
includes not only the prescriber, but also other health professionals who provide services 
to a patient including pharmacists and nurses.   
 
Patient-Provider relationship. 
Health care providers are aware that the quality of the health provider-patient 
relationship can greatly affect medication use. Well informed patients have been shown to 
use, require, and better use health professionals’ time as well as consume fewer health 
care resources, including medications (Shaw & Baker, 2004). Bodenheimer, Lorig, Holman 
and Grumbach (2002) reviewed research evidence on the extent to which the chronic care 
model can improve the management of chronic conditions (using diabetes as an example) 
and reduce health care costs. These authors reported that a low cost program for 
promoting health self-management can bring about improvements in health status while 
simultaneously reducing health care costs in a population with diverse chronic diseases. 
There are, however, limits to the efficacy of health self-management. Often the patient is 
not in a position to make an informed assessment of his or her condition or treatment 
options. These include patients with low levels of motivation, or those with cognitive 
impairment. Patients who are unable or unwilling to become involved in the management 
of their condition are often more dependent on the health care provider for the 
management of their illness than those who are (Hepworth, Ahern & Marely, 2012).  
 
For patients who are able to take on a more active role in the co-management of 
their health with their health provider, there are a number of resources to facilitate this. A 
recent Cochrane Review which evaluated the effectiveness of decision aids for people 
facing treatment or screening decisions concluded that decision aids have a positive effect 
on patient-practitioner communication (Stacey et al., 2011). These authors concluded that 
decision aids designed to support patients' decision making by providing information about 
treatment options and associated outcomes enabled the patient to: 1) improve their 
knowledge of the options; 2) acquire more accurate expectations of possible benefits and 
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harms; 3) reach choices that are more consistent with their informed values; and 4) 
increase participation in decision making. However, not all decision aids are applicable to 
all patients. For example, non-English speaking background persons and those who prefer 
to leave decision making to the health care provider may benefit less from decision aids 
(Hepworth et al., 2012) than other patients. 
 
Wilson et al. (2005) studied rates of medication skipping in a sample of Medicare 
beneficiaries in the United States and reported an increase in medication skipping rates 
from 9.5% in 1998 to 13.1% in 2000.  This study found the skipping of medications to be 
associated with several factors, including the quality of the doctor-patient relationship and 
cost of the medication. The authors concluded that a doctor-patient relationship which 
includes discussion of lower cost options helps patients make more informed spending 
decisions. However, this does take time, and some patients do not want to be “forced” into 
making a decision they feel ill equipped to make. For example, while access to generic 
medications assists patients with problems paying for their medications, generic 
substitutes may be declined by patients due to misconceptions about safety and 
effectiveness (Piette, 2009). In cases such as this it might be more cost effective if the 
health provider made a unilateral decision to prescribe generic medications. 
 
On the other hand, there are clinical reasons that a doctor might not initiate 
conversations about lower priced generic medications. Tseng et al. (2010) conducted a 
survey to examine diabetes quality of care in 10 health care plans in the United States and 
found that some cost cutting strategies involve potential trade-offs such as increased 
dosing frequency, risk of adverse effects, or lower treatment effectiveness, and these 
disadvantages could outweigh the benefit for some patients. However the same study also 
reported that some patients with lower income, higher out-of pocket drug costs, and poorer 
health were significantly more willing to discuss trade-offs with their doctors. The authors 
concluded that knowing patients’ willingness to consider such less than optimal cost-
lowering strategies could encourage physicians to discuss drug costs with their patients. 
The doctor-patient relationship, including honesty, trust, and information sharing, may 
support patients to continue to use their treatments effectively despite the cost, improving 
adherence in ways that drug payment reforms cannot (Piette, 2009).  
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Piette (2005) published results from a survey of patients with diabetes to assess the 
relationship between level of physician trust and medication compliance in the face of cost 
pressures. The conclusion was that patients with higher out-of-pocket costs were more 
likely to forgo medications because of cost pressures when physician trust levels were low. 
This highlights the role that trust in the health care provider plays in patient compliance 
with medication regimes, where a positive relationship with the physician can moderate the 
impact of cost pressures. People will generally take more heed of advice proffered by 
someone they trust than from someone they don’t. 
 
Communication about medication costs. 
It is difficult not to overstate the importance of the doctor/patient relationship with 
regards to communication about medication costs. Most health care providers operate with 
the basic assumption that the patient would let them know if they were having problems 
taking their medication as prescribed (White, 2009). This assumption was tested in the 
United States by Piette et al. (2004b) in a survey of 660 adults with chronic diseases. This 
survey found that two thirds of the patients never told the doctor in advance that they 
planned to underuse medication because of the cost, and one-third never even discussed 
the issue with the prescriber at all. The main reasons for this were that a majority (66%) 
were not asked by their doctors about their ability to pay for the prescriptions. Further, 
more than half (58%) did not think the providers could help them, and 46% were too 
embarrassed to discuss it.  
 
These findings complement the findings of another study which surveyed a sample 
of doctors and their patients in community practices to examine barriers which prevent 
patient-physician communication about out-pocket-costs (Alexander, Casalino, Tseng, 
McFadden & Meltzer, 2004). Among patients the main barriers reported were discomfort, 
insufficient time, belief that the doctor did not have a viable solution, and concerns about 
the impact of the discussion on the quality of care. Among doctors the main barrier 
reported was insufficient time, which was reported by two-thirds of the sample, and the 
belief that they did not have a solution to offer. The authors concluded that strategies to 
address these barriers to the discussion of out-of-pocket costs should emphasize the 
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legitimacy of patients’ concerns and actionable alternatives that physicians can take to 
address them.  
 
One of the challenges for physicians in following this strategy is their own 
awareness of the factors associated with patients’ concerns about medication costs. Allan, 
Lexchin and Wiebe (2007) conducted a systematic review of literature to investigate 
doctors' knowledge of the relative and absolute costs of medications, and to determine the 
factors that influence awareness. This study found that doctors’ “cost accuracy” was low, 
with 31% underestimating the true cost of the medication by 20% or 25%, and fewer than 
50% being accurate by any definition of cost accuracy. An important pattern was doctors 
consistently overestimating the cost of inexpensive products and underestimating the cost 
of expensive ones. The authors concluded that doctors demonstrated a lack of 
appreciation of the large difference in cost between inexpensive and expensive drugs, and 
that the discrepancy in turn could have profound implications for overall drug expenditures 
for individual patients, and render as problematic meaningful conversations about 
medication costs with patients.  
 
The literature suggests two main factors for doctors’ lack of appreciation of costs. 
One factor is that the doctors simply do not include cost in their medication therapy plan 
for their patients because of uncertainty about prices, cost-sharing arrangements and 
future medical cost (Riggs & Ubel, 2014).  Pham, Alexander and O’Malley (2007) analyzed 
data on 6,628 patients and found that doctors do not routinely consider patients' out of 
pocket costs when making decisions regarding more expensive medication therapy. This 
could partly be due to reluctance to trade off less benefit for lower cost (Riggs & Ubel, 
2014).  Similarly, Patel, Coffman, Tseng, Clark and Cabana (2009) surveyed pediatricians 
and family physicians and asked if cost was a barrier to prescribing new asthma 
medications to children. Half of the doctors reported that they did not ask their patients 
about drug costs when they prescribed medication. However, it is possible that this 
percentage is conservative, due to the tendency by doctors to underreport actions that 
paint them in a negative light and over-report socially desirable ones (Krumpal, 2013) in 
order to present their prescribing practices in the best possible light.  
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The second factor contributing to doctors’ lack of consideration of medication cost is 
that the doctor may not appreciate the effect of patient beliefs regarding copayment. 
Kurlander, Kerr, Krein, Heisler and Piette (2009) suggest that willingness to pay needs to 
be distinguished from ability to pay. Unwillingness to adhere to prescribed medication is 
affected by factors such as dissatisfaction with some aspect of the medication such as 
information about the purpose of the medication, rather than the cost of medications. 
Kurlander et al. (2009) recommend that physicians and other health care providers ask 
patients specifically about which, if any, of their medications they have difficulty paying for. 
For patients who report difficulty in paying for only selected medications, providers need to 
further probe beliefs about prescription drugs, knowledge about their illness and 
medication-specific concerns.  
 
Use of generic and over-the-counter medications. 
Policies for increasing uptake of generic substitutes were created to decrease health 
care spending at the population level. They also result in lower out-of-pocket costs for 
patients because less expensive drugs are favored. However physicians influence out-of-
pocket costs by not prescribing cost-effective medications. Piette et al. (2004b) found that 
when patients talked with clinicians about medication costs, 31% reported that their 
medications were never changed to a generic or less expensive alternative, and few 
patients were given other forms of assistance such as information about programs that 
help pay drug costs (20%), or where to purchase less expensive medication (28%). This 
indicates that doctors, at least in the United States, do not usually respond to the problem 
of high prescription cost by prescribing generic substitutes or changing to lower cost 
alternatives.  
 
Research from the United Kingdom suggests that increases in the copayment may 
have a flow on effect on the use of over-the-counter medicines, particularly for those 
required to make a higher copayment contribution. For example, in Wales where 
copayment for prescription medicines was abolished in 2007, there was a statistically 
significant (p = 0.03) rise in the number of prescription items purchased, and a statistically 
significant fall (p = 0.02) in the number of non-prescription medicines purchased (Groves 
et al., 2010). These authors also reported a fall in nonadherence between the pre- and 
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post-abolition periods. Interestingly, the age group most associated with the increase in 
prescriptions was 45-59 years. In the Australian PBS environment, these groups would 
represent working age general patients who pay a copayment about six times higher than 
concessional beneficiaries. Similarly, patients who reported a fall in non-prescription 
medications were males, persons aged 25-34 years and those with a higher household 
income. These characteristics are also characteristics of Australia’s general (i.e., non-
concessional) PBS patient pool. 
 
Increasing adoption of lower-cost generic medications plays a key role in cost 
containment for government, as well as in increasing affordable access to medicines for 
the patient. The World Health Organization estimates that the use of expensive medicines, 
when cheaper, equally effective generic options are available, is a major contributor to 
inefficiencies and wasted resources in the health sector (WHO, 2010a, p.64). In Australia, 
pharmacists have played an important role in facilitating the uptake of generic medicines 
on the PBS. Since the introduction of generic substitution at the pharmacist level in 
December 1994, the proportion of PBS prescriptions dispensed at the benchmark price 
compared to the brand price has increased markedly (McManus, Birkett, Dudley & 
Stephens, 2001).  
 
Access to generic medicines may also address the problem of nonadherence and 
promote compliance with the medication therapy in the face of increases in user charges. 
For example, Tamblyn et al. (2001) and Lexchin and Grootendorst (2004) found patients 
faced with high levels of cost sharing may not discontinue or reduce therapy, but are more 
likely to switch to non-prescription medicines or cheaper generic brands. Saito, Davis, 
Harrigan, Juares and Mau (2010) analysed utilisation of medication at five levels of patient 
copayment (<$5; $5; $5-$15; $15; and >$15) for patients with Type 2 Diabetes, and found 
that each $5 increase in copayment was associated with an increased rate of switching to 
drugs of equal or lower cost. The authors concluded that cost sharing can shift patients 
with diabetes towards use of less expensive drugs and that clinical and sociodemographic 
factors also play a role in the switch to less expensive medications. Paradoxically, 
increasing demand for generic medications may be an incentive for manufacturers to 
increase their price, thereby removing this cost benefit option from the patient.  
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Health System Factors and Medication Use 
 
The second, broad contextual factor that interacts with cost to influence consumer 
purchasing and use of medications is related to the health system, and includes policies 
regarding pharmaceutical financing, copayment legislation, and provider initiatives. The 
purpose of these initiatives is to keep expenditure on medications under control and 
promote cost-effective use of medications. However, some of these may have unforeseen 
flow-on effects on the consumer’s ability to pay. 
 
Pharmaceutical financing policies. 
There is ample evidence in the international research literature that copayment 
policies influence medication adherence. Hirth, Greer, Albert, Young and Piette (2008) 
examined drug costs and adherence in similar patient cohorts across 12 countries using 
representative samples of haemodialysis patients. The authors examined out-of-pocket 
medication spending and cost-related nonadherence and found that the proportion of 
patients reporting nonadherence because of cost ranged from 3% in Japan to 29% in the 
United States. The explanation provided for difference in cost-related nonadherence 
between countries was that out-of-pocket spending was related to national pharmaceutical 
financing policies and predicted national nonadherence rates. 
 
There is also evidence that caps and copayment policies reduce government 
expenditures on medicines at the expense of reduced medication use, particularly for 
patients with chronic illness. This was the conclusion of a Cochrane review (Austvoll-
Dahlgren et al., 2008) which analysed data from 21 studies including randomised clinical 
trials, non-randomised control trials, interrupted time series analyses, repeated measures 
studies and controlled before-after studies of copayment policies. The review concluded 
that the reduction in medications for the treatment of chronic conditions may increase use 
of other health care services and overall expenditure. In Australia, with free public 
hospitals, the savings made by increased patient copayments could be more than offset by 
the cost of free (to the patient) hospital admissions resulting from inappropriate medication 
use.  
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In Australia, public hospitals are jointly funded by the state and territory 
governments and the Federal Government (AIHW, 2013c, p.7), while medications suppled 
through community pharmacies are subsidised on the PBS by the Federal Government. 
This environment of multiple funding sources may encourage cost shifting which not only 
undermines the quality use of medication objectives of the National Medicines Policy but 
also has important continuity of care implications (McLachlan, 2014). For example, a 
patient with neuropathic pain admitted to a public hospital can be offered gabapentin, an 
off-patent drug with a number of alternative brands enabling the hospital to negotiate the 
best possible price for the patient. When discharged from hospital the patient is unable to 
obtain gabapentin at a subsidised price as gabapentin is only subsidised on the PBS for 
the “treatment of partial epileptic seizures which are not controlled satisfactorily by other 
anti-epileptic drugs” (DoHA, 2014c). Hence, subsidised access to gabapentin for 
neuropathic pain is only available when a patient is admitted to public hospital or presents 
to the hospital emergency department. Pregabalin, on the other hand, a therapeutically 
equivalent drug, is subsidised on the PBS for neuropathic pain (DoHA, 2014d). Being the 
only brand on the Australian market, pregabalin costs more than gabapentin.  However, a 
public hospital with access to PBS-subsidised medications is likely to stock and offer their 
inpatients pregabalin for neuropathic pain with the cost being borne by the Federal 
Government.  
 
Legislation regarding copayment for medication. 
In the event that increased subsidies may motivate some consumers to acquire 
more medications than they normally may consume, there are policies which impose 
barriers to refilling of prescriptions within a specified time in order to reduce this risk. This 
is evident from a comparison of PBS utilization data in Australia before and after the 
implementation of a policy to discourage the stockpiling of PBS medicines after the safety 
net threshold is reached by the patient. As discussed in the previous chapter, patient 
copayments are subject to a safety net threshold which allows for a reduction in the 
copayment once the total cost incurred by the patient during the calendar year exceeds 
the amount set as the safety net threshold for that year. Therefore, once a general patient 
reaches the safety net threshold for general patients the copayment becomes the same as 
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that for a concessional patient for the rest of the year (See for example, Donnelly, 
McManus, Dudley & Hall, 2000; McManus, 1993).  
 
For a concessional patient there is no copayment (except for brand price premium) 
once the Safety Net level is reached. For these patients, the safety net scheme, which 
operates over the calendar year, introduced a disproportionately high number of repeat 
prescriptions being filled towards the end of the safety net year (McManus, 1993). In 
response to this, legislation was introduced in 1994 which increased the minimum re-
supply interval for a repeat dispensing for chronic disease medications from three to 20 
days, and medications for acute conditions from three to four days. This measure was 
associated with a significant decline in the December peak in PBS medicine supply 
(Donnelly et al., 2000). However, Donnelly and colleagues also found that the initial impact 
of the policy in reducing stockpiling and hoarding was not sustained over time. As a result, 
a new policy initiative, the 'Safety Net 20-day Rule’, was implemented in 2006 for selected 
PBS chronic disease medications. This measure included a financial penalty to prevent 
persons on the Safety Net Card stocking up on additional supplies of their medicines at the 
end of a calendar year (Department of Human Service [DHS], 2014).  
 
While the revised policy has not been formally evaluated for its impact as a 
disincentive to stockpiling, its implementation shows that appropriate policy and supporting 
legislation can act as a barrier to inappropriate medication use. However, while saving 
money on government expenditure on the PBS, this policy may provide an additional 
barrier to PBS medicines for some patients by reducing the number of cheaper medicines 
that can be purchased at the end of the calendar year (Kemp et al., 2011). According to 
the National Association of Practising Psychiatrists, this policy would be “unintentionally 
punitive and perhaps discriminatory” against psychiatric patients who are more likely to 
unintentionally misplace their medications (Limprecht, 2005).  The policy’s impact on 
financially challenged and vulnerable groups such as the elderly, rural residents, and 
persons with mental health issues may need regular monitoring to ensure that the timely 
access to essential medications to these sub-groups of PBS beneficiaries are not 
compromised.  
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Provider incentives. 
Health sector incentives directed at health care providers have the potential to 
provide savings to the health system through improved efficiencies and optimising value 
for money (AIHW, 2014). Important provider incentives in Australia with the potential to 
influence medication use include evidence based clinical guidelines and written action 
plans, for example, for asthma, and medicines review for aged persons living in the 
community and aged care institutions. In the case of the medicines review, the incentive 
has the potential to influence medication consumption and save costs. However the 
sustainability of the medicines review and asthma practice incentives is limited by funding 
constraints, doctors being too busy with other clinical priorities and lack of coordination 
between the doctor and the pharmacist. All these issues highlight the importance of not 
only rectifying the mismatch between evidence and policy development needs but also 
addressing barriers to the adoption of policy incentives by health care providers. 
 
Other health sector incentives such as clinical guidelines are a familiar part of 
medical practice in Australia, as is the case with most other first world countries. In 
Australia, clinical guidelines have been implemented to facilitate best practice as well as 
change prescribing behavior (Weekes, Mackson, Fitzgerald & Phillips, 2005). Clinical 
guidelines can indirectly provide benefits to the patient by influencing public policy 
regarding delivery of services to neglected patient populations and high risk and 
marginalised groups (Woolf, Grol, Hutchinson, Eccles & Grimshaw, 1999). Furthermore, 
guidelines may be effective in improving the efficiency of health care resources. For 
example, the implementation of certain guidelines may improve outlays for hospitals and 
prescription drugs, and free-up scarce hospital resources for surgery and important 
procedures.  
 
This positive effect of guidelines is evident in the case of asthma, which is one of 
the Australia’s chronic disease health priorities. The introduction of evidence-based care 
and general practitioner (GP) incentives, such as the Asthma Cycle of Care, GP 
Management Plans and Team Care Arrangements, has contributed to a reduction in 
hospital admissions (Rudolphy, 2008). However, a recent investigation of the quality of 
primary care asthma management in Australian general practices identified a number of 
gaps in the provision of evidence-based care (Barton et al., 2009). This raises doubts 
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about whether the simple dissemination of guidelines is more effective than other 
interventions and incentives in changing medical practice. Addressing these gaps has 
important implications in preventing asthma complications and hospitalisations. They 
include the use of preventer (inhaled corticosteroids) medications which have been shown 
to be effective in controlling the symptoms of asthma and in preventing complications 
(Rowe, Spooner, Ducharme, Bretzlaff & Bota, 2008).  
 
However, while research has shown that programs that assist doctors to improve 
their prescribing result in statistically significant reductions in the number and doses of 
medications (Bolton, Tipper & Tasker, 2004), the extent to which clinical guidelines can 
improve efficiency remains unclear. Most guidelines have a one-size-fits-all mentality and 
do not build flexibilities and contextualisation into the recommendations (Shaneyfelt, Mayo-
Smith & Rothwangl, 1999; Boyd et al., 2005). To ensure that advice is clinically relevant 
and applicable, the information must be contextualised to reflect the reality of everyday 
clinical situations, including comorbidities, patient characteristics and the affordability of 
treatment options. These issues, particularly affordability of medications, tend not to be 
considered in the development of the guidelines for Australia’s NHPA medical conditions.  
 
Clinical guidelines have other limitations which may have an impact on the 
affordability of medications. The evidence on which clinical guidelines are based usually 
stems from randomized clinical trials or meta-analyses, which are often biased by the 
exclusion or under-representation of elderly people, especially those affected by 
multimorbidity and polypharmacy (see for example Tinetti, Bogardus & Agostini, 2004; 
Rehman, 2005; Lang & Lidder, 2010; Cherubini et al., 2011). Often clinical guidelines are 
too narrowly focussed on a single disease (Shaneyfelt & Centor, 2009), with the decision 
to prescribe being based on guideline recommendations for each single disease or clinical 
problem (Tinetti et al., 2004; Tinetti & Studensky, 2011). These limitations make them 
ineffective in providing guidance for managing polypharmacy, especially in those aged 65 
and over who have multiple medical conditions. Paradoxically, focussing on possible 
combinations of multiple illnesses could significantly add to the complexity of the clinical 
guidelines (Shaneyfelt & Centor, 2009), making them impractical as well as costly.  
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This limitation to clinical guidelines has been addressed in Australia through the 
provision of a formal review of patient medications, although this is optional and initiated 
by the doctor, who may not choose to avail him/herself of this service. Prescribers have 
the option of referring a patient to a pharmacist for a medication review through the Home 
Medicines Review (HMR) and Residential Medication Management Review (RMMR) 
programs. The National Prescribing Service, which provides evidence-based information 
to health professionals, defines the medication review as “a retrospective critical review of 
all prescribed, over-the-counter, and complementary (herbal) medications” with the aim to 
“optimise therapy and minimise medication-related problems” (NPS, 2000). This health 
sector incentive has been found to be effective in addressing concerns such as 
polypharmacy and quality use of medications. A recent evaluation has demonstrated that 
the medication review process was meeting these aims (Castelino et al., 2010). It also 
found that the provision of medication reviews by accredited pharmacists can improve the 
appropriateness of prescribing and assist in optimizing medication therapy in older people. 
 
In addition to reducing inappropriate medication use, health sector initiatives 
directed at the providers have the potential to buffer the impact of cost-related 
nonadherence in at-risk patients. This was evident for the RMMR especially when an 
additional incentive, introduced in November 2004, enabled the referring doctor to claim a 
scheduled fee for initiating RMMRs and collaborating with a Pharmacist accredited in 
providing RMMRs in facilitating them (DoHA, 2010). A recent review of the RMMR service 
concluded that doctors find the service to be most useful in providing recommendations for 
ceasing medications and decreasing dosages (DoHA, 2010), both of which may reduce 
polypharmacy as well as medication cost. However, medication reviews are only available 
to patients aged 65 and over, the majority of whom are concessional patients which, while 
being extremely beneficial for the patients, provides limited financial benefits to the 
Government. General patients with chronic illness on multiple medications are not eligible 
for this service at all. 
 
While there are many evidence-based guidelines to help clinicians start drug 
treatment, there is much less evidence to guide clinicians about withdrawing medications. 
The term deprescribing might be new to prescribers, but the concept is not. It is defined as 
a process of tapering or stopping unnecessary and harmful medications (Hardy & Hilmer, 
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2011), with the goal of minimising polypharmacy and improving outcomes (Scott, 
Anderson, Freeman & Stowasser, 2014). Deprescribing  is documented in the World 
Health Organisation (WHO) Guide to Good Prescribing, and embodies quality use of 
medication (QUM) principles, namely, the safe, judicious, effective and cost effective use 
of medications (de Vries, Henning, Hogerzeil & Fresle, 1994). The principles of 
deprescribing include: 1) reviewing all current medications; 2) identifying medications to be 
ceased, substituted or reduced; 3) planning a deprescribing regime in partnership with the 
patient; and 4) frequently reviewing the medications (Woodward, 2003).  
 
While the benefits of deprescribing for specific medications may not translate to all 
medications, deprescribing in selected cases can be done safely and may result in 
benefits to patients (Iyer, Naganathan, McLachlan & Le Couteur, 2008). These benefits 
include reduction in polypharmacy and associated adverse effects, and cost saving to the 
consumer. However, unlike medication reviews, there are no formal health sector 
incentives in Australia to facilitate deprescribing.  A recent Australian study of 
polypharmacy among 1,216 inpatients aged 70 years and over found that three-quarters of 
the patients were using five medications or more, and one-fifth, ten or more medications 
on admission (Hubbard et al., 2015). This study also reported that there was no clinically 
meaningful change to the number or type of medications by treating physicians during the 
admission. This represents a lost opportunity not only in improving quality of medication 
use but also in reducing waste in government medication expenditure.  
 
A feasibility study to reduce polypharmacy in community-dwelling older adults found 
that over half of their medicines could be discontinued with a resultant improvement in 
cognition and overall health (Garfinkel & Mangin, 2010). Extending the scope of existing 
health sector initiatives such as HMRs and RMMRs to include deprescribing gives the 
pharmacist the opportunity to collaborate with the prescriber and patient to minimise 
wasteful and unnecessary health expenditure to both save money and reduce medication-
related adverse outcomes. 
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Patient Characteristics and Medication Use 
 
In addition to provider and health system factors, the conceptual framework of 
Piette et al. (2006) identified factors related to the patient and the medication which can 
also interact with cost to affect medication use. These are patient-related factors of gender 
and age which are not modifiable, and others such concessional status (for concession 
card holders or non-welfare recipients), and medication-related characteristics (i.e., level of 
medication use, perceived risks and benefits of the therapy, type of medication) which are 
modifiable to varying degrees (see for example, Steinman, Sands & Covinsky, 2001; 
Lexchin & Grootendorst, 2004; Goldman et al., 2004; Klein, Turvey & Wallace, 2004; 
Gibson et al., 2005a; Safran et al., 2005; Wilson et. al., 2005; Goldman et. al., 2007; Zivin, 
Ratliff, Heisler, Langa & Piette, 2010).  
 
The elderly and the chronically ill are particularly sensitive to cost-related changes 
to medication use according to longitudinal studies conducted in North America by 
Tamblyn et al. (2001); Schneeweiss, Maclure and Soumerai (2002); and Piette, Heisler 
and Wagner, (2004a). Evidence from a cross-sectional population health survey from 
Australia (Deussen, Taylor, Wilson, & Hiller, 2001) has also identified associations 
between the purchasing of medicines and age, gender and income level (proxy for 
payment category under the PBS), with females, young adults and people on low incomes 
reporting cost as a barrier to accessing medicines more than the other groups surveyed. In 
the United States, a national internet survey conducted after the implementation of 
Medicare Part D among 27,302 participants found more than one-third of the respondents 
aged 65+ who were working or looking for work to be affected by cost-related non 
adherence (Piette,  Rosland, Silveira, Hayward & McHorney, 2011). This internet survey 
also found that among younger respondents aged 40–64 and looking for work, 66% 
reported CRN in 2008. That the survey was conducted during the start of the financial 
crisis indicates that the prevailing economic climate may have eroded some of the early 
benefits of Medicare Part D (Piette et al., 2011). 
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Gender. 
In Australia, women account for a higher number (56%) of consultations with the 
general practitioner than men (Britt et al., 2010). This phenomenon is related to both 
biological and socio-cultural factors. While it is generally true that in most societies women 
live longer than men, it is also the case that women tend to be more affected by long-term 
and chronic illness, which significantly affects their quality of life (Abdelaziz, 2007), and 
take more medications than men for most medication groups except CVD medications 
(Loikas, Wettermark, Von Euler, Bergman & Schenk-Gustafsson, 2013; Zhong et al., 
2013).  
 
While the burden of medication use starts early for females and is the widest 
around puberty, the gender differences actually narrows with increasing age (Roe, 
McNamara & Motheral, 2002). But, as women live, on average, four to five years longer 
than men (Eskes & Haanen, 2007) medication cost burden for them lasts longer and 
continues into older age. This gender imbalance in medication use, however, is not a 
universal pattern. Haug et al., (2005) report that, contrary to the research discussed 
above, female patients who were HIV positive and in a methadone maintenance regime 
did not differ from males in their adherence to antiretroviral medications. This indicates that 
the presence of a life threatening medical condition may play a part in narrowing the 
gender difference in medical consultations and medication use.  
 
Gender differences in medication use could also be the result of women accruing 
chronic diseases associated with ageing (Payne, Neutel, Cho & DesMeules, 2004), as a 
result of living longer than men.  At the other end of the age continuum there is also 
evidence that younger women use more prescription medicines then men, including 
analgesics, antidepressants and antianxiety agents, especially after and around puberty 
years, (Roe et al., 2002). A recent German study of sex differences in the treatment of 
chronic diseases also reported that women use more prescription medications than men, 
but on average, prescriptions for men were 14%–26% more expensive than prescriptions 
for women (Stock, Stollenwerk, Redaelli, Civello, & Lauterbach (2008). The authors 
explained this latter finding to differences in treatment patterns for cardiovascular diseases 
(CVD), for which men were treated with different drug classes compared with women. 
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Gender differences in medication use could also be explained by women redeeming 
(filling) prescriptions more often than men and, in general, being more compliant with 
medication therapy (Hagström, Mattsson & Gunnarsson, 2004). This, coupled with a 
higher prevalence of chronic diseases puts women at a higher risk of nonadherence to 
medications due to cost (Heisler, Piette & Wagner, 2005).  The increased use of 
medications by women, however, is mitigated to some extent by cardiovascular 
prescription patterns. For example, Roe et al. (2002) found that with the exception of 
diuretics, men start using cardiovascular medications at an earlier age than women. These 
authors also found that the use of female hormones represents only a small proportion of 
the difference in total medication use between genders. 
 
Chronic conditions with a higher prevalence in females include painful 
musculoskeletal conditions such as arthritis, which was reported in the latest Global 
Burden of Disease study to account for 15% of the total burden of disease in Australia 
(Smith et al., 2013). The same study reported the prevalence of low back pain to be higher 
in women, peaking in adolescence and at age 65. The Australian Institute of Health and 
Welfare has reported that while arthritis is more common among men than women aged 
25-44, its prevalence is higher among women in all older age groups (AIHW, 2010b, p.3). 
For other common pain conditions, including migraine and tension-type headache, facial 
pain, myalgia and abdominal pain, population-based studies and major reviews indicate 
higher prevalence rates in adult women than in adult men (Fillingim, 2000; Richardson & 
Holdcroft, 2009).  
 
Munce & Stewart (2007) investigated gender differences in the prevalence of 
depression in four chronic pain conditions and pain severity indices in a national United 
States adult database (n = 131,535). These authors found one-third of the population 
(32.8%) had a chronic pain condition (fibromyalgia, arthritis/rheumatism, back problems, 
and migraine headaches). The prevalence of depression in women (9.1%) was almost 
twice that of men (5%). Furthermore, the prevalence of depression in individuals with 
chronic pain conditions was 11.3%, compared to 5.3% in those without. In short, women 
reported higher rates of chronic pain conditions, higher pain severity, and depression 
compared to men. The authors concluded that depression and chronic pain conditions 
represent significant sources of disability, especially for women.  
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Women in Australia have also been reported to be affected by depression more 
than men, with the highest levels of depression, both major and other, being observed 
among females aged 15-29 years (Hawthorne, Goldney & Taylor, 2008). That study 
reported that poor overall health status was the strongest predictor of depression, 
suggesting that depression in Australia could be a comorbid condition with other NHPA 
chronic diseases and conditions. This has cost implications regarding medication use, 
particularly for women. 
 
The research literature has identified that sociocultural differences also provide an 
explanation for women’s greater use of medications. For example the use of pain 
medications can partially be explained by gender differences in the perception of pain 
(Payne et al., 2004). It also appears likely that gender affects pain conceptualizing and 
reporting behaviours (Richardson & Holdcroft, 2009). For example, while the likelihood of 
health conditions requiring medications may not differ by gender (Obermeyer et al., 2007), 
the reporting of health symptoms and conditions related to body aches, as well as 
psychosomatic conditions is higher among women than men (Möller-Leimkühler, 2002; 
Obermeyer et al., 2004; Obermeyer et al., 2007) which can be attributed to a discrepancy 
between perception of need, attitudes regarding health and help-seeking behaviours 
(Obermeyer, Price, Schulein, Sievert & Anderton, 2007).  
 
Women’s higher reporting of health conditions can also be attributed to women 
communicating with each other more than men, enabling them to draw on a richer 
repertoire of knowledge, perceptions and attitudes regarding medications (Obermeyer et. 
al., 2004). In a more recent study on health seeking behaviours, Obermeyer et al., (2007) 
found networks based around females, which comprised mostly friends and relatives, to be 
an important source of advice on medications for both men and women. This latter study 
also reported women more likely to be taking five or more medications in the month (major 
polypharmacy) than men.  Multiple medication use and its correlates are discussed in 
more detail later in this chapter.  
 
Gender differences in medication use could also be related to women using the 
health system more than men, providing them with additional opportunity to be assessed, 
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diagnosed and prescribed a medicine (Vaidya, Partha & Karmakar, 2012). Men have been 
shown to be less likely to seek preventative health care in particular (Pinkhasov et al., 
2010). This is despite men being more likely to be regular and heavy alcohol drinkers, 
heavier smokers who are less likely to quit, greater illicit drug users, and more overweight 
compared to women (Pinkhasov et al., 2010). 
 
This demonstrates that, compared with women, men’s fewer interactions with the 
health system cannot be explained by their better health, but rather by a discrepancy 
between perception of need and help-seeking behaviour. It can be argued that social 
norms of traditional masculinity make help-seeking by men more difficult (Delenardo & 
Terrion, 2014; Sullivan, Camic, & Brown, 2015). This could be partly because of the 
inhibition of emotional expressiveness which influences men’s perception of health and 
wellbeing (Tyler & Williams, 2014).  
 
Help-seeking patterns in men are consistently lower than in women, especially in 
the case of emotional problems and depressive symptoms (Möller-Leimkühler, 2002). Men 
may also regard the doctor’s office as unfamiliar and male unfriendly territory making it 
difficult to negotiate (Banks, 2001). The gender imbalance among medical practice staff in 
favour of female nurses and receptionists may also be embarrassing for men, especially 
those with sexual or mental health issues (Banks, 2001).  
 
Gender differences in medication use could also be the result of differences in the 
attitudes and beliefs of healthcare providers. For example, unsubstantiated beliefs that 
women have a higher pain threshold and are better able to tolerate pain pervade both lay 
and medical communities (Richardson & Holdcroft, 2009). There is also evidence that at 
least some medical practitioners attribute the aetiology of pain differently. In a frequently 
cited (but dated) study, women were reported to be more likely to be given sedatives for 
their pain after cardiac surgery while men were more likely to be given analgesics 
(Calderone, 1990). More recently, in the emergency department, women were less likely 
than men to receive analgesics for abdominal pain (Chen et al., 2008). Paradoxically, rates 
of substance abuse involving pain medications are significantly higher for men than 
women, except for tranquilizers (Cotto et al., 2010).  
 
51 
 
In summary, the research literature indicates that the gender based pattern of 
medication use is more complex than can be understood by broad generalisations based 
on the total amount of prescription medicines being purchased and used by one gender or 
the other. Factors that have been found to have an effect on gender based patterns of 
medication use include biological and socio-cultural factors. 
 
Age. 
It is generally accepted that the use of medications for chronic conditions increases 
with age for both genders, although the pattern may vary with the medication. For 
example, Zhong et al., (2013) analysed changes in prescribing with age and found that, 
while the prescribing of most medications generally increased with age, the rate of 
increase varied according medication types. For example, antibiotic prescriptions were 
higher in children, decreasing in young adults, then increasing with age. However 
antidepressants, narcotic analgesics, gastrointestinal medications and cardiovascular 
prescriptions increased sharply with age. By contrast, prescriptions for reliever and 
preventer asthma medications remained stable across all age groups. Zhong et al., (2013) 
also reported very little difference in medication use in younger and older children and 
adolescents less than 19 years old, except for central nervous stimulants which were more 
commonly prescribed to boys than girls in this age group. Antidepressants, oral 
contraceptives and narcotic analgesics were more commonly prescribed to young and 
middle age adult females, and cardiovascular disease medications were most commonly 
prescribed to older adults aged 65 and over.  
 
Multiple medication use also increases with age. A national postal survey of 
Australians aged 50 and over found that 87% of respondents used at least one medicine 
on the day of the survey (Morgan et al., 2012). The survey also found that one-third of the 
respondents aged 50-64 years, almost half of the 65-74 year olds, and two-thirds of 
persons aged 75 and over were taking five or more medications. Other studies have found 
that nine out of ten persons aged 65 and over take at least one prescription medication, 
and approximately five in ten take more than four medications on a regular basis (Byles, 
Heinze, Nair & Parkinson, 2003; Goldney & Fisher, 2005). These findings indicate that 
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persons 65 and over who are prescribed multiple medications for chronic conditions could 
be spending a high proportion on their income on medications. 
 
Not surprisingly, given this latter finding, advanced age is associated internationally 
with nonadherence to medication. The research evidence is that this phenomenon is due 
primarily to the number of conditions and medications elderly patients require and the 
complexity of the medication regime. For example, Kennedy, Tuleu & Mackay (2008) 
reported that most Medicare beneficiaries in the United States fill their prescriptions, but 
subpopulations of patients with multiple chronic conditions requiring critical medications 
are significantly at higher risk of nonadherence. These medications include those for the 
treatment of acute and chronic diseases, including cholesterol lowering agents, 
antidepressants and antibiotics. Kocurek (2009) reviewed literature on reasons for lack of 
medication adherence in the United States, and concluded that for older adults on multiple 
medicines, it is not so much a matter of the cost per drug that influences nonadherence, 
but the sheer number of medications required on a regular basis.  
 
However, there is also evidence that medicine cost pressures do contribute to 
elderly consumers reducing or ceasing the use of essential medications (Lexchin & 
Grootendorst, 2004). In one longitudinal study the elderly were found to be vulnerable to 
higher levels of copayment resulting in treatment disruptions and nonadherence to therapy 
(Fendrick, Smith, Chernew & Shah, 2001). Heisler et al., (2004) analyzed data from two 
prospective cohort studies of adults in the United States and found that the elderly and 
near-elderly who reported cost as a barrier to accessing essential medicines were almost 
twice as likely as other patients to experience a decline in health status. These authors 
also reported that both the number and cost of medications affect medication adherence in 
older people and that these have the potential to seriously undermine the prevention of 
complications from chronic diseases. However, the data for these studies predate the 
implementation of Medicare Part D which extended prescription coverage to seniors and 
welfare recipients previously not covered by drug insurance plans. 
 
As with other variables affecting medication use described above, the age-
medication use relationship is complex and multifactorial. In the elderly, medication use is 
modified by multiple inter-related factors such as the type and number of medications and 
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the complexity of the medication regime. Cost has been identified as one factor. However, 
as discussed in the previous chapter, some researchers have argued that seniors are 
more likely to adhere to medications that are an essential part of their treatment, and as a 
result may be less sensitive to price than other age groups (Siminski, 2008).  
 
Concession status and the ability to pay. 
Another patient factor which affects medication use is the ability to pay the 
copayment. There is clear evidence that higher copayments contribute to lower adherence 
to medication. This was the main finding of a systematic review of literature on barriers to 
medication adherence (Gelland, Grenard & McGlynn, 2009). This review also concluded 
that cost-sharing could be reduced as a barrier when the appropriate use of a particular 
medication has health or financial benefits, such as avoiding complications, functional 
decline, or more expensive future treatments.   
However while a relatively high copayment on medications may induce patients to 
modify or reduce medication use, patients faced with no or low levels of copayment have 
no financial disincentive to use medicines efficiently. As discussed earlier in this chapter, 
regulatory changes introduced into the PBS to counter this behaviour contributed to a 
decline in the December peak in dispensed PBS medications (Donnelly et al., 2000). 
However these effects were not sustained over time, requiring the imposition of financial 
penalties to prevent persons on the Safety Net Card obtaining additional supplies of 
chronic disease medications medicines at the end of a calendar year (Limprecht, 2005). 
These are important points as they demonstrate not only that an increased level of subsidy 
increases access to PBS medications, but also that changes in policy can be effective in 
modifying medication use.   
In Australia, about 80% of the PBS expenditure is directed at concessional patients 
(Abello et. al., 2008) who comprise up to 25% of PBS beneficiaries (Sweeney, 2007). The 
level of expenditure directed at concessional patients has generated concerns that 
concession card holders may be taking advantage of higher prescription subsidies and 
using medicines more than are necessary, thereby creating a ‘moral hazard’, where 
people use more resources purely because they cost less or are free. Moral hazard has 
been found to be a serious problem for health care insurance in the United States where 
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studies show that consumers who are better insured tend to over-consume health care, or 
to demand treatments which they would not choose if they were directly paying for them 
(Dong, 2012; Koc, 2010). However, Qingyue, Liying and Yuan (2011) reviewed the effects 
of cost sharing methods in health insurance schemes in developed countries and found 
that, compared with schemes with no cost-sharing component, cost sharing leads to a 
decrease in the utilisation of most medical services and medications. The authors 
concluded that the prescription cost sharing policy could be a successful tool in controlling 
moral hazard especially by decreasing the consumption of high priced medications and 
improving use of generic substitutes. 
 
Although the extent to which moral hazard affects PBS medication use in Australia 
has not been definitely established, it should not be discounted. The National Medicines 
Policy (DoHA, 2000), has stated that easy access to medicines can work against the 
quality and rational use of medications through consumers stocking up unnecessarily on 
free or low cost medications. However, Doran, Robertson and Henry (2005) investigated 
the association between prescription cost and PBS medicine use and reported affordable 
prescription cost was not a sufficient incentive for medicine users to actively seek a 
medicine. These conflicting findings highlight the importance of research to assess the 
extent to which moral hazard contributes to the large difference in medication use between 
concessional and general beneficiaries in the Australian PBS environment. 
 
Further evidence that out-of-pocket cost affects purchasing of medicines comes 
from the Australian arm of a five-nation telephone survey comprising 1,412 non-
institutionalised adults (Blendon et al., 2002), a community survey of 950 households in 
Newcastle/Hunter region of New South Wales (Doran, Robertson, Rolf & Henry, 2004), 
and a cross-sectional population health survey (Deussen et al., 2001). In the telephone 
survey, 21% of participants whose income was below the national median household 
income in 2001 reported they did not fill a prescription because of cost. In the community 
survey (Doran et al., 2004), 21% of respondents reported not collecting their prescription 
from a pharmacy, with nearly half citing cost as the reason. While the 44% response rate 
of the Doran et al.’s (2004) survey limited its scope to identify sub-groups of the population 
more sensitive to cost, the study did identify strategies commonly used to minimise the 
effect of cost on adherence to prescription medicines. These included not having a 
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prescription dispensed at all, sharing prescribed medicines, reducing the prescribed dose 
to stretch supply, and not collecting a medicine from the pharmacy.  
 
The literature also indicates that, for at least some medications, general patients in 
Australia are more sensitive to cost than concessional patients. Ampon et al. (2009) 
examined the effect of the patient copayment on the rate of purchase of inhaled 
corticosteroids (ICS) by patients with obstructive lung disease. These investigators 
analysed PBS claims data between 2003 and 2006 and found that, after adjusting for age, 
sex, geographical remoteness and socioeconomic status, concessional beneficiaries were 
dispensed 2.5 times the number of ICS as general beneficiaries. The authors concluded 
that, as general beneficiaries pay a much higher copayment than concessional patients, 
cost represented a significant potential barrier to the purchase of preventer asthma 
medications by general patients.  
 
Another study, which also used PBS claims data, reported a greater reduction in 
asthma medications use among general patients (Hynd et al., 2008). These researchers 
compared changes in prescriptions over a wider time frame than Ampon et al. (2009), 
namely, prescriptions purchased between January 2000 and December 2004 inclusive 
compared to prescriptions purchased between January 2005 and September 2007 
inclusive. This timeframe coincided with a 21% increase in copayment for both categories 
of PBS beneficiaries which came into effect in January 2005.  
 
In additional to general patients being particularly cost-sensitive to asthma 
medications, Hynd et al. (2008) found concessional patients to be cost sensitive to a wide 
range of chronic disease medications. These included osteoporosis treatments, proton 
pump inhibitors, and non-aspirin anti-platelet medications. The largest decrease in PBS 
medication purchase, however, was for medications used in treating conditions that are 
asymptomatic and those for which over-the-counter substitutes are available.   
 
These findings indicate that the differential responses of general and concessional 
patients to copayment increases may also lie in the different types of medicines used by 
these two groups of PBS beneficiaries. Concessional patients include large numbers of 
aged pensioners who are more likely to have a higher proportion of chronic conditions or 
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conditions with obvious symptoms, such as chronic pain and arthritis. Changes in prices 
may have less influence on their purchasing decisions. General patients tend to be 
younger and more likely to be on medications for more acute or asymptotic conditions, 
such as pain and infections or hypertension, making their medication purchases more 
vulnerable to increases in price. 
 
Studies from overseas countries where consumer access to medications is 
governed by cost sharing and subsidy frameworks, support Australian evidence that out-
of-pocket costs affects patient adherence to medication therapy and treatment outcomes. 
These studies also show that reducing out-of-pocket costs or increasing drug insurance 
coverage increases drug use. A Cochrane review which comprised 30 evaluations from 21 
studies concluded that the introduction of, or increase in direct copayments saved 
expenditure on drugs through fewer medications being purchased (Austvoll-Dahlgren et 
al., 2008).  In the United States prior to Medicare Part D patients who exceeded their caps 
on drug benefits had lower levels of drug use, poorer control of blood pressure, lipid and 
glucose levels and greater levels of nonadherence than those who did not exceed it (Hsu 
et al., 2006). On the other hand, analysis of prescription data after Medicare Part D 
revealed that gaining prescription drug insurance was associated with a 60% increase in 
the annual number of prescriptions (Kaestner & Khan, 2012).  However even those with 
insurance are affected by cost-related nonadherence to medications. For example, in 
Canada, after copayments were introduced in the province of Quebec, the number of 
prescription drugs used per day decreased by 9% in older persons, and 16% among low 
income persons receiving social assistance (Tang, Ghali & Manns, 2013).  
 
It is of concern that the Austvoll-Dahlgren (2008) review also found that the 
reduction in medication use was accompanied by reductions in both life-sustaining drugs 
and chronic disease medications. Similarly, Tamblyn et al. (2001) and Lexchin & 
Grootendorst (2004) found that at higher levels of cost sharing, patients may not initiate 
therapy, discontinue therapy, reduce therapy or be more likely to switch to non-prescription 
or cheaper generic brands. However, this might represent a false economy because, while 
the cost of medications is reduced, the costs associated with chronic or asymptomatic 
illness may end up being shifted to acute care if exacerbations result from reduced 
medication use (Tamblyn et al., 2001).   
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The large difference in the patient copayment is expected to contribute to some 
differences in the medication use between the two categories of PBS beneficiaries, even in 
the absence of a copayment increase. However, there is evidence that differences in the 
level of decision making between the doctor and the two categories of PBS beneficiaries 
may also contribute to some of these differences. Robertson Doran, Henry and Salkeld 
(2014) conducted telephone interviews in the Hunter Valley, NSW, Australia, with 
randomly selected regular medicine users aged 18 years and over, comprising 408 
concessional and 412 general beneficiaries. These authors found that concessional 
beneficiaries (equivalent to high insurance patients) were more likely to favour doctors 
having more say in the decision-making process relating to medication use. They were 
also found to be more likely to report treatment decisions being made by the doctor alone. 
On the other hand, general beneficiaries (low insurance) tended to favour a bi-lateral 
decision making process with a greater input by the patient in treatment decisions.  
 
From a social justice perspective, higher cost sharing places a financial burden on 
the poorest and sickest members of society. Kurlander et al. (2009) surveyed patients who 
had both diabetes and back pain, and found that lower income and higher out-of-pocket 
medication costs significantly increased the odds that diabetic patients would report 
nonadherence to medications for both diabetes and chronic pain. In addition, lower income 
also increased patients' likelihood of cutting back on chronic pain medications alone. Hsu 
et al (2006), compared clinical and economic outcomes of 157,275 Medicare beneficiaries 
whose annual drug benefits were capped at $1,000 and 41,904 beneficiaries whose drug 
benefits were unlimited.  These researchers found that a cap (limit) on drug benefits was 
associated with lower drug consumption and unfavourable clinical outcomes, which 
included poorer adherence to drug therapy and poorer control of blood pressure, lipid 
levels, and glucose levels.  
 
The optimum level of cost-sharing associated with minimal disruption to medication 
adherence has been the subject of a number of investigations but remains unclear. Eaddy, 
Cook, O’Day, Burch and Cantrell (2012), reviewed evidence on the effects of cost sharing 
on adherence and outcomes and found that each dollar increase in cost sharing was 
related to an average decrease of up to 0.4% in medication adherence. This corresponds 
to a 3.8% decrease in medication use for each $10 increase. The authors also concluded 
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that the change in adherence might be larger or smaller depending on factors such as the 
population subgroup and medication type. However, these findings need to be interpreted 
with caution, as it is likely that the strength of the evidence may have been compromised 
by the multiple number of studies reviewed and the many assumptions made in arriving at 
the relationship between cost-sharing and adherence. Goldman et al. (2007) conducted a 
synthesis of published evidence on the associations among cost-sharing features of 
prescription drug benefits and use of prescription drugs in the United States. They 
reported that for each 10% increase in cost sharing, prescription drug spending decreased 
by 2% to 6% depending on the type of medication and condition of patient. The level of 
copayment increase investigated by Goldman and colleagues ($10) is about twice the 
increase for PBS general patients ($4.90) being investigated in the research for this thesis. 
 
Barron, Wahl, Fisher and Plauschinat (2008) conducted a retrospective analysis to 
determine the relationship between the level of copayment for Type-2 diabetes 
medications and adherence to therapy and treatment failure. These authors found that for 
every $10 increase in copayment, treatment was 26% more likely to fail, indicating a 
relationship between cost and adherence. Likewise, Roblin at al., (2005) conducted a 
quasi-experimental study using a time series design with comparison group, and reported 
that a large increase greater than $10 was more likely to result in an immediate and 
persistent reduction in oral hypoglycaemic use, than small and moderate increases less 
than $10.  
 
These studies show that patients value their various medications differently 
according to patient demographics and type of illness, and that cost is an important factor 
in this dynamic. They also show that both the copayment level and the magnitude of the 
copayment increase affect medication use. Kessler, Cantrell, Berglujnd and Sokol (2007) 
analysed data from a large managed care database in the United States and found that 
patients paying high existing copayments faced with increases in copayment were more 
likely to terminate medication use compared to those on lower or no copayment. Kessler 
and colleagues also reported that the higher the copayment change, the greater the 
likelihood of medication termination earlier rather than later in the treatment. In the 
Australian context, general patients pay an almost six times higher PBS copayment than 
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concessional patients and were subjected to a much greater magnitude of copayment 
increase in 2005.   
  
An explanation for the differential patient response to copayment increases may 
also lie in differences in response to cost by existing and newly diagnosed patients. 
Gibson, McLaughlin, and Smith (2005b) investigated this in a study which estimated the 
price elasticity of demand for prescription medications among employees enrolled in a 
large health plan. They found that while the primary effect of the copayment increase was 
a weakening of the trend in prescription drug use, employees with a newly diagnosed 
chronic condition responded less to drug price increases than those with existing chronic 
conditions. The authors concluded that employees with existing chronic conditions were 
more sensitive to copayment changes than those requiring medications to treat newly 
diagnosed chronic conditions. These findings however, are contrary to those of Solomon, 
Goldman, Joyce, and Escarce (2009) who conducted a retrospective cohort study of 
272,474 elderly persons to assess the relationship between prescription drug cost-sharing 
and the time taken to initiate drug therapy after a new diagnosis of hypertension, 
hypercholesterolemia, or diabetes. These authors found that high cost sharing delayed the 
initiation of drug therapy for patients newly diagnosed with chronic diseases, with the effect 
being greater among newly diagnosed patients who lack experience with prescription 
drugs.  
 
While detailed mechanisms for changes in medication use were not established, the 
findings of Gibson et al. (2005b) above does not necessarily mean that the chronically ill 
patients reduced their medication intake. It could be that they switched to cheaper 
medications or purchased over-the-counter medications. When translated to the PBS 
environment it is possible that general patients, who generally face a greater magnitude of 
copayment increase than concessional patients, are more likely to seek generic options or 
opt for alternative non-medication treatments when faced with cost pressures. Gibson et 
al. (2005a) also reviewed evidence on the effects of changes in prescription drug cost 
sharing on medication use and found that patients when faced with rising out-of-pocket 
costs are likely to search for less expensive options, including generic substitutes,. Other 
studies have shown that, when faced with rising costs, patients are more likely to choose 
less expensive over-the-counter medications (Ashton, 1991), and non-medication 
60 
 
therapies such trans electrical nerve stimulation (TENS) and alternative therapies such as 
acupuncture (Gore, 2012).  
 
Medication Characteristics and Medication Use 
 
The fourth group of factors that interacts with cost to influence purchase of 
medications is the characteristics of the medication itself. These include the filling 
(dispensing) of the prescription, perceived benefits of therapy, medication type and 
presence of polypharmacy.   
 
Filling of the prescription. 
A recommendation by a doctor for a medication does not always translate to the 
prescription being filled at the pharmacy or the medication being taken in accordance with 
the directions. A survey of adults aged 65 and over conducted by the Commonwealth 
Fund International Health Policy reported that in 2013, 8% of Australians encountered 
problems with medical services due to cost (Osborn, Moulds, Squires, Doty & Anderson, 
2014). This included, not following the recommended treatment, not filling a prescription at 
the pharmacy and skipping doses because of cost.  
 
A recent Canadian study found  primary nonadherence to be common among 
Quebec residents, with almost one-third of 37,506 incident (new) prescriptions not filled 
despite the residents being covered by health and drug insurance (Tamblyn, Eguale, 
Huang, Winslade & Doran, 2014). The authors concluded that primary nonadherence with 
chronic disease medications can be reduced by lower drug costs and copayments, as well 
as increased follow-up care with the prescribing physician. Similarly, in the United States, 
Shank et al. (2008) reported a prescription abandonment rate of 3.27%, prior to Medicare 
Part D implementation in 2006. These researchers also reported an association between 
cost and prescription abandonment, with prescription copayments of $40 to $50, and 
prescription cost of more than $50 being up to three (3) and five (5) times more likely, 
respectively, to be abandoned than prescriptions with no copayment. 
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Kennedy et al. (2008) also analysed prescription data collected prior to Medicare 
Part D and estimated the prevalence of prescription abandonment to be about 4% of 
Medicare beneficiaries. These authors conducted a secondary analysis of data on 
prescriptions dispensed to community-based beneficiaries (n=14,464) and reported 
working age beneficiaries, dual-eligible beneficiaries, and beneficiaries with multiple 
chronic conditions to be associated with a majority of the unfilled prescriptions. That the 
infilled prescriptions included medications such as antibiotics, cholesterol lowering agents 
and antidepressants indicated that patients with acute as well as chronic medical 
conditions were affected by nonadherence due to the non-filling of prescriptions.  Medicare 
Part D implementation in 2006 was associated with a small but significant decrease in 
CRN overall (Goedken, Urmie, Farris & Doucette, 2011).  However no net decrease was 
observed among the sickest beneficiaries, who continued to experience high rates of CRN 
(Madden, 2008). An internet survey of 27,302 participants conducted between March and 
April 2009 found that among respondents aged 40–64 and looking for work, 41% did not 
fill a prescription in 2008 due to cost pressures (Piette et al., 2011). While it is plausible 
that the economic recession of 2008 may have affected prescription use during this period 
(Piette et al., 2011), these results also indicate that the presence of multiple chronic 
conditions continued to be a factor in CRN after the implementation of Medicare Part D.    
 
In addition to primary nonadherence, the length of the refill (resupply) interval may 
also affect adherence to therapy independent of cost. For example, Piette, Heisler, 
Ganoczy, McCarthy and Valenstein (2007) selected a national sample of United States 
veterans and assessed the effect of several variables on adherence, including the average 
days of medication supplied per refill medication. These authors found that patients with 
schizophrenia and comorbid physical conditions had lower levels of adherence for 
antipsychotic medication, which the authors considered to be associated with a shorter 
interval between supplies. This is an important finding because, as discussed later in this 
chapter, some medications used in the treatment of nervous system disorders are also 
likely to be underused due to adverse side-effect profiles. 
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Perceived risks and benefits of medication therapy. 
The value a consumer places on the medication influences its purchase. According 
to Kocurek (2009), medication purchases are influenced by a number of factors related to 
patients' experiences, perceptions and understanding about their disease. This latter 
includes an assumption that, for example, once the symptoms improve, the patient can 
discontinue use of the medication. Kurlander et al. (2009) surveyed American patients 
using medications for both diabetes and chronic pain looking at the extent to which 
patients cut back because of the cost of these medications. The conclusion was that 
patients who forgo medications for both diabetes and chronic pain appear to be influenced 
primarily by economic pressures, but patients who cut back selectively on their diabetes 
treatments were influenced by their mood and medication beliefs. These beliefs included 
negative beliefs about pharmacotherapy. 
 
Aikens and Piette (2009) investigated how patients' beliefs about hypoglycaemic 
and antihypertensive medications relate to medication under-use. They found that, even 
after adjustment for economic factors, patients who were younger, African-American, or of 
low health literacy expressed concerns about medication harmfulness which in turn was 
associated with medication underuse and higher blood pressure. The authors concluded 
that to enhance adherence and outcomes, interventions should address patients’ 
underlying concerns about potential adverse treatment effects and focus on both cultural 
factors and health literacy.  
 
Piette (2009) suggests that decisions to forgo treatment due to cost pressures often 
additionally reflect other issues in addition to patients' perceptions about medication safety 
and efficacy. In the Harris Interactive Survey of Persistence and Compliance (BCG, 2003), 
which asked patients why they did not fill prescriptions or comply with drug regimens, cost 
was identified as a barrier by 17% of the patients. By contrast, more patients (24%) 
suggested that they occasionally forget to refill a prescription, while another 20% did not 
want to experience real or perceived side effects, and another 14% felt they did not really 
need the drug at all. 
 
Research has also identified that patient-related medication factors include 
misunderstanding, or denial of disease and the failure to see the treatment as necessary, 
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especially if the disease is asymptomatic, and the patients have low expectations about 
the treatment (Kocurek, 2009). As a result, the authors recommend that doctors should 
have an open discussion about potential medication-related concerns that may be driving 
patients' adherence behavior. This is particularly relevant with patients who exhibit 
symptoms of depression, in addition to other medical conditions. For example, Selby et al. 
(2008) compared 1,003 patients with good control of their diabetes to patients with poor 
control. They found that poorly controlled patients were more likely to report symptoms of 
depression and hopelessness than well controlled patients. Briesacher et al. (2007) also 
reported that older patients with chronic diseases and mood disorders are at particular risk 
of medication nonadherence, even if enrolled in the United States’ Medicare drug benefit 
scheme. 
 
Another important non-cost issue for patients, especially for the elderly who choose 
not to adhere to their medication regime, is the wish to avoid side effects. Troublesome 
side effects pose one of the biggest challenges to patient adherence across chronic 
diseases (See for example, Horne, Weinman, Barber, Elliott & Morgan, 2005). McHorney, 
Schousboe, Cline and Weiss (2007) reported that 67% of patients categorised as ‘non-
adherers’ rated the presence of side effects as an ‘extremely important’ or ‘very important’ 
reason for nonadherence. For example, in patients on medications for osteoporosis, the 
side effects of oral bisphosphonates include gastrointestinal discomfort, which can 
significantly interfere with day to day life. It is therefore not surprising that side effects are 
frequently cited as the main reason for treatment nonadherence and discontinuation in 
osteoporosis (see for example, McHorney et al., 2007; Lau et al., 2008). Adherence to 
medications for psychiatric disorders is also commonly affected by side effects. In the 18-
month Clinical Antipsychotic Trials for Intervention Effectiveness (CATIE) study, 
Lieberman et al., (2005) reported that 74% of patients discontinued their antipsychotic 
medication within 18 months. The most common reasons for discontinuation were 
perceived lack of effectiveness and intolerability of side effects.  
 
Medication type. 
The research literature indicates that the likelihood of cost-related under-use varies 
across medication classes (Goldman et al. 2004; Landsman, Liu, Teutsch & Berger, 2005; 
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Piette, Heisler & Wagner, 2006; Hynd et al., 2008). Paradoxically, however, one study 
indicates that response to cost varies for different medications within the same medication 
class. Cole, Norman, Weatherby & Walker (2006) reported that a $10 increase in 
copayment for ACE inhibitors for blood pressure was associated with a 2.6% decrease in 
purchasing as measured by the medication possession ratio (MPR), compared to a 1.8% 
decrease for beta-blockers. The reason for consumers’ differential response is unclear. 
This is concerning, given the authors’ conclusion that even a small reduction in medication 
use is sufficient to significantly increase the predicted risk of hospitalization for congestive 
heart failure. 
 
The literature also supports the view that a reduction of price of some classes of 
medications improves adherence and reduces the risk of hospitalisation. Chernew et al. 
(2008) investigated the impact of a copayment reduction on adherence to angiotensin-
converting-enzyme (ACE) inhibitors/Angiotensin receptor blockers (ARBs) for 
hypertension, diabetes medications, beta-blockers for heart failure and inhaled 
corticosteroids for asthma maintenance and prevention. These researchers reported a 7%-
14% reduction in nonadherence for all four classes of medications. They also reported the 
magnitude of the adherence-improving effect with the copayment reduction to be similar to 
those estimated in the existing literature for increases in copayment rates. Choudhry et al., 
(2012) found that lowering copayments for cholesterol lowering statin medications and the 
blood thinning medication, clopidogrel, was associated with reductions in health care 
resource use. These authors compared an intervention group (n=3,513) which had a 
reduced copayment for statins for patients with diabetes or vascular disease and reduced 
copayment for clopidogrel for all patients prescribed this drug with a control group 
(n=49,803), and found significant reductions in rates of physician visits, hospitalisations 
and emergency department admissions. This finding is important in that it shows that a 
copayment reduction may reverse the negative adherence outcomes of copayment 
increases as well as having positive flow-on effects downstream on the health system, 
independent of patient compliance.  
 
Taira, Wong, Frech-Tamas and Chung (2006) also reported positive effects of lower 
copayments for antihypertensive medications in a retrospective analysis of data for 
114,232 subjects. The authors analysed prescription data and found that, relative to a 
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medication with a $5 copayment, compliance with an antihypertensive medication with a 
$20 copayment was 24% lower. Similarly, with an antihypertensive medication which 
required a copayment of $20 to $165, compliance decreased by a massive 52%. The 
authors concluded that copayment level independent of other determinants was a strong 
predictor of compliance with antihypertensive medications, with greater compliance among 
patients who had a lower copayment. 
 
Behavioural research suggests that individuals make decisions which favour short 
term benefits rather than benefits which take a long time to become manifest (Ortendahl & 
Fries, 2002). When generalised to the taking of medications, this suggests that individuals 
may value medications which provide short term symptomatic relief (such as for pain or 
allergy) more than those used for long term treatment of asymptomatic conditions such as 
blood pressure or cholesterol control.  
 
However other research suggests otherwise, namely, that individuals may value 
medications which treat asymptomatic conditions more than is often assumed. Goldman et 
al. (2004) demonstrated this in a retrospective analysis of pharmacy claims data of 
privately insured beneficiaries (n = 528,969) aged 18-64 years. This research showed that 
patients were more cost-sensitive to short term symptom relieving medications such as 
antihistamines and NSAIDS than medications for treating asymptomatic chronic conditions 
such as high cholesterol, hypertension and diabetes. This pattern was also identified by 
Piette et al. (2004a) who demonstrated that the probability of cost-related reduction in use 
was lowest for chronic diseases such as hypertension (9%), heart failure (10%), and 
diabetes (11%). By contrast, patients’ likelihood of foregoing medications due to cost was 
twice as high for medications intended for symptom relieving conditions such as asthma 
(20%), arthritis (20%) and back pain (23%). 
 
Essential and discretionary medication use. 
Despite the literature discussed in the previous section, there is a general 
consensus that medications regarded as essential are less sensitive to cost than 
discretionary medications. Essential medicines are generally considered necessary to 
maintain and improve health. These include maintainence medications (eg., 
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antihypertensives) and asthma reliever medications, such as bronchodilators, which are 
used sporadically for conditions which can be life-threatening (Gibson et al. 2005a).  
 
Piette (2005) showed that at increased levels of cost sharing, consumers tend to 
forgo less essential medicines at a higher rate than essential medicines. Other studies 
have also shown that increased costs to the patient result in greater reductions in their use 
of discretionary medications (Goldman et al., 2004; Wilson et al. 2005). These studies 
have shown that doubling the copayment was associated with reductions in the use of 
NSAIDs by 45% and antihistamines by 44%. By contrast, reductions of much smaller 
magnitude were observed for essential medications for cholesterol (34%), blood pressure 
(26%), depression (26%), and diabetes (25%). Interestingly, the same study reported 
medium level reductions for ulcer and reflux (33%) and asthma (32%) medications. This 
was most likely the result of these latter classes of medications being regarded by the 
patients as either essential or discretionary, depending on the severity and chronicity of 
their condition.  
 
These findings suggest that the patient’s perception of a medication being essential 
or discretionary may differ from that of the doctor’s and the treatment plan. Wang, Liu, 
Bryson, Sharp and Maciejewski (2011) compared changes in medication adherence after 
a copayment increase in United States veterans with high- or low-comorbidity burden. 
These authors found medication copayment increases were associated with different 
outcomes for low- and high-risk patients. High-risk patients incurred greater out-of-pocket 
costs from continued adherence to prescribed medication, while low-risk patients put 
themselves at increased risk for adverse health events due to greater nonadherence. The 
actions of this latter group might potentially cause them further comorbidities. 
 
Other studies have also demonstrated that high copayments result in decreasing 
the use of essential “maintenance” medications (Goldman et al., 2004; Gibson et al., 
2005a). Gleason et al. (2005) demonstrated this in their analysis of pharmacy claims from 
25 employers and data from 402,486 members. This study found that a two to fourfold 
increase in copayment resulted in a 10% discontinuation rate in the use of angiotensin-
converting enzyme (ACE) inhibitors for blood pressure, statins for hypercholesterolaemia 
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and proton-pump inhibitors for chronic gastric conditions among lower paid workers 
compared to their higher paid worker counterparts.  
 
Lexchin and Grootendorst (2004) reported a decline in the use of essential 
medicines at higher levels of cost sharing in patients with a range of chronic illnesses. 
Medicines most affected by increasing copayments include ACE inhibitors for the 
treatment of hypertension (Schneeweiss et al. 2002), statins for lowering cholesterol (Ellis 
et al., 2004, Gibson, Mark, McGuigan, Axelsen & Wang, 2006b), oral hypoglycaemics for 
Type 2 diabetes (Roblin et al., 2005), and inhaled corticosteroids for the prevention of 
asthma attacks (Blais, Couture, Rahme & LeLorier, 2003). If similar trends emerge as a 
result of a sudden, across-the-board 20% in copayment, general patients in Australia on 
multiple medications, who pay about six times more for their medicines than concessional 
patients, are being subjected to significant, ongoing financial outlay which might lead them 
to forgo essential medication purchases.  
 
Multiple medication use. 
Many definitions have been used to describe polypharmacy (see for example, 
Werder & Preskorn, 2003; Viktil, Blix, Moger & Reikvan, 2006; Bushardt, Massey, 
Simpson, Ariail & Simson, 2008; Patterson et al., 2014).  ). As discussed in Chapter 1, this 
thesis defines major polypharmacy as the use of five or more medications at the same 
time, including prescribed, over-the-counter and complementary medicines (Hilmer, 2008). 
Minor polypharmacy in this thesis refers to the use of two to four concurrent medications 
(Werder & Preskorn, 2003).  
 
Polypharmacy is potentially problematic because inappropriate medication use and 
readmisions to hospital are common in those exposed to multiple medication therapy. 
These adverse outcomes translate to increased financial costs to the patient and the 
health system (Sehgal et al., 2013). In addition, the multiple dosage regime, redundancy 
and duplication of medicines, and side effects resulting from polypharmacy may interfere 
with medication adherence and health outcomes.  
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The Australian Institute of Health and Welfare reports that 25% of Australians aged 
65 years and over use four or five medicines concurrently (AIHW, 2007a;  p. 111). The 
prevalence of multiple medication use increases with age. Byles et al. (2003), and Goldney 
and Fisher (2005) estimate that nine in ten people aged 65 and over take at least one 
prescription medicine, and approximately 50% take more than four medications on a 
regular basis.  A cross-sectional postal survey of a random sample of 4,500 Australians 
aged 50 and over also reported a significant increase in polypharmacy with increasing age 
(Morgan et al., 2012). This survey was conducted between June 2009 and February 2010 
and was based on an intake of conventional and complementary medications in the 
previous 24 hours. These authors reported that almost 50% of persons aged 65-74, and 
two-thirds of those aged 75 and over, were using five medications or more concurrently 
(major polypharmacy) in 2012.  A limitation of this study, apart from its response rate 
(37.3%), is that even though the patient recall of medication use was only for the prior 24 
hours, it is likely the reported level of medication use may have been affected by the use of 
self-reports. In this form of data collection the derived estimates for medication use may 
differ from actual use due to a number of factors including self-reporting biases (Alinia & 
Feldman, 2014) and age (Pit & Byles, 2010). Other factors such as the recall time frame 
and frequency of medication intake may also contribute to the difference between reported 
use and actual use (Bhandari & Wagner, 2006).  While all these factors may contribute to 
some misclassification in the level of medication use, the findings of Bhandari and Wagner 
(2006) also suggest that recall bias might not be a major issue in self-reported medication 
use if the recall time frame is short, which was the case in the study by Morgan and 
colleagues (2012).  
 
However, there is also evidence that data collected solely on the basis of self-
reported medication use may not reliably estimate medication use at the population level. 
Johnson and Fendrich (2005) compared three sets of information from a community 
survey of 627 adults to evaluate the effects of each potential source of reporting error on 
the quality of drug use reporting. These information sets were medication use self-reports, 
multiple biological samples that permitted self-report validation, and a series of probes 
designed to collect systematic information regarding respondent comprehension and 
memory difficulties, and social desirability concerns. The authors concluded that while 
social desirability concerns were often predictive of under-reporting of drug use, and 
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memory difficulties over-reporting, differences in the predictive power of these variables 
varied across race and ethnic groups.  
 
As mentioned in Chapter 1, previous studies on polypharmacy in Australia have 
primarily been conducted on samples of elderly individuals admitted to hospitals or living in 
aged care institutions. Prescribing medications for the elderly is difficult (see, for example, 
Poudel, Hubbard, Nissen & Mitchell, 2013) because polypharmacy has been shown to be 
a statistically significant predictor of hospitalization, falls, fractures, nursing home 
placement, death, hypoglycemia, pneumonia, and malnutrition (Frazier, 2005, Hajjar, 
Cafiero & Hanlon, 2007); Kaufman, 2013). These conditions appear to be independent of 
the underlying diseases (Hilmer & Gnjidic, 2009). Exposure to polypharmacy has the 
potential to affect younger patient groups as well. Morgan et al.’s findings (2012) suggest 
that the practice of multiple medication use may be creeping into the younger age groups. 
These authors reported that, while overall 43.3% of Australians aged 50+ used five or 
more medicines of any type (pharmaceutical and complementary), this level of medication 
use was common in one third of those aged 50-64. 
 
Very few studies on multiple medication use in Australia have used population-
based samples, age groups other than the elderly, and analysis of medication use at levels 
other than major polypharmacy. This is surprising as minor polypharmacy is more common 
than major polypharmacy in all age groups across the age continuum (Stawicki & Gerlach, 
2009). This includes the working age groups of 25-44 and 45-64 which comprise mostly 
general beneficiaries under the PBS. Despite this widespread prevalence our 
understanding of the predictors and consequences of minor polypharmacy remains 
unclear.  
The number of persons exposed to both forms of polypharmacy is increasing. In the 
United States, Gu et al. (2010a) reported that the proportion of persons who used two or 
more prescription drugs increased from 25% in 1999-2000 to 31% in 2007-2008.  In 
Australia, the elderly aged aged 85 years and over who are most affected by 
polypharmacy comprised 1.6% of the population in 2007, and is projected to more than 
treble by 2050 (ABS, 2008a). These changes and the current focus on early and 
aggressive treatment of chronic diseases are expected to have important implications for 
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both forms of polypharmacy in Australia. While the focus of this thesis is changes in 
medication use in response to a large increase in patient copayment the distribution of 
polypharmacy will be investigated, as multiple medication use has cost complications for 
the patient and the PBS. This study will also aim to identify issues for further research in 
relation to factors associated with medication use at the minor polypharmacy level. 
 
Although the above discussion identified some of the factors that might explain why 
women consume more medications than men in general, the association between 
polypharmacy and gender is not clear cut. Morgan et al. (2012) in their postal survey of 
Australians aged 50+ found a much higher prevalence of polypharmacy in women than 
men (50.2% v 35.4%). However the response rate (37.3%) suggests that the magnitude of 
the gender difference might have been affected by this relatively low response rate and the 
age of the sample, although, Aparasu, Mort and Brandt (2005) did find female gender was 
still a factor in polypharmacy after adjusting for advanced age. They also found 
prescriptions for hormonal preparations to be commonly associated with polypharmacy. 
These findings suggest that a gender difference in polypharmacy in the United States can 
be partly explained by the use of hormones and modulators of the female genital system.  
 
Recent research suggests that polypharmacy is increasing for both males and 
females independent of increasing age. Venturini et al., (2011) reported that the gender-
difference in polypharmacy actually narrows after age 80. Hovstadius, Hovstadius, Astrand 
& Petersson (2010) examined data from a population-based prescription registry in 
Sweden and found that the increasing trend in polypharmacy is associated with doctors’ 
prescribing patterns, the introduction of new clinical guidelines for the treatment of various 
chronic diseases, the public becoming increasing informed and proactive in requesting 
prescriptions and more medications being prescribed for preventive use. Other studies 
show that the demand for certain prescription medications (e.g. narcotic analgesics, 
benzodiazepines) and the increased likelihood of receiving a new prescription during a 
consultation can further influence movement towards polypharmacy (Frazier, 2005; 
Planton and Edland, 2010).  
 
Health status factors such as a presence of certain chronic diseases have been 
shown to contribute to polypharmacy. These include depression, hypertension, anaemia, 
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asthma, angina, diverticulosis, osteoarthritis, gout, diabetes, poor self-perceived health 
status and poor life satisfaction (Patterson et al., 2014; Hajar et al., 2007). Medication 
classes mostly associated in polypharmacy include cardiovascular (mainly lipid and blood 
pressure lowering drugs), hormonal preparations, analgesics, psycholeptics (e.g. 
antidepressants) and gastrointestinal medications (Aparasu et al., 2005; Hovstadius & 
Petersson, 2012; Hovstadius & Petersson, 2013). Diabetes has been found to be 
associated with polypharmacy in all adult age groups, while hypertension is associated 
with polypharmacy in people aged 30-49 and 50-64 years (Moen et al., 2009). Insomnia 
has also been found to be associated with polypharmacy (Bin, Marshall & Glozier, 2012; 
Austin, 2006).  
 
Factors related to access to health care such as number of health care visits and 
access to multiple health care providers may also contribute to polypharmacy. A recent 
study on the impact of polypharmacy on the health of seniors aged over 64 in Canada 
reported that more than 80% of patients visiting a doctor for treatment of hypertension or 
depression left with a prescription, compared with only 2% of patients visiting a doctor for a 
general medical or health check-up (Reason, Terner, McKeag, Tipper & Webster, 2012). 
 
The application of some clinical guidelines and evidence-based prescribing can also 
affect the number of medications prescribed to individual patients. Many guidelines for 
prevention and management of diseases common in older people recommend adding 
medications for secondary prevention. In fact for diabetes and hypertension, treatment 
with multiple medications is the recommended standard therapy (Ismail-Beigi, 2012; 
National Heart Foundation of Australia [NHFA), 2010). However, while aggressive 
treatment of chronic diseases may be necessary in younger aged persons to prevent 
progression to more serious disease in later life, guideline-based medication therapy in the 
elderly who tend to have multiple morbidities remains controversial. A recent review of the 
applicability of clinical guidelines to the ageing population concluded that evidence from 
which clinical guidelines are developed stem from randomized clinical trials or meta-
analyses, which are often biased by the under-representation of elderly people, especially 
those affected by multiple chronic diseases (Nobili, Garattini & Mannucci, 2011). As a 
result, doctors’ application of clinical guidelines based on standardised treatment in 
72 
 
persons with multiple morbidities may inadvertently be contributing to untherapeutic 
polypharmacy.  
 
Finally, as discussed in the previous chapter, at a policy level the PBS medication 
subsidy provided to patients in an effort to improve access to essential medicines may also 
be inadvertently promoting polypharmacy. For example, concessional patients who pay a 
much lower copayment than general patients, or no copayment when they reach a safety 
net threshold, may not have the financial incentive to use medicines more efficiently 
(DoHA, 2000).  
 
Summary of Contextual Factors Affecting Medication Use 
 
In summary, the literature on cost sharing supports a statistically significant 
association between copayment and medication use. The association appears to be 
influenced by the absolute level of the copayment, the size of the copayment change, the 
time horizon over which the impact of the copayment change is examined, presence of 
existing medical conditions and type of medication for which the copayment changes are 
applied (e.g. generic or branded; chronic or acute treatment).  
 
This multi-factorial influence on people’s medication purchasing behaviour is 
arguably best seen in the behaviour of Australian patients. Despite Australia having a 
universal health system, recent research indicates that people who are ineligible for 
government support and those with comorbidities report economic hardships which 
compromise their capacity to engage in self-management and risk-reduction behaviors. In 
these cases, it is not solely the matter of the cost of a particular medication, but the 
cumulative costs of requiring many prescriptions over a period of time (Hynd et al., 2008; 
Jeon, Essue, Jan, Wells & Whitworth, 2009). Decisions to forgo medication may lead to 
less than optimal health outcomes on the short term and increased costs to the health 
system in the long run. 
 
Previous research on consumer response to cost has focussed on prescription use 
in general rather than on subgroups of patients. These studies tend to rely on descriptive 
methodologies and time-series changes in broad prescription use. Most of the research 
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literature has reported changes in medication purchase in an environment of modest cost 
increases in the range 2% to 5%.  This thesis will investigate changes in medication 
purchasing after unprecedented copayment increases of 21% to both categories of PBS 
beneficiaries. 
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Major Issues Identified in the Literature Relevant to this Study 
Australian research presented in this chapter on the impact of cost on the 
purchasing of medications has focussed on concessional beneficiaries and the elderly in 
aged care, who are generally on multiple medication and complex treatment regimens. 
These studies are mostly based on changes in drug utilisation over time with the focus 
being on the type of the prescription rather than the users of the prescription. This has 
contributed to gaps in our knowledge of medication use by general beneficiaries and 
patients affected by levels of medication use other than major polypharmacy. As a result 
the response of these patient groups to changes in cost sharing is not well understood.  
Gaps also exist in our knowledge of the distribution medication use across patient 
demographics of age, gender and insurance status, and medication-related categories of 
type and level of medication use. Information on the impact of these variables on 
medication use can however be sourced from research conducted outside Australia, 
particularly from the United States.  The findings from these research may not be directly 
applicable to PBS medication use in Australia due differences in pharmaceutical financing 
and insurance policies. However, some of the issues that affect cost-related medication 
use in these countries may also be relevant to the PBS environment in Australia, 
particularly in relation to changes medications use after a copayment increase. These 
issues will be addressed in the following chapters in five unique ways.  
First, the research presented in this thesis uses a large dataset and follows the 
same cohort of consumers over two consecutive years. Second, it examines changes in 
the purchasing of medications from the perspective of the patient rather than changes in 
prescriptions purchased in the population. Third, as the focus of most studies to date has 
been concessional patients who pay a much lower copayment, this thesis will also 
examine the impact of cost on general patients who pay a much higher copayment. 
Fourth, in addition to variation with cost, the literature has identified that medication use 
varies with patient characteristics, medication type, and level of medication use. The role 
these factors play within the context of an unprecedentedly large PBS copayment increase 
in patterns of medication purchase will be investigated.  
Finally, a distinctive feature of this current study which sets it apart from other 
studies on this topic is the use of the Piette framework. The use of this framework enables 
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an examination of a range of factors across the health care continuum which has a 
potential impact on cost-related medication adherence, especially in the NHPAs of 
hypertension, arthritis, depression, asthma and diabetes. 
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CHAPTER 3.  METHODOLOGY 
 
This chapter describes the methodology applied to answer the research questions 
posed in Chapter 1. Somewhat unusually, discussion of the ethical issues occurs early in 
this chapter. There are two reasons for this. The first is that patient privacy was a priority 
during all phases of this research, and considerations of anonymity influenced every 
aspect of the research methodology. Secondly, the need for anonymity, which precluded 
the matching of patient and medication purchases, presented significant challenges in 
matching medication purchase over two consecutive years. These challenges informed a 
great deal of the methodology employed in data cleaning and preparation for analysis 
described later in this chapter. 
 
Data Source 
 
Data on prescription medication use were obtained from Medicare Australia, an 
organisation which administers Australia’s national health programs, including the 
Pharmaceutical Benefits Scheme (PBS) and the Medicare Public Enrolments. As part of 
this role, Medicare Australia collects statistics on the programs it administers. Appendix A 
provides information about the programs administered by Medicare Australia in 2004-05 
and associated data collections. Updated information on the programs and health statistics 
available from Medicare Australia can be found on its website 
(http://www.medicareaustralia.gov.au/about/stats/index.jsp).  
 
As part of its role of administrating the PBS, Medicare Australia maintains a 
computerised database of medications purchased from pharmacies and claims made by 
the pharmacist. Data on medication use are routinely collected when a PBS prescription is 
presented and processed at the pharmacy and the medication dispensed to the patient. 
Appendix B presents details concerning the process for requesting data from Medicare 
Australia, and the criteria used in assessing the request. It shows that the criteria include 
privacy considerations, which are discussed in more detail later in the chapter. The data 
requisition process for this thesis started with an e-mail to Medicare Australia (Appendix 
C). This e-mail specified the variables on which data were required and was assessed by 
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Medicare Australia’s Information Strategy and Delivery Section against the criteria for its 
release prior to its approval and release (Appendix B). 
 
The data for this thesis were extracted by an Information Officer from the Medicare 
Australia Information Strategy Unit. These data were derived from two separate Medicare 
Australia databases. The first was the Medicare Public Enrolments database, the purpose 
of which is to enrol, store and identify patients for the purpose of issuing the Medicare 
card. Information stored on this database includes date of birth, gender, Medicare card 
number and the personal identification number (PIN). The patient PIN is a unique nine digit 
number associated with the Medicare card and does not change with the reissue of the 
card. The second database was the PBS database which contains data on the 
medications dispensed to the patient at the pharmacy, and the PIN of the patient receiving 
the medication. As the PBS database does not include information on patient 
demographics, such as gender and age, these data were obtained by linking the PBS 
database with the Medicare Public Enrolments database using the consumer (PIN) which 
is common to both databases. Appendices D and E present e-mail communication with the 
Information Officer who extracted the data on the construction and allocation of PINs, size 
of the proposed sample and the structure of the dataset.  
 
The sampling frame for this study was Queensland residents (whose residential 
postcodes ranged from 4000-4999), who were Medicare cardholders and were supplied 
PBS medicines during the both calendar years 2004 and 2005. The data were extracted 
by the Information Officer in two stages (as described in Appendices F and G). In Stage 1 
of the extraction process, one in every 100 consumers was randomly selected from the 
Medicare Public Enrolments database on the basis of the PINs associated with 
Queensland postcodes. Note that while the consumer PIN is associated with the Medicare 
card, it is not related to the Medicare card number or personal characteristics such as age, 
gender and the payment category. The use of the PIN as a basis of sample selection 
therefore ensured a random sample of patients for the study. In Stage 2 of the extraction 
process, which was also carried out by Medicare Australia Information Officer, 
prescriptions dispensed during 2004 and 2005 for the PINs randomly selected in Stage 1, 
were extracted from the PBS database.  
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The extraction of prescription data based on the consumer PIN also enabled the 
identification of multiple episodes of supply of prescription medicines to the same 
consumer. However as PBS data is collected on the basis of “dispensing episodes”, the 
data were supplied to the researcher in an ASCII format with a row for each episode of 
dispensing. The data files for 2004 (comprising 299,639 episodes of dispensing) and 2005 
(307,896 episodes) represented medications supplied to the same cohort of patients over 
two consecutive years. An extract of the ASCII format data file for 2004 provided by 
Medicare is presented as Appendix H.  Appendix I shows the ASCII data file for 2004 after 
it was exported to Excel with another column named “Row” representing row number 
added to it. The data file for 2005, which was identical in structure except that it comprised 
307,896 episodes of dispensing, was also exported to Excel. As the PIN was common to 
both tables it was possible to combine the two Excel tables in an Access database and 
store as a master copy. All manipulations to convert the format to one patient/case per row 
were carried out using a copy of the master copy. These are described in more detail later 
in the chapter.  
 
As the data files were not in a format to be immediately analysed with SPSS, they 
had to be reconfigured to show each consumer’s data in a single row. The process used to 
convert this data to one row per patient posed a significant challenge. Details of these 
challenges and how they were overcome are described later in this chapter. 
 
Ethical and Privacy Considerations 
 
The use of PBS data in this study was approved by the External Requests 
Evaluation Committee (EREC) of Medicare Australia. This committee assessed the 
request for the use of PBS data for research against the Privacy, Information Access and 
Release Policy of Medicare Australia. Correspondences relating to the granting of the 
approval for the use of PBS data, storage of the data and reporting of the findings in the 
thesis are presented as Appendices J and K. This includes a letter approving the use of 
data for research and specifying the conditions on which the data will be released 
(Appendix J), responsibilities in relation to protecting patient privacy and approval to 
publish the findings as a thesis (Appendix K).  Ethical clearance was also obtained from 
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the Behavioural and Social Sciences Ethical Review Committee (BSSERC) at the 
University of Queensland. This is presented as Appendix L.  
 
This study did not involve direct contact with patients/consumers. It consisted of an 
analysis of existing data which is routinely collected in the course of consumer purchase of 
PBS medications. Prescriptions subsidized by the PBS are supplied on the understanding 
that any data collected is likely to be used for audits and research, subject to safeguards 
on privacy, confidentiality and anonymity. 
 
Data relating to PBS claims are not stored by an individual’s name or Medicare card 
number, but by the Medicare PIN which is generated internally by Medicare Australia. The 
Medicare PIN is a unique number for each individual, and is not related to the individual’s 
Medicare card number, address or date of birth. While an individual’s “PBS claims data” 
will contain the individual’s name and Medicare card number, the data is organized, stored 
and handled using the Medicare PIN. It is not possible, for example, for anyone who 
knows the name, date of birth and/or Medicare number of another person to be able to 
work out that person’s Medicare PIN. Conversely it is not possible to work out a person’s 
name, address, date of birth or other personal characteristics by using their Medicare PIN. 
In this study, the Medicare PIN was de-identified and scrambled prior to data release to 
the researcher, thus ensuring a second layer of confidentiality and anonymity for the 
patients/consumers who purchased medication. 
 
During analysis, data on medication use was stored in a password protected 
database. The researcher and the principle supervisor were the only persons to have 
access to these data. As this study did not use data on medical consultations from the 
Medicare Benefits Scheme (MBS) database, it was not possible to link an individual’s 
medical profile from the MBS and medication profile from the PBS database.   
 
Study Variables 
 
The structure of the data files for 2004, which comprised 299,639 dispensing 
episodes with the variables as column headings, is shown in Appendix M. The layout of 
the 2005 data file was identical with respect to the variables except that it contained 
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307,896 episodes of dispensing, with each dispensing representing the purchasing of one 
prescription medicine.  
 
Dependant Variable. 
The key outcome measure for the number of PBS medications purchased was the 
number of prescriptions supplied to the consumer, and the difference in prescriptions 
between 2004 and 2005. These two years were chosen because in January 2005 there 
was an unprecedented 21% increase in patient copayment for PBS medication.  
 
Independent Variables. 
Independent variables included factors pertaining to the patient and the medication 
purchased. 
 
Patient Variables were age, gender and payment category (general, concessional). 
For the descriptive overview of patients, age was categorised into six groups, 0-14, 15-
24, 25-44, 45-64, 65-74, 75 and over. For the inferential analysis, age was re-
categorised into three groups to represent young adults aged 25-44, middle aged 
persons aged 45-64; and, older persons aged 65 and over. This collapsing of 
categories enabled a more meaningful analysis of the data and interpretation of the 
findings. 
 
Medication Variables were the Year of Supply (2004 or 2005) and Level of 
Medication Use, which was calculated from the total number of prescriptions using the 
following categories: less than 24 prescriptions during the calendar year (representing 
a mean of fewer than 2 prescriptions per month during the calendar year); 24-59 
prescriptions during the calendar year (mean of 2 to less than 5 medications per 
month); and, 60 prescriptions and more during the calendar year (mean of 5 
prescriptions or more per month).  In this thesis these levels of medication use 
represented non-polypharmacy, minor polypharmacy and major polypharmacy 
respectively.  Medication variables also included the PBS item name of the medication 
and the description of the medicine at level 5 of the ATC classification system.  
81 
 
 
Table 3.1 presents the oral hypoglycaemic medication “metformin” as an example to 
demonstrate the hierarchical nature of the ATC classification system. Level 5 is the lowest 
level of classification which corresponds to the chemical name of the medication. Under 
the ATC system of classification, medications are divided into different groups according to 
the organ or system of the human body on which they act, and their chemical, 
pharmacological and therapeutic properties.  
 
Table 3.1. Classification of the oral hypoglycaemic medication metformin using  
ATC classification system 
ATC level ATC code Description 
ATC level 1 A Alimentary tract and metabolism (Anatomical main group) 
ATC level 2 A10 Drugs used in diabetes  (Therapeutic subgroup) 
ATC level 3 A10B Blood glucose lowering drug, excl. Insulin (Pharm subgroup) 
ATC level 4 A10BA Biguanides (Chemical subgroup) 
ATC level 5 A10BA02 Metformin (Chemical substance) 
Source: WHO (2010b) 
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  As mentioned above, the data file supplied to the researcher described the 
medication only at level 5 of the ATC classification system. The descriptive analysis and 
inferential statistics components of the study required analysis of medication use at ATL 
levels 1, 2 and 3. Variables describing the medications at other levels (i.e. levels 1-4) of 
the ATC classification system were constructed using a reference table which mapped the 
medication from level 5 to other levels of the ATC classification system. An extract of this 
reference table is presented in Appendix N 
 
Data Cleaning and Pre-analysis Procedures 
 
The aim of the pre-analysis procedure was to check the integrity of the data set, 
assess the variables in the dataset for adequacy in the analysis of the research questions 
and prepare the dataset for compatibility with SPSS. This included reconfiguring the data 
from one row per episode of dispensing to one row per patient.   
 
Reliability and validity checking. 
The data file was checked for consistency with the data specifications and data 
requirements for the analysis, including all the variables needed to investigate the 
research questions. Preliminary checks were conducted on the data file for accuracy, 
consistency and missing values. As the PBS database is used for payment of claims the 
data, as expected, were found to be relatively clean and free of missing values. After 
preliminary checks the data for 2004 and 2005 were transferred into Microsoft Excel and 
stored as the master data file. All data manipulations, such as recoding interval to 
categorical data, were conducted on a copy of the Excel master so that the original file 
was kept pristine. 
 
Data inclusion and exclusion criteria. 
Only those consumers who were supplied prescription medicines in both the 
calendar years 2004 and 2005 were included in the study. The use of this criterion 
ensured that consumers who passed away or started purchasing medications from a state 
other than Queensland during 2004 were not included in the study. Outliers were 
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considered on a case by case basis. They were included if they represented plausible high 
and low users of prescription medicines and were not determined to be the result of coding 
errors. For example, a patient aged 75-84 who purchased 294 mostly chronic disease 
medications in 2004 but only 54 in 2005 was excluded as it was considered plausible he 
did not purchase medications throughout the 2005 calendar year. 
 
As shown in Table 3.2, the initial combined dataset for 2004 and 2005 comprised a 
total of 561,648 unit records of dispensing, representing 20,639 consumers. A total of 
7,116 consumers (3,397 in 2004 and 3,719 in 2005) were excluded because they did not 
have prescriptions supplied in both 2004 and 2005. This resulted in the exclusion of 
21,237 unit records from the study (Table 3.3). At this point the dataset comprised a total 
of 540,411 prescriptions to 13,523 consumers (representing 267,164 prescriptions in 2004, 
and a slightly higher number of prescriptions in 2005, namely, 273,247).  
 
Table 3.2. Effects of inclusions and exclusions on the study cohort 
Item 2004 2005 Total 
Unit records in raw dataset 277,734 283,914 561,648 
No of consumers in raw data set 20,639 20,639 20,639 
Consumers excluded due to 0 
prescriptions 
3,397 3,719 7,116 
Records excluded due to 0 supplies 10,570 10,667 21,237 
Total unit records in study cohort 267,164 273,247 540,411 
Total consumers in study cohort 13,523 13,523 13,523 
 
 
Reconfiguration of the dataset. 
Prior to reconfiguration, the data file comprised 540,411 unit records, with each 
record representing an episode of dispensing during the calendar years 2004 and 2005. 
As mentioned earlier, this format was not compatible with the version of SPSS used in the 
analysis of the data for the thesis as the statistical package treated each record as a 
84 
 
dispensing event not a different consumer. The data were therefore reconfigured to have 
each consumer’s data for 2004/2005 as a single case in a single case (row) in SPSS.  An 
extract of the combined 2004 and 2005 data file (n=540,411 dispensing events) prior to 
the reconfiguration to one row per consumer is presented in Appendix O.  
  
The reconfiguration to one row of data per consumer was performed in two stages 
as described in Guy and Ciguere (2006), which provides the procedures required in 
converting a one line per episode/observation dataset into one line per patient/case.  
 
Stage 1 – Aggregation in SPSS. The first stage was performed in SPSS and 
involved the use of the Aggregate procedure to obtain summary statistics for the 
dependent variable for each consumer and for each of the independent variables. Using 
the Aggregate procedure in SPSS, break variable(s) are variables for which a summary 
statistic is to be computed and aggregate variable(s) are the variables to be summarised. 
In this data file the aggregate variable was the dependent variable and the break variables 
were the independent variables.   
 
The application of the Aggregate procedure produced summary statistics for the 
number of prescriptions supplied under each of the five ATC categories and reduced the 
data set from 540,411 rows to 168,839 rows.  Appendix P provides a snapshot of the 
result of the first stage of the Aggregate procedure. Note that while the dataset was still not 
in the form of one row per consumer, the data file at this point was reduced to one row per 
unique prescription medicine supplied under each of ATC levels 1 - 5.  
 
Stage 2 – Crosstabulation in MS Access. To complete the reconfiguration to one 
row per consumer, the aggregated data file was exported into an MS Access database 
and saved as a table. The second stage of reconfiguration of the data was performed 
using queries and crosstabulation functionalities of MS Access. This stage required the 
creation of additional variables from individual categories of selected independent 
variables. Three steps of data manipulation were required in MS Access to generate a 
data file with one row per consumer. In the first step the query function was applied to the 
aggregated table (n=168,839 rows) produced in Stage 1 to select variables of interest in 
relation to the research questions. In the second step the crosstabulation function was 
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used to transform categories of selected independent variables from row to column 
variables. These variables were selected on the basis of their relevance to the research 
questions and included ATC Level_1 Description (14 categories), payment category (three 
categories) and year of supply (two categories).  Appendix Q shows the 14 categories of 
medicines that comprise level 1 of the ATC classification system. 
 
As a result of a sequence of queries and crosstabulations in Access, four tables 
were generated, each with one-row per consumer, and with the index variable “Person_id” 
present in all four tables. Tables 1 and 2 contained data on the number of prescriptions in 
2004 and 2005 respectively. In both these tables the column heading of “Person_id” and 
anatomical categories (n = 14) that represent ATC level 1 were used. The third table 
contained data pertaining to the prescriptions supplied under columns headed “Person_id”, 
“year of supply” (2004, 2005) and “payment category” (concessional, general and entitled). 
The fourth table referenced “Person_id” to age in 2004 and gender. It was assumed that in 
2005 the gender of the patient would remain the same, and that they would have been one 
year older than in 2004. 
 
In the final step, the query function in Access was used to link the four tables using 
the index variable common to all four tables, which in this case was “Person_id”. All 
variables were copied into a new table. The new table with 13,523 rows showing each 
consumer’s data in a single row was imported to SPSS as a data file and was used for the 
descriptive and inferential analyses. An extract of this table is shown in Appendix R.  
 
More recent versions of SPSS have better procedures for working with ‘Long’ forms 
of data such as PBS unit records. This includes processes for moving from ‘Long’ to ‘Wide’ 
formats, which may have simplified the process described above. However this data 
reconfiguration process was the only option available in 2007 when the process was 
undertaken as a part-time doctoral candidate. 
 
Analysis  
 
Statistical analysis was performed with SPSS version 15 (SPSS Inc., 2009). The 
distribution of data for each variable was examined using box plots and tables of 
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percentiles. For categorical variables, frequencies and percentages were reported. Tests 
for assumptions of normality were conducted. For the analysis of the research questions, 
variables where the distributions were non-normal, nonparametric analysis was conducted 
using the median and interquartile range for descriptive, and tests such as the Wilcoxon 
Matched Pairs Signed Rank, for inferential statistics. Non-parametric statistic was chosen 
because the dependent variable (number medications purchased) showed a non-normal 
distribution and as expected was skewed towards the older age groups. Comparisons of 
purchases in 2004 and 2005 according to payment category (concessional/general), age, 
gender and level of medication use were made using crosstabs and chi-square statistics.  
 
The first stage of analysis was a descriptive analysis. Data on prescription use were 
summarised across patient categories of age and gender and payment category (based on 
level of copayment in 2004), and prescription related variables of medication type (based 
on the 14 categories of medicines that comprise level 1 of the ATC classification system) 
and level of multiple medication use in 2004. Nonparametric inferential statistics were used 
to investigate the research questions. A listing and properties of all the variables used in 
the descriptive and inferential analyses is presented as Appendix S.  The classification of 
medications at ATC levels 2 and 3 are provided in Appendices T and U respectively. 
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As listed in Chapter 1 the Research Questions for this study were: 
 
1. Did the copayment increase in 2005 coincide with a change in the volume of 
prescriptions purchased compared to 2004? 
 
2. If there was a change in volume of prescriptions purchased, did it vary 
according to age, gender and the concessional status of the consumer?  
 
3. Did consumers on multiple medications respond differently to the increase in 
copayment? 
 
4. If there were differences in medication purchases between 2004 and 2005, 
were they distributed equally across therapeutic classes of medications, or 
did some classes experience bigger changes in prescriptions than others? 
 
Research Question 1 was addressed through analysis of the change in the total 
number of prescriptions from 2004 to 2005. This included changes in purchasing at the 
patient level to identify subgroups based on payment category (concessional, general) that 
demonstrated increased and decreased medications purchased in 2005.  
 
Research Question 2 was answered by a comparison of the total number of 
prescriptions by age, gender and payment category of the prescription in 2004 and 2005.  
 
Research Question 3 pertained to changes in medication use in 2005 compared 
with level of medication use (i.e., polypharmacy) in 2004. Three levels of medication use 
were analysed: less than 24 prescriptions in 2004; 24-59 prescriptions in 2004; and 60 
prescriptions or more in 2004. These categories represented no polypharmacy (mean of 
fewer than 2 prescriptions per month for a year), minor polypharmacy (mean of 2 to less 
than 5 prescriptions per month) and major polypharmacy (mean of 5 or more prescriptions 
per month) respectively.  
 
Research Question 4 was answered by a comparison of changes in prescription 
use from 2004 to 2005 by class of medication classified at ATC levels 2 and 3. Medication 
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classes selected for analysis as part of RQ 4 belonged to the National Health Priority 
Areas (NHPAs) of cardiovascular, nervous, musculoskeletal, alimentary and respiratory 
system disorders. Prescriptions belonging to the anti-infective class were also chosen to 
facilitate an investigation into changes in discretionary medication use with increase in 
price. Appendices T and U present categories of medicines that comprise levels 2 and 3 of 
the ATC classification system respectively. 
 
Results of these analyses are presented in the next chapter. 
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CHAPTER 4.  RESULTS 
 
Introduction 
 
This chapter presents an overview of medication purchase patterns for 2004 and 
2005, and the findings pertaining to the research questions. The first part of this chapter 
describes the patient demographic characteristics of age and gender, and the prescription-
related variables of payment category and level of medication use. This is followed by a 
description of prescription use. The second part of this chapter presents the findings 
regarding changes in medication purchasing patterns following the introduction of a 21% 
copayment increase.   
 
As discussed in the previous chapter, the findings are based from analyses that were 
undertaken on a single dataset that was from two independent sources of data.  This new 
dataset was examined for outliers and missing data.  In order to test assumptions for 
analysis, distributions of the sample and subsamples were conducted. Outliers and 
missing data were dealt with on a case by case basis. For example, 0.7% (n=88) of the 
sample lacked information about their payment status (general or concessional), so these 
patients were excluded from analyses involving payment category. Outliers represented 
patients associated with a very high number of prescriptions in 2004 or 2005. These 
patients were examined for the type of medications purchased.  For example, of the four 
(4) patients who purchased 539, 345, 295 and 294 medications respectively in 2004, three 
(3) were included in the study as the level of purchasing was similar in 2005 and the profile 
comprised a mixture of acute and chronic disease medications. The fourth patient aged 
75-84 who purchased 294 mostly chronic disease medications in 2004 but only 54 in 2005 
was excluded as it was considered plausible that he did not purchase medications 
throughout the 2005 calendar year due to either death or migration out of Queensland. 
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Sociodemographic Characteristics 
 
Age and gender. 
Table 4.1 presents a distribution of the patients (n=13,523) and prescriptions 
(n=267,164) according to age, gender, payment status and level of medication use. As can 
be seen in this table, slightly over half the subjects were female. Compared to the gender 
distribution at the Queensland census of 2006, males were under-represented (49.7% v 
43.1%) and females were over-represented (50.5% v 56.9%) in the study cohort.  
 
Adults in the pre-retirement age group of 45-64 years comprised approximately one-
third of the study cohort, with a further one-quarter (24.2%) being 65 years and over. The 
next largest age group, 25-44 years, represented 21% of the study cohort. Children from 
birth to 15 years were under-represented (20.7% v 11.7%), as were young adults aged 15-
24 (13.8% v 8.5%). Retirees aged 65 and over were substantially over-represented in the 
study cohort (12.4% v 24.2%) compared to the Queensland population.  
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Table 4.1. Overview of patients (N=13,523) and prescriptions (N=267,164) purchased 
in 2004 
  Patients   Prescriptions  
 n (%) n (%) mean 
Gender 
Female 7,690 (56.9%) 159,177 (59.6%) 20.7 
Male 5,833 (43.1%) 107,987 (40.4%) 18.5 
Total cohort 13,523  267,164  19.8 
Payment category 
Concessional* 7,285 (53.9%) 102,697 (38.4%) 14.1 
Concess/Entitle** 1,827 (13.5%) 111,734 (41.8%) 61.2 
General*** 3,260 (24.1%) 25,764 (9.6%) 7.9 
Gen/Concess**** 1,063 (7.9%) 23,781 (8.9%) 22.4 
Other***** 88 (0.7%) 3,188 (1.2%) 36.2 
Age 
0-14 1,584 (11.7%) 7,896 (3.0%) 5.0 
15-24 1,144 (8.5%) 7,303 (2.7%) 6.4 
25-44 2,984 (22.1%) 33,792 (12.6%) 11.3 
45-64 4,533 (33.5%) 95,262 (35.7%) 21.0 
65-74 1,962 (14.5%) 67,898 (25.4%) 36.4 
75 and over 1,316 (9.7%) 55,013 (20.6%) 41.8 
Level of Medication Use 
<24 prescriptions 9,789 (72.4%) 76,620 (28.7%) 7.8 
24-59 prescriptions  2,748 (20.3%) 103,021 (38.6%) 37.5 
>=60 prescriptions  986 (7.3%) 87,523 (32.8%) 88.8 
*Concessional patient throughout 2004; **Concessional patient who reached the safety net threshold during 
the calendar year; ***General patient throughout 2004; ****General patient who reached the safety net 
threshold during the calendar year; *****Unable to establish status of the payment. 
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While the total number of female patients (56.9%) outnumbered the total number of 
male patients (43.1%), there were more males than females in all age groups except in the 
age groups 15-24, and 75 and over (Figure 4.1). The age group 45-64 comprised the 
highest proportion of patients for both genders.  
 
 
Figure 4.1. Gender and age of patients 
 
Distribution of payment category. 
As discussed in Chapter 1, payment categories under the PBS reflect different 
levels of subsidy to the patient. All PBS patients start the calendar year either as general 
or concessional patients.  Table 4.1 shows that 9,112 (7,285 + 1,827) of the study cohort 
started 2004 as concessional patients. They represented 67.4% of the study cohort. Of 
this, 53.9% remained concessional throughout 2004 paying a highly subsidised copayment 
of $3.80 per PBS medication (Table 1.1), while the remaining 13.5% reached the safety 
net threshold for the concessional patients and qualified for free medications for the 
remainder of the calendar year.  
 
Table 4.1 also shows that about one third (24.1% + 7.9%) of the patients in the 
study cohort started 2004 by paying the general copayment rate of $23.70 for their 
0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
40.0%
0-14 15-24 25-44 45-64 65-74 75 and
over
Female
Male
 93 
 
medications. Of this 24.1%, (n=3,260) paid the general copayment throughout the 
calendar year.  However, just over one thousand (7.9%) of the general patients in the 
study cohort reached the general patient safety net (prescription medication expenditure of 
$726.80 in 2004).  This qualified them to purchase medicines at the concessional rate 
($3.80) for the remainder of the year.  
Female concessional patients outnumbered males (n = 5,443; 59.7% and n = 3,669; 
40.3% respectively).  In comparison, for the general patients in the study cohort the 
proportion of males and females was similar (50.9% v 49.1%).  
 
Distributions of Medications in 2004 
 
By level of medication use. 
Table 4.1 shows that over 70% of the patients (n=9,789) used fewer than 24 
prescription medications in 2004, that is, an average of less than two prescriptions per 
month for the calendar year. Approximately 7.3% of the study cohort (n=986) used 60 
prescriptions or more in 2004. This is an average of five prescription medicines or more 
per month, and constitutes major polypharmacy. The remaining 20.4% of the patients used 
between 24-59 prescriptions in 2004 (between two and almost five prescription medicines 
per month, on average), constituting minor polypharmacy. 
 
Age and gender. 
The literature review identified age and gender to be predictors of health and 
medication use. Age is also an important consideration in the analysis of PBS medications 
because entitlement to an aged pension card is age-related, and pensioners make up a 
large component of concessional patients.  
Females purchased a median of 11 prescriptions in 2004 and males purchased a 
median of ten. This difference was significant (mean rank for males = 6649.34, and for 
females = 6847.46: z= -2.93, p=.003). Figure 4.2 plots the mean number of prescriptions 
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(number of prescriptions for the age group divided by number of persons in that age 
group) for males and females. It shows that while females purchased slightly more 
medications than males overall, the gender difference in favour of females started to 
emerge in the older working age persons (45-64 years), and was the highest in the post 
retirement age groups. 
 
 
Figure 4.2. Mean number of prescriptions purchased per person by age and 
gender, 2004 
 
The trend towards increased prescriptions with age is better illustrated in Figure 4.3 
which plots the median scores for the number of prescriptions purchased in 2004. This 
shows a pattern of gradual increases in prescriptions for both genders to age 25 followed 
by sharp increases thereafter. It also shows very little gender difference in prescriptions up 
to age 45 and a Mann-Whitney U Test revealed no significant gender difference in these 
age groups. After this, females start to steadily increase the number of prescriptions 
purchased as they age, with women 75 and over purchasing ten more prescriptions than 
men.  For ages 65-74, the difference in the number of prescriptions for males (Mdn = 24; 
n=931) and females (Mdn = 30; n = 1,031) was significant (U = 411497, z = -5.46; p<.001), 
as was the difference for those aged 75 and over (Mdn for males = 30; n=462; females 
Mdn = 40; n = 854; U = 159818, z = -5.69; p<.001, r = 0.16). 
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Figure 4.3. Median number of prescriptions in 2004 by age and gender 
 
Gender and multiple medication use in 2004. 
Table 4.2 provides the distribution of patients and prescriptions for each level of 
prescription use. As mentioned in the Preface in this thesis major polypharmacy refers to a 
mean five or more medications purchased per month during 2004, and minor 
polypharmacy refers to a mean of two to fewer than 5 medications purchased per month 
during 2004. Non-polypharmacy represents the purchase of fewer than two medications 
purchased per month during 2004.  
More than half the patients at every level of medication use were women, and more 
than half the prescriptions were also for women, except for patients who purchased less 
than 25 prescriptions, and 60 or more prescriptions in 2004. However for the minor 
polypharmacy group, the difference in prescriptions between men (Mdn=34; n=1,162) and 
women (Mdn=37; n=1586) was significant, (U=832178, z= -4.35, p<.001).  
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Table 4.2. Gender and multiple medication use in 2004 
 Female patients  Male patients 
Level of 
polypharmacy 
% of total 
scripts 
purchased 
Median 
annual 
purchase 
 % of total 
scripts 
purchased 
Median 
annual 
purchase 
none 55.2% 6  44.8% 7 
minor 58.9% 37  41.1% 34 
major 64.3% 77.5  35.7% 78 
 
Age, gender and multiple medication use in 2004. 
To facilitate interpretation and comparison, age was collapsed into three categories, 
25-44, 45-64 and 65 and over, and subjected to cross tabulation. As can be seen in Figure 
4.4, while the majority of younger patients aged 25-44 years were not exposed to 
polypharmacy, minor polypharmacy was present in 8.4% of patients in this age group.  
This proportion increased to just over 42% in patients aged 65+.  Figure 4.4 also shows 
minor polypharmacy to be more prevalent than major polypharmacy in each of three age 
categories. Major polypharmacy existed in only 2% of patients aged 25-44, compared to 
almost 20% in patients age 65+. The increases in major and minor polypharmacy with age 
were all statistically significant, χ² (4, n=10,795) =1899.28, p<0.001, Cramer’s V=0.30.  
 
Figure 4.4.  Medication use at major, minor and non-polypharmacy levels according 
to age in 2004 
25-44 45-64 65 and over
>=60 prescriptions 2.1% 6.5% 18.9%
24-59 prescriptions 8.4% 23.2% 42.2%
<24 prescriptions 89.4% 70.4% 38.8%
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As can be seen in Figure 4.5, polypharmacy (minor and major) increased with age 
for both genders.  In the younger age groups, men and women exhibited more or less the 
same proportions of minor and major polypharmacy.  However, there was a significant 
increase in multiple medication use in those aged 65 and over.  In this group a higher 
proportion of women than men demonstrated significantly higher levels of both minor 
polypharmacy and major polypharmacy (χ² (2, n = 3278) = 62.93, p<0.001, phi =.139).  
 
 
Figure 4.5.  Medication use at major and minor polypharmacy levels according to 
gender and age, 2004 
 
Distribution of Prescriptions classified at ATC Level 1  
 
The Anatomical Therapeutic Chemical (ATC) classification level 1 was used to 
investigate the type of prescriptions purchased. In ATC level 1 the medication is divided 
into 14 main groups reflecting the anatomical systems within the body on which the 
medication acts (WHO, 2010b).  
 
Overall, 267,164 prescriptions were dispensed to the 13,523 patients in 2004. Table 
4.3 presents the distribution of these prescriptions for 5 of the 14 categories that comprise 
ATC Level 1 groupings. In terms of prescriptions, three classes of medications, those that 
act on the cardiovascular system, nervous system and alimentary/metabolic system, 
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accounted for almost two thirds (65%) of the total prescriptions purchased in 2004. The 
latter class includes subclasses of medications for disorders such as gastric reflux and 
diabetes. The nervous system group includes analgesics, anti-psychotics and medications 
for anxiety and depression.    
 
The National Health Priority Area (NHPA) medication groups comprise prescriptions 
for conditions that require treatment with nervous system agents, cardiovascular agents, 
musculoskeletal agents, respiratory system agents and alimentary tract medications. 
These medication groups were the focus of this study.  Prescription purchases for another 
ATC level 1 medication group, anti-infectives, was investigated further in this study 
because it was the most commonly used medication group (49.7%), and its use has been 
found to be independent of age and gender.  This acts as a quasi-control in analyses of 
the purchase patterns of medications that show differential use according to age, gender 
and concessional status.  The inclusion of anti-infectives also enabled an examination of 
the impact of cost on the purchasing of medications for the treatment of acute illness 
compared to chronic illnesses.  
 
The first part of the analysis of specific medications focused on Anatomical 
Therapeutic Chemical (ATC) classification level 1, which refers to the part of the human 
anatomy the medication acts on (Appendix Q). Subsequent analyses investigated each of 
the six medication groups selected for this study (the five NHPA medications and anti-
infectives) and their distribution at the therapeutic sub-group level (ATC level 2; see 
Appendix T).  
 
Table 4.3 lists patients and prescriptions for each of the five major NHPA medication 
classes investigated in this study. Anti-infective medications, a majority of which are oral 
antibiotics, accounted for 7.6% of the prescriptions overall, but was the most commonly 
used medication group in terms of the number of patients prescribed a medication from 
this group (50%). Similarly, medications acting on the respiratory and musculoskeletal 
systems accounted for less than 10% of total prescriptions but were associated with a 
much higher number of patients. Other medication groups were associated with a much 
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higher number of patients relative to prescriptions. These were for chronic disease 
medications belonging to cardiovascular, nervous and musculoskeletal classes.   
 
Table 4.3. NHPA prescriptions classified at ATC level 1 and patients in 2004 
Anatomical Main 
Group Prescriptions 
 
Patients 
Average 
prescriptions 
per patient 
 N % of total*  
 
N % of total**  mean median 
Cardiovascular  83,601 31.3%  5378 39.8% 15.5 12 
Nervous system 56,833 21.3%  6007 44.4% 9.5 5 
Alimentary tract  34,13 5 12.8%  4553 33.7% 7.5 6 
Musculoskeletal  20,516 7.7%  3817 28.2% 5.4 3 
Respiratory  15,123 5.7%  2816 20.8% 5.4 3 
Anti-infectives 20,232 7.6%  6,720 49.7% 3.0 2 
*Total number of all types of prescriptions purchased was 267,164.  **Total number of patients was 13,523. 
 
Gender and medication type. 
Table 4.4 presents a breakdown on the purchase of prescriptions for the above six 
medication groups according to gender and their Mann-Whitney U statistics.  As can be 
seen in this table, women accounted for over half (58.3%) of the prescriptions overall. 
They purchased significantly more prescriptions for the nervous system (N.S.), alimentary 
tract (abbreviated to A.T. in the table), musculoskeletal system (M.S.) and anti-infectives 
than men.  There was no significant difference in prescription purchase in 2004 between 
men and women for medications for the management of cardiovascular and respiratory 
system disorders.  
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Table 4.4.  Prescriptions classified at ATC level 1 and gender 
 
Male 
 
Female 
 
Mann-Whitney U 
Statistics 
ATC 
group 
No. 
scripts Med 
Mean 
rank 
 No. 
scripts Med 
Mean 
 rank 
 
U Z p 
CVD  39,091 12 2669.85  44,510 15.5 2706.68  354986 -0.869 .38 
N.S.  21,500 5 2901.96  35,333 9.6 3069.07  405104 -3.662 
.000* 
AT 14,218 6 2336.48  19,917 7.4 2235.54  239736 -2.566 .01* 
M.S.  7,523 3 1834.09  12,993 5.6 1959.39  163644 -3.497 
.000* 
Resp. 6,300 3 1428.56  8,823 5.3 1394.49  93675 -1.119 .263 
Anti-
infect. 
7,569 2 3270.27 
 
12,663 3.0 3417.62 
 
512474 -3.151 
.002* 
* Significant at .05 level or better 
 
Prescriptions classified at ATC level 3 and gender.  
Results of a similar analysis with the medications classified at a lower ATC level 
(ATC 3) are presented in Table 4.5. This analysis revealed that, when classified at ATC 
level 3, gender differences in prescriptions were statistically significant for 1) the 
antihypertensive class of medications which act on the renin-angiotensin system, the 
majority of which are ACE Inhibitors (use by females exceeded use by males), 2) non-
opioid analgesics, and antidepressants (use by females exceeded use by males), and 3) 
anti-infectives (use by females exceeded use by males).  In contrast, there was no 
significant gender difference in the purchasing of cholesterol lowering medications, opioid 
analgesics, antianxiety agents, anti-ulcerants (for peptic ulcer and reflux), antidiabetics, 
musculoskeletal agents and asthma inhalants. 
 
 101 
 
Table 4.5.  Prescriptions classified at ATC level 3 by gender 
  Males  Females  Mann-Whitney U Test 
  N (%)  Mean rank  N (%)  Mean rank  U Z sig 
Cardiovascular disease medications 
Renin-Ang. agents  1454 
(46.9%) 
 2151107.5  1649 
(53.1%) 
 2664748  1093322.5 -4.278 <.001 
Cholesterol agents  1554  
(50.2%) 
 1542.81  1540 
(49.8%) 
 1552.23  1189296.5 0.295 0.768 
Nervous system medications 
Opioid analgesics  728  
(40.1%) 
 918.13  1087 
(59.9%) 
 901.22  388293.5 -0.709 0.478 
Simple  analgesics  669 
(35.8%) 
 879.17  1202 
(64.2%) 
 967.63  364049.5 -3.492 <.001 
Antidepressants  1018 
(34.7%) 
 1410.87  1918 
(65.3%) 
 1499.09  917592.5 -2.692 0.007 
Anxiolytics  348  
(34.1%) 
 503.46  672 
(65.9%) 
 514.15  114477.5 -0.563 0.573 
Hypnotics and sedatives  305 
(33.7%) 
 432.07  600 
(66.3%) 
 463.64  85116.5 -1.784 0.074 
Alimentary tract medications 
Diabetes  300  
(47.0%) 
 320.72  338 
(53.0%) 
 318.42  50334 -0.158 0.875 
Anti-ulcerants  1297  
(43.9%) 
 1480.88  1655 
(56.1%) 
 1473.07  1067592 -0.248 0.804 
Musculoskeletal medications 
Anti-inflammatories   1365  
(40.7%) 
 1653.28  1990 
(59.3%) 
 1694.94  1324436.5 -1.252 0.211 
Respiratory medications 
Asthma inhalants  918  
(40.2%) 
 1163.84  1364 
(59.8%) 
 1126.47  605568.5 -1.368 0.171 
Anti-infective medications 
Antibiotics  2605  
(38.8%) 
 3270.27  4115 
(61.2%) 
 3417.27  5124742 -3.151 0.002 
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Age and medication type. 
There were statistically significant (p<.001) increases in medication use with 
increasing age in prescriptions for anti-infective, respiratory, musculoskeletal, alimentary 
and cardiovascular system medications (See Figure 4.6). For nervous system 
medications, the age-related increase in medication use was also significant (p=0.041) but 
not as strong. 
  
 
Figure 4.6. Median number of prescriptions by age, 2004 
 
Kruskal-Wallis analyses were conducted to determine the extent of medication use 
at ATC level 3 according to age.  These results are provided in Table 4.6.
0 2 4 6 8 10 12 14 16 18
Cardiovascular 
Nervous system
Alimentary tract 
Musculoskeletal system
Respiratory system
Anti-infectives 
Median number of prescriptions
65+
45-64
25-44
 103 
 
Table 4.6.  Prescriptions classified at ATC level 3 by age 
 Age 25-44 (n=2,984) Age 45-64 (n=4,533) Age 65+ (n=3,298)  
 n (%) mean 
rank 
n % mean 
rank 
n % mean 
rank 
Chi-
square 
sig 
Cardiovascular system 
Renin-Angiotensin agents 198 6.4% 1128.72 1405 45.3% 1446.74 1485 47.9% 1992.43 102.849 <.001 
Cholesterol lowering agents 216 7.6% 945.51 1364 48.3% 1309.87 1238 43.8% 1600.22 161.497 <.001 
Nervous system 
Opioid analgesics 456 25.1% 804.77 618 34.0% 878.22 619 34.1% 846.94 6.462 0.04 
Non-opioid analgesics 163 8.7% 610.84 434 23.2% 779.11 1078 57.6% 896.06 60.602 <.001 
Antidepressants 956 32.6% 1239.57 1098 37.4% 1369.85 602 20.5% 1394.32 20.603 <.001 
Anxiolytics 223 21.9% 487.54 350 34.3% 473.93 397 38.9% 494.56 1.071 0.585 
Alimentary tract 
Diabetes 52 8.2% 288.72 289 45.3% 307.64 292 45.8% 331.3 3.797 0.15 
Drugs for peptic ulcer and reflux 455 15.4% 1087.55 1244 42.1% 1395.98 1146 38.8% 1585.52 123.416 <.001 
Musculoskeletal system 
Anti-inflammatory agents 533 15.9% 1152.07 1417 42.2% 1629 1259 37.5% 1769.74 174.642 <.001 
Respiratory system 
Asthma inhalants 495 21.7% 748.22 640 28.0% 855.39 543 23.8% 903.98 29.121 <.001 
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As can be seen in Table 4.6, the change in medication use (classified at ATC level 
3) with age was significant for every medication class except antianxiety agents and 
antidiabetics. The pattern of change with age differed, however, indicating that the burden 
of medication use started earlier for some medication classes ( opioids, antidepressants,  
anxiolytics, for example) while for others (such as non-opioid analgesics) the increases 
took place later in life.  
 
Level of polypharmacy and medication type. 
Figure 4.7 shows that more than half (55.8%) of patients on medications for the 
cardiovascular system were exposed to either minor polypharmacy or major 
polypharmacy. Multiple medication use was also common in patients taking alimentary 
tract (55% of patients), musculoskeletal (52.1%) and nervous system medications.  Figure 
4.7 also shows that just over 60% of patients on medications for respiratory system 
disorders and anti-infectives, and about half the patients taking nervous system 
medications, were not affected by any form of polypharmacy. 
 
Figure 4.7. Multiple medication use and medication type at ATC level 1 
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Distribution of prescriptions classified at ATC level 2. 
  As can be seen in Table 4.7, medications for hypertension (i.e., agents acting on 
the renin-angiotensin system and calcium channel blockers) represented almost 50% of 
prescriptions for the cardiovascular group of medications, indicating the central role of 
blood pressure management in the treatment of cardiovascular and cerebrovascular 
diseases. The next largest group was prescriptions for cholesterol lowering medications, 
which accounted for 30% of the prescriptions in this group.  
 
Antidepressants and analgesics were the highest prescribed nervous system 
medications in 2004. The next largest ATC 2 group, comprising antipsychotics, antianxiety 
agents and hypnotics and sedatives, collectively accounted for one-fifth of the 
prescriptions. In the musculoskeletal system, anti-inflammatory agents accounted for 
about three-quarters of prescriptions in 2004 for musculoskeletal agents. The next largest 
groups were medications for bone disorders (e.g. osteoporosis) which represented about 
one-fifth of prescriptions.  
 
For medications acting on the respiratory system, almost all prescriptions were for 
obstructive lung diseases such as asthma and chronic obstructive pulmonary disease. 
Table 4.7 also shows that about 60% of prescriptions for alimentary tract disorders were 
for medications for acid-related disorders while medications for diabetes accounted for 
21% of the prescriptions and about 18% of the patients. 
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Table 4.7. Distribution of prescriptions in 2004 classified at ATC level 2 
Anatomical main group (ATC 1) and therapeutic subgroup 
(ATC 2) 
Patient  
(%) 
Prescription  
(%) 
Cardiovascular (n=5,378 patients)   
Agents acting on the renin-angiotensin system  57.7% 35.2% 
Lipid reducing agents 52.5% 29.2% 
Calcium channel blockers 24.6% 13.9% 
Beta blockers (for heart failure) 23.9% 10.3% 
Cardiac therapy 15.2% 6.5% 
Diuretics 16.9% 3.5% 
Nervous system (n=6,007)   
Analgesics 53.0% 31.8% 
Antiepileptics 7.7% 5.1% 
Antiparkinson 1.9% 1.7% 
Psychoanaleptics (includes antidepressants) 50.0% 39.5% 
Psycholeptics (includes anti-psychotics, anxiolytics) 31.4% 21.5% 
Alimentary tract (n=4,553)   
Anti-diarrheals  11.1% 4.2% 
Anti-emetics and anti-nauseants 11.2% 3.0% 
Drugs for acid related disorders  65.6% 60.3% 
Drugs for functional gastrointestinal disorders 11.0% 3.1% 
Drugs used in diabetes 17.4% 20.7% 
Mineral supplements 11.0% 4.4% 
Musculoskeletal system (n=3,817)   
Anti-gout preparations 10.2% 6.3% 
Anti-inflammatory medications 87.9% 74.3% 
Medications for the treatment bone diseases 12.0% 18.8% 
Other musculoskeletal agents 0.6% 0.6% 
Respiratory system (n=2,816)   
Cough and cold preparations 5.1% 2.0% 
Drugs for obstructive airway diseases  96.4% 98.0% 
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 Results of Inferential Analysis 
The following section present the results obtained from the analysis of the research 
questions posed in Chapter1:  
 
1. Did the volume of medication purchases change following the increase in 
copayment in Jan 1, 2005? 
2. If there was a change in volume of prescriptions purchased, did it vary according 
to age, gender and cost to the patient (copayment)?  
3. Did patients on multiple medications (polypharmacy) respond differentially to the 
increase in copayment compared to patients who did not require multiple 
medications for their medical condition? 
4. Was the impact of the copayment increase distributed equally across NHPA and 
anti-infective medication classes, or did some classes of medication experience 
bigger changes in prescriptions than others? 
 
Change in Total Prescriptions in 2005 
 
The aim of Research Question 1 was to determine whether the increase in copayment, 
which commenced Jan 1, 2005, resulted in a change in the number of prescription 
medicines dispensed compared to prescription medications purchased in 2004.  
 
The total number of medications purchased increased by 6,083 prescriptions in 2005, 
representing an increase of 2.8% over the 2004 total (Table 4.8). Concessional 
prescriptions increased from 180,252 prescriptions in 2004 to 185,047 prescriptions in 
2005, an increase of 2.7%. General prescriptions decreased from 33,068 in 2004 to 
33,499 prescriptions in 2005, representing a decrease of 7.1%. 
 
Positive ranks, which represented an increase in purchasing, outnumbered negative 
ranks, which represented a reduction in purchasing. About 44.6% (n=6,027) of the patients 
purchased more medications in 2005 than in 2004. A slightly lower 44.1% (n=5,964) of 
patients purchased fewer medications in 2005, and for 11.3% (n=1,532) of the study 
cohort there was no change in the number of medications purchased in 2005. 
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The median scores for the total number of prescriptions decreased from 11 in 2004 to 
10 in 2005. A Wilcoxon Signed Rank Test found the change in total prescriptions in 2005 
(mean rank of 5806.36 vs 6183.66) to be statistically significant (Z= -3.49, p<.001).  
 
Table 4.8. Change in the number of prescriptions between 2004 and 05 
 
N 
Mean  
Rank 
Sum of  
Ranks 
05 - 04 scripts Neg. ranks* 5964 5806.3 34629112.5 
Pos. ranks** 6027 6183.6 37268923.5 
Ties*** 1532   
Total 13523   
     *2005 < 2004; **2005 > 2004; ***2005 = 2004 
 
There was no significant gender difference between 2004 and 2005 medication 
purchases, with females comprising about 57% of consumers in both years. The ages of 
consumers was similar over the two years, except for those aged 65 and over, with 
significantly more people in this age group purchasing medications in 2005. By contrast, 
the group of patients who purchased fewer medications in 2005 had a higher proportion of 
individuals whose medication purchase patterns indicated minor polypharmacy and major 
polypharmacy.  
 
Change in Prescriptions in 2005 by Patient Demographics. 
The aim of Research Question 2 was to determine whether the change in the 
purchasing of medications varied across patient-related factors of gender, age and 
payment category (level of copayment) of the patient. The literature has identified these 
variables as predictors of medication use and cost-related changes in the purchasing of 
medications. 
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Changes in purchasing in 2005 by gender. 
For females, negative ranks slightly outnumbered positive ranks indicating more 
females reduced their number of prescriptions in 2005 than increased them (Table 4.9). 
However, although there was a reduction in the median number of prescriptions from 11 in 
2004 to 10.5 in 2005, this was not statistically significant (Z= -1.76, p=.078).   
By contrast, a higher number of males purchased more medications in 2005. A 
Wilcoxon Signed Rank Test found the increase in prescriptions for males in 2005 to be 
statistically significant, Z= -3.30, p=.001.  
Table 4.9 Change in prescriptions from 2004 – 2005 by gender 
Gender N 
Mean  
Rank 
Sum of  
Ranks 
F 05 - 04 scripts Neg Ranks* 3445 3331.6 11477672 
Pos Ranks** 3415 3530.1 12055558 
Ties*** 830   
Total 7690   
M 05 - 04 scripts Neg Ranks* 2519 2474.8 6234137 
Pos Ranks** 2612 2653.9 6932009 
Ties*** 702   
Total 5833   
*2005 < 2004; **2005 > 2004; ***2005 = 2004 
 
Changes in purchasing in 2005 by age. 
For this part of the analysis, the variable Age was re-categorised into three age 
groups to represent young adults (25-44 years), middle aged adults (45-64 years) and 
older adults (65 and over). These age groups represented 79.8% of the patients and 
94.3% of the prescriptions in 2004.  
For patients aged 25-44, negative ranks outnumbered positive ranks indicating more 
patients in this age group reduced purchases in 2005 than increased, but the change in 
the number of prescriptions in 2005 was not statistically significant. For middle-aged adults 
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(45-64 years), while the median number of prescriptions was unchanged, the increase in 
positively ranked medications purchased in 2005 was statistically significant (Z= -2.28, 
p=.023). In patients aged 65+, the positive ranks were higher than the negative ranks. A 
Wilcoxon Signed Ranks Test found the increase in prescription volume in 2005 for patients 
aged 65 and over to be significant (Z= - 5.75, p<0.001). Details are provided in Table 4.10.  
  
Table 4.10. Change in prescriptions from 2004 – 2005 by age 
Age                No of Scripts   N Mean Rank Sum of Ranks 
25-44 05 – 04 Neg. ranks* 1308 1270.2 1661522 
Pos. ranks** 1267 1306.3 1655078 
Ties*** 409   
Total 2984   
45-64 05 – 04 Neg. ranks* 2042 1972.0 4027005.5 
Pos. ranks** 2056 2126.3 4371845.5 
Ties*** 435   
Total 4533   
65+ 05 – 04 Neg. ranks* 1413 1495.2 2112845.5 
Pos. ranks** 1684 1594.0 2684407.5 
Ties*** 181   
Total 3278   
    *2005 < 2004; **2005 > 2004; ***2005 = 2004 
 
Changes in purchasing in 2005 by payment category. 
In this study, payment category of the prescription was used as a proxy for level of 
copayment. As stated in Chapter 1, general patients pay a much higher patient 
contribution for PBS medications than concessional patients. Under PBS all patients start 
the calendar year either as a general or concessional patient. When general patients reach 
the “general patient threshold”, they qualify for additional subsidy and pay the 
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concessional rate for the rest of the year. Similarly, when a concessional patient reaches 
the “safety net threshold” set for concessional patients they pay a much reduced payment 
for the rest of the calendar year, which in most cases is supplied at no cost to the patient. 
For concessional patients positive ranks outnumbered negative ranks, indicating that more 
concessional patients increased purchasing in 2005 than decreased (Table 4.11). 
 
Table 4.11 Change in concessional and general prescription from 2004 to 2005 
 Payment category 
  
  N 
Mean  
Rank 
Sum of  
Ranks 
No of concessional 
prescriptions  
Neg. ranks* 4712 4611.90 21731254 
Pos. ranks** 4804 4902.30 23550632 
Ties*** 4007  
Total 13523 
No of general 
prescriptions  
Neg. ranks* 2283 2156.27 4922774 
Pos. ranks** 1914 2030.68 3886729 
Ties*** 9326  
Total 13523 
*Negative Ranks = No. of prescriptions in 2005 < No. of prescriptions in 2004; **Positive Ranks = No. of 
prescription in 2005 > No. of prescription in 2004; ***Ties = No. of prescriptions in 2005 = No. of 
prescriptions in 2004. 
 
Analysis of mean ranks indicated this increase was statistically significant (Z= -3.40, 
p=.001). By contrast, for general patients negative ranks outnumbered positive ranks, 
indicating general patients reduced medication purchases in 2005. A Wilcoxon Signed 
Rank Test indicated this decrease was statistically significant (Z= -6.63, p<.001). 
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Change in Purchasing in 2005 by Level of Medication Use.  
To assess the relationship between level of medication use and purchasing behaviour, 
patients were grouped by the total number of medications purchased in 2004 into three 
levels of medication use: less than 24 prescriptions (representing no polypharmacy); 24-49 
prescriptions (minor polypharmacy); and 60+ prescriptions (major polypharmacy). 
 
For patients taking fewer than 24 prescriptions in 2004, positive ranks outnumbered 
negative ranks, indicating more patients in this group increased purchasing in 2005 than 
reduced their medication purchase (Table 4.12). The median number of prescriptions 
remained unchanged at six, but the mean positive ranks were higher than the mean 
negative ranks, indicating a significant overall increase in medication purchases in 2005 
(Z= -8.37, p<.001).  
 
For the minor polypharmacy category of patients, negative ranks outnumbered positive 
ranks by 100 cases, indicating that more patients reduced rather than increased 
purchases in 2005. Nearly half the patients (49.8%) purchased fewer medications in 2005 
than in 2004. Although the median number of prescriptions increased from 35 in 2004 to 
36 in 2005 and there was an increase in the overall number of medications purchased in 
2005 (mean rank 1301.69 v 1338.71), a Wilcoxon Signed Rank Test found this increase 
not to be statistically significant (Z= -1.06, p=.288).  
 
For the major polypharmacy group, 57.8% (n=570) of the patients purchased fewer 
medications in 2005 than in 2004 while 39.5% purchased more. The median number of 
prescriptions decreased from 78 in 2004 to 77 in 2005. The mean rank of the negative 
ranks was higher than that of the positive ranks indicating a reduction in the number of 
prescriptions. The reduction in prescriptions was statistically significant (Z= - 6.30, p<.001).  
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Table 4.12. Change in the level of medication use in 2005  
Level of  Medication  Use in 2004 
N 
Mean 
Rank 
Sum of 
Ranks 
< 24 scripts  
 
05 – 04 scripts Neg. ranks* 4025 3915.4 15759540 
Pos. ranks** 4368 4456.4 19465881 
Ties*** 1396   
Total 9789   
24 – 59 
scripts  
05 – 04 scripts Neg. ranks* 1369 1301.6 1782015 
Pos. ranks** 1269 1338.7 1698826 
Ties*** 110   
Total 2748   
>= 60 
scripts  
05 – 04 scripts Neg. ranks* 570 499.6 284800 
Pos. ranks** 390 452.5 176480 
Ties*** 26   
Total 986   
*2005 < 2004; **2005 > 2004; ***2005 = 2004 
 
Change in multiple medication use for general patients. 
For general patients who purchased less than 24 medications in 2004 (n=3,837), an 
equal proportion (42%) of the patients changed their number of medications purchased in 
2005 (Table 4.13). While the median number of prescriptions remained unchanged at 
seven prescriptions, the mean rank for the positive ranks was higher than that of the 
negative ranks, indicating a statistically significant increase in prescriptions for this group 
in 2005 (Z= -3.02, p=.003).  
 
General patients (n=484) who were in the minor polypharmacy category (24-49 
prescriptions) in 2004, 58.3% purchased fewer medications in 2005. The associated 
reduction in the number of medications purchased in 2005 was significant (Z= -4.71, 
p<.001). 
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Over half (56.2%) of the general patients with major polypharmacy (n=67) in 2004, 
purchased fewer medications in 2005. This reduction was not significant (Z= -1.84, 
p=.066). Relative to other categories, this category of patients represented a much smaller 
sample, and it is possible that with a larger subsample statistical significance would be 
reached. Although not reaching statistical significance, these findings have potential 
socioeconomic significance and are discussed in the next chapter. 
 
Table 4.13. Medications purchased at the general payment rate 
No of scripts in 2004   N 
Mean  
Rank 
Sum of 
Ranks 
< 24 Scripts Total scripts 05 
minus (-) 
Total scripts 04 
 Neg. ranks* 1623 1530.1 2483372 
 Pos. ranks** 1629 1722.5 2806006 
 Ties*** 585   
 Total 3837   
24 - 59 Scripts Total scripts 05 
minus (-) 
Total scripts 04 
 Neg. ranks* 282 244.4 68939 
 Pos. ranks** 187 220.7 41276 
 Ties*** 15   
 Total 484   
60 + Scripts  Total scripts 05 
minus (-)  
Total scripts 04 
 Neg. ranks* 38 33.5 1276.5 
 Pos. ranks** 25 29.5 739.5 
 Ties*** 4   
 Total 67   
*2005 < 2004; **2005 > 2004; ***2005 = 2004 
 
Changes in multiple medication purchase for concessional patients.  
In 2005, just under half (45.4%) of the concessional patients increased their total 
number of medication purchases while 41.5% reduced their purchasing. As can be seen in 
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Table 4.14, patients not exposed to polypharmacy in 2004 (who purchased less than 24 
medications), increased their medication purchases in 2005 and the increase in 
prescriptions was significant (Z= -7.48, p<.001). 
For concessional patients in the minor polypharmacy category in 2004, negative 
ranks outnumbered positive ranks. Although more patients reduced rather than increased 
their number of medications in 2005 (49.3% v 46.6%), the difference was not statistically 
significant (Z= -0.79, p=0.428). By contrast, the majority of patients in the major 
polypharmacy category (57.8%) reduced their medications in 2005. The mean rank of the 
negative ranks was higher than that of the positive ranks, indicating that the reduction of 
overall prescription purchase in 2005 was significant (Z= -6.30, p<.001). This latter finding 
is important from the polypharmacy and socioeconomic perspectives and is discussed in 
the next chapter.   
 
Table 4.14. Change in concessional patients’ medication purchases 
No of scripts in 2004 
 
   N Mean 
Rank 
Sum of  
Ranks 
<24 scripts Total scripts 05 
minus ( - ) 
Total scripts 04 
 Neg. ranks* 2735 2650.6 7249565.5 
 Pos. ranks** 2985 3052.7 9112494.5 
 Ties*** 858   
 Total 6578   
24-59 scripts Total scripts 05 
minus ( - ) 
Total scripts 04 
 Neg. ranks* 1315 1264.0 1662217.5 
 Pos. ranks** 1240 1292.8 1603072.5 
 Ties*** 107   
 Total 2662   
60+ scripts Total scripts 05 
minus ( - ) 
Total scripts 04 
 Neg. ranks* 570 499.6 284800 
 Pos. ranks** 390 452.5 176480 
 Ties*** 26   
 Total 986   
* 2005 < 2004; **2005 > 2004; ***2005=2004 
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Effect of Copayment Increase on NHPA and Anti-infective medications  
This section presents the results of the analysis of change in prescriptions in 2005 by 
medication class. The analysis for each medication class was conducted at ATC level 1. 
Changes were analysed for each medication class in terms of total prescriptions, gender, 
age, level of medication use, and payment status (copayment level) of the prescription. 
Within the payment status category, further analysis was conducted at level of medication 
use.  
 
The medication groups investigated were for the cardiovascular, nervous, alimentary, 
musculoskeletal, and respiratory systems. These groups of medications are of significance 
to the NHPA areas of hypertension, depression, diabetes, arthritis and asthma. The anti-
infective group of medications was included because it represents medications for the 
treatment of acute conditions. As discussed in Chapter 2, the literature identifies that cost-
related changes in medication use are influenced by factors such as age, gender, level of 
medication use and type of medication. Further analysis was conducted at ATC level 3 to 
identify the effect of these factors on the purchase of specific medication groups within the 
medication class.  
 
Change in the purchasing of cardiovascular system medications. 
For the total cardiovascular (CVD) system class of medications, positive ranks 
outnumbered negative ranks by 565 patients (Table 4.15), indicating more patients 
increased than reduced purchase of CVD medications in 2005. There was a statistically 
significant increase in total prescriptions for this class of medication in 2005, as indicated 
by the higher mean rank for the positive ranks (Z= -8.95, p<.001). The increase in 
purchasing for CVD medications was evident for both males and females, and in both 
cases the increases were statistically significant (Female, Z= -6.99; Male, Z= -5.64, both 
p<.001). There were also statistically significant increases in medication purchasing for all 
three age groups investigated (25-44, Z= - 2.18, p=.029; 45-64, Z= -4.70, p<.001; 65 and 
over, Z= -7.64, p<.001). 
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Table 4.15. Change in cardiovascular system medications  
05 minus (-) 04 scripts    N Mean  Rank Sum of Ranks 
Total scripts Neg ranks* 2281 2467.1 5627474.5 
 Pos ranks** 2846 2641.6 7518153.5 
 Ties *** 8396   
 Total 13523   
Female Neg ranks* 1207 1302.6 1572322.0 
 Pos ranks** 1519 1411.8 2144579.0 
 Ties *** 4964   
 Total 7690   
Male Neg ranks* 1074 1164.63 1250817.5 
 Pos ranks** 1327 1230.43 1632783.5 
 Ties *** 3432   
 Total 5833   
Age 25-44 Neg ranks* 210 234.1 49178.5 
 Pos ranks** 261 237.4 61977.5 
 Ties *** 2513   
 Total 2984   
Age 45-64 Neg ranks* 1072 1155.6 1238857.5 
 Pos ranks** 1289 1202.0 1549483.5 
 Ties *** 2172   
 Total 1061   
< 24 scripts 04 Neg ranks* 953 1105.2 1053309.0 
 Pos ranks** 1449 1264.8 1832694.0 
 Ties *** 7387   
 Total 9789   
24-59 scripts 04 Neg ranks* 891 929.9 828539.5 
 Pos ranks** 1020 978.8 998376.5 
 Ties *** 837   
 Total 2748   
60+ scripts. 04 Neg ranks* 437 405.5 177227.5 
 Pos ranks** 377 409.7 154477.5 
 Ties *** 172   
 Total 986   
Concess. 04 Neg ranks* 1789 1932.6 3457433.5 
 Pos ranks** 2284 2118.7 4839267.5 
 Ties *** 615   
 Total  10226   
Gen. status 04 Neg ranks* 790 840.6 664119.0 
 Pos ranks** 844 795.8 671676.0 
 Ties *** 2754   
 Total 4388   
* Negative Ranks = 2005 < 2004; positive ranks = 2005 > 2004; *** Ties = 2005 = 2004 
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As can be seen in the above table, there were statistically significant increases for 
patients who purchased fewer than 24 prescriptions and those in the minor polypharmacy 
category (Z= 11.52, and Z= - 3.53 respectively, both p<.001). By contrast, while the 
change in CVD medication purchases for patients in the major polypharmacy group was 
not significant (Z= -1.70, p=.0890) an increasing trend was evident from the results.  
 
General patients in 2004 did not significantly change their purchasing patterns of 
CVD medications in 2005 (Z= -0.20, p=.842). However, for general patients who 
purchased fewer than 24 medications in 2004 there was a significant increase in the 
purchasing of CVD medications (Z= -3.07, p=.002). By contrast, general patients whose 
level of medication use in 2004 averaged two to four prescriptions per month (minor 
polypharmacy) and those in the major polypharmacy category significantly reduced their 
purchase of CVD medications in 2005 (Z= -3.73, p<.001 and Z= -2.01, p=.045 
respectively). 
 
Table 4.15 also indicates that concessional patients (Z= -9.24, p<.001) who 
purchased fewer than 24 cardiovascular medications in 2004 (Z=13.03; p<.001) 
significantly increased their medication purchases in 2005.  
 
Analysis at ATC level 3 revealed a significant decrease in prescriptions for the 
antihypertensive ACE-Inhibitors. This group of drugs was the fifth highest prescribed 
medication overall (5.1% of the total prescriptions) and the highest prescribed blood 
pressure medication in 2004. This decrease was found to be to be statistically significant 
(Z= -3.16, p=.002). Further analysis revealed that the decrease in the purchasing of ACE-
Inhibitors was associated with middle aged patients (Z= -3.17; p=.002), and those aged 
65+ (Z= -4.00; p<.001). In addition, patients in the major polypharmacy category (Z= -3.70; 
p<.001) and general payment category (Z= -7.59; p<.001) also reduced their purchase of 
ACE-inhibitors. 
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Angiotensin II Antagonists are commonly used when a patient is intolerant to ACE-
Inhibitors and might be expected to show an increase in use that corresponds to the 
decrease in ACE-Inhibitors. However, there was no statistically significant overall increase 
in these prescriptions in 2005 (Z= -1.03; p=.302). Further analysis revealed decreases in 
purchases of Angiotensin II Antagonist in 2005 which were statistically significant for males 
(Z= -3.21; p=.001), patients aged 45-65 (Z= -3.06; p=.002) and general patients (Z= -6.90; 
<.001). For patients aged 65 and over there was a statistically significant increase in the 
purchasing for this antihypertensive in 2005 (Z= -2.02; p=.043). Patients in the major 
polypharmacy category in 2004 demonstrated a trend towards a slight increase in the 
prescriptions for this antihypertensive (Z= -1.84; p=.065), as did patients in the 
concessional payment category (Z= -1.69; p=.092). 
 
Change in the purchasing of nervous system medications. 
Overall, there was a trend for patients to increase their nervous system medication 
prescriptions in 2005 (Z= -1.82, p=.069). Change in nervous system medication 
purchasing by gender was not statistically significant for either gender (males, Z= -1.15, 
p=.251; females, Z= - 1.42, p=.156) and the only age group that showed a statistically 
significant increase in purchase in 2005 was patients aged 65 and over (Z= -2.07, p=.039). 
Table 4.16 provides specific details. 
 
There was, however, a significant increase in the purchasing of nervous system 
medications in 2005 for patients who purchased fewer than 24 prescriptions in 2004 (Z= -
4.32, p<.001). For patients in the minor polypharmacy category in 2004 there was no 
significant change in purchasing patterns (Z= -0.76, p=.449), but for patients in the major 
polypharmacy group there was a significant reduction in the number of nervous system 
medications purchased in 2005 (Z= -2.28, p=.022). 
  
 120 
 
Table 4.16. Change in nervous system medications 
05 minus (-) 04 scripts    N Mean  
Rank 
Sum of  Ranks 
Total scripts  Neg ranks* 3187 3122.9 9952713 
  Pos ranks** 3206 3270.6 10485708 
  Ties *** 7130   
  Total 13523   
Female  Neg ranks* 1930 1877.9 3624417.5 
  Pos ranks** 1928 1981.1 3819593.5 
  Ties *** 3832   
  Total 7690   
Male  Neg ranks* 1257 1245.1 1565171.5 
  Pos ranks** 1278 1290.4 1649208.5 
  Ties *** 3298   
  Total 5833   
Age 25-44  Neg ranks* 787 765.7 602679.5 
  Pos ranks** 786 808.2 635271.5 
  Ties *** 1411   
  Total 2984   
Age 45-64  Neg ranks* 1014 994.6 1008526 
  Pos ranks** 1006 1026.5 1032684 
  Ties *** 2513   
  Total 4533   
Age 65+  Neg ranks* 961 963 925442 
  Pos ranks** 1016 1013.5 1029811 
  Ties *** 1301   
  Total 3278   
< 24 scripts 04  Neg ranks* 1829 1795.91 3284711.5 
  Pos ranks** 1950 1978.2 3857598.5 
  Ties *** 6010   
  Total 9789   
24-59 scripts 04  Neg ranks* 909 883.9 803483.5 
  Pos ranks** 865 891.2 770941.5 
  Ties *** 974   
  Total 2748   
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Table 4.16 cont’d. Change in nervous system medications 
05 minus (-) 04 scripts  N Mean 
Rank 
Sum of  
Ranks 
60+ scripts 04  Neg ranks* 449 429.0 192649 
  Pos ranks** 391 410.6 160571 
  Ties *** 146   
  Total 986   
Concess. 04  Neg ranks* 2667 2647.8 7061898 
  Pos ranks** 2716 2735.3 7429138 
  Ties *** 4843   
  Total 10226   
Gen. status 04  Neg ranks* 814 754.2 613963 
  Pos ranks** 752 815.1 612998 
  Ties *** 2822   
  Total 4388   
* Negative Ranks = 2005 < 2004; positive ranks = 2005 > 2004; *** Ties = 2005 = 2004 
 
General patients, overall, did not significantly change their purchase of nervous 
system mediations (Z= -0.03, p=.978), but the subgroup of patients who used fewer than 
24 prescriptions in 2004 significantly decreased their purchase of medications in 2005 (Z= 
-2.47, p=.013). Although general patients in the major polypharmacy category in 2004 
slightly decreased nervous system medication purchases, this reduction was not 
statistically significant (Z= - 0.11, p=.914). 
 
For concessional patients, overall, there was no significant change in purchasing of 
nervous system agents in 2005. For concessional patients who purchased fewer than 24 
medications in 2004, however, there was a significant increase (Z= -4.58 p<.001), and for 
concessional patients in the major polypharmacy category there was a significant 
decrease in the purchasing of nervous system agents in 2005 (Z= -2.28, p=.022). 
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Analysis at ACT level 3 revealed an increase in the purchasing for opioid analgesics 
in 2005 which was statistically significant (Z= -2.1, p=.035) and showed a gender variation. 
Males did not significantly change their purchase of opioids while females demonstrated a 
trend of increasing opioid purchase (Z= 1.85; p=.065). Statistically significant increases in 
the number of opioid prescriptions were also found for patients aged 45-64 (Z= -2.06; 
p=.04), patients who purchased fewer than 24 prescriptions in 2004 (Z= -4.08; p<.001) and 
patients who purchased at the general payment rate (Z= -2.78; p=.005). For patients in the 
major polypharmacy category there was no significant difference. 
 
For non-opioid prescriptions there was a decrease in prescriptions in 2005 which 
was significant (Z= -2.07; p=.038).  Further analysis revealed decreases in the purchasing 
of non-opioid analgesics for males and females, for all age groups and for all levels of 
prescription use. However these reductions only reached statistical significance for 
females (Z= -2.30; p=.021), patients with major polypharmacy (Z= -2.66; p=.008) and 
concessional patients (Z= -2.32; p=.021).  
 
Patients aged 45-64 and who purchased anti-migraine medications at the general 
payment rate, demonstrated statistically significant reductions in purchasing in 2005 (age 
group 45-64, Z= -2.79; p=.005; general patient, Z= -2.39; p.017). Analysis at ATC level 3 
for other nervous system medications revealed no significant changes except for increases 
in the purchasing of antidepressants for patients aged 65 and over (Z= -2.37; p=.018). 
Patients who purchased fewer than 24 medications in 2004, also increased their 
purchases of antidepressants (Z= -2.24; p=.025).  
 
The purchase of anxiolytics, which include benzodiazepines, increased in 2005 (Z=-
1.82; p=.069). Further analysis revealed statistically significant increases in prescriptions 
for females (Z= -2.67; p=.008), patients aged 25-64 (Z= -2.02; p=.043), patients who 
purchased fewer than 24 prescriptions in 2004 (Z=-2.82; p=.005), patients in the minor 
polypharmacy category (Z= -2.11; p=0.035) and general patients (Z= -2.66; p=.008). By 
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contrast, for patients in the major polypharmacy category there was a reduction in the 
purchase of anxiolytics in 2005 (Z=1.76; p=.079). 
 
Change in the purchasing of alimentary tract medications. 
Overall, positive ranks outnumbered negative ranks for these medications, 
indicating that more patients increased rather than reduced their purchase of alimentary 
tract medications in 2005 (Table 4.17). In addition, the higher mean of the positive ranks 
for overall prescriptions for alimentary tract medications in 2005 indicates a significant 
increase (Z= -5.89, p<.001).  
 
Positive ranks, indicating increased purchases, were significantly higher for both 
males and females (Females Z= -4.12; Males Z= - 4.27, p<.001 in both cases). Although 
there was an overall increase in the number of prescriptions for all age groups in 2005, it 
was only statistically significant for patients aged 45-64 and 65+ (Z= -5.14, and Z=-3.49 
respectively, p<.001 in both cases).  
 
Patients who purchased fewer than 24 medications and those in the minor 
polypharmacy category in 2004 significantly increased their purchase of alimentary tract 
medications (<24 prescriptions, Z= -8.50, p<0.001; minor polypharmacy, Z= -3.03, 
p=0.002). By contrast, those in the major polypharmacy category who were high users of 
prescription medications in general, significantly reduced their alimentary tract medication 
purchases (Z= -3.01, p=.003). 
 
In 2005, for general patients, there was a statistically significant increase in the 
number of prescriptions for alimentary tract medications, (Z= -4.01, p<.001). This was also 
the case for general patients who purchased fewer than 24 medications in 2004 (Z= -5.05, 
p<.001). Patients exposed to minor polypharmacy and major polypharmacy did not 
demonstrate a significant change in purchasing patterns for alimentary tract medications in 
2005 (minor polypharmacy, Z= -0.61, p=.545; major polypharmacy, Z=-0.04, p=.972). 
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Table 4.17 Change in the purchasing of alimentary tract medications 
05 minus (-) 04 scripts    N Mean Rank Sum of Ranks 
Total scripts  Neg ranks* 2319 2374.4 5506331 
  Pos ranks** 2616 2550.9 6673249 
  Ties *** 8588   
  Total 13523   
Female  Neg ranks* 1377 1431.6 1971357 
  Pos ranks** 1561 1502.9 2346034 
  Ties *** 4752   
  Total 7690   
Male  Neg ranks* 942 943.2 888556.5 
  Pos ranks** 1055 1048.7 1106446.5 
  Ties *** 3836   
  Total 5833   
Age 25-44  Neg ranks* 425 431.2 183287.5 
  Pos ranks** 450 444.3 199962.5 
  Ties *** 2109   
  Total 2984   
Age 45-64  Neg ranks* 850 876.0 744616.5 
  Pos ranks** 1007 973.7 980536.5 
  Ties *** 2676   
  Total 4533   
Age 65+  Neg ranks* 841 862.8 725644 
  Pos ranks** 949 924.4 877301 
  Ties *** 1488   
  Total 3278   
< 24 scripts 04  Neg ranks* 1105 1168.2 1290927.0 
  Pos ranks** 1422 1338.4 1903201.0 
  Ties *** 7262   
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Table 4.17 Cont’d. Change in the purchasing of alimentary tract medications 
05 scripts minus (-) 04 scripts   N Mean  
Rank 
Sum of 
Ranks 
  Total 9789   
24-59 scripts 04  Neg ranks* 776 777.0 602974.0 
  Pos ranks** 848 844.9 716526.0 
  Ties *** 1124   
60+ scripts 04  Neg ranks* 438 394.7 172891 
  Pos ranks** 346 389.6 134829 
  Ties *** 202   
  Total 986   
Concess. 04  Neg ranks* 1983 1989.8 3945891.5 
  Pos ranks** 2138 2126.9 4547489.5 
  Ties *** 6105   
  Total 10226   
Gen. status 04  Neg ranks* 588 624.5 367248 
  Pos ranks** 709 669.2 474505 
  Ties *** 3091   
  Total 4388   
* Negative Ranks = 2005 < 2004; positive ranks = 2005 > 2004; *** Ties = 2005 = 2004 
 
In 2005 there was an increase in the number of alimentary tract prescriptions for 
concessional patients as a group (Z= -3.98, p<.001), as well as for the subgroups of 
concessional patients who purchased fewer than 24 alimentary tract medications (Z= -
6.34, p<.001). For patients in the minor polypharmacy category in 2004, there was also a 
significant increase in the number of prescriptions in 2005 (Z= -2.90, p=.004). Negative 
ranks outnumbered positive ranks, however, for patients who paid the concessional rate in 
2004 and who were in the major polypharmacy category, indicating that for this this group, 
there was a reduction in their number of prescriptions in 2005 (Z= -3.01, p=.003). 
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Further analysis at ATC level 3 revealed an increase in the number of prescriptions 
for oral diabetes medications in 2005. This increase was found to be statistically significant 
(Z= -5.51; p<.001). In 2005, there was a statistically significant increase in the number of 
prescriptions for anti-ulcerant medications, which include essential oral medications for 
gastric ulcers and reflux (Z= -5.45; p<.001). For patients in the major polypharmacy 
category, however, there was a decrease in the number of prescriptions for anti-ulcerants 
(Z= -1.71; p=.086) but not for oral diabetes medications.  
 
Change in the purchasing of musculoskeletal agents. 
For this group of medications negative ranks outnumbered positive ranks (Table 
4.18), indicating that more patients reduced purchases of musculoskeletal agents in 2005 
than increased their purchases. There was also a reduction in overall prescriptions in this 
class of medications in 2005 which was significant (Z= -15.26, p<.001). For both genders 
there were reductions in prescriptions in 2005 which were statistically significant (Females, 
Z= -11.73; Males, Z= -15.26, p<.001 for both groups). There were also reductions in 
prescriptions for all three age groups which were statistically significant (25-44 years, Z= -
6.25; 45-64 years, Z= -10.41; 65 years and over, Z= -9.16; all three p<.001). Furthermore, 
patients at all three levels of multiple medication use in 2004 reduced their purchases in 
2005. In each case the reductions were statistically significant (<24 prescriptions, Z= -7.44; 
24-59 prescriptions, Z= -11.29; 60 prescriptions and over, Z= -7.96; all three p<.001). 
 
For general patients who purchased fewer than 24 medications in 2004 there was a 
significant decrease in prescriptions in 2005 (Z= -6.22 p<.001). Significant increases in 
prescriptions for musculoskeletal agents in 2005 (minor polypharmacy, Z= -3.64, p<.001; 
major polypharmacy, Z= -2.03, p=.043) were found, however, for patients exposed to 
minor polypharmacy and major polypharmacy.   
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Table 4.18. Change in the purchasing of musculoskeletal agents 
05 minus (-) 04 scripts    N Mean  
Rank 
Sum of  
Ranks 
Total scripts  Neg ranks* 2548 2110.4 5377345.5 
  Pos ranks** 1565 1970.0 3083095.5 
  Ties *** 9410   
  Total 13523   
Female  Neg ranks* 1536 1249.2 1918821 
  Pos ranks** 922 1196.6 1103290 
  Ties *** 5232   
  Total 7690   
Male  Neg ranks* 1012 861.6 871995.5 
  Pos ranks** 643 775.0 498344.5 
  Ties *** 4178   
  Total 5833   
Age 25-44  Neg ranks* 403 348.3 140369.5 
  Pos ranks** 261 308.0 80410.5 
  Ties *** 2320   
  Total 2984   
Age 45-64  Neg ranks* 1043 836.2 872202.5 
  Pos ranks** 599 795.8 476700.5 
  Ties *** 2891   
  Total 4533   
Age 65+  Neg ranks* 982 828.10 813193.00 
  Pos ranks** 623 763.44 475622.00 
  Ties *** 1673   
  Total 3278   
< 24 scripts 04  Neg ranks* 1258 1076.51 1354255.50 
  Pos ranks** 883 1063.14 938755.50 
  Ties *** 7648   
  Total 9789   
 
 
Cont’d next page 
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Table 4.18 cont’d. Change in musculoskeletal agents 
05 minus (-) 04 scripts   N Mean  
Rank 
Sum of 
Ranks 
24-59 scripts 04  Neg ranks* 891 696.81 620862.00 
  Pos ranks** 464 641.87 297828.00 
  Ties *** 1393   
  Total 2748   
60+ scripts 04  Neg ranks* 399 326.9 130463.5 
  Pos ranks** 218 276.1 60189.5 
  Ties *** 369   
  Total 986   
Concess. 04  Neg ranks* 2194 1813.9 3979751 
  Pos ranks** 1353 1709.2 2312627 
  Ties *** 6679   
  Total 10226   
Gen. status 04  Neg ranks* 608 493.3 299946.5 
  Pos ranks** 362 472.3 170988.5 
  Ties *** 3418   
  Total 4388   
* Negative Ranks = 2005 < 2004; positive ranks = 2005 > 2004; *** Ties = 2005 = 2004 
Patients who purchased musculoskeletal medications at the concessional rate in 
2004 demonstrated a statistically significant decrease in the number of prescriptions in 
2005 (Z= -13.84, p<.001). For the subgroup of concessional patients who purchased fewer 
than 24 medications overall in 2004, and for those in the major polypharmacy category, 
there was a significant increase in prescriptions (Z= -4.86; p<.001 and Z=-7.96; p<.001 
respectively). By contrast, concessional patients who used two to four prescriptions a 
month in 2004 significantly decreased their purchases in 2005 (Z= -11.13, p<.001).  
Analysis at ATC level 3 revealed an overall decrease in the purchasing of non-
steroidal anti-inflammatory drugs (NSAIDS) in 2005 (Z= -20.74; p<.001). Further analysis 
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indicated that the decrease in the purchasing of NSAIDs in 2005 was significant for both 
genders, all age groups, all levels of medication use and both payment types (p<.001 for 
all variables). Prescriptions for gout and osteoporosis medications, however, significantly 
increased in 2005 (Z= -2.56; p=.010 and Z= -7.32; p=<.001, respectively).  
 
Change in the purchasing of respiratory system agents. 
As can be seen in Table 4.19, the overall purchase of respiratory medications did 
not change significantly between 2004 and 2005 (Z= -0.97, p=.333). This was true for 
females (Z= -0.98, p=.327), but not for males. There was an increase in prescriptions in 
2005 for males which was statistically significant (Z= -2.64, p=.008). Similarly, the only age 
group that showed a significant increase in respiratory medication purchase was patients 
aged 65+ (Z= -3.08, p=.002).  
 
There was a trend to increased prescription purchase in 2005 by patients who 
purchased fewer than 24 prescriptions in 2004 (Z= -1.87, p=.062), but patients in the minor 
polypharmacy and major polypharmacy groups did not change their purchasing of 
respiratory system agents (Z= -0.03, p=.978 and Z= -1.03, p=.302 respectively). 
 
There was no change in respiratory medication purchase by general patients (Z= -
0.41, p=.686), regardless of their levels of medication use. For patients who purchased 
respiratory system agents as concessional patients in 2004, the change in the number of 
prescriptions in 2005 was also not significant (Z= -0.12, p=.904). This was also the case 
for concessional patients who purchased fewer than 24 prescriptions in 2004 (Z= -1.07, 
p=.285) and those exposed to minor polypharmacy (Z= -0.21, p=.838) and major 
polypharmacy (Z= -1.03, p=.302).  
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Table 4.19. Change in the purchasing of respiratory system agents 
05 minus (-) 04 scripts   N Mean Rank Sum of Ranks 
Total scripts  Neg ranks* 1635 1569.6 2566401 
  Pos ranks** 1600 1667.3 2667829 
  Ties *** 10288   
  Total 13523   
Female  Neg ranks* 1003 923.2 926039 
  Pos ranks** 897 980.9 879911 
  Ties *** 5790   
  Total 7690   
Male  Neg ranks* 632 647.5 409237.5 
  Pos ranks** 703 686.4 482542.5 
  Ties *** 4498   
  Total 5833   
Age 25-44  Neg ranks* 369 330.9 122115 
  Pos ranks** 306 346.5 106035 
  Ties *** 2309   
  Total 2984   
Age 45-64  Neg ranks* 456 432.5 197241.5 
  Pos ranks** 439 464.0 203718.5 
  Ties *** 3638   
  Total 4533   
Age 65+  Neg ranks* 380 389.4 147991.5 
  Pos ranks** 441 429.5 189439.5 
  Ties *** 2457   
  Total 3278   
< 24 scripts 04  Neg ranks* 1023 990.2 1013046 
  Pos ranks** 1038 1071.1 1111845 
  Ties *** 7728   
  Total 9789   
24-59 scripts 04  Neg ranks* 373 346.5 129268 
  Pos ranks** 346 374.4 129572 
  Ties *** 2029   
  Total 2748   
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Table 4.19 cont’d. Change in the purchasing of respiratory system agents 
05 minus (-) 04 scripts  N Mean  
Rank 
Sum of  
Ranks 
60+ scripts 04  Neg ranks* 239 229.1 54755.5 
  Pos ranks** 216 226.7 48984.5 
  Ties *** 531   
  Total 986   
Concess. 04  Neg ranks* 1316 1278.2 1682206 
  Pos ranks** 1281 1320.2 1691297.00 
  Ties *** 7629   
  Total 10226   
Gen. status 04  Neg ranks* 479 419.2 200839.5 
  Pos ranks** 410 475.0 194765.5 
  Ties *** 3499   
  Total 4388   
* Negative Ranks = 2005 < 2004; positive ranks = 2005 > 2004; *** Ties = 2005 = 2004 
 
Analysis at ATC 3 level revealed a significant increase in prescriptions for inhaler 
medications used in asthma management (Z= -1.97; p=.049). Further analysis revealed, 
however, that patients in the major polypharmacy category decreased their purchase of 
asthma inhaler medications in 2005. This decrease was significant (Z= -2.15; p=.032).   
 
Change in the purchasing of anti-infective agents. 
As expected, the Wilcoxon signed rank test found that the change in the total 
number of prescriptions or in the number of patients using anti-infectives in 2005 was not 
significant (Z= -0.51, p=.613). Table 4.20 provides details for this group of medications. 
This held true both for males (Z= -0.28, p=.778) and females (Z= -0.86, p=.391) and 
patients aged 25-44 and 65+ (Z= -0.76, p=.448; Z= -0.19, p=.849 respectively). Patients 
aged 45-64, however, demonstrated a significant reduction in the number of anti-infective 
prescriptions (Z= -2.17; p=.030). 
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For patients who purchased fewer than 24 prescriptions in 2004, there was a 
significant increase in the overall number of prescriptions for anti-infective medications in 
2005 (Z= -3.13, p=.002). By contrast, patients who used an average of two to four 
medications per month (minor polypharmacy) in 2004 used significantly fewer anti-infective 
medications in 2005 (Z= -2.28, p=.023), as did those with major polypharmacy, i.e. those 
who used an average of five or more prescription medications per month (Z= -4.15, 
p=0.005).  
 
General patients as a group did not change their purchases of anti-infective 
medication in 2005 (Z= -1.69, p=.091), but those who purchased fewer than 24 
medications in 2004 significantly increased their purchase of anti-infective medications in 
2005 (Z= -4.48, p<.001). For general patients exposed to minor polypharmacy and major 
polypharmacy in 2004, negative ranks outnumbered positive ranks, indicating that fewer 
patients purchased medications, but those that did use anti-infectives bought more. There 
were statistically significant increases in prescriptions in 2005 for both groups (minor 
polypharmacy, Z= -2.95, p=.003; major polypharmacy, Z= -2.22, p=.026). 
 
The same pattern occurred for concessional patients: fewer patients purchased 
anti-infectives, but those that did, bought significantly more in 2005 than in the previous 
year (Z= -2.03, p=.043). For concessional patients in the minor polypharmacy category in 
2004, there was a statistically significant decrease in the number of prescriptions in 2005 
(Z= -2.37, p=.018). This was also the case for concessional patients in the major 
polypharmacy category (Z= -4.15, p<.001). 
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Table 4.20. Change in the purchasing of anti-infective agents 
05 minus (-) 04 scripts         N Mean  
Rank 
Sum of  
Ranks 
Total scripts  Neg ranks* 3701 3637.3 13461958.5 
  Pos ranks** 3612 3677.1 13281682.5 
  Ties *** 6210   
  Total 13523   
Female  Neg ranks* 2263 2185.5 4945945 
  Pos ranks** 2152 2231.5 4802375 
  Ties *** 3275   
  Total 7690   
Male  Neg ranks* 1438 1451.8 2087824 
  Pos ranks** 1460 1447.1 2112827 
  Ties *** 2935   
  Total 5833   
Age 25-44  Neg ranks* 715 674.9 482592.5 
  Pos ranks** 658 700.0 460658.5 
  Ties *** 1611   
  Total 2984   
Age 45-64  Neg ranks* 923 990.9 914685.5 
  Pos ranks** 1045 978.7 1022810.5 
  Ties *** 2565   
  Total 4533   
Age 65+  Neg ranks* 1121 1088.6 1220346 
  Pos ranks** 1093 1126.8 1231659 
  Ties *** 1064   
  Total 3278   
< 24 scripts 04  Neg ranks* 2279 2294.3 5228788 
  Pos ranks** 2417 2399.5 5799768 
  Ties *** 5093   
 
Cont’d next page 
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Table 4.20 cont’d. Change in the purchasing of anti-infective agents 
 
05 minus (-) 04 scripts N Mean  
Rank 
Sum of  
Ranks 
  Total 9789   
24-59 scripts 04  Neg ranks* 972 923.1 897295.5 
  Pos ranks** 867 916.4 794584.5 
  Ties *** 909   
60+ scripts 04  Neg ranks* 450 394.2 177405.5 
  Pos ranks** 328 383.0 125625.5 
  Ties *** 208   
  Total 986   
Concess. 04  Neg ranks* 3561 3412.1 12150818.5 
  Pos ranks** 3315 3466.7 11492307.5 
  Ties *** 3350   
  Total 10226   
Gen. status 04  Neg ranks* 484 498.7 241399 
  Pos ranks** 529 514.5 272192 
  Ties *** 3375   
  Total 4388   
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Summary of Chapter 4 Results 
 
In summary, 267,164 prescriptions were dispensed to the 13,523 consumers in 2004. 
Compared to the Queensland census of 2006, males in this study were under-represented 
and older people were over-represented. Concessional patients represented about two-
thirds of the study cohort, while the remaining third started 2004 as general patients. Of 
these, 14% and 8% respectively reached the Safety Net thresholds for further subsidy for 
the remainder of the calendar year.   
 
Anti-infective medication was used as a defacto benchmark for medication purchase 
patterns. This group of medications (mainly oral antibiotics) is used to treat acute 
infections that tend to affect patients of all ages. The analysis indicated little change in 
2005 with the exception of patients in the major polypharmacy group, demonstrating a 
marked decrease in use in 2005. 
 
Over 70% of the patients used fewer than 24 prescription medications (“no 
polypharmacy”) in 2004 and about 7% of the study cohort used 60 prescriptions or more in 
2004 (major polypharmacy). Overall, females purchased significantly more PBS 
medications than males at all ages except for the age group 0-14 years. The trend towards 
increases in the number of prescriptions with age was seen for both sexes, but after age 
64 the gender differences in prescriptions widened.  
 
Major polypharmacy increased from 2.1% in patients aged 25-44, to 6.5% in patients 
aged 45-64 and 18.9% in patients 65+. Three classes of medications, those that act on the 
cardiovascular system, the nervous system (including analgesics, anti-psychotics and 
antidepressants) and the alimentary/metabolic system (which includes medications for 
gastric reflux and diabetes) accounted for over 65% of the total number of prescriptions 
purchased in 2004. Medications acting on the respiratory and musculoskeletal systems 
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accounted for less than 10% of the total number of prescriptions but were associated with 
a much higher number of patients.  
 
Medication groups which were associated with a higher number of patients relative to 
prescriptions include chronic disease medications belonging to cardiovascular, nervous 
and musculoskeletal classes. Gender differences in prescriptions were statistically 
significant for medications which act on the nervous system, alimentary tract, and 
musculoskeletal system, but not for medications for the management of cardiovascular 
and respiratory system disorders.  
 
For patients prescribed fewer than 24 prescriptions in 2004 there was a significant 
increase in medications purchased, but for the major polypharmacy group there was a 
significant reduction in the number of prescriptions purchased in 2005. This pattern 
occurred for both concessional and general patients. 
In 2004, medications for hypertension represented approximately 63% of the 
prescriptions for the cardiovascular group of medications. The next largest group was 
prescriptions for cholesterol lowering medications, which accounted for 29% of the 
prescriptions in this group. Patients increased their total prescriptions for cardiovascular 
medications in 2005 and this increase was statistically significant. There was a significant 
decrease in prescriptions for ACE-Inhibitors without a corresponding increase in ARB 
which are commonly prescribed as an alternative to ACE-Inhibitors.  
 
Purchase of antidepressants in 2005 significantly increased for patients aged 65+, and 
also for patients who purchased fewer than 24 medications in 2004. For anxiolytics there 
was an increase in medication purchases, especially for females and working aged adults.  
 
In 2005 there was a highly statistically significant decrease in the purchase of non-
steroidal anti-inflammatory drugs (NSAIDS). This was significant for both genders, all 
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ages, all levels of medication use, and both general and concessional patients. 
Medications for diabetes accounted for 21% of the prescriptions and approximately 18% of 
consumers in 2004. The purchase of this group of medications increased in 2005 for 
patients of both genders.  
 
The majority of the medications for respiratory system agents were for obstructive lung 
diseases such as asthma and chronic obstructive pulmonary disease. In both 2004 and 
2005, these classes of medications represented almost 98% of respiratory medication 
purchases. In 2005 for patients in the major polypharmacy category, there was, however, 
a significant decrease in the number of prescriptions for inhaled corticosteroids which are 
used as a “preventer” medication.   
 
In conclusion, the findings demonstrate that the large copayment increase coincided 
with an increase in the volume of prescriptions purchased in 2005. There was a decrease 
in prescriptions, however, for patients on multiple medications. The change in volume of 
prescriptions purchased was complex, and varied according to age, gender, concession 
status, level of medication use and type of medication. The implications of these findings 
will be discussed in the following chapter. 
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CHAPTER 5. DISCUSSION 
Overview 
The aim of this research was 1) describe the pattern of PBS medication use in 
Queensland, Australia during the calendar year 2004 prior to an unusually large 
copayment increase; 2) establish whether the copayment increase in January 2005 
resulted in a change in the purchasing of PBS medicines; and, 3) if there was a change, to 
investigate whether it differed according to characteristics of the patient and the type of the 
medication.  
 
As stated in Chapter 1, this research was undertaken in light of Australian studies on 
medication use and response to copayment increases which have relied mainly on 
observational studies and time series changes in prescription use. These studies have 
generally focused on older adults, a majority of whom are concessional patients, and 
multiple medication users (see for example, Elliot, 2006; Runganga et al., 2014).  As a 
result, little is known about medication use that is representative of the population as a 
whole. 
 
This current research is based on a retrospective analysis of paired data over two 
consecutive years with the focus being on patient and medication characteristics rather 
than on the total number of prescriptions dispensed as is commonly reported in the 
research literature. This analysis enabled an examination of the modifying impact of 
sociodemographic and medication-related contextual factors on the purchasing of PBS 
medications.  
 
The analysis of the data was carried out in two parts. The aim of the first part was to 
establish a baseline of prescription use in 2004 by sociodemographic and medication 
factors. The second part of the analysis investigated changes in medication use after a 
larger than usual copayment change in January 2005.   
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This chapter is presented to reflect these two parts, with the first part of the chapter 
discussing baseline prescription use in 2004 within the context of the sociodemographics 
of the Queensland population.  This is followed by a discussion of the changes that 
occurred following a 21% increase in copayment for both categories of PBS beneficiaries.  
A critique of the strengths and limitations of the study will follow, with the final section 
presenting conclusions and recommendations for future research and policy. 
 
Baseline Prescription Use in 2004  
 
The focus of the research for this thesis was medication classes belonging to the 
National Priority Health Area (NHPA) chronic diseases and conditions of cardiovascular 
disease (CVD), mental health, diabetes, arthritis and other musculoskeletal conditions and 
asthma. While infections are not a NHPA condition, the anti-infective class of medications 
was included in the analysis to enable an investigation of changes in the purchasing of a 
class of medication which is generally independent of age and gender.  This decision was 
based on the assumption that bacterial infections occur in all age groups and in both 
genders.   
 
The discussion presented in this chapter is loosely structured around the framework of 
Piette et al., (2006) which will be referred to as “Piette’s framework”.  As discussed in 
Chapter 1, while this framework is primarily used to inform patient adherence to prescribed 
medication in response to cost, it can also be used as a tool to examine the impact of a 
range contextual factors on medication use, which is how it is used here.   
 
It must be noted that although many aspects of Piette’s framework are relevant, many 
factors included in this thesis are unique.  The main reason for this is that Australian 
medication purchasing patterns are contextualised in a country with universal healthcare 
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and uniform medication pricing structures.  Both of these socio-political factors have not 
been operant in Piette’s framework, or in the countries where related research on 
purchasing patterns of medication has been conducted.  In Australia, these contextual 
factors are major drivers of medication use, and their inclusion in this study will both test 
Piette’s framework and suggest evidence-based modifications relevant to the international 
community.   
 
The most common prescription medications purchased in 2004. 
This study found CVD medications to be the most commonly prescribed in 2004 
(31% of total prescriptions). This indicated that CVD prescriptions were prescribed to four 
out of ten Queenslanders.  A majority of the CVD medications were those for high blood 
pressure and high cholesterol.  This finding was not surprising given the central role of 
blood pressure and cholesterol management in heart disease and stroke prevention, as 
recommended for this priority chronic disease strategy (National Health Priority Action 
Council [NHPAC], 2006; DoHA, 2007).  
 
Apart from this increased profile consistent with NHPA status, another likely driver 
of the cholesterol reducing and antihypertensive medications prescribing in 2004 may 
have been the cumulative application of clinical guidelines for single health conditions (a 
health system characteristic according to Piette’s framework) to patients with multiple 
morbidities. As discussed in Chapter 2, clinical guidelines are provided for individual 
conditions, and a patient presenting with two conditions can be prescribed medication for 
both the conditions separately, even though there might be considerable overlap in the 
treatment or an increased potential for adverse drug interactions.  
 
It has been argued that clinical guidelines tend to be too narrow, focussed on a 
single disease, with the decision to prescribe being based on guideline recommendation 
for each single disease or risk factors (Shaneyfelt & Centor, 2009; Tinetti & Studenski, 
2011).  In fact, the hypertension and some dyslipidaemia clinical guidelines actually 
recommend treatment with multiple medications for each condition. These clinical 
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cumulative recommendations, coupled with aggressive prevention and treatment of CVD 
risk factors (AIHW, 2013b) may have contributed to the level of CVD prescriptions 
observed in 2004.  It is beyond the scope of this thesis to investigate whether or not this is 
problematic from a clinical or government expenditure point of view.  However, given the 
potential risk to patients of over-prescribing of medications, the potential problem identified 
in this research merits urgent investigation.   
 
A similar phenomenon regarding clinical guidelines could also underpin the use of 
nervous system agents, which was found to be the second most prescribed medication 
class overall in 2004 (21% of total prescriptions) and the most widely used chronic disease 
medication (44% of the study cohort).  This pattern of nervous system medication use is 
consistent with the increasing trend in the utilisation of antidepressant medications and a 
relatively high use of antianxiety and hypnotic agents reported in Australia since 2000 
(Stephenson et. al., 2013).  Collectively, the data for 2004 and the literature (see for 
example Davison et. al., 2007 and Hawthorne et al., 2008) suggest that the increasing 
trend in antidepressant use in Australia is continuing. 
 
The prevalence of antidepressant use was 8.2% of the study cohort in 2004, which 
on its face, is on par with an estimated 8% in the general community in 2008 (Hawthorne 
et al., 2008). However, there is an important difference between these two findings.  The 
2004 data used in this current study included a random sample of ALL Queenslanders 
including those in aged care facilities.  The estimate of antidepressant use in aged care 
residents has been reported as high as 14% to 26% (Davison et. al., 2007).  Therefore, 
even though the prevalence of the total population of Queenslanders’ using 
antidepressants revealed by this study is similar to the prevalence reported in 2008 by 
Hawthorne and colleagues, there is one important methodological difference.  Hawthorne 
et al. excluded aged care residents in their analysis, a group which has double or even 
triple the community use of antidepressants (Davison et. al., 2007).  In other words, the 
8.2% revealed in the 2004 population data used in this thesis included, but did not 
exclusively focus on, aged care residents; while the 8% reported by Hawthorne excluded 
the very high antidepressant using residents in aged care facilities reported by Davison et 
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al., (2007).  Together, these two findings indicate that antidepressant use in the general 
population in Australia increased in the period between 2004 and 2008. 
 
There are several possible explanations for the increasing trend in antidepressant 
use in the general population.  The most likely one from an Australian perspective is an 
increase in the diagnosis of major depression due to a broadening in the concepts of need 
for the treatment of depression (a treatment characteristic according to Piette’s 
framework).  Another possible factor is what Piette has described as a sociocultural 
moderating effect, the growing public acceptance of mental health diagnosis and 
treatments (Olfsen & Marcus, 2009).   
 
Results showed that 28% of patients in this study purchased medications for 
arthritis and other musculoskeletal disorders in 2004.  The prevalence in use of 
musculoskeletal medications found in this study is consistent with the self-reported 
prevalence of arthritis and other musculoskeletal conditions (31%) reported in the National 
Health Survey (NHS) of 2007-08 (AIHW, 2010a, p.187), although arthritis, alone was 
reported by about half (15%) of persons with musculoskeletal disorders surveyed in the 
2007-08 survey. It appears that the level of arthritis medication purchases (28%) found in 
this study is almost double that of the number of persons reporting arthritis in the National 
Health Survey. This is probably because the number of females and patients aged 75+ in 
the study cohort were higher than the distribution of these characteristics in the general 
population. Both these demographic characteristics (advanced age and gender) have 
been reported to be associated with a high prevalence of arthritis and musculoskeletal 
disorders (AIHW, 2010a).     
This is where the unique characteristics of this analysis become important.  The 
number of patients using musculoskeletal medications (28% of patients) was much higher 
than the proportion of medications purchased for musculoskeletal conditions, which was 
only 8% of total medications purchased in 2004.  These differences could be explained by 
differences in discretionary and essential medication use.  Musculoskeletal medication 
classes include a higher proportion of discretionary and under-copayment medications 
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than do CVD and nervous system classes, which comprise predominantly essential 
medications for chronic disease management.  For example naproxen, an anti-
inflammatory agent which is sometimes used to treat arthritis, is available over the counter 
in pharmacies and even in supermarkets so its purchase would not show up on the PBS 
(prescription) database.  The same holds true for medications for many alimentary tract 
symptoms (antacids, for example).  This could be the reason 34% of patients with 
alimentary tract symptoms made only 13% of the PBS prescription purchases in this study. 
 
In contrast, essential medications for CVD, for example, are more likely to be 
subsidised on the PBS for both categories of PBS beneficiaries, and therefore was 
included on the 2004 PBS database used in this research.  As a result there is a much 
closer relationship between the percentage of patients with CVD (40%) and PBS 
medications purchased for CVD (31%).  The effect of the PBS cost threshold for 
discretionary and essential medications is discussed in more detail later in this chapter in 
the context of the 2005 copayment increase.  
 
Almost all prescriptions for respiratory system medications were for medications for 
the management asthma and chronic obstructive pulmonary disease (COPD), which is 
consistent with the effect of breathlessness on quality of life associated with both these 
conditions. In 2005 people with asthma rated their health lower, had a higher prevalence of 
psychological distress and reported a higher number of days away from work or study than 
persons with other NHPA conditions (Australian Centre for Asthma Monitoring [ACAM], 
2005, p.150).  
 
Paradoxically, compared to medications for the other NHPA diseases and 
conditions, respiratory system medications were the least used in terms of the number of 
prescriptions (6% of total prescriptions in 2004).  However, they were used by 21% of the 
patients, which is more than double the age-adjusted prevalence of self-reported asthma 
in Australia of 10% in 2004-5 (ABS, 2006c).  This difference can be partly be explained as 
an artefact of the data for the study as it was not possible to distinguish medications 
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purchased for asthma from those for COPD. The medications are the same for both 
conditions in many cases. The difference could also be due to an underestimation of 
asthma prevalence resulting from the use of self-reported data to estimate the prevalence 
of asthma in the community.  Nevertheless, the large difference observed in this study 
between the number of prescriptions purchased (6% of the total prescriptions) and the 
number of patients purchasing respiratory system medications in general (21%) suggests 
both discretionary and intermittent use of asthma medications.    
 
This finding has important clinical implications. According to the Australian Bureau 
of Statistics, in 2004-05, 55% of people with asthma used pharmaceutical medications to 
prevent and/or relieve their asthma symptoms (ABS, 2006c).  Of this 85% reported using a 
reliever in the previous two weeks, and 39% used preventers.  This large imbalance 
between reliever and preventer use is inconsistent with asthma management guidelines 
which recommend the use of preventer medications on a regular basis (Kandane-
Rathnayake et al., 2009). The purchasing patterns identified in this study support that 
over-the-counter reliever medications are being used rather than the PBS prescribed 
preventer medications, which is a clinically suboptimal practice.  
 
Notwithstanding the above point, the high prevalence of respiratory system 
medication use relative to the number of prescriptions purchased might also be the result 
of the status of asthma as an NHPA from as early as 1999 (a health system characteristic 
unique to Australia). It could also be related to Australia’s current focus on treating asthma 
in the community via comprehensive GP led “asthma plans” (another health system 
characteristic according to Piette’s framework) since preventing asthma-related inpatient 
admissions equates to significant savings in hospital costs (Simonella, Marks, Sanderson 
& Andrews, 2006).  
 
As outlined in Chapter 2, asthma management in Australia has been influenced by 
models of care and provider incentives (health system factors in Piette’s framework) 
designed to facilitate early diagnosis and aggressive management of asthma episodes out 
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of hospital (Beilby,& Horton, 2005). It is therefore quite possible that the observed pattern 
of respiratory system medication use was largely influenced by a paradigm of care which 
focuses on a combination of health sector incentives to manage asthma in the community, 
which might tend to encourage cheaper non-prescription over the counter (OTC) reliever 
medication use by asthmatic patients.  In fact, the Australian sector has created a financial 
incentive for general patients to use OTC medications because they usually have to pay a 
GP copayment of around $35.00 per GP visit in addition to the cost of the prescription.  
This can add up to $70 to the out of pocket costs for a preventer medication, compared 
around $7.00 for an OTC reliever.  In 2004 the relative costs associated with asthma 
medications were comparable, and are discussed in more detail, below. 
 
This research also found a significant increase in respiratory system medication use 
with age.  This is a surprising finding for medications which are primarily used for 
conditions that tend to flare up in all age groups and require both intermittent (reliever) and 
long term (preventer) medications use.  A likely explanation for this increasing trend with 
age can be attributed to health system factors typical to Australia.  Only about two-thirds of 
Australians receiving asthma medications are subsidised by the PBS, and most of those 
who benefit from this subsidy are older patients (ACAM, 2011). These patients tend to be 
concessional rather than general beneficiaries, so their purchases are recorded as PBS 
transactions.  This is because below-copayment respiratory medications purchases by 
general patients who paid a copayment of $23.70 in 2004 were not recorded in the PBS 
claims database.   
 
Below-copayment purchases included the commonly used short-acting reliever 
medication, salbutamol, and prednisone, an oral corticosteroid for reducing inflammation 
associated with asthma.  Salbutamol, which is mainly delivered through a metered dose 
inhaler (e.g., Ventolin puffer) was the 6th most prescribed medication in 2004 (DoHA, 
2007). The dispensed price of Salbutamol was between $7 and $10 in 2004 (DoHA, 2004), 
which is below the PBS copayment threshold for general patients.  That both these 
commonly used asthma medications were only subsidised to concession cardholders in 
2004 indicates that the increasing pattern of asthma medication use with age observed in 
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the research for this thesis was most likely due to below-copayment asthma medication 
purchases by general patients not being captured and reported by the PBS.   
 
In contrast, although Ventolin puffers were available to concessional patients as 
OTC medication, the over-the-counter cost to them was greater than the concessional 
copayment.  This means there was a financial incentive in 2004 for concession 
cardholders to purchase these reliever medications on the PBS. It is therefore likely that 
most, though not all, reliever medications dispensed to concession card holders were 
supplied with a prescription and recorded on the PBS database.  Thus, the apparent 
increasing use of asthma medications with age, is most likely attributable to health system 
factors that incentivise concessional patients to purchase Ventolin on prescription, than in 
any clinical differences in sub-populations.   
 
This latter point highlights the complexity involved in interpreting findings of 
medication use at the population level based on the analyses of PBS data. It is also worth 
noting that the context and purpose for which PBS data is collected in not research but 
rather payment of claims to pharmacies. This is discussed in more detail later in this 
chapter. 
 
In summary, the pattern of total prescriptions found in the research for this thesis is 
similar to that reported in other studies (see for example AIHW, 2010a, p. 393).  The 
pattern also reflects the findings of a recent PBS utilisation study which also used the ATC 
classification system (DoHA, 2012d).  That study reported levels for cardiovascular (34%), 
nervous system (20%) and alimentary tract disorders (14%) respectively, showing that 
they collectively accounted for two-thirds of the medications subsidised by the PBS, a level 
also found in this current research.  However, unique to this current research, the 
distribution of prescriptions found in the analysis is disproportionate to the number of 
Australians affected by the NHPA chronic disease for which they are used.  This suggests 
that health systems factors play an almost invisible, but nevertheless significant role in the 
purchase of medications for some conditions.  Importantly, these health systems factors 
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do not necessarily act to support clinical guidelines for some patients, as can be seen in 
the observed pattern of reliever rather than preventer inhaler purchases by general 
patients with asthma. 
 
Distribution of prescriptions in 2004 by gender 
 
Results pertaining to the second research question indicated that 56% of the total 
prescriptions in Queensland in 2004 were dispensed to women, and 44% to men. This 
gender difference in prescriptions (12%) is greater than the gender difference in the 
population at the 2006 Queensland Census of Population and Housing (females 50.5%; 
males 49.5%; ABS, 2007) and is approximately double the gender difference in medication 
use (6.4%) found by Morgan et al. (2012) in a recent survey of medication use in Australia.  
However, the gender difference found in this research is consistent with international 
studies which show that women use more medications than men. For example, large scale 
population-based studies of prescription drug use from the United States (Zhong et al., 
2013) and Sweden (Loikas et al., 2013) confirm higher medication use by women for most 
medications at a similar rate to that identified in this research.   
 
However, this pattern was not consistent in different sub-groups of men and women. 
There was very little gender difference in medication use up to age 64.  This was a 
surprising finding.  It contradicts the extant literature worldwide, which indicates that 
women have a higher medication use than men throughout the lifespan at all ages from 
age 20 (Roe et. al., 2002; Loikas et al., 2013), with the gender difference narrowing with 
increasing age (Verbrugge, 1985; Mustard et al., 1998).  However, the Queensland data 
used in the analysis for this thesis presents an opposite pattern, with little gender 
difference prior to age 65, and females using significantly more medicines than males after 
the age of 65.   
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One possible explanation is in factors idiosyncratic to this study design.  Notably, the 
study cohort had randomly included a slightly higher proportion of women (56% versus 
44%) than men aged 65 and over compared to the Queensland population in 2004 (54% 
versus 46%; ABS, 2008c).  However, uneven sampling as the result of randomization does 
not explain the full picture.   
 
Simple biology also does not provide an adequate explanation.  The relationship of 
gender to purchase of medications is much more complex than gender merely being a 
biological patient characteristic in Piette’s framework.  For example, while some of the 
gender differences can be explained by biological differences between men and women, 
they could also reflect sociocultural factors including unequal treatment by health 
professionals and prescriber attitudes.  This phenomenon is described in more detail in the 
discussion pertaining to medications for pain, below.  
 
The finding of this thesis of little gender difference in total prescriptions for younger 
age persons could be partly due to biology, in terms of oral contraceptive (OC) use in 
women of child-bearing age not being recorded in the PBS claims database.  Once again, 
the health systems factor unique to Australia, the PBS, makes this a study specific factor 
not generalizable to populations outside Australia. This is because the majority of PBS 
consumers in the child-bearing age group are general patients, and OCs cost less than the 
general patient copayment rate requiring the consumer to pay the full price.  Had the 
database included below-copayment PBS data, it would give a better picture of the 
contribution of OCs to the gender difference in medication use Australia.  However, this 
data were not available in 2004.  As a result the role of the PBS in biasing the picture of 
OC use in female general patients remains hypothetical at this point.  
 
On the other hand, hormone use in peri- and post-menopausal women is captured in 
PBS claims data because hormone replacement therapy is subsidized on the PBS for 
concessional patients only. In the United States where gender differences in prescribing 
start to emerge much earlier in the life cycle, about half the women aged 15-24 and one-
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third aged 25-29 use OCs, with a progressive decline to 11% at age 40-44 (Mosher & 
Jones, 2010).  In contrast, however, in Sweden, Loikas et al. (2013) analysed data from a 
large drug utilization database and found that women were dispensed more prescription 
drugs in all age groups after age ten, even when hormonal contraceptives were excluded. 
These contradictory findings in prescriptions of OCs worldwide are puzzling and suggest 
that socio-cultural factors in addition to biological gender differences might play more of 
role in gender related prescription purchases.   
 
For example, women use the health system in general more than men, providing them 
with additional opportunity to be assessed, diagnosed and prescribed a medicine (Vaidya 
et al., 2012). In Australia, women account for a higher proportion of consultations with a 
general practitioner (GP) compared to men (Britt et al., 2010). This is mainly because men 
are less likely to seek preventative health care, despite being heavier alcohol drinkers, 
heavier smokers, and more overweight than women (Pinkhasov et al., 2010).   
 
For Australian women aged 65 and over, requesting a prescription was the most 
common reason for a consultation with a GP in 2005-06 (AIHW, 2007a; p 106). For men it 
ranked second after request for a general check-up, which not always resulted in a 
prescription.  It has also been reported that patients’ request and expectations, and 
prescribers’ perceptions of patients (another clinician factor) are strong influences on 
prescribing behaviour in Australia (Knight, 2013) and elsewhere.  In the United States, a 
survey of prescribing habits found that patients who requested a prescription were more 
likely to receive one or more new prescriptions (Mintzes et al., 2002).   
 
These gender-based studies might explain why women aged 65+ were prescribed and 
dispensed more medications than men in this age group, but they do not explain why 
Australian women under 65 years were not.  Analysis of prescription purchase for specific 
classes of medication such as analgesics, discussed below, reveals possible explanations 
why younger Australian women did not follow international patterns of medication use for 
some medications.   
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Pain medications and gender. 
Women in this study used more PBS medications for pain, probably reflecting both 
women’s longevity and associated chronic pain of musculoskeletal conditions, which is 
more prevalent in women (AIHW, 2010b). It could also be the result of better compliance 
by women to medication therapy (Hagström et. al., 2004). Pain is also a comorbid 
condition with other medical conditions that are more common in women, and this may 
have contributed to the observed higher use of antidepressants and antianxiety agents by 
women described in the previous chapter.  This latter issue is discussed in more detail in 
the next section. 
 
An interesting finding from this research was a higher per-person prescriptions for 
opioids analgesics in men, which suggests that men who were prescribed opioid 
analgesics in 2004 were prescribed higher amounts than women. This was a surprising 
finding given that there was no significant gender difference in the overall number of 
prescriptions purchased. Furthermore, while the research literature does support the view 
that women do suffer from more chronic pain conditions than men (Munce & Stewart, 
2007), there does not seem to be much evidence of a gender difference in cancer-related 
pain for which strong opioid-based pain killers are commonly indicated.  
 
The finding of this study that men are being prescribed higher amounts of opioid 
analgesics could reflect a sociocultural factor in Piette’s framework, as there is the 
commonly held (mis)belief that women have a higher threshold for pain and are able to 
tolerate pain better than men (Richardson & Holdcroft, 2009).  Alternatively it could reflect 
patterns of opioid illicit misuse and abuse by males, which is discussed in more detail later 
in this chapter.   
 
Cardiovascular medications and gender. 
Among the cardiovascular class of medications there was a gender difference in 
favour of women in the purchasing of ACE-inhibitors, which is surprising because the 
literature indicates that these medications are prescribed at similar rates for both sexes 
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(AIHW, 2007b).  However, as noted with pain, this finding could be an artefact of a random 
over-sampling of females as discussed earlier in this chapter.   
 
Purchase of cholesterol lowering medications (statins) was equally distributed 
between the sexes, a finding which is inconsistent with published patterns of 
cardiovascular disease.  For example, ischemic heart disease has a higher prevalence in 
men, putting them in a higher risk group than women for primary prevention of high 
cholesterol (Loikas et al., 2013).  In contrast women have a greater incidence of chronic 
pain and muscle pain, the latter of which is a major adverse effect of long term statin use 
(Fillingham, 2000) in cholesterol reduction.  The lower risk of women for ischemic heart 
disease, coupled with their increased prevalence of musculoskeletal pain suggests that 
Queensland women might be being medicated with cholesterol-lowering medications 
unnecessarily and perhaps to their detriment.  This is also important in the long-term 
health of women because statin use has several potential adverse side effects. 
 
What is more troubling is that the equal gender prescription of cholesterol lowering 
medications is at odds with current recommendations for statin use in CVD prevention.  
Evidence-based recommendations for statin use in CVD prevention (Abramson, 
Rosenberg, Jewell & Wright, 2013; Savoiel & Kazanjian, 2002) include a focus away from 
women to high risk groups which include men with risk factors for coronary heart disease 
and stroke.   
 
Nervous system medications and gender. 
More women used antidepressant medications than men in the study cohort, and of 
the women who used antidepressants, they used more per person.  The observed gender 
difference in antidepressant prescriptions could be related to the higher prevalence of 
mental health disorders in women which was found to be the case in a comparison of data 
from the National Health Surveys of 1995 and 2004-05 (ABS, 2006b). This analysis found 
increases in the reported prevalence of mental problems between 1995 and 2004-05 with 
the rates being higher among females than males. 
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This finding is also probably related to differences in help-seeking patterns which 
are consistently higher in women, especially in the case of emotional problems and 
depressive symptoms (Moller-Leimkuhler, 2002).  Both of these explanations would fit into 
Piette’s sociocultural influences of medication framework, which also appear to be operant 
in the United States.  For example, Zhong et al.’s (2013) study found antidepressants to be 
the second most prescribed medication after antibiotics, particularly in middle-aged 
women.  A gender difference in antidepressant use was also reported by Anthony et al., 
(2008) in an analysis of prescriptions dispensed through a large national chain drug store 
in the United Sates over a one year period.  
 
This current research did not find a gender difference in total prescriptions for 
antianxiety medications, such as benzodiazepines. However the number of women using 
antianxiety agents in 2004 was higher.  In other words, more women were using 
antianxiety medications, but, as was found to be the case with opioids, males who were 
prescribed anti-anxiety medications purchased more medication.  The larger number of 
women purchasing anti-anxiety medication is consistent with a higher prevalence of 
anxiety disorders in women (McEvoy et. al., 2011).  Anxiety disorders are also comorbid 
with depression the prevalence of which is higher in women as well.  The possibility of 
benzodiazepines being purchased on the PBS for illicit use, especially by men, however, 
cannot be ruled out, and is discussed further later in this chapter. 
 
Anti-infective medications and gender. 
The use of anti-infective agents was assumed to be relatively stable across all age 
groups.  This turned out to be the case. However a large gender difference in absolute 
numbers of patients and prescriptions was observed for women. Some of this difference 
can be explained by a gender-difference in infection rates, particularly urinary tract 
infections which are much more prevalent in women (Dielubanza & Schaeffer, 2011).   
 
Another possible explanation, discussed above, is related to women being more likely 
to consult a medical practitioner and seek treatment for infections and be given a 
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prescription.  This could also be the result of an increased likelihood of repeat 
prescriptions being given for antibiotics through the introduction of computer-assisted 
prescribing (a health system factor).  The default setting of the computerised prescribing 
program is set to generate a repeat prescription. As a result, the program was found to be 
associated with a significantly higher rate of repeat antibiotic prescriptions (Newby & 
Robertson, 2010) which may also have contributed to this gender difference.  This 
potential excess of anti-infective prescriptions has been occurring on the background of a 
gradual decline in antibiotic prescriptions over time (AIHW, 2003), especially those for 
upper respiratory tract infections which are the most commonly used in the community 
(Wutzke et al., 2007). 
 
Distribution of Prescriptions in 2004 by Age 
Another important finding of this research is the similar distributions across age of 
prescriptions for anti-inflammatory agents (NSAIDs) and peptic ulcer and reflux 
medications.  While prescriptions for both of these medication classes increased with age, 
the peak in use started in age group 45-64 indicating concurrent high burdens for 
inflammatory diseases and gastrointestinal disorders in middle-aged adults.  Both 
gastrointestinal disease and reflux are associated with lifestyle risk factors including heavy 
alcohol intake, smoking and obesity, all of which are more prevalent in working-age adults 
(Pinkhasov et al., 2010).  In addition, there is a peak in the number of patients aged 45-64 
using medications for peptic ulceration, a condition which is an adverse outcome of 
chronic NSAID use (Sung, Kuipers & El-Seraj, 2009).   
 
However, apart from the concurrent peak in the use of anti-ulcerant and NSAID 
medications in working age adults, medication use generally reflected international 
patterns.  Middle-aged Queenslanders aged 45-64, who comprised two thirds (67%) of the 
Queensland population in 2004 (ABS, 2007), purchased about one third (36%) of the 
prescriptions dispensed in 2004.  Queenslanders aged 65 and over, who represented 12% 
of the population at the Queensland Census of 2006 (ABS, 2007), purchased 46% of the 
prescriptions in 2004. This utilisation rate is consistent with that reported by the World 
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Health Organisation which estimates that in developed countries, people aged 60 and over 
consume approximately 50% of all prescription medicines even though they represent 
between 12% to 18% of the population (WHO, 2003).  
 
The pattern of prescriptions for antidepressants and opioids most commonly 
prescribed in young and middle-aged adults identified in this study has also been reported 
by Zhong et al. (2013) in their analysis of population-based prescribing in the United 
States.  Although this pattern reflects the main chronic diseases common at these ages, it 
may also reflect the increasing trend of aggressive treatment for chronic diseases such as 
high cholesterol and blood pressure in middle-aged adults as recommended by updated 
clinical guidelines (NHFA, 2010; Royal Australian College of General Practitioners 
[RACGP], 2012).  
 
Other factors which may have contributed to the observed distribution of 
antidepressants for working aged adults in this study include the increasing use of 
antidepressants in wider range of conditions including anxiety and pain (Olfsen & Marcus, 
2009); and clinical guidelines which focus on early detection and treatment of depression 
in young adults (McDermott et al., 2010). However, it is also possible that patients are 
staying on antidepressants for longer periods of time.  This is supported by Moore et al., 
(2009) who concluded that the rise in antidepressant prescribing is mainly due to small 
changes in the proportion of patients receiving long term treatment rather than increase in 
the prevalence of depression.   
 
However, the prescription and use of antidepressants continues to be contentious.  
Mojtabai (2008) argues that antidepressants are overused especially in the younger age 
groups who do not have a psychiatric diagnosis. Others believe that high antidepressant 
use reflects the ‘medicalization of normality’ (Parker, 2007; Smith, 2012; Spence, 2013) in 
which sadness and situational distress are viewed as an illness to be treated rather than a 
normal part of the human experience.  This could be the result of validity issues related to 
the diagnosis of depression as a mental illness.  This diagnostic validity issue is seen in 
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the shift away from antidepressants in older people, which Kessler et al. (2010) has 
attributed to the diagnostic criteria being less valid for older people.  This has resulted in 
an under-diagnosis of depression in the elderly.   
 
As a result of the multiple views regarding the diagnosis of depression in the young 
and elderly, and its treatment with antidepressants, it is apparent that anti-depressants do 
not fit neatly into Piette’s framework.  The non-cost related factors that influence the use of 
this class of medication include sociocultural influences (such as the stigma of mental 
health and the ‘medicalization’ of normal human emotional states), treatment guidelines, 
and health system factors such as depression being a health priority area.  All of these 
elements play a role in the pattern of antidepressant use in all age groups, and all are 
unrelated to cost concerns.  
 
One-quarter of the patients aged 25-44 and one-third of those aged 45-64 in the study 
cohort were prescribed opioid analgesics in 2004, with the peak in prescriptions being in 
patients aged 45-64. It is of concern that there is a relatively stable prescription pattern of 
opioid use across all three age groups, including young adults, which was not expected. 
This pattern of opioid use contradicts both the PBS restrictions for its listing as a 
subsidised benefit, as well as best practice guidelines for its use in chronic pain. Opioids 
(except codeine and tramadol) are restricted on the PBS for severe disabling pain not 
responsive to non-narcotic analgesics.  Their use in chronic non-cancer pain is not 
recommended (NPS, 2006a, b).  
 
While this finding does not necessarily indicate that opioids are being prescribed for 
the management of acute pain, this possibility cannot be ruled out. For example, the high 
use in the younger age groups could be explained by the use of opioids to manage acute 
pain associated with “day” surgery, where patients who are prescribed strong pain killers 
are usually instructed to use the analgesic for a short period if needed. Another possible 
explanation for this pattern of opioid analgesic use with age is the use of this medication in 
arthritis and joint disorders and back pain. These conditions represent a major disease 
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burden for working-aged adults. When the Australian Bureau of Statistics (ABS) surveyed 
Australians about their health in 2005, arthritis and back pain were among the most 
common long-term conditions reported by young adults (ABS, 2006a). However, the high 
number of opioid users aged 25-44 observed in this study suggests that opioid prescribing 
in 2004 might not have been consistent with best practice and clinical guideline 
recommendations.    
 
Distribution of Prescriptions in 2004 by Payment Category  
 
As part of the second research question this study examined the distribution of total 
prescriptions in 2004 across categories of payment status (concessional and general). The 
analysis revealed that concessional patients (those with the Pensioner Concession Card, 
the Commonwealth Seniors Health Card and the Health Care Card) were about four times 
more likely than general patients to purchase PBS medicines in 2004.  Although this 
reflects the characteristics of the above population subgroups of the elderly and chronically 
ill, this difference could also be the result of Australia’s PBS subsidy framework (i.e., a 
health system factor) which requires general patients to pay about six times more 
copayment for each prescription than concessional patients.  If any group were to be 
sensitive to a 21% increase in the cost of medication, it would be general patients with 
chronic illnesses, not concessional patients. 
 
In fact, this is what the literature supports.  For at least some medications, general 
patients in Australia are more sensitive to cost than concessional patients.  Ampon et al. 
(2009) examined the effects of the copayment level on the purchase of prescription-only 
asthma inhalers and found the rate of purchasing for concessional patients to be twice that 
of general beneficiaries. Hynd et al. (2008) also reported general patients to be more cost-
sensitive to asthma medications in their analysis of the impact of the 21% copayment 
increase on the purchasing of PBS medications in 2005. The conclusion in each case was 
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that cost represented a significant potential barrier to the purchase of asthma medications 
by general patients.  
 
In contrast, concessional patients who do not face a cost barrier are exposed to the 
potential phenomenon of moral hazard.  This phenomenon, described in Chapter 2, occurs 
when concession card holders may use more PBS-subsidised medicines than are 
necessary, purely because they are free or highly subsidised. Although moral hazard was 
not directly investigated in this thesis, it cannot be ruled out in explaining the large four-fold 
difference in medication use between concessional and general patients observed in this 
study.   
 
The National Medicines Policy, which provides the framework for policy development 
on medicines in Australia, has stated that easy access to medicines can contribute to 
consumers stocking up unnecessarily on prescription medicines when they are available 
free or at low cost (DoHA, 2000) and this would explain in part why concessional patients 
used so many more prescription medications than general patients.  However, Doran et al. 
(2005) concluded that affordable prescription cost was not a sufficient incentive for PBS 
consumers to actively seek a medication, indicating that moral hazard is not the sole factor 
in explaining why concessional patients with chronic illnesses purchased so much more 
medication than their wage earning counterparts.     
 
Moral hazard on the part of prescriber may also have contributed to the difference in 
prescriptions between the two categories of PBS beneficiaries.  It makes no difference to 
the prescriber whether he or she provides a prescription or a recommendation for an OTC 
equivalent.  However, some prescribers may be more likely to prescribe PBS-subsidised 
medications to concessional patients in the knowledge that they pay much lower 
copayment for their medications.  In this way the GPs might make a conscious effort to 
ensure concessional patients are prescribed PBS medications such as Ventolin puffers.  
For general patients, for whom there is no short term advantage in prescription medication, 
over the counter (OTC) medications or even therapies not involving medications (such as 
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physiotherapy) may be recommended because there is an assumption that general 
patients can afford to pay or private health insurance would subsidise it.   
 
The result is that working adults with asthma and other chronic illnesses are arguably 
paying more than their fair share for prescriptions.  This current study has found that 
general (employed) patients bear a much higher cost burden than other subgroups, and 
that the copayment for medications is just one of the contributors to this cost burden.  
General beneficiaries who are employed also contribute to government funded health 
programs through the taxation system. This includes a Medicare levy (1.5% of the income 
in 2011-12). In addition to this, general patients are required to pay private insurance 
annually (or pay a tax penalty), and commonly a gap payment for a GP visit.  On top of this 
they pay the full copayment, which as of the writing of this thesis is $37.70 per 
prescription.  Concessional patients pay none of these taxes, levies and copayments, and 
were able to purchase their medication for $6.10 in 2015.  
 
Although concessional card holders are generally older, have lower levels of education 
and employment, tend to report poorer health (Robertson et al., 2014) that prevents them 
following a healthy lifestyle, it can be argued that subsidised access to PBS medications 
and bulk-billed medical services may give some chronically ill concessional patients less 
incentive to control their illnesses through healthier living and preventative check-ups. 
Poor health may also prevent people from engaging in ongoing education programs to 
maintain general literacy skills (patient factors according to Piette’s framework) which are 
required for coping with the many demands of life, including decisions relating to 
medications (ABS, 2009).  A lack of general literacy, in turn, disempowers them in 
interactions with their doctor. 
 
This is borne out by Robertson et al., (2014) who interviewed a randomly selected 
sample of regular medicine users and found that concessional card holders were more 
likely to favour doctors having more say in the decision-making process (a patient 
characteristic according to Piette’s framework) and more likely to report treatment decision 
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being made by the doctor alone, compared with general beneficiaries.  This latter group 
tended to favour a bilateral decision making model, which would include questioning the 
need for a particular medication.  It could be that concessional patients simply accept 
whatever prescriptions the GP provided, leading them to purchase relatively more 
medications.  GPs might not feel the need to explain pharmaceutical alternatives to 
compliant, poorly educated patients.  Medicine cost incentives that might otherwise lead 
the patient to question the necessity for multiple prescriptions do not exist because of the 
low cost of their medications.  These various scenarios highlight the potential interactions 
between patient, prescriber and health systems factors.  
 
Indeed, the framework of Piette and colleagues includes health literacy as a patient 
characteristic that moderates the effects of cost on medication compliance. Health literacy 
is defined as “the knowledge and skills needed to understand and use information relating 
to health issues such as drugs and alcohol abuse, disease prevention and treatment, 
safety and accident prevention, first aid, emergencies and staying healthy” (ABS, 2009).  
In Australia, the issue of health literacy is directly relevant to low income individuals, such 
as concessional patients, who tend to have lower education levels.  This can create a 
social gap between doctor and patient, contributing to greater influence of the doctor on 
decision-making and potentially, a greater reliance by the patient on medication as 
therapy.  
 
Low health literacy can also influence doctors’ prescribing practices.  Smith, Mao, 
Perkins and Ampeuro (2011) demonstrated this phenomenon with graduate students 
enrolled in clinical psychology. They were presented with vignette describing a 
hypothetical client named Michael who presented to the psychologist with difficulty in 
sleeping and an increasing concern that co-workers from his internship were spreading 
unfavorable evaluations of him. The only feature of the vignette that differentiated the four 
conditions of the study was the description of Michael’s social class.  The authors found 
that participants who evaluated hypothetical working-class clients had the lowest 
expectations for them and concluded that this was because the educated clinicians self-
identified as middle-class and were simply unfamiliar with working class people.   
 160 
 
 
The concern is that if doctors also have an unconscious assumption that patients with 
limited education or health literacy have a poorer prognosis they may over-prescribe 
medications in favor of undertaking a more in-depth engagement with the patient that they 
might otherwise do with their more educated, “socially familiar” patients.  This possibility is 
supported by Smith, Trevena, Nutbeam, Dixon, and McCaffrey (2009) who concluded that 
general patients have a higher level of education and tend to see themselves as sharing 
responsibility with the doctor throughout the decision making process.  This may entail 
verifying the credibility of the information and exploring options beyond a prescription for a 
medical condition presented at the consultation.  
 
Distribution of Medications with Abuse and Dependence Potential 
 
A concerning finding from this research was that the number of opioid prescriptions 
per-person was higher in males, suggesting that in 2004 males were accessing opioids on 
the PBS in higher quantities than females.  This could reflect the potential for diversion of 
opioids into non-medical and illicit use, drug dependence and abuse.  Research from the 
United States and Canada suggests that prescription shopping is the most common 
method of diverting prescription drugs out of the medical system for illegitimate 
consumption (Inciardi et al., 2007; El-Aneed et al., 2009). Concurrent prescribing of opioid 
analgesics by multiple prescribers has been reported from a retrospective analysis of 
Medicare insurance claims in the United States (Jena et al., 2014). This study also 
reported men to be more likely to engage in the practice of prescription shopping.  
Analyses of data on criminal methods of obtaining prescription drugs suggest that the illicit 
use of prescription medicines, particularly opioids, is increasing in Australia as well 
(Rodwell et al., 2010). 
 
The current research also found the per-person use of benzodiazepines in 2004 was 
higher in males than females.  In Australia, benzodiazepines are the main target 
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medications associated with prescription shopping and the illicit use of prescription 
medicines (Rodwell et al., 2010).  In the 2007 National Drug Strategy Household Survey 
about 15% of the respondents admitted to doctor-shopping or forging prescriptions to 
source tranquillizers such as benzodiazepines (AIHW, 2008b), a figure which is likely to be 
an underestimate because of self-reporting bias.  It is plausible that some of the patients in 
the database used in this current research associated with a high per-person prescriptions 
for benzodiazepines may have accessed benzodiazepines on the PBS for illicit use.   
 
However, the possibility that some men are being prescribed higher quantities of 
benzodiazepines for “legitimate” use has important public health implications because very 
little is known of practices associated with the prescribing of benzodiazepines in high 
doses.  A recent study from the United States reported that benzodiazepines are often 
abused in combination with alcohol or other prescription drugs (particularly opioids) and 
that admissions due to benzodiazepine abuse, a majority of whom are for men, nearly 
trebled from 1998 to 2008 (Substance Abuse and Mental Health Services Administration 
[SAMHSA], 2011).   
 
The 2007 National Survey of Mental Health and Wellbeing in Australia identified 
substance abuse as particularly problematic in young persons aged 25-34 with anxiety 
disorders (ABS, 2008b). The comorbidity of anxiety and substance abuse and alcohol use 
disorders is highest in the age group 25-44 (McEvoy et. al., 2011). Moreover, as opioid 
analgesics, benzodiazepines, antidepressants, and sleep aids are frequently prescribed in 
combination their additive effects are potentially harmful to health. This combination of 
medications is frequently found in the toxicology reports of people dying of overdoses in 
the United States (Paulozzi, 2012).  This current study confirms that patterns of opioid and 
benzodiazepine purchase in males have important policy and prescribing implications that 
warrant urgent attention.  
 
This is especially the case because despite growing concern about the increase in 
prescribing of opioids in Australia (Roxburgh et al., 2011) there are no national estimates 
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for the frequency of opioid prescribing by multiple prescribers. The findings in this study 
clearly suggest that the purchasing of PBS-subsidised opioids and benzodiazepines by 
males especially, is worryingly high, which supports the possibility that prescription 
shopping might be occurring.  Thus the illicit use of opioids and benzodiazepines is not 
only a health system related factor in the purchase of medication for non-medical 
purposes, but is also a patient characteristic, and a diagnosis related characteristic of the 
medication (i.e., the potential for addiction).  Furthermore, the use of doctor- or prescription 
shopping could also be conceptualised as a clinician factor, with some clinicians being 
more willing or easier to coerce into prescribing opioids and benzodiazepines 
inappropriately than others (Sheridan & Butler, 2011).  This is a clear example of the inter-
relatedness of the various factors in Piette’s model.  The unique aspect of the use of the 
Australian PBS database is the indication that that illicit use of prescription medications is 
being subsidised by the Australian taxpayer. More research is needed to describe the 
population sub-group in Australia associated with accessing of PBS medications with 
addiction and dependence potential.  
  
Distribution of Multiple Medication Use in 2004 
 
Very few studies of multiple medication use (polypharmacy) have used population-
based samples, age groups other than the elderly, analysis by levels of medication used, 
or minor polypharmacy.  Our current knowledge of multiple medication use predictors is 
therefore limited to people of advanced age, institutionalised patients, and those with 
multiple chronic diseases. This research sought to address these gaps by describing the 
distribution of polypharmacy in 2004 by age, gender, concessional status and medication-
related variables, and then investigating the effects of a larger than usual copayment 
increase the distribution of polypharmacy in 2005.   
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Overall 25% of Queenslanders who purchased PBS medications in 2004 were 
exposed to either minor polypharmacy (a mean of 2-4 medications per month) or major 
polypharmacy (a mean of five or more medications per month).   
 
Polypharmacy and age. 
This study found that one in ten young adults aged 25-44 in Queensland were 
exposed to either minor or major polypharmacy in 2004.  Unlike older persons where the 
focus is on adverse events associated with multiple medication use, the main concerns for 
younger adults is prescription drug abuse and illicit diversion, discussed above.  Studies 
have shown that the demand for certain prescription medications, e.g. opioid analgesics 
and benzodiazepines by young adults (Planton & Edland, 2010) and the use of multiple 
prescribers to source these medications (Jena et. al., 2014) encourages polypharmacy in 
some younger adults.   
 
The findings presented in the previous chapter also revealed an increasing trend in 
polypharmacy with age, which was statistically significant.  This confirms age as an 
important risk factor for polypharmacy, with six out of 10 patients aged 65 and over being 
affected by either minor or major polypharmacy. The analysis also showed that minor 
polypharmacy decreased with age while major polypharmacy increased.  
 
Polypharmacy creep into younger age groups. 
In 2004, minor polypharmacy was about three times more common than major 
polypharmacy. This is an important finding which has not been reported elsewhere, 
although Morgan et al. (2012) report from their survey of Australians aged 50 and over that 
both forms of multiple medication use could be affecting younger Australians (in addition to 
older aged persons).  While there is a paucity of research on factors associated with 
medication use at the minor polypharmacy level, it is plausible that the current clinical 
focus on early detection and aggressive treatment of chronic diseases is not only 
increasing the number of persons affected by polypharmacy overall, but is shifting the 
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distribution of minor polypharmacy into younger age groups.  This has significant policy 
implications, discussed later in this chapter. 
 
The number of patients affected by minor polypharmacy in this research increased 
sharply with age from 8% in people aged 25-44 to 23% in middle aged persons, to just 
over 40% in older persons aged 65 and over.  The finding that almost one in four persons 
aged 45-64 was affected by minor polypharmacy in 2004 is important because the majority 
of this age group are working age persons who purchase medications at the general 
copayment rate.  With a changing pattern of population growth from older interstate 
retirees to younger overseas immigrants and natural increase (Barker, 2008), the number 
of general beneficiaries in Queensland is expected to increase. This may turn out to be a 
key predictor of the number of Queenslanders affected by minor polypharmacy in the next 
decade, with more general patients having considerable out of pocket expenses.   
 
Polypharmacy and gender. 
No significant overall gender difference in the prevalence of non-polypharmacy and 
major polypharmacy was identified in the total study cohort, although minor polypharmacy 
was found to be significantly more prevalent in women.  This suggests that minor 
polypharmacy could be the major driver of gender differences in medication use discussed 
earlier in this chapter. For the oldest age group (65 and over) a significantly higher 
proportion of women than men were affected by both forms of polypharmacy.   
 
These findings are contradictory to the findings of Venturini et al. (2011) who 
reported that that the gender-difference in polypharmacy, defined as the use of more than 
three drugs that have the potential to cause drug interactions and side effects, actually 
narrows after age 80.  The authors explained the decreased use of medications among the 
over-80 population to physician awareness that inappropriate drug use is a risk factor to 
adverse drug events and preference to minimise the number of medications.  This is a 
clinician factor according to Piette’s framework and it suggests that GPs in Queensland 
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might benefit from initiatives to increase their awareness of the potential of adverse drug 
events related to polypharmacy in the elderly.  
 
More than half the patients on CVD (e.g., for blood pressure, cholesterol), 
alimentary tract (e.g., for diabetes, gastric reflux) and musculoskeletal (e.g., for arthritis, 
back pain) medications were found to be associated either minor or major polypharmacy. 
These findings are on par with other studies which show that medication classes most 
commonly associated in polypharmacy are those for the cardiovascular system and 
alimentary tract (Aparasu et al., 2005; Hovstadius & Petersson, 2012; Hovstadius & 
Petersson, 2013), and diabetes Austin, 2006). These finding are not surprising as therapy 
with multiple drugs has become the standard medication therapy of care for chronic 
diseases such as diabetes (Ismail-Beigi, 2012) and hypertension (NHFA, 2010). The 
management guidelines for hypertension in fact recommend the use of up to four 
antihypertensives in combination to achieve the target blood pressure.    
 
Venturini et al. (2011) also reported an increase in polypharmacy for both genders 
independent of increasing age, suggesting other factors could be playing a role in the 
development of polypharmacy. In Australia one other possible factor is the use of clinical 
guidelines to facilitate evidence-based prescribing, which is represented in Piette et al., 
framework as a systems based incentive for health providers to buffer the effects of cost-
related nonadherence. However, as the decision to prescribe a drug is often based on a 
disease-oriented approach that stems from guideline recommendations for each single 
clinical problem (Tinetti et al., 2004; Tinetti & Studensky, 2011) the use of clinical 
guidelines in persons with multiple chronic diseases may inadvertently be contributing to 
polypharmacy identified in the PBS database, which has the potential to increase adverse 
drug interactions.   
 
Furthermore, the utility of some of the existing clinical guidelines to the ageing 
population has also been questioned.  Nobili et. al. (2011) concluded that evidence for 
clinical guidelines are developed from randomized clinical trials or meta-analyses which 
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are often biased by the under-representation of elderly people, especially those affected 
by multiple chronic diseases.  This is supported by Lang and Lidder (2010) who found that 
patient enrolment in clinical trials for cancer drugs included only 20% of patients older than 
70 and 9% of patients older than 75 years, compared with 46% and 31% for the whole 
cancer population in the United States. Another study showed that despite the high 
prevalence of heart failure in older patients, more than 40% of clinical trials had one or 
more poorly justifiable exclusion criteria that limited the inclusion of elderly patients 
(Cherubini, et al., 2011). 
 
In short, there is growing evidence that the deprescribing of medications in some 
patient populations can contribute to improved patient outcomes and decrease adverse 
drug events as well as medication costs (Garfinkel & Mangin, 2010; Bain et al., 2008). 
However, there is little evidence that this is occurring in Australia, at least according to the 
PBS medication purchases in 2004. 
 
Concluding comments  
 
As discussed in Chapter 1 this research is based on a retrospective analysis of paired 
data over two consecutive years, with the focus being on patient characteristics, rather 
than the total number of prescriptions dispensed. This section of the discussion chapter 
has provided a profile on medication use in 2004 overall and across categories of age, 
gender, level of medication use and medication class.  An inferential analysis of paired 
data was carried out to 1) establish whether the copayment change in 2005 resulted in a 
change in the overall purchasing of PBS medicines; and, 2) whether the change in 
purchasing associated with the copayment change differed along characteristics of the 
patient and the therapeutic classes of the medication.  The findings for these analyses 
were presented in Chapter 4, and the following sections presents a discussion of the 
changes that occurred following a 21% increase in copayment on January 2005. 
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Change in Total Prescriptions in 2005 
 
The change in total prescriptions after the copayment increase in January 2005 was 
examined as part of the second research question. It was hypothesised that the unusually 
large copayment increase would contribute to a reduction in prescriptions even on the 
short term. However, this was found not to be the case as the total prescriptions increased 
by 2.7% after the 21% copayment increase, which is on par with patterns of contiguous 
years.   
 
The Australian Institute of Health and Welfare reported that PBS prescriptions grew at 
an annual average rate of 3% from 1994 to 2004 and continued to grow at this rate from 
2004 to 2006 (AIHW, 2008a; p. 384); a period which coincided with the implementation of 
the copayment increases being investigated in this thesis. This suggests that the large 
copayment (21%) increases to both categories of PBS beneficiaries in January 2005 may 
not have had an immediate, disproportionate impact on total prescription dispensed on the 
PBS during the calendar year 2005.  However, although the total number of prescriptions 
increased, almost half (44%) of the patients in the study cohort purchased fewer 
medications in 2005 than 2004.  This decrease was offset by about the same number of 
patients (45%) increasing their medication purchases in 2005.  Only 11% of 
Queenslanders did not change in the number of medications purchased in 2005.   
 
This suggests that for at least some subgroups of patients, the copayment increase 
may have resulted in reduced use of PBS medications.  This is a very important finding 
related to the unique design of the study which used paired data over two years.  Paired 
data has not previously been examined, and the pairing of data in this study identified 
which types of patients/illnesses are potentially sensitive to price increases.  Studies 
relying solely on changes in total prescriptions to assess the impact of copayment 
increases would miss these effects at the patient level; a conclusion that the investigator 
would have made had he investigated only the total number of prescriptions purchased, 
presented in the first paragraph of this section. 
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The response to the copayment increase differed across categories of 
sociodemographic and medication-related variables included in this study, creating a 
complex picture.  However, this complexity was expected, being consistent with Eaddy et 
al. (2012) who showed that cost-related adherence might be larger or smaller depending 
on many factors such as the population subgroup being investigated, medication class, 
number of comorbidities and level of insurance (copayment). Some of these differences 
could be related to factors such as perceived benefits and risks of a medication 
(prescription characteristics according to Piette’s framework), which has also been shown 
to vary across patient subgroups (Aikens & Piette, 2009).   
 
The study of Piette and colleagues found that even after adjusting for economic 
factors, patients who were younger, African Americans, and patients of low literacy were 
especially concerned about medication harmfulness, which in turn was associated with 
medication underuse and high blood pressure (Aikens & Piette, 2009).  The research in 
this thesis revealed similar subgroups of the population in Australia to be vulnerable to 
cost-related changes in medication use.  General beneficiaries who tend to be working age 
persons, and those using multiple medications, who are mainly older concessional 
patients, were most affected by the copayment increase in 2005.  This is discussed in 
more detail further in this Chapter.  
 
Change in total prescriptions in 2005 by gender and age. 
The copayment increase in 2005 did not result in a significant decrease in the 
number of prescriptions for women.  For men however, the number of prescriptions 
increased significantly in 2005.  These findings suggest that women may have been 
affected by the copayment increase more than men. The findings are consistent with those 
of Heisler et al., (2005) who reported women to be more at risk of cost-related 
nonadherence to medications.  The main reason is the impact of a higher prevalence of 
chronic diseases in women and the associated requirement for multiple and long term 
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medication therapy (Kennedy et. al, 2004). Both factors may put women at a higher risk of 
cost-related nonadherence to medications.   
 
Another possibility, described in more detail in the previous section, is women’s 
higher use of health care services in general (Rustgi, Doty & Collins, 2009), which puts 
them at higher exposure to the effects of changes at the health system level (health 
system factors according to Piette’s framework), including copayment increases. In 
contrast, if the finding from this study of higher per person opioid and benzodiazepine 
purchases by men in 2004, which persisted after the 2005 copayment increase, is 
accurate, then men’s higher illicit use of these medications would probably be price-
insensitive. 
 
There were significant increases in prescriptions for adults aged 65 and over in 
2005. The finding in relation to older persons could be partly the result of a 
disproportionately higher number of concessional patients in the study cohort.  This finding 
is consistent with that of Piette et al. (2004a) who reported that after controlling for out-of-
pocket medication costs and other socioeconomic variables, people aged 65 and over are 
less likely to cut back on medication use due to cost than those in younger age groups.  
The main reason for this is a higher need for chronic disease medications in older persons 
and higher risks associated with not complying with medication therapy (Piette et al., 
2006).  
 
However, age may not be the sole determining factor in cost-related medication 
purchase. The framework of Piette at al. (2006) identifies factors associated with the 
health system and the medication which may interact with age to influence cost-related 
adherence to medications. It is likely that patients aged 65 and over in the study cohort 
were not affected by the copayment change to the same extent as the young and middle-
aged persons because as concessional patients they were better insulated against price 
increases. In contrast, younger persons aged 25-44 were affected more because they 
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were predominantly general patients who were suddenly exposed to a very large 
copayment increase which was not phased in over time. 
 
Change in total prescriptions in 2005 by Payment Category.  
The copayment increase in 2005 affected the purchasing of general prescriptions 
more than concessional prescriptions.  While an increase in total prescriptions dispensed 
in 2005 was in line with the existing trend, a decline in the growth of PBS prescriptions was 
observed for general patients. This suggests that the increase in total prescriptions in 2005 
was largely driven by increased purchasing by concessional patients.   
 
In 2005, copayment increases of $4.90 for general patients and $0.80 for 
concessional patients represented a 21% increase for both categories of PBS 
beneficiaries. The increase in concessional prescriptions of 3% in 2005 compared to 2004 
levels was statistically significant.  This finding is consistent with that of Kessler et al., 
(2007) who reported that a lower existing copayment level is associated with lower rates of 
medication termination, although other factors such as population subgroup, medication 
class, number of comorbidities would also play a role in medication purchase decisions 
(Eaddy et al., 2012). 
 
The decrease in general prescriptions of 7% in 2005 was also statistically 
significant. This suggests that the immediate impact of the copayment increase was 
greater for general patients because they were subjected to a higher absolute increase in 
copayment.  In fact, the 21% increase in copayment resulted in a 7% decrease in 
medication purchases for general patients.   
 
It is generally accepted in the literature that a 10% increase in cost sharing is 
associated with a decrease of 1% to 6% in medication use (Thomas, 2008).  The decrease 
in medication purchases of Queenslanders fell within this range, with a 10% increase in 
cost being associated with slightly over a 3.5 % decrease in medication use (i.e. half of the 
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7% decrease in use that occurred with a 21% increase in cost).  The decrease in 
prescriptions for general patients (7%) observed in this study in response to a $4.90 
increase in copayment however is almost double that reported by Eaddy and colleagues 
(2012). These authors reviewed recent evidence on the effects of cost sharing on 
adherence and outcomes and found that a $10 increase in copayment to be associated 
with an average across the board decrease of 3.8% in prescriptions.  
 
That a much higher decrease was observed in this study is most likely due to the 
patient sub-group being general patients who already paid a higher existing copayment 
than concessional patients and were subjected to a much higher copayment increase in 
2005. This finding for general patients from this study also confirms that copayment 
increases affect different population subgroups differently (Eaddy et al., 2012) and that 
analysing changes in total prescriptions alone may not give a complete picture of the 
impact of copyment increases on medication use at a population level.    
 
However, it is also possible that the results for concessional patients could be an 
artefact of the relatively short time frame of this current study (the first year following the 
copayment increase).  Hynd and colleagues (2008) investigated the impact of same 
copayment change over a wider time frame (January 2000 – December 2004 compared 
with January 2005 – September 2007) and found concessional patients to be cost 
sensitive to a wide range of chronic disease medications, including osteoporosis 
treatments, proton pump inhibitors, and non-aspirin anti-platelet medications.  This 
suggests that, as opposed to general patients, concessional patients, feel the effects of a 
price increase in the longer term rather than an immediately, as occurred with the general 
patients. This differential time frame supports Gibson et al.’s (2005a) conclusion that the 
effects of a copayment increase are not static, but change over time.  This current 
research indicates this is particularly the case for concessional patients. 
 
Furthermore, the significant decrease in general prescriptions in 2005 occurred in 
the context where general patients had both a higher existing copayment than 
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concessional patients, and a higher increase in absolute dollar terms relative to previous 
increases (because the increase was a percentage of the 2004 price).  Both these factors 
have been found to be predictors of medication termination.  Kessler et al. (2007) analysed 
data from a large managed care database in the United States and found that patients 
paying high existing copayments faced with increases in copayment are more likely to 
terminate medication use earlier rather than later in the treatment compared to those on 
lower or no copayment.   
 
As mentioned previously, general patients in Australia pay a copayment which is 
about six times greater than that paid by concessional patients.  Then, on top of this, they 
were subjected to a much greater copayment increase in 2005 compared to previous 
increases.  As a result, there was an immediate and significant reduction in the number of 
prescriptions purchased by general beneficiaries.  The conclusion is that the cost increase 
was a pivotal factor in the cessation or reduction of medication therapy in general patients, 
although other factors such as the presence of multiple chronic illnesses and medication 
type may also have an effect (Hynd et al., 2008).  
 
However, these findings do not necessarily mean that general patients reduced 
their medication intake solely in response to the large copayment increase in 2005.  Other 
changes were made to the PBS at that time which would have affected the data that was 
collected in the PBS database.  Fewer medications were subsidised on the PBS for 
general patients in 2005 than in 2004.  Thus, as the general patient copayment increased 
in 2005, the dispensed prices of many of the cheaper medications fell below the PBS 
copyment for general patients, and were therefore no longer on the subsidy list.  As 
discussed in Chapter 1, in 2004, 12% of all community prescribing were not subsidised as 
the cost was less than the general copayment of $23.70 (Colvin et al., 2009).  Medications 
affected included many commonly prescribed NSAID, antibiotic, diuretic, benzodiazepine 
and older antidepressant medications. These were only subsidised to concessional 
patients who paid $3.80 per prescription.  It is likely that the larger than usual general 
copayment increase in 2005 of $4.90 per medication resulted in more medications 
becoming unsubsidised therefore not recorded on PBS claims data for general patients.   
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Between 1996 and 2006, prescriptions which cost below the copayment threshold 
decreased from 19% to 15% of total prescriptions. However, in 2008 they increased to 
19% (AIHW, 2010a). This suggests that each copayment change since 2005 has resulted 
in more medications falling off the subsidy list for general patients requiring them to pay full 
cost for more medications.  This represents a significant cost burden to employed persons 
on low incomes, who tend to be largely invisible in research on medication use patterns.  
This current research highlights the importance of monitoring the medications which 
become below-copayment every year, and therefore are unsubsidised to general patients.  
It is essential in a fair and universal health scheme that vulnerable low wage earners are 
not compromised by copayment increases, especially a large one as was the case in 
2005.  
  
This vulnerability also the case when a doctor prescribes a medication not listed on 
the PBS schedule (private prescription), or when a low income general patient purchases 
OTC medications at a pharmacy (such as cold and flu tablets, Ventolin puffers, fish oil 
capsules and vitamins).  Because these medicine purchases are not collected by the PBS, 
the findings of this research are based on an underestimate of total amount of medication 
purchases by general patients.  This systems factor limitation in the monitoring of drug 
purchases was corrected when the collection and reporting of below-copayment PBS 
transactions became mandatory in 2012 (DHS, 2012).  This system factor adjustment 
makes it possible to monitor loss of PBS subsidy for general patients resulting from 
medications falling below the general patient copayment after each copayment change in 
a way that was not possible in 2004/5.  However, this still does not collect the total amount 
of medications purchased by general patients. A complete picture of medication utilization 
by general patients will only be possible if below-copayment and private prescriptions are 
recorded as PBS transactions and OTC medication purchases are taken into 
consideration.  
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Complicating the picture further for general beneficiaries, PBS reforms (health 
system factors according to Piette et al.) which are designed to protect patients from 
higher out of pocket costs paradoxically have the potential to increase the number of 
medication falling below the general copayment (and become unsubsidised for general 
patients).  As explained in Chapter 1 these reforms are unique to the Australian PBS 
environment and include “Statutory Price Reduction” and “Price Disclosure and Expanded 
and Accelerated Price Disclosure” (EAPD).  Under statutory price reduction, a 16% 
reduction is applied to existing PBS-listed products when the first new brand or item that is 
bioequivalent with the same manner of administration to an existing brand or item is 
introduced into the PBS (DoHA, 2014e).  This can potentially bring the price of the 
medication to below the subsidised rate for general patients. 
 
Under EAPD, the pharmacy is required to disclose discounts and incentives 
provided by the manufacturers whenever medications which have more than one brand 
listed on the PBS are purchased.  As the government pays the pharmacist on the basis of 
actual wholesale prices they pay for generic drugs, price disclosure reforms have the 
potential to save money for the government and concessional patients, but not necessarily 
general patients.  For example, when a hypothetical medication costing $100 is subjected 
to price disclosure and the price is reduced to $50 (i.e. an amount above the copayment), 
both categories of PBS beneficiaries would continue to pay their stipulated copayment 
amount.  The most a patient will pay is the relevant copayment of either $37.70 (general) 
or $6.00 (concessional), but the cost to the PBS and taxpayers for this the medicine would 
be reduced.  However, despite savings to the Government, price disclosure reforms have 
the potential to increase the pool of below-copayment medications for general patient and 
result in general patients paying the full price for more medications.  For example, if the 
cost of a hypothetical medicine drops from $60 to $25, the general patient will pay the $25 
(below-copayment) rather than the higher $37.70 copayment, which on the face of it 
appears to be a saving. However, by not having these medications included on the PBS 
subsidy list, the general patient (due to paying $25 rather than $36.10) at each dispensing 
will be less able to reach the safety net threshold and qualify for medications at the 
concessional rate.  This effect is cumulative if the general patient is using ongoing and 
multiple medications for chronic conditions. The more medications that are pushed off the 
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PBS subsidy list, the harder it gets for general patients on multiple medications to reach 
the safety net threshold (SNT) and qualify for additional subsidy at the concessional rate 
for the remainder of the calendar year. 
 
An increase in the number of below-copayment and PBS-unsubsidised medications 
may provide some general patients with financial incentives to seek cheaper over the 
counter (OTC) substitutes, or alternative types of therapy.  This is not necessarily a bad 
thing if the patient can afford this.  However, in the worst case scenario of a low income 
general patient with multiple chronic illnesses, it can lead a patient to forgo the medication.  
It is likely that the drop in general prescriptions after the copayment increase in 2005 was 
partly due to various actions by general patients including purchases of OTC equivalents 
and perhaps ceasing medication therapy. Gibson et al. (2005a) found that when faced with 
rising out-of-pocket costs patients with lower insurance in the United States are more likely 
to search for less expensive options such as purchasing generic medications. However 
these options do not always involve a switch to generic medications. They may include 
OTC medications which do not require a prescription or the cost of a medical consultation, 
or complementary and alternative therapy which may not involve a medication at all.   
 
Access to OTC alternatives outside Australia have increased in the last ten years, 
with many medications that were originally prescription-only now available either from 
pharmacies or general retail outlets worldwide.  In the United Kingdom more than 90 
medicines have been reclassified from "prescription-only" to "pharmacy" availability, and 
many of these have further been deregulated to "general sales" status (Paudyal, Hansford  
Cunningham & Stewart, 2013).  In contrast switches to non-prescription medicine in 
Australia usually requires the substance to have been used for at least two years as a 
prescription medicine, and is regulated by the Therapeutic Good Administration (TGA) 
which assess the medication for quality, efficacy and safety prior to the switch (McEwen, 
2004). Ventolin puffers are an example of a prescription medication that eventually 
became OTC.  However, these puffers are also an example of how general patients might 
be influenced to purchase discretionary symptom-reliever medications rather than 
essential PBS prescription-only preventer medications.  This is not necessarily the best 
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thing for the patient or the health care system if a preventable acute asthma attack leads 
to hospitalisation.  
 
Therefore, switching to unsubsidised OTC and alternative therapies may benefit 
both the general patient who does not have to pay the cost of the GP consultation, and the 
health care system which also does not have to subsidise the visit to the doctor. Other 
benefits may include increased convenience to patients, greater self-management of minor 
ailments and a reduction in government expenditure on medicines (Bond & Hannaford, 
2003). However there are important differences between medicines supplied OTC, and on 
a doctor’s prescription which may represent risks to the patient and false economy on the 
long run.  
 
For example, with OTC medicines there is less/no physician input in relation to 
indication for use and ongoing monitoring of use. In fact many doctors are unaware of the 
range of OTC products available or do take them into consideration when making 
prescribing decisions. In the absence of linkages between medication purchasing 
databases, the purchasing of OTC and other medications without a prescription may lead 
to a fragmentation of patients’ medication history. In addition, if OTC medicines are 
purchased from more than one pharmacy or outlets, patient medication histories become 
lost to the pharmacist as well.  All these may contribute to fragmentation of care, 
inappropriate use, unmet expectations and limited opportunity for ongoing follow up and 
monitoring of safety.  If OTC medications are recommended, patients should be made 
aware that these medications should be treated with the same care as prescribed 
medicines and advice on dose, contraindications, and interactions adhered to.   
 
As with OTC medications, complementary and alternative medicine (CAM) use also 
provides benefits to the government in the form of reduced expenditure on 
pharmaceuticals and medical consultations.  The use of CAMs has been reported to be 
common in patients with arthritis and musculoskeletal disorders when faced with rising 
costs (Gore, Sadosky, Leslie, and Stacey, 2012). These non-pharmacological 
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interventions include trans-electrical nerve stimulation and acupuncture, chiropractic, 
physical therapy, massage therapy and hydrotherapy. In Australia, while pharmaceutical 
therapy with opioids and NSAIDs remains the mainstay in the management of pain, 
expenditure on CAMs continues to rise (Xue, Zhang, Lin, Da Costa, & Story, 2007), 
despite not being subsidised by the PBS.  As a result their use is skewed towards 
individuals with higher household incomes and with private health insurance (Xue et al., 
2007), who tend to be younger and general PBS beneficiaries.  The move to CAMs by this 
subpopulation could be potentially operant in the reduction of prescribed purchase of 
medications by general patients in 2005, but still, it does not explain the timing of the 
reduction (immediately after the 21% increase in price). 
 
Another explanation for different responses by general and concessional patients to 
the copayment increase in 2005 may lie in the different types of medicines consumed by 
these groups of PBS beneficiaries.  Concessional patients, who are generally older, are 
more likely to have diagnosed chronic conditions or conditions requiring regular 
medications, so an increase in cost sharing may have less influence on their purchasing 
decisions because they need those medications.  This is supported by the extant literature 
which reports that patients on medications for existing chronic conditions have 
demonstrated only modest and insignificant reductions in use (Goldman et al., 2004), as 
have older persons aged 65 and over (Piette et al., 2004a).  
 
General patients, on the other hand, being younger than 65 years, are more likely to 
be on medications to treat symptoms of acute conditions which flare up sporadically.  
These patients tend to be more sensitive to copayment changes. Goldman et al. (2004), in 
a retrospective analysis of pharmacy claims in the United States, found increases in cost-
sharing to be associated with significant decreases in the use of antihistamines and 
NSAIDs which are taken intermittently to treat symptoms.  However, Piette et al. (2004a) 
did not report this, rather that the presence of lower prescription drug coverage was 
associated with reductions in medicines for both acute conditions with symptoms (e.g. 
reflux) and asymptomatic chronic conditions such as hypertension and hyperlipidaemia.  
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In summary, the combined trends of OTC and alternative therapies use by general 
patients could act to obscure the real price general patients are paying for their healthcare. 
In Australia, a country which prides itself on the provision of affordable medical care to 
every citizen, the movement of general patients away from PBS medications arguably 
attenuates the picture painted via the National Medicines policy of timely and affordable 
access to essential medicines for everyone. 
 
Change in Prescriptions in 2005 by Chronic Diseases and Conditions 
The focus of the research for this thesis was medication classes belonging to the 
National Priority Health Area (NHPA) chronic diseases of cardiovascular disease (CVD), 
mental health, diabetes, arthritis and asthma.  As described in Chapter 3, in order to apply 
the data provided by Medicare, an identification of the health priority area disease or 
condition being treated was extrapolated by the medications prescribed according to the 
ATC classification system. For example, the NHPA of diabetes was investigated by 
examining purchases for medications belonging to alimentary tract and metabolism (ATC 
level 1) which comprises antidiabetics and anti-ulcerants. Differentiation of diabetes 
medications from anti-ulcerants was made possible by analysing at ATC levels 2 and 3 of 
the ATC classification system so that the findings could be meaningfully discussed.   
 
Antibiotics were also included because they are a commonly used to treat infections 
which affect patients regardless of age, gender and payment category, and were used as 
a quasi-control variable.  They also facilitated an examination of the impact of cost on the 
purchasing of medications for the treatment of acute illness, and provided a useful 
benchmark for the interpretation of medication use in patients with chronic conditions.  
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Infections. 
There was no change in total prescriptions or number of patients using anti-infective 
agents in 2005, suggesting that the copayment increase did not affect the purchasing of 
this medication class (predominantly antibiotics). This pattern however was not observed 
for patients aged 65 and over on multiple medications.  For this patient subgroup there 
was a significant reduction in antibiotic use, suggesting that both cost (financial pressure 
according to Piette’s framework) and number of medications associated with older patients 
(regimen complexity) may have played a role in the decreased consumption of antibiotics. 
Since this age group are mostly concessional patients who pay the lowest copayment, it is 
likely that antibiotic use was influenced more by regimen complexity than financial 
pressures.  It is worth noting at this point that because the data for 2004 and 2005 were 
paired according to patient, individuals who might have died of an infection or any other 
causes in 2005 were excluded from the database created for this study during data 
cleaning.  
 
A likely explanation from the health system perspective for the drop in antibiotic use 
in older persons is the shift from prescriptions for influenza vaccines (which were 
dispensed through pharmacies at the concessional rate) to GP-supplied influenza 
vaccinations which were provided at no cost to concessional card holders.  This change in 
the provision of influenza vaccines which began in 2003-04 (Henderson & Pan, 2009), and 
an associated vaccination awareness campaign, may have contributed to an increased 
uptake of free vaccination for eligible patients.  It is also possible that the introduction of 
the Pneumococcal Vaccine Program in January 2005 (Henderson & Pan, 2009), and its 
accompanying promotional campaign, also affected the rate of vaccinations for both this 
and influenza.  Finally, the impact of “rational antibiotic prescribing” (a health system factor 
according to Piette’s framework) could also be a cause for the reduction of antibiotic use in 
older patients with chronic illnesses.  It must be noted, however, that analysis of the impact 
of these Australian health sector initiatives was outside the scope of this study so these 
possible explanation remain informed conjecture at this point.   
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Cardiovascular disease.  
Overall, patients on CVD medications showed an increasing but non-significant 
trend in total prescriptions in 2005. However this was not the case for all subgroups of 
patients.  Decreases in CVD prescriptions were observed for general and concessional 
beneficiaries with major polypharmacy. This suggests general and concessional 
beneficiaries on multiple medications may have reduced the purchasing of CVD 
medications in response to the copayment increase in 2005. 
 
Within CVD medication group, a decrease in prescriptions was observed for blood 
pressure lowering medications in 2005. This is consistent with other studies from Australia 
(Doran et al., 2004) and the United Sates (Taira et al., 2006) which have reported 
antihypertensive medications to be particularly sensitive to the cost increases.  
 
Within the antihypertensive class of medications, a drop in prescriptions was 
observed for angiotensin-converting enzyme (ACE) inhibitor class, a recommended first-
line therapy for hypertension (NHFA, 2010).  This decrease in the purchasing of ACE 
inhibitors was associated with middle aged and older general patients with polypharmacy.  
Surprisingly, the decrease in ACE inhibitors occurred without a corresponding increase in 
prescriptions for a related antihypertensive medication class, angiotensin II receptor 
blocker (ARB), which is also a recommended first-line therapy (NHFA, 2010) commonly 
prescribed as an alternative to ACE inhibitors.  This means that the explanation for the 
reduction in ACE inhibitors cannot be explained by a commensurate increase in 
recommended alternative ARB medications. 
 
The findings regarding CVD medications suggest that a major driver of the reduction 
in prescriptions was the decrease in the purchase of ACE inhibitors, a medication class 
which has been reported to be sensitive to cost in other studies (Schneeweiss, 2002; Cole 
et al., 2006). Further evidence that the use of ACE inhibitor class of antihypertensive 
medications is sensitive to copayment increases comes from research by Chernew et al. 
(2008). These authors demonstrated that a copayment reduction actually improved 
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compliance to both ACE inhibitors and ARBs.  In this current research the patient sub-
groups most affected were general beneficiaries and concessional patients on multiple 
medications, which suggest that cost of medication may have been a factor in this result.   
 
High blood pressure is the most commonly reported disease of the circulatory 
system in Australia (ABS, 2006a) and a major focus of the NHPA of cardiovascular 
disease.  The observed decrease in the purchasing of antihypertensives, particularly ACE 
inhibitors, in response to the 2005 copayment increase is cause for concern because this 
class of medication represents the first line treatment of hypertension; and a decrease in 
use may have potentially serious implications for the treatment and prevention of heart 
disease and stroke.    
 
Mental health.  
Total prescriptions for the nervous system class of medications increased in 2005. 
This increase was associated with persons aged 65 and over, and those not exposed to 
polypharmacy in 2004.  This increase in prescriptions for nervous system medications in 
2005, which was mostly for antidepressants, occurred in spite of the copayment increase.  
This was surprising, as the literature indicates that the level of psychological disorders in 
the community has changed only slightly in the last decade (Atlantis, Sullivan, Sartourius & 
Almeida, 2012), yet prescriptions for mental health disorders in Queensland increased 
significantly between 2004 and 2005. 
 
However, this increase was not reflected across the board.  For the sub-group of 
general patients with major polypharmacy there was a reduction in prescriptions for 
nervous system agents in 2005.  This suggests that cost-sensitivity was associated with 
multiple medication users.  A similar decrease in prescriptions for nervous system agents 
was also observed for concessional patients with major polypharmacy, which was 
unexpected because concessional patients are highly subsidised under PBS and cost 
should not have informed a decision to decrease medication.  These findings suggest that 
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the presence of polypharmacy rather than level of subsidy affected the purchasing of 
nervous system agents in 2005.   
 
It is possible that characteristics of concessional patients (such being over 65 years) 
drove the reduction of this class of medications, perhaps because depression and anxiety 
are under diagnosed in this age group, especially in aged care residents (Davison et al., 
2007) as discussed earlier in this chapter. However, although this prescriber factor might 
explain a lower use of these medications in general, it does not explain a reduction in their 
purchase in 2005.  The exact reason for this finding in concessional patients with 
polypharmacy remains unclear. 
 
For older persons a decrease in antidepressant prescriptions in particular was 
observed in 2005.  This could have been related to the impact of provider initiatives (health 
system factors according to Piette’s framework) directed exclusively at older persons. 
These include the impact of the Residential Medication Management Review (RMMR) 
service which is available to eligible residents of aged care institutions.  An RMMR service 
is a comprehensive medication review, by an accredited pharmacist, that is resident-
focussed and involves a systematic evaluation of a resident’s complete medication 
regimen (regimen complexity according to Piette).   
 
Additional financial incentives introduced in November 2004 (a health system factor) 
which enabled referring doctors to claim money for initiating RMMRs, and collaborating 
with an Accredited Pharmacist in providing them to age care residents (DoHA, 2010) may 
have further incentivised GPs to instigate RMMRs for their nursing home patients. The end 
result could well have been the deprescribing of antidepressant medications to nursing 
home residents.  In fact, a recent review of the RMMR service concluded that doctors 
considered this service to be most useful in providing recommendations around the 
cessation of medicine as well as decreasing dosage (DoHA, 2010). This is an extremely 
significant finding of this research because it highlights the impact of financial incentives 
directed at providers in limiting unnecessary polypharmacy.  Not only does the elimination 
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of an unnecessary medication have clinical benefits for the individual patient, it can also 
have financial benefits for the PBS. 
 
Findings in the previous chapter also revealed a reduction in antidepressant 
prescriptions in 2005 for patients who purchased fewer than 24 medications in 2004.  This 
was an unexpected finding because this cohort is not high medication users so costs 
associated with multiple medication use would not be operant.  This finding might be 
associated with the majority of this group being general patients who paid a higher 
copayment, so cost-related nonadherence for a single medication cannot be totally ruled 
out.  However, it is more likely that medication-related factors (prescription characteristics) 
including side effects may have also played a role in the observed decrease in 
antidepressant use among young and first time users.  These relatively common side 
effects include akathisia (feeling of inner restlessness), agitation, loss of libido, 
nervousness and anxiety associated the selective serotonin re-uptake inhibitor (SSRI) 
class of antidepressants (ADRAC 2005a), and increased risks of suicidal behaviour in 
children and young adolescents (ADRAC 2004) which was also reported to be associated 
with the SSRIs (Jick, Kaye & Jick, 2004).  If these side effects rather than cost increases 
are leading young, generally healthy adult patients to discontinue antidepressant 
treatment, then this provides support for the utility of Piette’s framework in directing 
consideration of a range of contextual factors in nonadherence to medication regimes.    
 
The unique contribution of this research in using paired patient data to examine 
elements of Piette’s framework is in confirming that a multiplicity of health system, 
prescription and medication regime factors can act more or less independently to influence 
patient use of prescription medication.  In this study, cost increase appears to have 
influenced patients with polypharmacy to reduce antidepressant use; while prescriber 
incentives are linked to reduced antidepressant use in concessional patients with 
polypharmacy.  Finally, cost is not likely to be a factor in the reduction of antidepressant 
use in young adults who rarely take medication, which suggests that medication side 
effects are possibly driving the reduction in medication use in this age group.  Every one of 
these areas exposes another area where further research is required. 
 184 
 
Medications with potential for abuse and dependence. 
A positive finding of this research was the increase in purchasing of opioid 
medications in 2005 by patients on multiple medications, who are mostly elderly and 
concessional patients. This suggests that that these patients are not forgoing pain 
medications as a result of increased out-of-pocket costs. As the prevalence of cancer 
increases with age the prevalence of both cancer and non-cancer pain would be expected 
to be highest in this age group.   
 
For benzodiazepines, which includes commonly used anti-anxiety agents with brand 
names such as Valium, Serepax and Xanax, this thesis found an increasing trend in 
prescriptions overall in 2005 despite the 21% increase in cost. Statistically significant 
increases in benzodiazepine prescriptions were found for general patients, young adults 
aged 25-44, patients exposed to minor polypharmacy and those not affected by 
polypharmacy at all. The increase in benzodiazepine prescriptions for young working age 
adults is cause for concern.  As the sociodemographic characteristics associated with 
benzodiazepine prescriptions are also associated with prescription drug misuse (Nielsen et 
al., 2013) this finding highlights the need for strategies aimed at minimising potential 
pharmaceutical misuse and trafficking.  There are both clinical, public health and health 
systems reasons for this recommendation, discussed earlier in this chapter. 
 
In addition to the increasing trend observed for benzodiazepines, this study found a 
statistically significant increase in opioids prescriptions in 2005. This was despite the 
higher copayment and best practice guidelines that recommend opioid analgesics be only 
used in carefully selected patients with moderate to severe chronic pain in whom more 
conservative treatment options have been found to be inadequate (Analgesic Expert 
Group, 2012). In contrast to age groups associated with benzodiazepine increase (25-44 
years), patients associated with the increased opioid prescriptions in 2005 were slightly 
older (45-64 years), but were also general beneficiaries and patients not exposed to 
polypharmacy. These patients are working age adults and tend not to experience multiple 
morbidities.  Given the risk of dependence associated with opioids, these findings indicate 
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that prescriber education about best practice guidelines for opioid analgesics is urgently 
required. 
 
These findings also suggest co-prescribing and co-use of opioids and 
benzodiazepines in younger working age groups.  This is consistent with the findings of a 
major review of literature on the use of opioids and benzodiazepines (Jones et. al., 2012).  
This review concluded that while opioids have considerable therapeutic utility, their 
euphoric effects make them among the most commonly abused drugs in the world. It also 
concluded that although benzodiazepines are a weaker euphoriant when administered 
alone and may have less abuse liability, drug users appear to have discovered that 
benzodiazepines are able to enhance the positive subjective effects of opioids. As such, 
individuals may be combining opioids and benzodiazepines in order to achieve a greater 
level of euphoria (Jones et. al, 2012) and this would explain the parallel increase in both 
these medications.   
 
The results of the analyses in relation to opioid and benzodiazepine use have 
important implications from a number of different perspectives. First, they suggest that 
increasing out-of-pockets costs may not be sufficient to deter the purchasing of 
medications with the potential for addiction, dependence and abuse.  Second, as the 
combination of opioid and benzodiazepine medications has serious and detrimental effects 
upon physical health, mental health and sobriety, the use of these medications requires 
constant vigilance among prescribers and use of best practice guidelines. Third, in addition 
to increasing risk of overdose, benzodiazepines and opioid co-drug use may exacerbate 
criminal, psychological and medical problems commonly seen among drug users leading 
to increased costs to the criminal justice system.  
 
Addressing the problem of prescription drug abuse may require a range of 
strategies including penalties for patients who access these medications in excess of 
therapeutic need.  However, this is not within the sphere of practice of GPs, nurses and 
pharmacists; there is a need for a systems approach.  This would necessitate further 
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research however to gain a better understanding of opioid and benzodiazepine prescribing 
patterns and their use in younger working age adults, methods addicts use to source these 
medications in excess of therapeutic need, and prescribers (the majority of whom are 
small business owners) who knowingly or unknowingly may be facilitating this practice. 
 
Arthritis. 
Non-opioid analgesics and anti-inflammatory agents 
There was a significant decrease in total prescriptions for non-opioid (simple) 
analgesics prescriptions in 2005.  This appears to be largely driven by a decrease in 
prescriptions for paracetamol, a first-line pain killer commonly recommended for people 
with chronic pain (Nikles et al., 2005)  In fact, the ranking of paracetamol in the 10 most 
prescribed medications dropped from third in 2004 (4,801,359 prescriptions) to fourth 
(4,583,476 prescriptions) in 2005 (DoHA, 2007).  As paracetamol is not an expensive 
medication, and is also available OTC it is likely that factors other than the 2005 
copayment increase contributed to the decline in total prescriptions. These factors may 
include Adverse Drug Reactions Advisory Committee notifications of serious liver injury 
associated with paracetamol overdose (ADRAC, 2005b) in 2005. The drop in ranking of 
paracetamol also coincided with the implementation of mandatory warning labels which 
came into effect on 1 April 2005 to promote safe and appropriate use of paracetamol in 
Australia. For adults these warnings recommended a maximum adult daily dose of 4g 
paracetamol (equivalent to a maximum of 8 tablets per day). For children and adolescents 
the warning labels recommended not to give paracetamol for more than 48 hours at a time 
unless otherwise advised to by a doctor (ADRAC, 2005b).   
 
The sequence of events which coincided with the decrease in paracetamol 
prescriptions in 2005 demonstrates the usefulness of Piette’s framework in explaining 
socio-political changes in prescription use.  The framework facilitates the consideration of 
a range of contextual factors which drive nonadherence to medications in an environment 
of cost changes. In this case the primary driver does not appear to be cost because the 
use of paracetamol also reduced for subgroups of patients, such as general patients and 
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those with polypharmacy which have shown to be sensitive to cost increases of other 
prescriptions. This leads to the conclusion that a very significant across the board 
reduction in paracetamol use is most likely due to the 2005 notification of adverse effects 
associated with paracetamol overdose (which is a combination of health system factors 
and prescription characteristics).  
 
Another likely contextual factor associated with the observed decrease in purchasing 
non-opioid analgesics in 2005 was cost of some medications falling below the general 
copayment due to the copayment increase, and therefore no longer being subsidized to 
general beneficiaries on the PBS (health system factor according to Piette’s framework). 
For example, in 2004, 21% of community prescribing of simple analgesics was not 
subsidised as the cost was less than the general copayment (Colvin et al., 2009).  These 
analgesics included paracetamol, commonly used NSAIDs such as naproxen (brand name 
Naprosyn) and ibuprofen (Brufen), and paracetamol/codeine combinations such as 
Panadeine Forte. These medications were only subsidised (and recorded by the PBS 
claims database) for concessional patients who paid a much lower copayment of $4.60 in 
2005. It is possible that the large increase in the general copayment to $28.60 in 2005 
resulted in more non-opioid (simple) analgesic coming off the subsidy list for general 
patients; therefore the purchasing of these medications by general patients was not 
captured in the PBS claims database.  
 
However the finding that concession card holders on multiple medications also 
decreased purchasing of analgesics commonly used for arthritic pain suggests that factors 
other than loss of PBS subsidy may have contributed to the decrease in NSAID 
prescriptions in 2005.  These contextual factors include the fallout of the withdrawal from 
the market of the arthritis medication rofecoxib (trade name Vioxx). This NSAID, a COX-2 
inhibitor, reduced pain by selectively targeting an enzyme responsible for pain and 
inflammation. This selectivity reduced the risk of peptic ulceration, which is a common side 
effect of other more commonly available non-selective NSAIDs (ns-NSAIDs).  Vioxx was 
withdrawn from the market in September 2004 because of concerns that the use of the 
medication raised risk of heart attack and stroke (DeMaria, 2004).  
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When COX-2 inhibitors were introduced in the market there was an increase in NSAID 
use as a group which was largely driven by an increase in COX-2 inhibitor use (rather than 
a switch from ns-NSAIDs to COX-2 inhibitors) (Ortiz, 2004).  It is likely that the withdrawal 
of the COX-2 inhibitor, Vioxx, may have raised fears amongst patients about the potential 
for adverse effects for the entire class of drugs, which then affected prescription purchases 
for all anti-inflammatory medications.  For concessional patients on multiple medications, 
the drop in NSAID prescriptions in 2005, could be related to an increased switching from 
NSAIDs to paracetamol, which is both cheaper and safer than either the ns-NSAIDs or 
COX-2 inhibitors, particularly in elderly persons (Courtney & Doherty, 2002).  This 
switching to paracetamol was a very logical response to the dual stimuli of increased cost 
and concerns about potential side effects.    
 
In contrast, cost alone was most likely responsible for the reduced use of anti-migraine 
medications in 2005. There were statistically significant reductions in anti-migraine 
medications for patients aged 45-64, a majority of whom were general patients. This 
reduction appears to have been the result of general beneficiaries having access to fewer 
subsidised anti-migraine medications on the PBS in 2005 than they did in 2004. This was 
especially the case in relation to the triptan class of anti-migraine medications which is 
used when simple analgesics do not relieve migraine symptoms. In 2004, when the 
general patient copayment was $23.70, all three triptan medications: naratriptan (brand 
name Naramig); sumartriptan (Imigran); and, zolmitriptan (Zomig) cost more than the 
general copayment (DoHA, 2004, p 240, 241) and therefore were subsidised to general 
patients. In 2005, with the copayment increasing to $28.70, the cost of all three 
medications fell below the general patient copayment threshold (DoHA, 2005, p.260) and 
therefore were no longer subsidised to general patients. 
 
The significant reduction in the purchasing of Triptan anti-migraine medications by 
general patients following this medication’s removal from the PBS subsidy list for general 
patients is clinically relevant.  Triptan medications are effective in about two-thirds of 
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people who suffer from migraine and work best if they are taken when the migraine 
headache is just starting to develop (NPS, 2005).  This quick effect in heading off a 
migraine is not provided by OTC analgesics.  Therefore, if general patients are switching 
to simple analgesics, this has important implications for general patients in the workforce.  
Quick access effective anti-migraine medications such as Triptan has been shown to be 
effective in decreasing absenteeism associated with migraines and increasing productivity 
(Medicines Australia, 2009).  As a result of the copayment increase in 2005 that led to 
these medications falling off the subsidy list for general patients, migraine patients 
arguably were disadvantaged through more pain and days off work. This is a good 
example of how a relatively minor cost increase of one medication can inadvertently lead 
to a disproportionately high cost ultimately shouldered by the entire population. 
 
Diabetes.  
There was an increase in total prescriptions for alimentary tract and metabolic class 
of medications in 2005, driven mainly by an increase in prescriptions for diabetes 
medications. This increase could partly be attributed to evidence-based diabetes 
guidelines which recommends therapy with multiple medications (Bauer & Nauk, 2014), 
which are essential medications and need to be taken regardless of cost.  An opposite 
result was found for anti-ulcerants, which are discretionary alimentary tract medications 
under the ATC classification system, the purchase of which went down after the price 
increase. Differences in essential and discretionary medication use are discussed in more 
detail in the next section.    
 
Asthma. 
For asthma patients exposed to major polypharmacy there was a significant 
decrease in prescriptions for inhalants in 2005, suggesting patients on multiple 
medications may have reduced their asthma medication use.  As the major reliever 
medication, salbutamol (Ventolin) inhaler is not subsidised to general patients, and 
therefore purchases were not recorded as PBS data in 2004 and 2005.  This suggests that 
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the decrease in asthma inhalers in general observed in this thesis was driven mainly by a 
decrease in prescriptions for preventer medications.   
 
As mentioned in Chapter 2, other Australian studies have also reported cost-
sensitivity associated with asthma preventer medications (Hynd et al., 2008; Ampon et. al., 
2009). Both these studies used time series methodologies to compare change in 
dispensing over a time frame which included the 2005 copayment change.  Hynd and 
colleagues found a decrease in dispensing for general patients on combination (reliever 
plus preventer) asthma medications.  The Ampon study which compared the number of 
prescriptions for preventer inhaled corticosteroids dispensed to concessional patients with 
that dispensed to general patients during January 2003 to December 2006, reported 
concessional card holders to be about 2.5 times more likely to be dispensed preventer 
medications than general beneficiaries. 
 
The impact of the copayment increase on access to preventer asthma medications 
has important implications for the wellbeing of general patients with asthma patients, and 
health system costs associated asthma and COPD. Regular use of preventative 
medications has been shown to reduce hospitalisations due to asthma and COPD 
exacerbations in Australia (Calverly et al., 2007).  The savings in downstream costs are 
quite significant.  In the United States, Cloutier, Hall, Wakefield, and Bailit, (2005) 
estimated that increased use of inhaled corticosteroids contribute to a 35% decrease in 
paediatric hospitalisations and a 27% decrease in emergency department visits. It is 
therefore of concern that the copayment increase in 2005 may have compromised access 
to asthma preventer medications to subgroups of patients which includes general patients 
and those on multiple medications.  
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Change in Essential and Discretionary Medication Use 
 
Chapter 4 revealed that the patients most affected by the copayment increase in 2005 
were general patients and concessional patients on multiple medications.  However, not all 
patients on multiple medications showed the same level of cost-sensitivity across 
medication classes.  In fact some high-risk patients on essential chronic disease 
medications maintained adherence in the face of a copayment increase despite the burden 
of multiple medications. For example, reductions were not observed for patients on 
cholesterol, diabetes and most antihypertensive medications.  This suggests that the 
copayment increase in 2005 was associated with different impacts for low- and high-risk 
patients.  This is consistent with the findings of Wang et al., (2011) from their study of 
changes in medication use between patients with high and low comorbidity burden after a 
copayment increase. These authors reported that the copayment increase was associated 
with high-risk patients incurring greater out-of-pocket costs from continued adherence, and 
low-risk patients putting themselves at increased risk for adverse health events through 
reduced nonadherence. 
 
This current study similarly found that patients were more cost-sensitive with respect 
to symptom-relieving medications which are generally used to treat acute medical 
conditions that may flare up sporadically.  These include analgesic medications to treat 
arthritis, back pain, migraine and head aches, relievers for asthma and medications to 
relieve symptoms of gastric ulcer and reflux.  These conditions are generally more 
common in young and middle-aged adults, are amenable to lifestyle changes to some 
extent, and are treatable by over the counter substitutes. In contrast, patients with chronic 
diseases such as such high cholesterol, diabetes, coronary heart disease, heart failure 
and stroke, which are more common in older adults, are more likely to adhere to 
medication therapy in the face of a large copayment increase.  
 
Both Goldman et al., (2004) and Piette et al., (2004a) reported cost-related 
nonadherence to be more common for discretionary medicines which are used for 
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symptom-relief as opposed to essential medications for chronic disease prevention and 
management.  Piette and colleagues demonstrated that while the use of both categories of 
medications decreased in response to cost increase, the decrease was less for essential 
chronic disease medications for hypertension (down by 9%), heart failure (10%), and 
diabetes (11%). In contrast, patients’ likelihood of foregoing medications due to cost was 
twice as high for medications intended for symptom relieving conditions such as asthma 
(20%), arthritis (20%) and back pain (23%).     
 
The finding of this research that the 2005 copayment increase did not reflect Piette’s 
finding that all medication use reduced after a price increase.  Queensland patients’ 
medication use is more consistent with that reported in Hynd et. al. (2008). These 
researchers examined changes in prescription use over a much longer timeframe before 
and after the 2005 copayment increase and found that the change in prescriptions for 
essential chronic disease medications was much less compared to that of symptom 
relieving discretionary mediations.  For example they reported a decrease of 3% in 
prescriptions for anti-Parkinson medications, was much lower than that of proton pump 
inhibitor (PPI) class of anti-ulcerants (11%) and asthma inhalants (10%).   
 
While some of the differences could be due anti-Parkinson medications being 
essential to the management of Parkinson’s disease, which is a chronic disease without a 
cure, other factors could also be involved. These include consequences of nonadherence 
with recommended treatment and symptom re-occurrence on cessation, which is quite 
noticeable in the case of anti-Parkinson medications (prescription characteristics according 
to Piette’s framework), and lack of over the counter and lifestyle options available to 
control the disease. Interestingly, discretionary medicines such as PPIs and some asthma 
reliever medications have OTC availability, e.g.  antacids, omeprazole (Zantac) tablets and 
salbutamol (Ventolin) puffers respectively, which may reinforce their discretionary non PBS 
use. 
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However, not all symptom relieving medications demonstrated price sensitivity in this 
study.  As discussed above, opioids and benzodiazepines prescriptions increased in 2005 
despite the copayment increase.  The was especially the case for general patients who 
paid a much higher copayment in 2005 and multiple medication users who had a higher 
disease burden and expected to exhibit a degree of price sensitivity. Hynd and colleagues 
also found this to be the case for benzodiazepines which they classified as an essential 
medication for chronic symptomatic conditions in their study.  One Australian contextual 
factor that might be operating that is not related to these medications’ habit forming 
potential is that neither benzodiazepines nor opioids have effective over the counter 
substitutes or self-management options (as is the case with Ventolin puffers and antacids).  
This may have contributed to observed the lack of sensitivity to the copayment increase. 
 
Change in Polypharmacy in 2005 
 
This research found that patients exposed to major polypharmacy in 2004 were 
affected by the copayment increase in 2005 more than those exposed to minor 
polypharmacy.  In the case of patients purchasing fewer than 24 prescriptions in 2004 
(non-polypharmacy), there was a statistically significant increase in prescriptions in 2005. 
For patients in the minor polypharmacy category in 2004 there was a trend towards a 
decrease in prescriptions in 2005, which was not significant. However for patients exposed 
to major polypharmacy in 2004, a statistically significant reduction in prescriptions was 
observed in 2005.  
 
These findings can be interpreted in a number of different ways. The decrease in 
prescriptions for patients with major polypharmacy could be viewed as a positive effect of 
the copayment increase in that it may have brought about reductions in the number of 
unnecessary medications and risk of adverse effects associated with polypharmacy. In 
addition, a reduction in the number of patients exposed to major polypharmacy in 2005 
can be interpreted as cost saving to the affected patients, as well as the PBS. However, if 
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the reductions in prescriptions coincided with reductions in the purchasing of essential 
medications this could be viewed as a negative effect of the copayment change.  
Alternatively, aspects of both these phenomena could be operating, a point which 
becomes apparent when general and concessional patterns of purchase are compared. 
 
General patients not exposed to polypharmacy in 2004 were not affected by the 
change in copayment, which makes sense, because they were only purchasing, at most, 
an average of one medication per month (12 prescriptions per year). In contrast, 
decreases were observed for general patients exposed to both minor and major 
polypharmacy. The decrease in prescriptions for those affected by minor polypharmacy 
was from 16,517 prescriptions in 2004 to 13,733 in 2005.  This decrease was significant 
(p= <.001).   
 
While the decrease from 5,326 prescriptions in 2004 to 4,799 prescriptions in 2005 for 
general patients exposed to major polypharmacy approached significance (p = .06), this 
subsample of general patients with major polypharmacy (n=67) represented a relatively 
smaller group compared to other subgroups such as concessional patients with minor 
polypharmacy and major polypharmacy (n = 2,662 and 986 respectively).  Therefore while 
not reaching statistical significance, these analyses could have been affected by unequal 
sample sizes and lack of power; and it is likely that general patients with multiple chronic 
illnesses did experience potential socioeconomic hardship in purchasing prescribed 
medication.  Certainly these findings point to a need for closer examination of this 
subgroup’s medication purchasing. 
 
In contrast, concessional patients demonstrated significant changes in prescriptions at 
both ends of the medication use continuum, with 1) increases associated with the non-
polypharmacy category, 2) no changes in those exposed to minor polypharmacy, and 3) 
significant reductions in those affected by major polypharmacy. That a majority of the 
concessional patients in the major polypharmacy category reduced their medications in 
2005 after the copayment increase is a very important finding. It suggests that the 
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immediate impact of the 2005 copayment increase for concession card holders on multiple 
medications was a significant reduction in medication use.  This supports other findings 
which suggest that patients on multiple medications are sensitive to cost because of the 
number of medications they take (Thomas, 2008).  These findings for concessional 
patients inform the conclusion, above, that general patients with multiple chronic illnesses 
are also vulnerable to cost increases even though the significance of the change for this 
latter group was technically not significant (p = 0.06). 
 
Suggested strategies to manage polypharmacy. 
 
A major contributor of polypharmacy is medicines being prescribed by multiple 
prescribers at different times for different reasons, a scenario which is commonly 
encountered when medications are commenced in hospital and not re-evaluated for 
appropriateness on discharge (Hague, 2009).  Viktil and colleagues (2006) reported that in 
Norway nearly half the patients admitted to general hospitals used five medications or 
more; and during their hospital stay these patients were prescribed as many new drugs as 
those admitted with fewer medications.  A recent Australian study reported that three-
quarters of patients aged 70 and over admitted to a large teaching hospital were using five 
medications or more (major polypharmacy), and one-fifth, ten or more medications on 
admission (Hubbard et al., 2015).  More worryingly, this study also reported that no 
clinically meaningful changes were made to number or type of medications during the 
admission. Inpatients admissions provide an ideal opportunity for health professionals to 
intervene and act on polypharmacy.  Hospital nurses are in a unique position to monitor 
this and initiate steps to eliminate hospitalisation as a risk factor to polypharmacy.  
However, there is little evidence in the literature that nurses are routinely undertaking this 
role.  This current research supports the view that an expansion of this role by nurses 
would significantly reduce inadvertent polypharmacy through a discussion of discharge 
medications as well as pre-existing admission medications with the patient.  This would 
both benefit the patient and provide savings to the health care system. 
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Other specific strategies to reduce the number of medications would not only bring 
down cost to the individual and Australian taxpayer, but would also improve compliance. 
These strategies include doctors eliminating medications that are not needed, simplifying 
dosing regimen, using combination products, omitting medications with a low benefit/risk 
ratio, and discussing side effects in the context of medication benefits with the patient 
(Kocurek, 2009).  There is also growing evidence to support the conclusion that 
discontinuing specific medications in certain patient population, such as statins in women, 
does not worsen outcomes and can decrease adverse drug events as well as medication 
costs (Garfinkel & Mangin, 2010; Bain et al., 2008). 
 
Summary of Changes in 2005 
The research presented in this thesis revealed that the patients most affected by the 
copayment change in 2005 were those on multiple medications.  For these patients there 
were reductions in prescriptions across all medication classes except CVD medications. 
This is an important finding with significant implications. It suggests some high-risk 
patients on essential medications, for example, for CVD may remain adherent in the face 
of a copayment increase despite the burden of multiple medications, but other patients, 
such as asthmatics on preventer medications do not. 
 
The changes in prescriptions varied across sociodemographic and medication-related 
factors and have important implications for future research on the impact of copayment 
changes. This research demonstrates that investigating changes in prescriptions at the 
population level may not accurately reflect the impact of copayment changes at a patient 
level.  Hynd and colleagues (2008) investigated PBS prescription changes after the 
copayment change in 2005 and found a decrease in prescriptions across 12 of 17 
medication categories. They concluded that other factors in addition to changes in 
prescriptions must be considered to fully assess the impact of copayment changes at the 
patient level. This thesis investigated some of these sociodemographic and medicated-
related factors. This thesis adds to this body of knowledge by examining the contribution of 
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age, gender, payment category, level of polypharmacy and type of medication on changes 
in prescriptions after a large copayment change. 
 
Strengths and Limitations of this study 
 
Strengths of this study. 
This study has several strengths. These are related to the level of the copayment 
increase being investigated, data source, a focus on the patient rather than the 
prescription, the application of the evidence-based framework of Piette et al., and its 
linkages to Australia’s NHPA initiatives.  This study required extensive manipulation of 
data from two discrete datasets (Medicare patient demographic data and PBS prescription 
claims data) to create a new dataset of paired prescription purchases over a two year 
period for individual patients.  The use of patient pairing of two national databases to 
reduce confounding variables in research on medication purchasing patterns has not been 
reported in the research literature. 
 
While the data used in the research is no longer recent, the level of copayment 
increase being investigated (21%) remains unprecedented and continues to have 
relevance for future health care policy decisions.  Previous increases to the copayment in 
Australia have been between 2% to 5% in line with changes to the Consumer Price Index.  
The level of copayment increase being investigated in this study made it possible to 
identify effects that could not have been identified by previous or subsequent studies. 
Since 2005, copayment increases have returned to being on par with CPI increases.  
 
Another strength of this study was the use of a national database of PBS 
prescriptions, which enabled examination of a large cohort of patients.  This provides 
increased power to the statistical analyses and also increases the generalizability of the 
findings. Queensland data were selected because Queensland population demographics 
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are slightly different to the rest of Australia, with many retired people electing to relocate to 
this tropical/subtropical State.  This has ensured that this under-researched sub-population 
of older patients who do not live in nursing homes was well represented in the analyses.  
Even though these independent retirees were sampled in the Queensland PBS data, there 
is no reason to believe that the findings of this research are not generalizable to similar 
subpopulations across Australia. 
 
Pharmacy claims data are believed to more objective in measuring patient 
compliance compared with other measures such as self-reporting (Wang et al., 2004). 
While utilisation studies which rely on self-reported medication use may reflect actual 
medication use, rather than prescriptions filled, they can be affected by recall bias. In 
addition, in the case of medication use, self-reporting participants tend to underreport 
some medications due to social desirability concerns, and over-report other medications 
due to memory difficulties (Johnson & Fendrich, 2005).  Although it is important to realize 
that the dispensing of the prescription does not necessarily imply that the medication is 
actually consumed, data on dispensed and purchased medication are closer to actual 
intake than prescriber data, and is also free from recall bias common in patient reported 
data.  The use of Medicare patient identifier numbers to pair PBS data provides a richness 
of data hitherto unavailable in other methodologies.   
 
The pairing of the 2004 and 2005 data to each patient enables insights to be 
developed from a national prescription dispensing database at a patient level. An 
important strength unique to this study is its focus on the patient rather than prescription 
utilisation. This was achieved by the use of the Medicare patient identification number 
(PIN) which allowed the researcher to anonymously identify multiple prescriptions for the 
same patient within the PBS database.  Linking these data with sociodemographic 
information from the Medicare enrolments database using an encrypted PIN enabled the 
examination of patient-related factors such as age, gender and concessional status on 
changes to prescription use in the face of the 21% increase in copayment. 
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  Hynd et al. (2008) examined the impact of copayment increase on prescriptions and 
concluded that patient level data were required to fully understand the changes in 
prescription use.  This study met that need.  The linking of PBS prescription data with 
demographic data from the Medicare enrolments database in this research opens the 
opportunity for future studies to monitor changes in prescription use in Queensland across 
categories of age, gender, copayment level, polypharmacy and mediation type.  
 
The use of the framework of Piette and colleagues (2006) was unique to this study, 
and a major strength of it. This framework informed a systematic examination of a range of 
contextual factors which influence cost-related medication adherence across the health 
care continuum.  The application of this framework provided a conceptual tool to 
understand the influence of patient and medication factors on consumer responses to 
increased medication costs.  Importantly, the research for this thesis demonstrated that 
consumer response to increases in cost sharing should not be restricted to an 
investigation of a single effect of changes in the total number of medications purchased 
over time.   
 
However, while the influence of clinician and health system factors was not the 
focus of the study and therefore not investigated the literature review undertaken, as part 
of this research highlighted the importance of these factors to medication adherence. The 
literature review also identified areas in which the Piette framework is limited in its 
application in a single study.  It will be remembered that Piette and colleagues developed 
this framework from a review of the research literature.  It is unlikely that any individual 
study/methodology would be able to apply this complex framework in its entirety, and this 
research has supported this observation. 
 
The focus of much of contemporary research into cost sharing and medication use 
has been on concessional patients and aged care residents exposed to major 
polypharmacy.  The examination in this thesis of the impact of the copayment on general 
beneficiaries and patients exposed to minor polypharmacy is another unique feature of the 
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study.  This approach enabled the identification of general patients exposed to minor 
polypharmacy to be potentially at risk of cost-related non adherence to PBS medications, 
and the potential creep of polypharmacy into the younger working age groups. A 
recommendation for further research to monitor both these important findings by including 
below-copayment data is made below. 
 
This study establishes a baseline in 2004 of prescriptions classified at ATC level 1.  
It also explores in detail the impact of the large change in copayment in 2005 on 
prescriptions for five of nine NHPA diseases and conditions - hypertension, diabetes, 
depression, asthma and arthritis, as well as antibiotics.  While anti-infectives are not a 
national priority in terms of burden of disease they are widely used across all age groups, 
which is why they were included in the analysis.  The linking of this thesis to NHPA 
diseases and conditions and anti-infectives opens the opportunity to monitor changes over 
time in the use of these medications at the patient level. This study therefore has more 
generalizability in terms of medication classes than existing published studies on the 
impact of the copayment changes.  
 
Limitations of this study. 
The findings of this research must be interpreted in light of the following limitations. 
First, the main data source for this study is patients’ pharmacy claims data, the primary 
purpose of which is to reimburse pharmacists for dispensed PBS benefits, not research. 
Because prescription claims data do not include information on the indication for 
treatment, inferences made about medical conditions being treated are assumptions made 
on the basis of the usual intended use of a medication.   
 
This challenge is further complicated by the fact that some medications are used to 
treat a number of different medical conditions.  For example, medications that are used for 
asthma are also used for the treatment of other respiratory illnesses; in particular, chronic 
obstructive pulmonary disease (COPD) among older people, and for viral and other 
wheezing conditions in young children. Nevertheless, this research was designed to 
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investigate medication use at the NHPA level and this required inferences to be made 
about the NHPA condition being treated.  However, it must be noted that the medical 
condition being treated at the patient level was not the focus of the study. Such a study 
would require linkages with the Medicare services file which contains data on medical 
services provided by doctors. 
 
Second, only data on PBS prescriptions dispensed through community pharmacies 
were included in the research for the thesis. The PBS claims data set in general excludes 
medications dispensed in public hospitals (which do not participate in the PBS), so the 
analyses do not include medications dispensed to patients admitted to a public hospital for 
management of acute conditions. They also do not include prescriptions dispensed to war 
veterans and their dependents through the Repatriation Pharmaceutical Benefits Scheme 
(RPBS).  These reported findings therefore may not generalize to these population groups.   
 
Third, the length of the follow-up of 12 months minimised loss of longitudinal data 
and enabled an investigation of the immediate impact of the copayment change. This 
timeframe was not long enough to fully capture the long-term impact of the copayment 
increase on medications for chronic diseases, which represents a methodological trade-
off.  However the findings of this thesis do provide useful baseline information for other 
studies which could be designed to assess the longer term impacts of the copayment 
change of 2005.  
 
Another limitation of this study relates to the purchasing of medications which cost 
less than the general copyment.  As mentioned earlier many common prescription 
medications, for example those that belong to the NSAID, anti-infective, diuretic, 
benzodiazepine, and older antidepressant classes of medications, cost less than the 
general copayment so only prescriptions dispensed to concessional patients are recorded 
by the PBS claims database.  This creates an uncertainty regarding interpretation of some 
of the results, although considerable effort was made to ensure that interpretations and 
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recommendations were based on patterns identified in similar sub-groups, contextual data, 
and the extant literature.   
 
An example of how interpretation of findings was influenced by contextual data was 
in the application of the PBS copayment policy.  In 2004, when the general patient 
copayment was $23.70, 12% of all community prescribing was not subsidised, as the cost 
was less than the general copayment (Colvin et al., 2009).  The increase in the general 
copayment to $28.60 in 2005 resulted in more medications crossing the threshold that 
negated the value of the subsidy for general patients.  This fact informed the interpretation 
that patients were probably purchasing medications OTC when they had previously 
purchased them on PBS.  
 
A final delimitation of this study pertains to the narrow focus of the data collected by 
the PBS.  For example, when a patient is prescribed a medication not listed on the PBS 
schedule (private prescription), or makes purchases of medications over the counter at a 
pharmacy this is not reflected in the PBS data, and leads to under reporting of the actual 
medication use, especially by general patients. A more complete picture of medication 
utilization in Australia can only be possible if data on below-copayment and private 
prescriptions are included in data collection.  This is recommended for future research 
later in this section.    
 
Policy Implications 
 
Cost sharing in the form of a patient copayment was introduced into the PBS in 1960 
with the two main objectives being to offset the costs of the PBS to the Government, and 
to discourage “unnecessary” use of PBS medicines (Sloan, 1995). Larger than usual 
copayment increases were introduced in 2005 as the result of a 2002 Federal Budget 
measure aimed at curtailing government expenditure by shifting more costs back to 
consumers (Brown et al., 2006).  According to this study, while the existing increasing 
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trend in the number of prescriptions was not affected by the price increase overall, the 
copayment increase in 2005 coincided with reductions in prescriptions for general 
beneficiaries and concessional patients on multiple medications.  The challenge for policy 
makers posed by these findings is to ensure that “timely access to the medicines that 
Australians need, at a cost individuals and the community can afford” (DoHA, 2000) is not 
compromised when large copayment increases are implemented.  This is particularly the 
case for medication adherence in patients who use multiple medications. 
 
Adherence. 
According to the framework of Piette and colleagues (2006), change in medication 
adherence due to cost is affected by multiple factors, including drivers and moderators at 
the health system, health provider and patient levels. It follows that to maintain medication 
adherence in the face of copayment increases will require a multi-pronged approach 
across the PBS continuum.  
 
As discussed in Chapter 2 there are a number of initiatives currently in place in 
Australia at the health system and provider levels that influence the prescribing of 
medications. However, apart from medication reviews which are only available to the 
elderly, very few initiatives currently exist at the patient level.  Patient-centered initiatives 
that ease the burden of copayment increase, especially after a large copayment increase, 
should be encouraged. These include the phasing in of the copayment change over longer 
timeframe to groups most at risk of cost-related non adherence, rather than implementing 
across the board copayment increases all at once on the first of January.  
 
As discussed earlier, the long term effects of the copayment change were not 
examined in this thesis.  Longer-term monitoring is important to assessing adherence to 
chronic disease medications, prescription drug abuse and untended effects of copayment 
increases such as increased emergency department and hospital admissions.  These 
effects of copayment increases are amenable to monitoring and regular monitoring of 
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these effects is recommended to ensure that policy adjustments are made proactively to 
prevent unintended negative effects of copayment increases.  
 
Pharmacists and nurses are the last in the health care delivery chain to interact with 
patients receiving prescriptions. They are therefore ideally placed to explain and 
emphasize the value of compliance and address issues associated with nonadherence 
when inpatients are being presented with their discharge medications. These include 
offering consumer medication information and compliance-focused counselling at the point 
of discharge, and for long term management, advice about other health sector incentives 
for enhancing quality use of medications such as chronic disease management plans and 
medication reviews. Pharmacists in Australia are currently funded to provide a number of 
these services at no cost or copayment to the patient from a primary health care setting 
(see for example, O'Leary et al., 2013). 
 
Given that copayment for medications in Australia are among of the highest in the 
world (Kemp at al., 2011), and that out of pockets costs have nearly tripled between 1991 
and 2007 (Table 1.1), the findings of this study have important policy implications for 
general patients and concessional patients on multiple chronic disease medications. As 
discussed in Chapter 2, high prescription cost-sharing is a barrier to medication 
adherence. Forgoing annual copayment increases or phasing in large copayment 
increases over a longer timeframe for selected NHPA chronic disease medicines which 
this study demonstrated to be particularly sensitive to cost, e.g., antihypertensive 
medications, is therefore a recommendation for policy consideration.   
 
Polypharmacy. 
While polypharmacy is sometimes necessary, it may be associated with increased 
risk of adverse outcomes.  It is also a financial burden to the health system as well as the 
patient. Current initiatives in dealing with polypharmacy focus mainly on the elderly in aged 
care institutions when exposure to multiple medications is well established.  A broadening 
in scope of policy actions that addresses the other contextual factors associated with 
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polypharmacy will ensure a more comprehensive approach to dealing with this problem.  
At the provider level, awareness of the extent and changing pattern of polypharmacy is an 
important step in alleviating the burden associated with it. Pharmacists and nurses can 
work in collaboration with prescribers by identifying and referring patients at risk of 
polypharmacy for review of medications. Patient education by allied health professionals is 
an essential part of this process.   
 
Doctors should also be encouraged to refer a wider range of patients affected by 
polypharmacy to a pharmacist for medication review.  At the moment this service is only 
provided to the elderly on multiple medications at risk of medication-related adverse 
effects.  Addressing the problem of polypharmacy will therefore require current provider 
level incentives aimed at improving quality medication use in the older persons, e.g., HMR 
and RMMR, to be maintained and extended to include other age groups on multiple 
medications or at risk of polypharmacy. 
 
Research has shown that programs that assist doctors to improve prescribing result in 
statistically significant reductions in the number and doses of medications (Bolton et. al., 
2004).  Strategies at the prescriber level to reduce the financial and medical impact of 
polypharmacy include effective communication with the patient, and reviewing medications 
at each visit. However there are no formal guidelines or policies currently in place at the 
prescriber level to ensure that 1) a new medication is prescribed only when it is necessary, 
and 2) medications that are potentially inappropriate or redundant are deprescribed.  Thus, 
guidelines need to be developed for deprescribing to be implemented by doctors, 
independently or through doctor/pharmacist collaboration.  The latter option would require 
the scope of the HMR/RMMR initiative to be widened to accommodate deprescribing.  
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Research Implications  
 
A number of areas requiring further research were identified by this research. These 
relate to medication use by general patients, polypharmacy creep into younger age 
persons, and the changing pattern of opioid and benzodiazepine use.   
 
Medication use by general beneficiaries.  
Medication use by general beneficiaries has not been the focus of much research 
attention.  General patients comprise about 75% of the population, pay a much higher 
copayment and are mostly working age adults. The finding of this research that 
concessional patients purchased about four times more medications than general patients 
suggests that factors other than illness are influencing the purchasing of medications by 
general beneficiaries. The current paradigm of early detection and aggressive treatment of 
chronic diseases, a priority of the National Chronic Disease Strategy (NHPAC, 2006), is 
expected to expose working age general patients to chronic disease medications earlier in 
their lives and for a longer period. This highlights the importance of further research to get 
a more complete picture of medication use by general patients, including below-
copayment and private prescription purchasing, and the impact of copayment changes on 
this group of PBS beneficiaries.   
 
This research has established a baseline for PBS medication use in general patients 
in 2004, but it is incomplete because of the unavailability of below-copayment data.  Data 
on below-copayment purchases were not routinely collected by Medicare at the time of the 
2005 copayment change and as a result are not included in the analysis. The availability of 
below-copayment data since 2012 makes it possible to more fully monitor medication use 
by general patients, and it is recommended that analysis of this data be undertaken as a 
priority.  
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Polypharmacy and its creep.   
This research found that 25% of Queenslanders were exposed to either minor 
polypharmacy (mean of 2-4 medications per month) or major polypharmacy (mean of 5 or 
more medications per month) in 2004.  Research from the United States indicates a similar 
level of multiple medication use, and an increasing trend in both forms polypharmacy. 
Trend statistics are not available for Australia, but this current research provides a 
baseline prevalence estimate of multiple medication use in 2004 for Queensland to 
facilitate monitoring of this trend in Australia.  
 
This thesis identified a pattern of polypharmacy creep into younger age groups 
which could be related to the aggressive treatment of chronic diseases beginning earlier in 
life. The combined effects on medication use of early detection of chronic diseases and 
aggressive treatment to prevent their progression requires regular monitoring to prevent 
the development of polypharmacy in younger adults living in the community. Research is 
needed to assess the implications of polypharmacy in young adults as well as to determine 
whether the presence of minor polypharmacy in younger age groups is a risk factor for the 
more serious major polypharmacy in later life. 
 
Monitoring opioid and benzodiazepine use. 
The level of opioid and benzodiazepines prescribing and their association with 
young working age adults found in this research has important research implications.  
Firstly, distribution of opioid analgesic use among young users aged 25-44 is inconsistent 
with the distribution of severe cancer-related pain in the community.  This finding highlights 
the importance of research to determine whether opioid analgesic prescribing is consistent 
with best practice evidence and clinical guideline recommendations.   
 
Furthermore, by accessing opioid and benzodiazepines in high doses, some patients 
are putting themselves at risk of addiction, dependence, inappropriate use and diversion 
(which is a criminal activity). The National Drug Strategy household survey results of 2010 
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reported that 7.4% of Australians used a pharmaceutical drug, for “non-medical purpose" 
(AIHW, 2011a, b) and that a higher proportion of males used prescription pain-killers for 
this purpose than females.  Hospital separations associated with opioid poisoning have 
also been increasing in Australia (Roxburgh & Burns, 2009).  This thesis provides baseline 
data for the prevalence of benzodiazepine and opioid analgesic prescribing in 2004 and 
identifies the age groups most at risk of inappropriate use.  More targeted research is 
needed to establish the specific opioid and benzodiazepines medications being prescribed 
to persons aged between 25 and 44, and the indications for which they are being 
prescribed. A better understanding is also needed of the methods employed by patients to 
source opioids and benzodiazepines in higher than therapeutic doses, and the 
characteristics of the prescribers who facilitate access to these medications.  
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Conclusions 
This exploratory study is based on a retrospective analysis of paired data over two 
consecutive years with the focus being on patient characteristics, rather than being 
restricted to the total number of prescriptions dispensed as is typically reported in analyses 
of prescription databases.  The major finding was that copayment increases contribute to a 
change in the purchasing of PBS medications, but the changes are much more complex 
than it would first appear, varying across patient and medication factors.  The use of the 
framework of Piette and colleagues (2006) facilitated an examination of a broad range of 
factors that affect medication use, some of which are idiosyncratic to the Australian Health 
Care system and Queensland patient characteristics. 
 
The analysis for the thesis was carried out in two parts. The first part established a 
baseline of prescription use in 2004 by sociodemographic and medication factors. The 
second part applied the contextually based framework of Piette and colleagues to 
understand changes in the purchasing of medications after a larger than usual copayment 
increase across categories of gender, age, payment category, polypharmacy and 
medication class. 
 
The results for the first part of the analysis include that, consistent with other studies, 
about two-thirds of prescriptions dispensed in Queensland during 2004 were associated 
with cardiovascular disease, nervous system agents, and alimentary tract medications.  
Women accounted for over half (56%) of the total prescriptions in 2004.  The second part 
of the study, which investigated changes in prescriptions after the copayment increase 
demonstrated that focussing solely on changes in prescription use at the population level 
over time may not be a reliable indicator of prescription use at the patient level. It found 
that despite the short follow-up, general patients and concessional patients on multiple 
medications were affected by the large copayment change more than other subgroups.  
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The pattern of medication use is changing with the change in focus towards early 
detection, aggressive management and continued guideline-based treatment of chronic 
diseases. Multiple medication use is also on the rise and is extending into the younger age 
groups. Given the relationship between cost and medication adherence, general patients 
who pay a much higher copayment, and concessional patients on multiple medications are 
all at risk of nonadherence, especially when large copayment increases are implemented.   
Recommendations arising from this research include:  
 
1) phasing in large copayment increases over a longer timeframe rather than 
introducing increases all at once;  
2) putting systems in place to monitor the impact of large copayment increases on 
general patients and multiple medication users; 
3) maintaining health provider incentives aimed at promoting quality use of 
medications, and; 
4) reducing polypharmacy by implementing guidelines for identifying unnecessary 
medication use and deprescribing; 
5) adding modifications to Piette’s framework, which is used internationally, to 
include factors operant in countries with health systems different to that of the 
United States.  This includes relevant systems factors relating to “universal” 
healthcare and uniform medication pricing structures, both which have been 
identified in this research as major drivers of medication purchase in Australia. 
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APPENDIX A 
Programs administered by Medicare Australia in 2005, types of information available and 
associated privacy and data quality safeguards 
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APPENDIX B 
 
Medicare Australia process for data requests     
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APPENDIX C 
 
E-mail sent to Medicare Australia specifying data requirements for the thesis  
  
 
     Peter Balram   24/07/2006 11:50       
  
  
 
To: Rory King/CO/HIC@Prod 
cc:  
Subject: In-Confidence: Update on data request? 
  
 
 
Hi Rory 
 
How you going with the data request? 
 
I have had rethink about the variables I need - it is not much different from what was requested earlier. 
 
I need a random selection from the 2004 and 2005 PBS datasets on the following variables. 
 
PIN number (de-identified), Pension Entitlement No, Safety Net Entitlement Number,   
Approval #, Approval Name, item code, nordic code, item name, prescription date,  
item supply date, quantity supplied, date of birth, post code of consumer NHS_Benefit_Amount, 
GRS_Price_AMT 
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I am not sure whether the pension and safety net entitlement numbers need to be de-identified. If yes, then I 
do not have a problem. 
 
If giving Australia-wide dataset is not possible because of the size - i’ll settle for Qld data  
 
Please ring me if you have any queries. 
 
Peter Balram 
Pharmacist 
Program Review Branch 
Medicare Australia 
ph: 07 3004 5009;  fax: 07 3004 5402 
email: peter.balram@medicareaustralia.gov.au 
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APPENDIX D  
 
Request for information about the construction and allocation of the PIN and size of the 
dataset 
 
 
       Peter Balram 
     18/08/2006 10:33 AM 
 
  
To: Rory King/CO/HIC@Prod 
 cc: 
Subject: In-Confidence: qestions? 
Classification:    
 
Hi Rory 
 
I have thought about the following issues in preparation for the Monday's meeting: 
 
1.  Are Medicare PINs randomly allocated? 
2. How is the PIN number constructed - Does the number 2 in the PIN mean anything? 
(the reason I ask is - there was a major study done in the USA among army personnels  who are randomly 
allocated  a unique number when they joined up.  This study used randomly selected numbers ending in 3.  
However the number 3 was allocated to Corporals when the army numbers were constructed. As a result the 
randomly selected sample had more Corporals in it than other ranks personnel. 
 
3. If you do a 1:10 random selection for Qld what would be the approximate size for the 2004 and 2005 
datasets be? (I could be using statistics software called Stata) 
 
 268 
 
4. Can I get datasets for calendar years 2004 and 2005 rather than financial years (ie. PBS supply made 
between 1 January and 31 December (inclusive)  
 
5. It is possible to have the same PINs numbers for both years 2004 and 2005 calendar years? (This will 
make it possible to do follow up study)       
 
Thanks Rory 
 
Peter 
 
 
Peter Balram 
Pharmacist 
Program Review Branch 
Medicare Australia 
ph: 07 3004 5009;  fax: 07 3004 5402 
email: peter.balram@medicareaustralia.gov.au 
 
 
 
 
 
 
 
 
 
 269 
 
APPENDIX E  
 
 
Response from Information Strategy and Delivery Unit about the construction and 
allocation of the PIN and size of the dataset 
 
 
 
         Rory King 
       18/08/2006 02:34 PM 
 
 
 To: Peter Balram/QLD/HIC@Prod 
 cc: Simon Low/CO/HIC@Prod 
 Subject :Re: In-Confidence: questions?  
Classification:    
 
 
Hi Peter 
 
1 & 2. Numbers are allocated consecutively by state but only first or second digit of the pin indicate the state 
of enrolment.  These digits do not change once allocated.   So if you were to construct your sample by using 
the last few digits, there will not be any bias in your sampling 
 
3. the following link will give you some ideas about how many enrolees there are by state which will give you 
an indication of how big your sample might be.  Depending on your needs and resources, maybe 1 in 100 
might be more manageable for you. 
 
http://www.medicareaustralia.gov.au/about/about_us/annual_report/04_05/statistics/mcare1a.htm 
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4. calendar year is fine 
 
5. yes, the same pins can be used. 
 
 
Happy to clarify on Monday. 
 
Rory King 
Team Leader 
Information Strategy Section 
Legal, Privacy and Information Services Branch 
6124 7833 
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APPENDIX F 
 
 
Request for clarification about patient selection and steps in the data extraction process 
 
 
Peter Balram/QLD/HIC  
01/06/2007 12:05 PM 
 
To Simon Low/CO/HIC@Prod 
cc  
Subject In-Confidence: Thanks for the data 
 
  
  
 
Hi Simon 
 
I've received the data through the internal mail. Thanks 
 
I need to clarification regarding the patient selection process.  
 
The accompanying documentation says it was "de-identified data representing 1 in every 100 of Queensland 
population"  
 
Am I right in assuming the following steps:  
 272 
 
1. Records with Queensland post codes (ie . 4000-4999) were extracted from the National PBS data 
sets  for the calendar years 2004 and 2005 (Qld data set); 
2. From the Qld data set the sample was selected based on the Medicare PIN; 
3. This involved using a random number generator which randomly selected 1 PIN in every 100 PINs 
from the Qld data set) 
 
Simon, if the PIN was used for the basis of the selection, were all digits used, or part of it. 
   
Thanks Simon 
  
peter 
 
Peter Balram 
Pharmacist 
Compliance Operations 
Qld Region 
Program Review Division 
ph: 07 3121 5009;  fax: 07 3004 5402 
email: peter.balram@medicareaustralia.gov.au 
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APPENDIX G 
 
 
 
Medicare Australia response regarding patient selection and steps in the data extraction 
process 
 
 
Hi Peter, 
 
I've received the following advice regarding your queries; 
 
1.   The 1 in every 100 of Queensland population was selected from our consumer enrolment summary table 
with postcode range from 4000-4999. Total population for Queensland as at Dec 2005 was 4,037,470, I then 
randomly selected 40,375 people to get their Pins. 
2.    I extracted data using these selected Pins to get their PBS records in EDW table during date of 
processing period 2004 and 2005 calendar years as required. 
3.   Not all patients selected have scripts supplied during the requested time period. 
4.   We always use all digits of Pins to extract data.      
 
Let me know if you need anything further. 
 
Regards, 
 
Simon Low 
A/g Senior Information Officer 
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Information Strategy and Delivery Section 
Legal, Privacy, and Information Services Branch 
x47850 
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APPENDIX H 
Extract of unit record ASCII data file (n=299,639) for calendar year 2004 showing one row per episode of dispensing  
  
PIN;SEX;PAT_CAT;AGE GROUP;APPROVAL ID;ITEM #;NORDIC CODE;ITEM NAME;DOP;DOS;NHS_BENEFIT_AMOUNT;GRS_PRICE_AMT;RPT_ORDR_NUM;PREV_SUPP_NUM;REG24_IND;RJCT_IND;RJCT_RSN_CODE;
2 ;M ;CO ;65-74 ;2142 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;04AUG2003 ;28FEB2004 ;22.52 ;26.32 ;5 ;5 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2093 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;06NOV2003 ;13DEC2003 ;77.92 ;81.62 ;5 ;1 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2007 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;06NOV2003 ;13JAN2004 ;77.82 ;81.62 ;5 ;2 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;1902 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;06NOV2003 ;14FEB2004 ;77.82 ;81.62 ;5 ;3 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;06NOV2003 ;14MAR2004 ;77.82 ;81.62 ;5 ;4 ;N ;  ;  ;
2 ;M ;GE ;65-74 ;2018 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;06NOV2003 ;16APR2004 ;57.92 ;81.62 ;5 ;5 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2589 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;09DEC2003 ;10DEC2003 ;22.62 ;26.32 ;5 ;0 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;1902 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;09DEC2003 ;29JAN2004 ;22.52 ;26.32 ;5 ;1 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;09DEC2003 ;29MAR2004 ;22.52 ;26.32 ;5 ;2 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;09DEC2003 ;29APR2004 ;22.52 ;26.32 ;5 ;3 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;09DEC2003 ;29MAY2004 ;22.00 ;25.80 ;5 ;4 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;08607B ;A 10 B A 02 ;METFORMIN HYDROCHLOR TABLET 1G ;12DEC2003 ;04FEB2004 ;18.35 ;22.15 ;5 ;1 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;08607B ;A 10 B A 02 ;METFORMIN HYDROCHLOR TABLET 1G ;12DEC2003 ;20MAR2004 ;18.35 ;22.15 ;5 ;2 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;08607B ;A 10 B A 02 ;METFORMIN HYDROCHLOR TABLET 1G ;12DEC2003 ;04MAY2004 ;18.35 ;22.15 ;5 ;3 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;08607B ;A 10 B A 02 ;METFORMIN HYDROCHLOR TABLET 1G ;12DEC2003 ;17JUN2004 ;18.35 ;22.15 ;5 ;4 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2233 ;08607B ;A 10 B A 02 ;METFORMIN HYDROCHLOR TABLET 1G ;12DEC2003 ;04AUG2004 ;18.39 ;22.19 ;5 ;5 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2007 ;01903E ;J 07 A L 01 ;PNEUMOCOCCAL VACCINE INJECTION 0.5ML (23 ;03MAR2004 ;20APR2004 ;33.31 ;37.11 ;0 ;0 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;20APR2004 ;17MAY2004 ;75.22 ;79.02 ;5 ;0 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;03303W ;J 01 C A 04 ;AMOXYCILLIN          CHEWABLE TAB 250MG ;20APR2004 ;17MAY2004 ;5.07 ;8.87 ;0 ;0 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;20APR2004 ;17JUN2004 ;75.22 ;79.02 ;5 ;1 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;1902 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;20APR2004 ;16JUL2004 ;75.26 ;79.06 ;5 ;2 ;N ;  ;  ;
2 ;M ;GE ;65-74 ;2018 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;20APR2004 ;13AUG2004 ;55.36 ;79.06 ;5 ;3 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2752 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;20APR2004 ;17SEP2004 ;75.26 ;79.06 ;5 ;4 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2141 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;20APR2004 ;19OCT2004 ;75.26 ;79.06 ;5 ;5 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2007 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;30JUN2004 ;30JUN2004 ;22.00 ;25.80 ;5 ;0 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2142 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;30JUN2004 ;30JUL2004 ;22.04 ;25.84 ;5 ;1 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;1902 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;30JUN2004 ;30AUG2004 ;22.04 ;25.84 ;5 ;2 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2752 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;30JUN2004 ;28SEP2004 ;22.04 ;25.84 ;5 ;3 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;1902 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;30JUN2004 ;29OCT2004 ;22.04 ;25.84 ;5 ;4 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2752 ;08607B ;A 10 B A 02 ;METFORMIN HYDROCHLOR TABLET 1G ;10AUG2004 ;22SEP2004 ;18.39 ;22.19 ;5 ;0 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;1902 ;08607B ;A 10 B A 02 ;METFORMIN HYDROCHLOR TABLET 1G ;10AUG2004 ;06NOV2004 ;18.39 ;22.19 ;5 ;1 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2752 ;08173E ;C 10 A A 01 ;SIMVASTATIN          TABLET 40MG ;19OCT2004 ;18NOV2004 ;73.57 ;77.37 ;5 ;0 ;N ;  ;  ;
2 ;M ;CO ;65-74 ;2007 ;01369C ;C 09 A A 02 ;ENALAPRIL MALEATE    TABLET 20MG ;19NOV2004 ;19NOV2004 ;22.04 ;25.84 ;5 ;0 ;N ;  ;  ;
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APPENDIX I 
Unit record data for 2004 (n=299,639) with one row per episode of dispensing after importing into an Excel spreadsheet 
Row NoPIN SEX PAT_CAT AGE GROUPAPPROVAL IDITEM # NORDIC CODE ITEM NAMEDOP DOS NHS_BENEFIT_AMOUNTGRS_PRICE_AMTRPT_ORDR_NUMPREV_SUPP_NUMREG24_IND
1 2 M CO 65-74 2142 01369C C 09 A A 02 ENALAPRIL MALEATE TABLET 20MG4-Aug-03 28-Feb-04 22.52 26.32 5 5 N
2 2 M CO 65-74 2093 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG6-Nov-03 13-Dec-03 77.92 81.62 5 1 N
3 2 M CO 65-74 2007 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG6-Nov-03 13-Jan-04 77.82 81.62 5 2 N
4 2 M CO 65-74 1902 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG6-Nov-03 14-Feb-04 77.82 81.62 5 3 N
5 2 M CO 65-74 2142 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG6-Nov-03 14-Mar-04 77.82 81.62 5 4 N
6 2 M GE 65-74 2018 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG6-Nov-03 16-Apr-04 57.92 81.62 5 5 N
7 2 M CO 65-74 2589 01369C C 09 A A 02 ENALAPRIL MALEATE TABLET 20MG9-Dec-03 10-Dec-03 22.62 26.32 5 0 N
8 2 M CO 65-74 1902 01369C C 09 A A 02 ENALAPRIL MALEATE TABLET 20MG9-Dec-03 29-Jan-04 22.52 26.32 5 1 N
9 2 M CO 65-74 2142 01369C C 09 A A 02 ENALAPRIL MALEATE TABLET 20MG9-Dec-03 29-Mar-04 22.52 26.32 5 2 N
10 2 M CO 65-74 2142 01369C C 09 A A 02 ENALAPRIL MALEATE TABLET 20MG9-Dec-03 29-Apr-04 22.52 26.32 5 3 N
11 2 M CO 65-74 2142 01369C C 09 A A 02 ENALAPRIL MALEATE TABLET 20MG9-Dec-03 29-May-04 22 25.8 5 4 N
12 2 M CO 65-74 2142 08607B A 10 B A 02 METFORMIN HYDROCHLOR TABLET 1G12- ec-03 4-Feb-04 18.35 22.15 5 1 N
13 2 M CO 65-74 2142 08607B A 10 B A 02 METFORMIN HYDROCHLOR TABLET 1G12- ec-03 20-Mar-04 18.35 22.15 5 2 N
14 2 M CO 65-74 2142 08607B A 10 B A 02 METFORMIN HYDROCHLOR TABLET 1G12- ec-03 4-May-04 18.35 22.15 5 3 N
15 2 M CO 65-74 2142 08607B A 10 B A 02 METFORMIN HYDROCHLOR TABLET 1G12- ec-03 17-Jun-04 18.35 22.15 5 4 N
16 2 M CO 65-74 2233 08607B A 10 B A 02 METFORMIN HYDROCHLOR TABLET 1G12- ec-03 4- ug-04 18.39 22.19 5 5 N
17 2 M CO 65-74 2007 01903E J 07 A L 01 PNEUMOCOCCAL VACCINE INJECTION 0.5ML (233-Mar-04 20-Apr-04 33 31 37.11 0 0 N
18 2 M CO 65-74 2142 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG20- pr-04 17-May-04 75.22 79.02 5 0 N
19 2 M CO 65-74 2142 03303W J 01 C A 04 AMOXYCILLIN CHEWABLE TAB 250MG20-Apr-04 17-May-04 5.07 8.87 0 0 N
20 2 M CO 65-74 2142 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG20- pr-04 17-Jun-04 75.22 79.02 5 1 N
21 2 M CO 65-74 1902 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG20- pr-04 16-Jul-04 75.26 79.06 5 2 N
22 2 M GE 65-74 2018 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG20- pr-04 13-Aug-04 55.36 79.06 5 3 N
23 2 M CO 65-74 2752 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG20- pr-04 17-Sep-04 75.26 79.06 5 4 N
24 2 M CO 65-74 2141 08173E C 10 A A 01 SIMVASTATIN TABLET 40MG20- pr-04 19-Oct-04 75.26 79.06 5 5 N
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APPENDIX J 
 
Letter from Medicare Australia approving the release of data  
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APPENDIX J (cont) 
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APPENDIX K 
 
Approval from Medicare Australia to publish findings in the thesis and requirements for any 
further publications arising from the research  
 
 
From: Neoni.Banks@medicareaustralia.gov.au [mailto:Neoni.Banks@medicareaustralia.gov.au] On Behalf 
Of statistics@medicareaustralia.gov.au 
Sent: Monday, 30 August 2010 3:36 PM 
To: Craig McDonald 
Cc: statistics@medicareaustralia.gov.au 
Subject: Mr Peter Balram - Request id: 2006/CO01258 [SEC=UNCLASSIFIED] 
  
 
Dear Mr McDonald, 
 
Firstly please accept the delay in responding to you request dated 4/8/2010, where you have requested 
Medicare Australia to sign a data access agreement in relation to the data we provided to Mr Balram in May 
2007. 
 
I have sought advice from the relevant area within Medicare Australia and the view is that it is not necessary 
for Medicare Australia to sign the proposed agreement which was attached in the above mentioned email.  
This is because the data that Mr Balram received was for a specific purpose and the conditions imposed with 
the use and disclosure of that data as advised to Mr Balram still applies.  Please see the wording below 
which was given to Mr Balram. 
 
Use and storage of information 
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"The information provided by the Medicare Australia is only to be used by you, and for the purpose as 
specified in your request.  You must store the information in a secure environment, and ensure secure 
destruction of the information after the project completion.  If you intend to publish an article containing the 
information, or drawing conclusions based on the information, you must advise Medicare Australia of the 
impending publication and must acknowledge Medicare Australia as the source of that information". 
 
Mr Balram was given approval to publish his findings in his thesis on the 22 April 2010 and at that time was 
also advised that any further publishing of the data would need to be approved prior by Medicare Australia. 
 
  
Neoni Banks 
Team Leader - Information Management 
Information Strategy & Delivery Section 
Information Management Branch 
Medicare Australia| National Office 
PO Box 1001 (M-1) 
Tuggeranong DC ACT 2901  
Ph:   1800 101 099 
Fax:  02 612 46935 
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APPENDIX L 
Ethics Approval from the University of Queensland 
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APPENDIX M 
 
Structure of the data file provided showing variables as column headings
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APPENDIX N 
Extract of ATC reference table used for mapping ATC level 5 data to ATC levels 1-4. 
 
  
L5 ID ATC L5_DESCRIPTIONL4 ID ATC L4_DESCRIPTIONL3 ID ATC L3_DESCRIPTIONL2 ID ATC L2_DESCRIPTIONL1 ID ATC L1_DESCRIPTION
J 01 D D 05 Cefmenoxime J01DD Third-generation cephalosporinsJ01D OTHER BETA-LACTAM ANTIBACTERIALSJ01 ANTIBACTERIALS FOR SYSTEMIC USEJ ANTIINFECTIVES FOR SYSTEMIC USE
L 04 A A 06 Mycophenolic acid L04AA Selective immunosuppressive agentsL04A IMMUNOSUPPRESSIVE AGENTSL04 IMMUNOSUPPRESSIVE AGENTSL A INEOPLASTIC AND IMMUNOMODULATING AGENTS
A 01 A A 01 Sodium fluoride A01AA Caries prophylactic agentsA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A A 02 Sodium monofluorophosphateA01AA Caries prophylactic agentsA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A A 03 Olaflur A01AA Caries prophylactic agentsA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A A 04 Stannous fluoride A01AA Caries prophylactic agentsA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A A 30 Combinations A01AA Caries prophylactic agentsA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A A 51 Sodium fluoride, combinationsA01AA Caries prophylactic agentsA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 02 Hydrogen peroxide A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 03 Chlorhexidine A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 04 Amphotericin B A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 05 Polynoxylin A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 06 Domiphen A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 07 Oxyquinoline A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 08 Neomycin A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 09 Miconazole A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 10 Natamycin A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 11 Various A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
A 01 A B 12 Hexetidine A01AB Antiinfectives and antiseptics for local oral treatmentA01A STOMATOLOGICAL PREPARATIONSA01 STOMATOLOGICAL PREPARATIONSA ALIMENTARY TRACT AND METABOLISM
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APPENDIX O 
Extract of the combined data files for 2004 and 2005 data (n= 540,411 rows) after medications classified at ATC level 5 was mapped to 
other ATC levels (1-4) and prior to reconfiguration to one row per consumer/case  
 
Medicatio
n_ 
Purchased
_#
Person_Id Month
Month_Of_S
upply
DOP Gender SEX
Pay_Ca
t
PAYME
NT_CA
T
Age
AGE 
GROUP
Year
YearofSu
pply
ATC 
L1_ID
ATC 
L1_DESCR
IPTION
ATC 
L2_ID
ATC 
L2_DESCR
IPTION
ATC 
L3_ID
ATC 
L3_DESCR
IPTION
ATC 
L4_ID
ATC 
L4_DESCR
IPTION
ATC 
L5_ID
ATC 
L5_DESCR
IPTION
ITEM 
NAME
ITEM #
NHS_BEN
EFIT_AM
OUNT
GRS_PRIC
E_AMT
1 16690 2 FEB #### 1 M 1 GE 5 35-44 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 4MG PER03051N 1.02 24.72
1 6695 2 FEB #### 1 M 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09B ACE INHIBITORS, COMBI ATIONSC09BA ACE inhibitors and diureticsC 09 B A 04Perindopril and diureticsPERINDOPRIL ı INDAPA TAB 4MG PERINDOPRIL08449Q 8.77 32.47
1 14727 1 JAN #### 2 F 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 4MG PER03051N 1.02 24.72
1 6643 10 OCT #### 2 F 1 GE 7 55-64 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09B ACE INHIBITORS, COMBI ATIONSC09BA ACE inhibitors and diureticsC 09 B A 04Perindopril and diureticsPERINDOPRIL ı INDAPA TAB 4MG PERINDOPRIL08449Q 8.81 32.51
1 14346 6 JUN #### 2 F 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 8MG PER08704D 19.1 42.8
1 6643 11 NOV #### 2 F 1 GE 7 55-64 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09B ACE INHIBITORS, COMBI ATIONSC09BA ACE inhibitors and diureticsC 09 B A 04Perindopril and diureticsPERINDOPRIL ı INDAPA TAB 4MG PERINDOPRIL08449Q 8.81 32.51
1 6695 5 MAY #### 1 M 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09B ACE INHIBITORS, COMBI ATIONSC09BA ACE inhibitors and diureticsC 09 B A 04Perindopril and diureticsPERINDOPRIL ı INDAPA TAB 4MG PERINDOPRIL08449Q 8.77 32.47
1 6695 6 JUN #### 1 M 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09B ACE INHIBITORS, COMBI ATIONSC09BA ACE inhibitors and diureticsC 09 B A 04Perindopril and diureticsPERINDOPRIL ı INDAPA TAB 4MG PERINDOPRIL08449Q 8.77 32.47
1 6695 7 JUL #### 1 M 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09B ACE INHIBITORS, COMBI ATIONSC09BA ACE inhibitors and diureticsC 09 B A 04Perindopril and diureticsPERINDOPRIL ı INDAPA TAB 4MG PERINDOPRIL08449Q 8.81 32.51
1 6695 8 AUG #### 1 M 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09B ACE INHIBITORS, COMBI ATIONSC09BA ACE inhibitors and diureticsC 09 B A 04Perindopril and diureticsPERINDOPRIL ı INDAPA TAB 4MG PERINDOPRIL08449Q 8.81 32.51
1 6695 12 DEC #### 1 M 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09B ACE INHIBITORS, COMBI ATIONSC09BA ACE inhibitors and diureticsC 09 B A 04Perindopril and diureticsPERINDOPRIL ı INDAPA TAB 4MG PERINDOPRIL08449Q 8.81 32.51
1 19241 4 APR #### 1 M 1 GE 3 15-24 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 8MG PER08704D 19.1 42.8
1 14311 9 SEP #### 1 M 1 GE 7 55-64 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 4MG PER03051N 1.06 24.76
1 19241 1 JAN #### 1 M 1 GE 3 15-24 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 4MG PER03051N 21.08 44.78
1 14808 2 FEB #### 1 M 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 4MG PER03051N 1.02 24.72
1 19241 6 JUN #### 1 M 1 GE 3 15-24 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 8MG PER08704D 19.1 42.8
1 14346 3 MAR #### 2 F 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 2MG PER03050M 25.27 48.97
1 19241 5 MAY #### 1 M 1 GE 3 15-24 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 8MG PER08704D 19.1 42.8
1 7810 2 FEB #### 2 F 1 GE 6 45-54 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09B ACE INHIBITORS, COMBI ATIONSC09BA ACE inhibitors and diureticsC 09 B A 04Perindopril and diureticsPERINDOPRIL ı INDAPA TAB 4MG PERINDOPRIL08449Q 8.77 32.47
1 19241 3 MAR #### 1 M 1 GE 3 15-24 1 2004 C CARDIOVASCULAR SYSTEMC09 AG NTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMC09A ACE INHIBITORS, PLAINC09AA ACE inhibitors, plainC 09 A A 04PerindoprilPERINDOPRIL TABLET CONT 8MG PER08704D 19.1 42.8
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APPENDIX P 
Combined data for 2004 and 2005 (n= 168,839) after the first stage of aggregation by ATC levels 1 to 5. Note: the data is still not in a one 
row per patient format 
 
Person_Id SEX PAYMENT_CATAGE_GROUP YearofSupplyATC_L1_DESCRIPTIONATC_L2_DESCRIPTIONATC_L3_DESCRIPTIONATC_L4_DESCRIPTIONATC_L5_DESCRIPTIONITEM_NAMEMedication__Purchased_#_sum_sum
2 M CO 65-74 2004 ALIMENTARY TRACT AND METABOLISMDRUGS USED IN DIABETESORAL BLOOD GLUCOSE LOWERING DRUGSiguanidesMetforminMETFORMIN HYDROCHLOR TABLET 1G7
2 M CO 65-74 2004 ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEBETA-LACTAM ANT BACTERIALS, PENICILLINSPenicillins with extended spectrummoxicilli AMOXYCILLIN CHEWABLE TAB 250MG1
2 M CO 65-74 2004 ANTIINFECTIVES FOR SYSTEMIC USEVACCINES BAC RIAL VACCINESPneumococcal vaccinesPneumococcus, purified polysaccharides antigenPNEUMOCOCCAL VACCINE INJECTION 0.5ML (231
2 M CO 65-74 2004 CARDIOVASCULAR SYSTEMAGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMAC  INHIBITORS, PLAINACE inhibitors, plainEnalapril ENALAPRIL MALEATE TABLET 20MG11
2 M CO 65-74 2004 CARDIOVASCULAR SYSTEMERUM LIPID REDUCING AGENTSCHOLESTEROL AND RIGLYCERIDE REDUCERSHMG CoA reductase inhibitorsSimvastat SIMVASTATIN TABLET 40MG 9
2 M CO 65-74 2005 ALIMENTARY TRACT AND METABOLISMDRUGS USED IN DIABETESORAL BLOOD GLUCOSE LOWERING DRUGSiguanidesMetforminMETFORMIN HYDROCHLOR TABLET 1G8
2 M CO 65-74 2005 ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEBETA-LACTAM ANT BACTERIALS, PENICILLINSPenicillins with extended spectrummoxicilli AMOXYCILLIN CAPSULE 500MG 2
2 M CO 65-74 2005 CARDIOVASCULAR SYSTEMAGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMAC  INHIBITORS, PLAINACE inhibitors, plainEnalapril ENALAPRIL MALEATE TABLET 20MG11
2 M CO 65-74 2005 CARDIOVASCULAR SYSTEMAGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEMANGIOTENSIN II ANTAGONISTS, PLAINAngiotensin II antagonists, plainIrbesartanIRBE AR AN TABLET 75MG 1
2 M CO 65-74 2005 CARDIOVASCULAR SYSTEMERUM LIPID REDUCING AGENTSCHOLESTEROL AND RIGLYCERIDE REDUCERSHMG CoA reductase inhibitorsSimvastat SIMVASTATIN TABLET 40MG 11
2 M CO 65-74 2005 SENSORY ORGANSOTOLOGICALSCORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATIONCorticosteroids and antiinfectives in combinationDexamethaso e and antiinfectivesD XAMETHAS NEiFR MYC EAR DROPS 500MCG-5M1
2 M GE 65-74 2004 CARDIOVASCULAR SYSTEMERUM LIPID REDUCING AGENTSCHOLESTEROL AND RIGLYCERIDE REDUCERSHMG CoA reductase inhibitorsSimvastat SIMVASTATIN TABLET 40MG 2
3 F CO 15-24 2004 ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEBETA-LACTAM ANT BACTERIALS, PENICILLINSPenicillins with extended spectrummoxicilli AMOXYCILLIN CAPSULE 500MG 1
3 F CO 15-24 2004 ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEOTHER BETA-LACTAM ANTIBACTERIALSFirst-generation cephalosporinsCefalexin CEPHALEXIN CAPSULE 500MG 1
3 F CO 15-24 2005 ALIMENTARY TRACT AND METABOLISMDRUGS FOR ACID RELATED DISORDERSDRUGS FOR P PTIC ULCER AND GASTRO-OESOPHAGEAL REFLH2-receptor antagonistsani idineR NITIDIN  HCL TABLET 150MG (BASE)1
3 F CO 15-24 2005 ALIMENTARY TRACT AND METABOLISMDRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERSPROPULSIVESPropulsivesMetoclopramideMETOCLOPRAMIDE HYDRO TABLET 10MG1
3 F CO 15-24 2005 ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEBETA-LACTAM ANT BACTERIALS, PENICILLINSCombinations of penicillins, incl. beta-lactamasemoxicillin and enzyme inhibitorAMOXYCILLIN WITH CLA TABLET 875MG-125MG1
3 F CO 15-24 2005 ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEBETA-LACTAM ANT BACTERIALS, PENICILLINSPenicillins with extended spectrummoxicilli AMOXYCILLIN CAPSULE 500MG 1
3 F CO 15-24 2005 ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEOTHER BETA-LACTAM ANTIBACTERIALSFirst-generation cephalosporinsCefalexin CEPHALEXIN CAPSULE 250MG 1
3 F CO 15-24 2005 ANTIINFECTIVES FOR SYSTEMIC USEANTIBACTERIALS FOR SYSTEMIC USEOTHER BETA-LACTAM ANTIBACTERIALSFirst-generation cephalosporinsCefalexin CEPHALEXIN CAPSULE 500MG 4
3 F CO 15-24 2005 DERMATOLOGICALSCORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONSCORTICOSTEROIDS, PLA NCorticosteroids, potent (group III)BetamethasoneBETAMETHASONE VALERA OINTMENT 500MCG/G (1
3 F CO 15-24 2005 GENITO URINARY SYSTEM AND SEX HORMONESSEX HORMONES AND MODULATORS OF THE GENITAL SYSTEMHORMO AL CONTRACEPTIVES FOR SYSTEMIC USEProgestogens and estrogens, fixed combinationsLevo orgestrel and estrogenLEVONORGESTREL i ETH TAB 21X 150MCG-30MC3
3 F CO 15-24 2005 MUSCULO-SKELETAL SYSTEMANTIINF AMMATORY AND ANTIRHEUMATIC PRODUCTSAN IINFLAMMATORY AND AN RHEUMATIC PRODUCTS, NON-SPropionic acid derivativesIbuprofen BUPROFEN TABLET 400MG 4
3 F CO 15-24 2005 RESPIRATORY SYSTEMDRUG  FOR OBSTRUCTIVE AIRWAY DISEASESADRENERGICS, INHAL NTSSelective beta-2-adrenoreceptor agonistsSalbut molSALBUTAMOL SULFATE ORAL-PRESS-INHAL 101
4 F CO 25-34 2005 GENITO URINARY SYSTEM AND SEX HORMONESSEX HORMONES AND MODULATORS OF THE GENITAL SYSTEMHORMO AL CONTRACEPTIVES FOR SYSTEMIC USEProgestogensLevonorgestrelLEVONORGESTREL TABLET 30 MICROGRAM1
4 F GE 25-34 2004 GENITO URINARY SYSTEM AND SEX HORMONESSEX HORMONES AND MODULATORS OF THE GENITAL SYSTEMHORMO AL CONTRACEPTIVES FOR SYSTEMIC USEProgestogensEtonogestrelTONOG STREL SUBCUTANEOUS IMPLAN1
5 M CO 55-64 2004 ALIMENTARY TRACT AND METABOLISMDRUGS FOR ACID RELATED DISORDERSDRUGS FOR P PTIC ULCER AND GASTRO-OESOPHAGEAL REFLProton pump inhibitorsPantopraz leP NTOPRAZ LE SODIUM TAB EQUIV 40MG PANT11
5 M CO 55-64 2004 ALIMENTARY TRACT AND METABOLISMDRUGS USED IN DIABETESORAL BLOOD GLUCOSE LOWERING DRUGSiguanidesMetforminMETFORMIN HYDROCHLOR TABLET 1G6
5 M CO 55-64 2004 ALIMENTARY TRACT AND METABOLISMDRUGS USED IN DIABETESORAL BLOOD GLUCOSE LOWERING DRUGSiguanidesMetforminMETFORMIN HYDROCHLOR TABLET 850MG2
5 M CO 55-64 2004 ALIMENTARY TRACT AND METABOLISMDRUGS USED IN DIABETESORAL BLOOD GLUCOSE LOWERING DRUGSSulfonamides, urea derivativesGliclazide GLICLAZIDE TABLET 30 MG (MODIF1
5 M CO 55-64 2004 BLOOD AND BLOOD FORMING ORGANSANTITHROMBOTIC AGENTSANTI HROMBOTIC AGENTSVitamin K antagonistsWarfarin WARFARIN SODIUM TABLET 1MG4
5 M CO 55-64 2004 BLOOD AND BLOOD FORMING ORGANSANTITHROMBOTIC AGENTSANTI HROMBOTIC AGENTSVitamin K antagonistsWarfarin WARFARIN SODIUM TABLET 2MG5
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APPENDIX Q 
 
Classification of medications at the ATC Level 1 (Anatomical Main Group) 
ATC Level 1 ID ATC Level 1 Description  
A Alimentary tract and metabolism 
B Blood and blood forming organs 
C Cardiovascular system 
D Dermatologicals 
G Genitourinary system and sex hormones 
H Systemic hormonal preparations, excl. sex hormones and insulin 
J Anti-infectives for systemic use 
L Antineoplastic and immunomodulating agents 
M Musculoskeletal system 
N Nervous system 
P Antiparasitic products, insecticides and repellents 
R Respiratory system 
S Sensory organs 
V 
Various (includes allergens, diagnostic agents, general nutrients, 
dressings)  
Source: WHO (2010b)  
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APPENDIX R 
Final combined dataset for 2004 and 2004 (n=13,523) after crosstabulation for payment category (Con 2004, Gen 2004, Ent 2004) 
resulting in a one row per patient format     
  
After cross tabulation for gender, and concessional status n = 13,523
Prescriptions (ATCLevel 1) by Age by Sex By Pay Status Aug 2009 
Person_Id Gender Age2004AlimentMetab2004Antiinfectives2004An n oplas2004Antiparasitic2004BloodAgents2004CvdDrugs2004Dermat2004UrinaryAndSexHorm2004MusculoSkeletal2004NervousSys2004RespSys2004SensoryOrgans2004SystemicHormPreps2004Various2004Con2004 Gen2004 Ent2004 Total2004 AlimentMetab2005Antiinfectives2005Antineoplas2005
2 M 65-74 7 2 0 0 0 22 0 0 0 0 0 0 0 0 29 2 0 31 8 2 0
3 F 15-24 0 2 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 2 2 7 0
4 F 25-34 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 1 0 0 0
5 M 55-64 21 0 0 0 17 17 0 0 0 0 0 0 0 0 52 0 3 55 22 2 0
6 M 45-54 0 0 0 0 0 0 0 0 0 2 0 0 0 0 0 2 0 2 1 0 0
7 M 75-84 0 2 0 0 0 0 0 0 0 0 1 0 0 0 3 0 0 3 0 4 0
8 M 35-44 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 0 0 0
10 M 55-64 5 1 0 0 1 0 0 0 0 0 0 0 0 0 0 7 0 7 7 0 0
11 F 55-64 0 1 0 0 0 0 0 0 0 9 0 0 0 0 10 0 0 10 0 0 0
12 M 65-74 0 1 5 0 2 18 0 0 0 0 5 0 0 0 27 4 0 31 0 0 0
13 M 55-64 0 0 0 0 0 17 0 0 0 0 0 0 0 1 0 18 0 18 0 0 0
14 F 25-34 0 3 0 0 0 0 0 0 0 0 3 0 0 0 0 6 0 6 0 7 0
16 M 65-74 0 0 0 0 2 12 0 0 3 4 0 0 0 0 16 0 5 21 0 0 0
17 F 55-64 0 0 0 0 0 7 0 0 0 0 0 0 0 0 0 7 0 7 10 0 0
19 M 55-64 1 0 0 0 0 0 0 0 9 0 0 0 0 0 10 0 0 10 1 0 0
21 F 45-54 0 3 6 0 0 0 0 0 0 2 0 0 0 0 11 0 0 11 0 1 4
24 F 55-64 0 1 0 0 0 5 0 11 0 0 0 0 0 0 17 0 0 17 0 0 0
26 F 55-64 0 0 0 0 0 0 0 0 0 0 1 8 0 0 0 9 0 9 0 0 0
28 M 55-64 0 3 0 0 0 0 1 0 11 0 0 14 0 2 14 0 17 31 0 0 0
29 F 25-34 0 0 0 0 0 0 0 0 0 20 0 0 0 0 20 0 0 20 0 0 0
30 F 55-64 0 0 0 0 0 0 0 0 0 7 0 0 0 0 0 7 0 7 0 0 0
31 M 65-74 0 2 0 0 3 0 2 3 1 0 0 0 0 0 11 0 0 11 0 0 0
34 F 65-74 0 0 0 0 0 0 0 0 0 11 0 0 0 0 11 0 0 11 0 0 0
35 M 55-64 0 0 0 0 0 2 0 0 0 0 7 0 0 0 0 9 0 9 0 2 0
36 F 25-34 0 2 0 0 0 0 0 0 0 1 0 0 0 0 3 0 0 3 0 1 0
37 M 25-34 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 1 0 1 0 0 0
38 M 65-74 0 5 0 0 1 1 2 0 0 1 0 2 0 0 7 0 5 12 0 11 0
40 F 25-34 1 0 0 0 0 0 0 3 0 0 1 0 0 0 5 0 0 5 0 1 0
41 F 25-34 0 4 0 0 0 0 0 0 0 4 0 0 0 0 8 0 0 8 0 1 0
43 F 25-34 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 24 0 24 0 0 0
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APPENDIX S 
 
Sociodemographic and medication-related variables used in the description of medication 
use in 2004 and the analysis of changes in 2005   
Variable Name Type Description 
Pat_Id Continuous 
Patient identification number associated 
with the prescription (scrambled PIN) 
Age2004 Categorical 
Age of patient in 2004 in categories 0-14, 
15-24, 25-44, 45-64, 65-74, 75 and over 
(for descriptive analysis).   
Age2004Recat Categorical 
Age of the consumer in 2004 in 
categories 25-44; 45-64; 65 and over 
(for Research Question analysis) 
Gender Categorical M or F   
PayCat2004 Categorical 
Patient payment category in 2004: 
General (GE); General/Concessional 
(GEN/CO) Concessional (CO); 
Concessional/Entitled (CON/ENT)    
Total2004 Continuous Total prescriptions supplied in 2004  
Total2005 Continuous Total prescriptions supplied in 2005 
Con2004   Continuous Total concessional prescriptions in 2004  
Con2005 Continuous Total concessional prescriptions in 2005 
Gen2004 Continuous Total general prescriptions 2004 
Gen2005 Continuous Total general prescriptions 2005 
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Variable Name Type Description 
MultipleRxCat
2004  
Categorical 
Total2004 categorised: <24 
prescriptions (no polypharmacy), 24-59 
prescriptions (minor polypharmacy), >= 
60 prescriptions (polypharmacy) 
Aliment2004 
Aliment2005 
Continuous 
Prescriptions for alimentary tract 
medications in 2004 and 2005  
Anti-infect2004 
 
 
Continuous Prescriptions for antibiotics in 2004  
Cont’d next page 
Anti-infect2005 Continuous Prescriptions for antibiotics in 2005 
Cardio2004 
Cardio2005 
Continuous 
Prescriptions for cardiovascular system 
medications in 2004 for medication 
acting on the cardiovascular system 
 
 
 
Musculo2004 
Musculo2005 
Continuous 
Prescriptions musculoskeletal system  
medication in 2004 and 2005 
Nervous 2004 
Nervous 2005 
Continuous 
Prescriptions for nervous system 
medications in 2004 and 2005  
Resp2004 
Resp2005 
Continuous 
Prescriptions for respiratory system 
medications in 2004 and 2005 
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APPENDIX T 
 
Classification of medications at ATC Level 2 - Therapeutic Sub-group  
ATC  
Level2 
ATC 
l2_id 
 
ATC Level 2_description 
1 A01  Stomatological preparations 
2 A02  Drugs for acid related disorders 
3 A03  Drugs for functional gastrointestinal disorders 
4 A04  Anti-emetics and anti-nauseants 
5 A05  Bile and liver therapy 
6 A06  Laxatives 
7 A07  Anti-diarrheals, intestinal ant-iinflammatory/ant-iinfective  
8 A09  Digestives, incl. Enzymes 
9 A10  Drugs used in diabetes 
10 A11  Vitamins 
11 A12  Mineral supplements 
12 A14  Anabolic agents for systemic use 
13 B01  Antithrombotic agents 
14 B02  Anti-hemorrhagics 
15 B03  Anti-anemic preparations 
16 B05  Blood substitutes and perfusion solutions 
17 C01  Cardiac therapy 
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ATC  
Level2 
ATC 
l2_id 
 
ATC Level 2_description 
18 C02  Antihypertensives 
19 C03  Diuretics 
20 C04  Peripheral vasodilators 
21 C07  Beta blocking agents 
22 C08  Calcium channel blockers 
23 C09  Agents acting on the renin-angiotensin system 
24 C10  Serum lipid reducing agents 
25 D01  Antifungals for dermatological use 
26 D05  Anti-psoriatics 
27 D06  Antibiotics and chemotherapeutics for dermatological use 
28 D07  Corticosteroids, dermatological preparations 
29 D10  Anti-acne preparations 
30 D11  Other dermatological preparations 
31 G02  Other gynecologicals 
32 G03  Sex hormones and modulators of the genital system 
33 G04  Urologicals 
34 H01  Pituitary and hypothalamic hormones and analogues 
35 H02  Corticosteroids for systemic use 
36 H03  Thyroid therapy 
37 H04  Pancreatic hormones 
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ATC  
Level2 
ATC 
l2_id 
 
ATC Level 2_description 
38 J01  Anti-bacterials for systemic use 
39 J02  Anti-mycotics for systemic use 
40 J04  Anti-mycobacterials 
41 J05  Antivirals for systemic use 
42 J07  Vaccines 
43 L01  Antineoplastic agents 
44 L02  Endocrine therapy 
45 L03  Immunostimulants 
46 L04  Immunosuppressive agents 
47 M01  Anti-inflammatory and anti-rheumatic products 
48 M03  Muscle relaxants 
49 M04  Anti-gout preparations 
50 M05  Drugs for treatment of bone diseases 
51 N02  Analgesics 
52 N03  Anti-epileptics 
53 N04  Anti-parkinson drugs 
54 N05  Psycholeptics 
55 N06  Psychoanaleptics 
56 N07  Other nervous system drugs 
57 P01  Anti-protozoals 
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ATC  
Level2 
ATC 
l2_id 
 
ATC Level 2_description 
58 P02  Anthelmintics 
59 P03  Ectoparasiticides, incl. Scabicides, insecticides 
60 R03  Drugs for obstructive airway diseases 
61 R05  Cough and cold preparations 
62 R06  Antihistamines for systemic use 
63 S01  Ophthalmologicals 
64 S02  Otologicals 
65 S03  Ophthalmological and otological preparations 
66 V01  Allergens 
67 V03  All other therapeutic products 
68 V04  Diagnostic agents 
69 V06  General nutrients 
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APPENDIX U 
 
Classification of medications at ATC Level 3   
ATC 
level3 
ATC3 
ID 
 
ATC Level 3 description 
1 A01a  Stomatological preparations 
2 A02a  Antacids 
3 A02b  Drugs for peptic ulcer and gastro-oesophageal reflux disease 
(GORD) 
4 A03a  Drugs for functional bowel disorders 
5 A03b  Belladonna and derivatives, plain 
6 A03f  Propulsives 
7 A04a  Anti-emetics and anti-nauseants 
8 A05a  Bile therapy 
9 A06a  Laxatives 
10 A07a  Intestinal ant-iinfectives 
11 A07b  Intestinal adsorbents 
12 A07d  Anti-propulsives 
13 A07e  Intestinal anti-inflammatory agents 
14 A09a  Digestives, incl. Enzymes 
15 A10a  Insulins and analogues 
16 A10b  Oral blood glucose lowering drugs 
17 A11c  Vitamin a and d, incl. Combinations of the two 
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ATC 
level3 
ATC3 
ID 
 
ATC Level 3 description 
18 A11d  Vitamin b1, plain and in combination with vitamin b6 and b12 
19 A11h  Other plain vitamin preparations 
20 A12a  Calcium 
21 A12b  Potassium 
22 A14a  Anabolic steroids 
23 B01a  Antithrombotic agents 
24 B02a  Anti-fibrinolytics 
25 B03a  Iron preparations 
26 B03b  Vitamin b12 and folic acid 
27 B03x  Other anti-anemic preparations 
28 B05a  Blood and related products 
29 B05b  I.V. solutions 
30 C01a  Cardiac glycosides 
31 C01b  Anti-arrhythmics, class i and iii 
32 C01c  Cardiac stimulants excl. Cardiac glycosides 
33 C01d  Vasodilators used in cardiac diseases 
34 C02a  Antiadrenergic agents, centrally acting 
35 C02c  Antiadrenergic agents, peripherally acting 
36 C02d  Arteriolar smooth muscle, agents acting on 
37 C03a  Low-ceiling diuretics, thiazides 
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ATC 
level3 
ATC3 
ID 
 
ATC Level 3 description 
38 C03b  Low-ceiling diuretics, excl. Thiazides 
39 C03c  High-ceiling diuretics 
40 C03d  Potassium-sparing agents 
41 C03e  Diuretics and potassium-sparing agents in combination 
42 C04a  Peripheral vasodilators 
43 C07a  Beta blocking agents 
44 C08c  Selective calcium channel blockers with mainly vascular 
effects 
45 C08d  Selective calcium channel blockers with direct cardiac effects 
46 C09a  Ace inhibitors, plain 
47 C09b  Ace inhibitors, combinations 
48 C09c  Angiotensin ii antagonists, plain 
49 C09d  Angiotensin ii antagonists, combinations 
50 C10a  Cholesterol and triglyceride reducers 
51 D01b  Antifungals for systemic use 
52 D05a  Anti-psoriatics for topical use 
53 D05b  Anti-psoriatics for systemic use 
54 D06b  Chemotherapeutics for topical use 
55 D07a  Corticosteroids, plain 
56 D10b  Anti-acne preparations for systemic use 
57 D11a  Other dermatological preparations 
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ATC 
level3 
ATC3 
ID 
 
ATC Level 3 description 
58 G02b  Contraceptives for topical use 
59 G02c  Other gynecologicals 
60 G03a  Hormonal contraceptives for systemic use 
61 G03b  Androgens 
62 G03c  Estrogens 
63 G03d  Progestogens 
64 G03f  Progestogens and estrogens in combination 
65 G03g  Gonadotropins and other ovulation stimulants 
66 G03h  Anti-androgens 
67 G03x  Other sex hormones and modulators of the genital system 
68 G04b  Other urologicals, incl. Anti-spasmodics 
69 H01a  Anterior pituitary lobe hormones and analogues 
70 H01b  Posterior pituitary lobe hormones 
71 H01c  Hypothalamic hormones 
72 H02a  Corticosteroids for systemic use, plain 
73 H03a  Thyroid preparations 
74 H03b  Antit-hyroid preparations 
75 H04a  Glycogenolytic hormones 
76 J01a  Tetracyclines 
77 J01c  Beta-lactam anti-bacterials, penicillins 
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ATC 
level3 
ATC3 
ID 
 
ATC Level 3 description 
78 J01d  Other beta-lactam anti-bacterials 
79 J01e  Sulfonamides and trimethoprim 
80 J01f  Macrolides, lincosamides and streptogramins 
81 J01g  Aminoglycoside anti-bacterials 
82 J01m  Quinolone anti-bacterials 
83 J01x  Other anti-bacterials 
84 J02a  Anti-mycotics for systemic use 
85 J04a  Drugs for treatment of tuberculosis 
86 J05a  Direct acting antivirals 
87 J07a  Bacterial vaccines 
88 J07b  Viral vaccines 
89 L01a  Alkylating agents 
90 L01b  Antimetabolites 
91 L01c  Plant alkaloids and other natural products 
92 L01d  Cytotoxic antibiotics and related substances 
93 L01x  Other antineoplastic agents 
94 L02a  Hormones and related agents 
95 L02b  Hormone antagonists and related agents 
96 L03a  Cytokines and immunomodulators 
97 L04a  Immunosuppressive agents 
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ATC 
level3 
ATC3 
ID 
 
ATC Level 3 description 
98 M01a  Anti-inflammatory and anti-rheumatic products, non-steroids 
99 M01c  Specific anti-rheumatic agents 
100 M03b  Muscle relaxants, centrally acting agents 
101 M03c  Muscle relaxants, directly acting agents 
102 M04a  Anti-gout preparations 
103 M05b  Drugs affecting bone structure and mineralization 
104 N02a  Opioids 
105 N02b  Other analgesics and antipyretics 
106 N02c  Anti-migraine preparations 
107 N03a  Anti-epileptics 
108 N04a  Anticholinergic agents 
109 N04b  Dopaminergic agents 
110 N05a  Antipsychotics 
111 N05b  Anxiolytics 
112 N05c  Hypnotics and sedatives 
113 N06a  Antidepressants 
114 N06b  Psychostimulants, agents used for ADHD and nootropics 
115 N06d  Anti-dementia drugs 
116 N07a  Parasympathomimetics 
117 N07b  Drugs used in addictive disorders 
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ATC 
level3 
ATC3 
ID 
 
ATC Level 3 description 
118 P01a  Agents against amoebiasis and other protozoal diseases 
119 P01b  Anti-malarials 
120 P02c  Anti-nematodal agents 
121 P03a  Ectoparasiticides, incl. Scabicides 
122 R03a  Adrenergics, inhalants 
123 R03b  Other drugs for obstructive airway diseases, inhalants 
124 R03c  Adrenergics for systemic use 
125 R03d  Other systemic drugs for obstructive airway diseases 
126 R05c  Expectorants, excl. Combinations with cough suppressants 
127 R05d  Cough suppressants, excl. Combinations with expectorants 
128 R06a  Antihistamines for systemic use 
129 S01a  Anti-infectives 
130 S01b  Anti-inflammatory agents 
131 S01e  Anti-glaucoma preparations and miotics1) 
132 S01f  Mydriatics and cycloplegics 
133 S01g  Decongestants and antiallergics 
134 S01x  Other ophthalmologicals 
135 S02a  Ant-iinfectives 
136 S02c  Corticosteroids and anti-infectives in combination 
137 S03a  Anti-infectives 
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ATC 
level3 
ATC3 
ID 
 
ATC Level 3 description 
138 S03b  Corticosteroids 
139 V01a  Allergens 
140 V03a  All other therapeutic products 
141 V04c  Other diagnostic agents 
142 V06d  Other nutrients 
 
